<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0"/><link rel="preload" href="../fonts/Inter-Regular.woff2" as="font" type="font/woff2"/><link rel="preload" href="../fonts/Inter-SemiBold.woff2" as="font" type="font/woff2"/><script type="text/javascript">
window.dataLayer = window.dataLayer || [];
window.authRequired = false;
window.serverAuthenticated = false;
              </script><title>Invest in biomedical companies | Public.com</title><meta name="description" content="Invest in biomedical companies leading the charge to cure existing and emerging diseases.  Public offers commission-free trading and much more."/><meta name="apple-itunes-app" content="app-id=1204112719, app-argument=https%3A%2F%2Fapp.public.com%2Fthemes%2Fb6a2f00a-f413-4d26-8993-b56ea7d40863"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="article"/><meta property="og:title" content="Invest in biomedical companies"/><meta property="og:description" content="Invest in biomedical companies leading the charge to cure existing and emerging diseases.  Public offers commission-free trading and much more."/><meta property="og:image" content="https://public.com/images/og/themes/b6a2f00a-f413-4d26-8993-b56ea7d40863-og.jpg"/><meta property="og:image:width" content="1200"/><meta property="og:image:height" content="630"/><meta property="og:url" content="https://public.com/themes/fighting-disease"/><meta property="og:site_name" content="Public"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:description" content="Invest in biomedical companies leading the charge to cure existing and emerging diseases.  Public offers commission-free trading and much more."/><meta name="twitter:title" content="Invest in biomedical companies"/><meta name="twitter:site" content="@public"/><meta name="twitter:image" content="https://public.com/images/og/themes/b6a2f00a-f413-4d26-8993-b56ea7d40863-og.jpg"/><meta name="twitter:creator" content="@public"/><meta name="next-head-count" content="23"/><link rel="shortcut icon" href="../images/icon.png" type="image/png"/><link rel="preconnect" href="https://universal.hellopublic.com"/><link rel="preload" href="../_next/static/css/c43ab53f090cc2ae.css" as="style"/><link rel="stylesheet" href="../_next/static/css/c43ab53f090cc2ae.css" data-n-g=""/><link rel="preload" href="../_next/static/css/40884651acce11a5.css" as="style"/><link rel="stylesheet" href="../_next/static/css/40884651acce11a5.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="../_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="../_next/static/chunks/webpack-d84e9e85696641b3.js" defer=""></script><script src="../_next/static/chunks/framework-663f14bc8ac481eb.js" defer=""></script><script src="../_next/static/chunks/main-0d98400d7b2443d6.js" defer=""></script><script src="../_next/static/chunks/pages/_app-5a93c16e44bac4d4.js" defer=""></script><script src="../_next/static/chunks/1664-402522dac0871a46.js" defer=""></script><script src="../_next/static/chunks/1454-e3bbb12c4afed291.js" defer=""></script><script src="../_next/static/chunks/6406-3c6ef6a539e8b36f.js" defer=""></script><script src="../_next/static/chunks/920-5a7e04ac7f09af58.js" defer=""></script><script src="../_next/static/chunks/3707-b59547e02bc13bd5.js" defer=""></script><script src="../_next/static/chunks/6840-c8dd281ccea41814.js" defer=""></script><script src="../_next/static/chunks/1078-fe444151edabcc74.js" defer=""></script><script src="../_next/static/chunks/1852-bf14fe5709c35c21.js" defer=""></script><script src="../_next/static/chunks/8594-1ae4967cb2d6f0bc.js" defer=""></script><script src="../_next/static/chunks/7921-ecd3d82cfbc6d484.js" defer=""></script><script src="../_next/static/chunks/1483-5bc66fa4289689c2.js" defer=""></script><script src="../_next/static/chunks/356-8f95f9f2befef946.js" defer=""></script><script src="../_next/static/chunks/5156-bde4371170e2a121.js" defer=""></script><script src="../_next/static/chunks/pages/themes/%5Bname%5D-71dfba377ecd2729.js" defer=""></script><script src="../_next/static/vtCYKp0Ai9E1UhSXnGgkP/_buildManifest.js" defer=""></script><script src="../_next/static/vtCYKp0Ai9E1UhSXnGgkP/_ssgManifest.js" defer=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PCBFC3K" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="__next"><style data-emotion="css 1eer4ip">.css-1eer4ip{background:linear-gradient(
            180deg,rgba(0,0,0,0.25) 0%,rgba(0,0,0,0.02) 100%
          );background-image:url(https://prod-api.154310543964.hellopublic.com/static/themes/images/j7tsYLk5nOprVqlmnjpe0nxuopq0DIO5.jpg);-webkit-background-position:center;background-position:center;background-repeat:repeat-x;-webkit-background-size:cover;background-size:cover;height:400px;}@media (min-width:760px){.css-1eer4ip{height:548px;}}</style><div class="css-1eer4ip"><style data-emotion="css 1v2pizs">.css-1v2pizs{background:transparent;}.css-1v2pizs a{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}.css-1v2pizs a >svg path{fill:var(--pw-core-color-greyscale-100);}</style><header class="css-1v2pizs"><style data-emotion="css 1kwkp96">.css-1kwkp96{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin:0 auto;padding:12px 16px;position:relative;-webkit-box-pack:justify;-webkit-justify-content:space-between;justify-content:space-between;width:100%;}.css-1kwkp96 a{display:inline-block;outline:none;}</style><div class="css-1kwkp96"><a role="button" href="../index.html" aria-label="home"><svg width="147" height="28" viewBox="0 0 126 24" fill="none"><path d="M83.5876 18.5712C83.9239 18.5731 84.2531 18.4756 84.5338 18.2908C84.8145 18.1061 85.034 17.8424 85.1646 17.5332C85.2952 17.224 85.331 16.8831 85.2676 16.5536C85.2041 16.2241 85.0442 15.9207 84.808 15.6819C84.5719 15.4431 84.2701 15.2794 83.9407 15.2117C83.6114 15.144 83.2694 15.1752 82.9579 15.3014C82.6463 15.4276 82.3793 15.6432 82.1904 15.9208C82.0016 16.1984 81.8995 16.5257 81.8969 16.8612C81.8952 17.0843 81.9377 17.3056 82.0218 17.5123C82.1058 17.7191 82.23 17.9073 82.387 18.0661C82.544 18.2249 82.7309 18.3512 82.9369 18.4379C83.1429 18.5246 83.3641 18.5699 83.5876 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M92.2184 18.6362C94.2124 18.6362 96.0122 17.6193 97.0964 15.758L95.3404 14.6761C95.0469 15.246 94.5992 15.7225 94.0481 16.0515C93.497 16.3805 92.8646 16.5488 92.2226 16.5373C90.4228 16.5373 88.9262 15.3465 88.9262 12.9874C88.9262 10.5434 90.5305 9.39635 92.2878 9.39635C93.4797 9.39635 94.4986 9.96209 95.3447 10.9762L96.9036 9.63396C95.9286 8.3356 94.2109 7.29748 92.2864 7.29748C89.5101 7.29748 86.7593 9.39635 86.7593 12.9874C86.7537 16.5373 89.4421 18.6362 92.2184 18.6362Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M112.795 9.15309L113.403 9.28321V7.36112H111.299V18.3109H113.533V11.5575C113.533 10.2365 114.356 9.28462 115.571 9.28462C116.763 9.28462 117.609 10.2365 117.609 11.5575V18.3081H119.756V11.5575C119.756 10.2365 120.606 9.28462 121.75 9.28462C122.894 9.28462 123.68 10.1502 123.68 11.5575V18.3081H126V11.4302C126 8.8985 124.441 7.18716 122.293 7.18716C120.926 7.18716 119.821 7.85755 119.033 8.93952C118.448 7.85755 117.364 7.18716 116.019 7.18716C115.351 7.18154 114.695 7.36273 114.125 7.7102C113.555 8.05767 113.094 8.55753 112.795 9.15309Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M103.559 7.18857C100.328 7.18857 97.856 9.5689 97.856 12.8799C97.856 16.1908 100.328 18.5712 103.559 18.5712C106.875 18.5712 109.152 16.1668 109.152 12.8799C109.152 9.59294 106.875 7.18857 103.559 7.18857ZM103.623 16.4723C101.585 16.4723 100.024 14.9165 100.024 12.8148C100.024 10.7131 101.583 9.28745 103.623 9.28745C105.531 9.28745 106.984 10.7159 106.984 12.8148C106.984 14.9137 105.531 16.4723 103.623 16.4723Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M74.828 18.5712C75.8186 18.5553 76.7879 18.2814 77.6398 17.7765C78.4917 17.2717 79.1966 16.5534 79.6847 15.693L78.0223 14.611C77.7188 15.1879 77.2592 15.6681 76.6958 15.9972C76.1323 16.3262 75.4876 16.4908 74.835 16.4723C73.1443 16.4723 71.6038 15.2163 71.6038 12.8799C71.6038 10.4133 73.1443 9.28745 74.835 9.28745C76.0935 9.28745 77.1125 9.80651 78.0223 10.8885L79.4976 9.5689C78.9838 8.8385 78.3025 8.24133 77.5103 7.82725C76.7182 7.41317 75.8384 7.19418 74.9442 7.18857C72.1254 7.18857 69.3491 9.28744 69.3491 12.8799C69.3491 16.4723 72.0531 18.5712 74.828 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M66.1987 5.43622C66.5357 5.43789 66.8657 5.33957 67.1467 5.15372C67.4276 4.96788 67.6469 4.7029 67.7767 4.39243C67.9065 4.08197 67.9409 3.74001 67.8755 3.41C67.8102 3.07998 67.648 2.77679 67.4097 2.53892C67.1713 2.30106 66.8675 2.13924 66.5368 2.07403C66.2062 2.00881 65.8635 2.04313 65.5524 2.17264C65.2413 2.30215 64.9758 2.521 64.7896 2.8014C64.6034 3.0818 64.5048 3.4111 64.5065 3.7475C64.5037 3.97005 64.5455 4.19093 64.6295 4.3971C64.7135 4.60327 64.8381 4.79057 64.9958 4.94795C65.1535 5.10534 65.3412 5.22962 65.5477 5.31348C65.7543 5.39733 65.9757 5.43907 66.1987 5.43622Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M67.2389 7.53508H65.0918V18.3109H67.2389V7.53508Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M62.2291 1.865H59.8879V18.3109H62.2291V1.865Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M52.5596 7.18857C50.934 7.18857 49.7408 7.85897 49.069 8.94094V1.86925H46.6839V18.3109H49.069V16.9475C49.7408 17.9644 50.934 18.5712 52.5596 18.5712C55.6774 18.5712 57.85 16.1668 57.85 12.8799C57.85 9.76408 55.5513 7.18857 52.5596 7.18857ZM52.3711 16.3662C50.2254 16.3662 48.7728 14.9165 48.7728 12.8827C48.7728 10.8913 50.2254 9.39918 52.3711 9.39918C54.3013 9.39918 55.6887 10.7838 55.6887 12.8827C55.6816 14.9137 54.2942 16.3662 52.3711 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M38.878 18.4623C40.0273 18.4623 40.9811 17.9644 41.6968 16.9475V18.3109H43.9303V7.53508H41.6316V13.7667C41.6316 15.3465 40.6778 16.3634 39.1161 16.3634C37.7938 16.3634 37.0781 15.2164 37.0781 13.7667V7.53508H34.7355V14.1344C34.7355 16.6491 36.2973 18.4623 38.878 18.4623Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M27.6028 7.18857C26.0438 7.18857 24.8491 7.85897 23.8727 8.94094V7.53508H21.5967V22.165H23.8727V16.9475C24.8491 17.9644 26.041 18.5712 27.6028 18.5712C30.7036 18.5712 32.9371 15.9957 32.9371 12.8799C32.9371 9.5689 30.7036 7.18857 27.6028 7.18857ZM27.2995 16.3662C25.0872 16.3662 23.765 14.9165 23.765 12.8827C23.765 10.8913 25.0872 9.39918 27.2995 9.39918C29.4026 9.39918 30.7007 10.8913 30.7007 12.8827C30.7036 14.9137 29.4026 16.3662 27.2995 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M7.19935 14.396C11.1754 14.396 14.3987 11.1734 14.3987 7.19802C14.3987 3.22266 11.1754 0 7.19935 0C3.22326 0 0 3.22266 0 7.19802C0 11.1734 3.22326 14.396 7.19935 14.396Z" fill="var(--pw-core-color-blue-600-day)"></path><path d="M3.59968 24C4.31066 24 5.00571 23.7895 5.59717 23.395C6.18863 23.0005 6.65002 22.4398 6.92312 21.7835C7.19622 21.1271 7.26882 20.4047 7.13176 19.7072C6.99469 19.0096 6.6541 18.3683 6.15294 17.8641C5.65178 17.3599 5.0125 17.0153 4.31573 16.8739C3.61897 16.7325 2.89592 16.8005 2.23778 17.0695C1.57964 17.3384 1.0159 17.7962 0.617646 18.385C0.219396 18.9739 0.00447861 19.6675 0 20.3783C0.000352998 21.3348 0.378999 22.2524 1.05334 22.9308C1.72769 23.6093 2.64302 23.9936 3.59968 24Z" fill="var(--pw-core-color-blue-600-day)"></path></svg></a><style data-emotion="css 1r3qwl0">.css-1r3qwl0{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;position:relative;}.css-1r3qwl0[data-white='true'] ul li a{color:var(--pw-core-color-greyscale-100);}.css-1r3qwl0[data-white='true'] ul li a:after{border-color:var(--pw-core-color-greyscale-100);}</style><nav data-white="true" class="css-1r3qwl0"><style data-emotion="css hhpoyy">.css-hhpoyy{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin:0;list-style:none;padding:0;}.css-hhpoyy li{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:none;height:100%;margin:0;padding:0;}@media (min-width:1200px){.css-hhpoyy li{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;}}.css-hhpoyy li a{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;color:var(--pw-core-color-greyscale-1000);cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;font:var(--font-body-1-heavy);outline:none;padding:0 8px;position:relative;-webkit-transition:color 0.25s ease-in,background 0.25s ease-in,opacity 0.25s ease-in;transition:color 0.25s ease-in,background 0.25s ease-in,opacity 0.25s ease-in;}.css-hhpoyy li a:hover{color:var(--pw-core-color-blue-600);}.css-hhpoyy li a:focus{-webkit-text-decoration:underline;text-decoration:underline;}@media (min-width:1280px){.css-hhpoyy li a{padding:0 12px;}}.css-hhpoyy li[data-has-more]{position:relative;}.css-hhpoyy li[data-has-more] >a{background:transparent;border:0;border-left:1px solid rgba(0,0,102,0.08);display:block;margin-left:12px;font-size:14px;padding-left:24px;padding-right:24px;}.css-hhpoyy li[data-has-more] >a:after{display:inline-block;padding:3px;content:'';-webkit-transform:rotate(45deg) translateX(-5px);-moz-transform:rotate(45deg) translateX(-5px);-ms-transform:rotate(45deg) translateX(-5px);transform:rotate(45deg) translateX(-5px);margin-left:10px;border:solid var(--pw-core-color-greyscale-1000);border-width:0 1px 1px 0;transform-origin:center;}.css-hhpoyy li[data-has-more]:hover div[data-has-more-options]{opacity:1;pointer-events:all;}.css-hhpoyy li[data-link-get-started] a,.css-hhpoyy li[data-link-login] a{border-radius:100px;box-sizing:border-box;cursor:pointer;height:41px;font:var(--font-body-1-heavy);line-height:1;outline:none;width:auto;}.css-hhpoyy li[data-link-get-started] a:focus,.css-hhpoyy li[data-link-login] a:focus{opacity:0.5;-webkit-text-decoration:none;text-decoration:none;}.css-hhpoyy li[data-link-login] a{background:hsla(0,0%,100%,0.3);-webkit-backdrop-filter:blur(8px);backdrop-filter:blur(8px);border:1px solid rgba(0,102,20,0.08);color:var(--pw-core-color-greyscale-1000);min-width:auto;-webkit-transition:border 0.25s ease;transition:border 0.25s ease;padding:12px 15px 13px;}.css-hhpoyy li[data-link-login] a:hover{border:1px solid #b5c4d7;-webkit-filter:brightness(100%);filter:brightness(100%);}.css-hhpoyy li[data-link-get-started]{display:none;}@media (min-width:1024px){.css-hhpoyy li[data-link-get-started]{display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;}}.css-hhpoyy li[data-link-get-started] a{background:var(--pw-core-color-blue-600);color:var(--pw-core-color-greyscale-100);margin-left:8px;padding:13px 17px 14px;-webkit-transition:color 0.25s ease-in,background 0.25s ease-in;transition:color 0.25s ease-in,background 0.25s ease-in;}.css-hhpoyy li[data-link-get-started] a:hover{background:var(--pw-core-color-blue-500);}</style><ul class="css-hhpoyy"><li><a href="../stocks.html" aria-label="Visit Stocks Page">Stocks</a></li><li><a href="../etfs.html" aria-label="Visit ETFs Page">ETFs</a></li><li><a href="../invest/crypto.html" aria-label="Visit Crypto Page">Crypto</a></li><li><a href="../high-yield-cash-account.html" aria-label="Visit High-Yield Cash Account Page">High-Yield Cash Account</a></li><li><a href="../invest/options.html" aria-label="Visit Options Page">Options</a></li><li><a href="../invest/bonds.html" aria-label="Visit Bonds Page">Bonds</a></li><li><a href="../invest/investment-plans.html" aria-label="Visit Investment Plans Page">Investment Plans</a></li><li><a href="../premium.html" aria-label="Visit Premium Page">Premium</a></li><li data-has-more="true"><a href="#" aria-label="More options">More</a><style data-emotion="css 1uh0nk3">.css-1uh0nk3{padding-top:55px;position:absolute;pointer-events:none;opacity:0;top:0;right:5px;}.css-1uh0nk3 ul{-webkit-backdrop-filter:blur(20px);backdrop-filter:blur(20px);background:hsla(0,0%,100%,0.3);border:1px solid var(--pw-core-color-greyscale-400);border-radius:32px;list-style:none;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;margin:0;padding:0;width:220px;}.css-1uh0nk3 ul li{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:start;-ms-flex-pack:start;-webkit-justify-content:flex-start;justify-content:flex-start;padding:0 13px;width:100%;}.css-1uh0nk3 ul li:first-of-type{padding:17px 13px 0 13px;}.css-1uh0nk3 ul li:last-of-type{padding:0 13px 17px 13px;}.css-1uh0nk3 ul li a{padding:13px 20px;border-radius:16px;font-size:16px;}</style><div data-has-more-options="true" class="css-1uh0nk3"><ul><li><a href="../about-us.html" aria-label="Visit About Us Page">About Us</a></li><li><a href="../learn.html" aria-label="Visit Learn Page">Learn</a></li><li><a href="https://help.public.com" aria-label="Visit Support Page">Support</a></li></ul></div></li><li data-link-login="true"><a href="../login.html" title="sign-in">Sign In</a></li><li data-link-get-started="true"><a href="../signup.html">Get Started</a></li></ul><style data-emotion="css 89vnpg">.css-89vnpg{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:transparent;border:none;cursor:pointer;height:40px;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;line-height:1;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;-webkit-transform:translateX(10px);-moz-transform:translateX(10px);-ms-transform:translateX(10px);transform:translateX(10px);width:40px;}@media (min-width:1200px){.css-89vnpg{display:none;}}.css-89vnpg span{height:2px;position:relative;width:20px;}.css-89vnpg span:before{background:var(--pw-core-color-greyscale-1000);content:'';display:block;height:2px;left:0;top:-4px;position:relative;width:20px;}.css-89vnpg span:after{background:var(--pw-core-color-greyscale-1000);content:'';display:block;height:2px;left:0;position:relative;top:4px;width:20px;}</style><button type="button" class="css-89vnpg"><span></span></button></nav></div></header></div><style data-emotion="css wk33vf">.css-wk33vf{background:var(--pw-core-color-greyscale-300);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-flex-flow:wrap;-webkit-flex-flow:wrap;-ms-flex-flow:wrap;flex-flow:wrap;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;padding:16px;}.css-wk33vf >main{-webkit-box-flex:1;-webkit-flex-grow:1;-ms-flex-positive:1;flex-grow:1;width:100%;}.css-wk33vf >aside{display:none;}@media (min-width:970px){.css-wk33vf{padding:40px 0;}.css-wk33vf >aside{display:block;margin-left:14px;}}</style><div class="css-wk33vf"><style data-emotion="css 1yx4e2y">.css-1yx4e2y{background:var(--pw-core-color-greyscale-100);border-radius:12px;box-sizing:border-box;padding:24px;}@media (min-width:760px){.css-1yx4e2y{max-width:705px;padding:32px 48px;}}</style><main class="css-1yx4e2y"><style data-emotion="css 14sw3qr">.css-14sw3qr{margin-bottom:80px;}.css-14sw3qr >*{margin:0;}.css-14sw3qr >*+*{margin-top:16px;}</style><article class="css-14sw3qr"><style data-emotion="css 1v53bec">.css-1v53bec{font:var(--font-hxl);}</style><h1 class="css-1v53bec">Fighting Disease</h1><style data-emotion="css 1ouyzbq">.css-1ouyzbq{font:var(--font-body-1-light);}</style><p class="css-1ouyzbq">As humans have evolved so has our capacity to fend off and prevent diseases that threaten our wellbeing. From existing diseases like cancer—which stands to affect nearly 40% of people at some point in their lifetimes—to viruses like COVID-19, public companies remain tireless in their pursuit for a cure. This theme includes disease-fighting public companies like Eli Lilly, Exelixis, Moderna, and Pfizer.</p><style data-emotion="css 1inldgf">.css-1inldgf{color:var(--pw-core-color-greyscale-600);font:var(--font-body-1-light);}</style><p class="css-1inldgf">31 stocks • 5 ETFs</p></article><style data-emotion="css ib9iq6">.css-ib9iq6{margin-top:80px;}</style><style data-emotion="css 1gwnpnb">.css-1gwnpnb{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;line-height:34px;margin-bottom:24px;position:relative;margin-top:80px;}.css-1gwnpnb >h2{color:var(--pw-core-color-greyscale-1000);font:var(--font-h1);margin:0;}</style><div class="css-1gwnpnb"><h2>Stocks</h2><style data-emotion="css 79elbk">.css-79elbk{position:relative;}</style><div style="margin-left:auto" class="css-79elbk"><style data-emotion="css y8qn1t">.css-y8qn1t{border-radius:12px;font:var(--font-body-1-heavy);outline:none;padding:2px 4px 2px 6px;}.css-y8qn1t:focus{background-color:var(--pw-core-color-greyscale-200);}</style><style data-emotion="css jjef33">.css-jjef33{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:none;border:0;color:var(--pw-core-color-greyscale-600);cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;margin:0;outline:none;padding:0;-webkit-transition:color 0.3s ease-in-out;transition:color 0.3s ease-in-out;border-radius:12px;font:var(--font-body-1-heavy);outline:none;padding:2px 4px 2px 6px;}.css-jjef33:disabled{cursor:not-allowed;opacity:0.3;}.css-jjef33:focus,.css-jjef33:hover{color:var(--pw-core-color-greyscale-1000);}.css-jjef33:focus{background-color:var(--pw-core-color-greyscale-200);}</style><button aria-label="Sort" class="css-jjef33">Sort by <style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="ArrowDownIcon" color="inherit" width="20" height="20" viewBox="0 0 24 24" class="css-107d1c9"><path d="M4.99976 9.03436C5.00391 9.09486 5.00341 9.11026 5.01371 9.17016C5.03696 9.30487 5.08801 9.43442 5.16301 9.54873C5.20091 9.60653 5.24502 9.65698 5.29207 9.70739L11.2923 15.7076C11.3367 15.749 11.3468 15.7606 11.3952 15.7973C11.4496 15.8386 11.5083 15.8743 11.57 15.9036C11.8395 16.0318 12.1594 16.0318 12.429 15.9036C12.4907 15.8743 12.5493 15.8386 12.6037 15.7973C12.6521 15.7606 12.6623 15.749 12.7066 15.7076L18.7068 9.70739C18.7482 9.66303 18.7598 9.65288 18.7965 9.60448C18.893 9.47738 18.9581 9.32737 18.9853 9.17016C19.0046 9.05791 19.0046 8.94255 18.9853 8.8303C18.9698 8.74054 18.942 8.65299 18.9029 8.57074C18.7543 8.25832 18.4461 8.04081 18.102 8.00541C17.966 7.99146 17.8275 8.00571 17.6972 8.04707C17.5886 8.08152 17.4862 8.13457 17.3955 8.20337C17.347 8.24012 17.3369 8.25167 17.2926 8.29308L11.9995 13.5862L6.70633 8.29308L6.65643 8.24647C6.60942 8.20822 6.59847 8.19732 6.54767 8.16402C6.45247 8.10157 6.34661 8.05557 6.23601 8.02861C6.1475 8.00706 6.0561 7.99766 5.9651 8.00076C5.61933 8.01256 5.29707 8.20857 5.12751 8.51009C5.07171 8.60934 5.03306 8.71809 5.01371 8.8303C5.00341 8.8902 5.00391 8.9056 4.99976 8.9661C4.99976 8.98886 4.99976 9.01161 4.99976 9.03436Z"></path></svg></button></div></div><style data-emotion="css xw6udu">.css-xw6udu >*+*{margin-top:8px;}</style><section role="list" class="css-xw6udu"><style data-emotion="css 1wazmh6">.css-1wazmh6{height:80px;}@media (min-width: 760px){.css-1wazmh6{height:100px;}}.css-1wazmh6 >div{border-radius:12px;}.css-1wazmh6:hover >div{background-color:var(--pw-core-color-greyscale-200);border:2px solid var(--pw-core-color-greyscale-200);}</style><style data-emotion="css 9iapl">.css-9iapl{cursor:pointer;height:80px;outline:none;height:80px;}@media (min-width: 760px){.css-9iapl{height:100px;}}.css-9iapl >div{background:var(--pw-core-color-greyscale-200);border-radius:16px;box-sizing:border-box;height:100%;position:relative;-webkit-transition:-webkit-transform 0.2s ease-in;transition:transform 0.2s ease-in;z-index:1;}.css-9iapl:focus >div{background-color:var(--pw-core-color-greyscale-100);box-shadow:var(--elevation-300);}@media (min-width:560px){.css-9iapl:hover >div{border:2px solid var(--pw-core-color-greyscale-100);-webkit-transform:scale(1.04);-moz-transform:scale(1.04);-ms-transform:scale(1.04);transform:scale(1.04);z-index:2;background-color:var(--pw-core-color-greyscale-100);box-shadow:var(--elevation-300);}}@media (min-width: 760px){.css-9iapl{height:100px;}}.css-9iapl >div{border-radius:12px;}.css-9iapl:hover >div{background-color:var(--pw-core-color-greyscale-200);border:2px solid var(--pw-core-color-greyscale-200);}</style><div role="listitem" tabindex="0" class="css-9iapl"><div><style data-emotion="css 15lcc24">.css-15lcc24{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-background-size:688px auto;background-size:688px auto;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;height:100%;padding:16px;}@media (min-width: 760px){.css-15lcc24{padding:18px 24px;}}</style><article class="css-15lcc24"><a aria-label="Adaptimmune Therapeutics" href="../stocks/adap.html"><style data-emotion="css qeujau">.css-qeujau{height:48px;position:relative;}@media (min-width: 760px){.css-qeujau{height:64px;}}</style><div class="css-qeujau"><style data-emotion="css 1atggoe">.css-1atggoe{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background:var(--pw-core-color-greyscale-100);border-radius:100%;box-shadow:none;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;height:48px;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;overflow:hidden;padding:0px;width:48px;}@media (min-width: 760px){.css-1atggoe{height:64px;padding:0px;width:64px;}}</style><div data-logo="true" class="css-1atggoe"><style data-emotion="css 1dan62f">.css-1dan62f{border-radius:100%;height:100%;width:100%;object-fit:cover;}</style><img alt="ADAP logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/ADAP@2x.png" class="css-1dan62f"/></div></div></a><style data-emotion="css 1w41jg1">.css-1w41jg1{margin:0 8px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;}@media (min-width: 760px){.css-1w41jg1{margin:0 24px;}}</style><div class="css-1w41jg1"><style data-emotion="css 112zfr1">.css-112zfr1{color:var(--pw-core-color-greyscale-1000);display:block;font:var(--font-body-1-heavy);margin:0 0 4px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;}@media (min-width: 760px){.css-112zfr1{font:var(--font-h3);}}</style><a href="../stocks/adap.html" class="css-112zfr1">Adaptimmune Therapeutics</a><style data-emotion="css 16ty995">.css-16ty995{color:var(--pw-core-color-greyscale-600);display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;font:var(--font-body-2-light);margin:4px 0 0;}@media (min-width: 760px){.css-16ty995{font:var(--font-body-1-light);}}</style><p class="css-16ty995">ADAP</p></div><style data-emotion="css zdpt2t">.css-zdpt2t{margin-left:auto;}</style><style data-emotion="css 1cjm6w8">.css-1cjm6w8{border-radius:100px;font:var(--font-body-1-heavy);height:48px;min-width:96px;padding:0 16px;color:var(--pw-core-color-green-600);-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background-color:var(--pw-core-color-greyscale-300);border:0;border-radius:100px;box-sizing:border-box;cursor:pointer;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;margin-left:auto;}.css-1cjm6w8:focus{background-color:var(--pw-core-color-green-200);}.css-1cjm6w8 >span{display:block;}.css-1cjm6w8:disabled{cursor:default;}</style><button class="css-1cjm6w8"><span>+14.59%</span><style data-emotion="css 39e5zc">.css-39e5zc{font:var(--font-body-3-heavy);opacity:0;position:absolute;top:2px;-webkit-transition:visibility 0.5s ease-in-out,opacity 0.5s ease-in-out;transition:visibility 0.5s ease-in-out,opacity 0.5s ease-in-out;visibility:hidden;}</style><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Syros Pharmaceuticals" href="../stocks/syrs.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="SYRS logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/SYRS@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/syrs.html" class="css-112zfr1">Syros Pharmaceuticals</a><p class="css-16ty995">SYRS</p></div><button class="css-1cjm6w8"><span>+2.56%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="AstraZeneca" href="../stocks/azn.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="AZN logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/AZN@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/azn.html" class="css-112zfr1">AstraZeneca</a><p class="css-16ty995">AZN</p></div><button class="css-1cjm6w8"><span>+0.93%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Eli Lilly" href="../stocks/lly.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="LLY logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/LLY@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/lly.html" class="css-112zfr1">Eli Lilly</a><p class="css-16ty995">LLY</p></div><button class="css-1cjm6w8"><span>+0.82%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Exact Sciences" href="../stocks/exas.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="EXAS logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/EXAS@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/exas.html" class="css-112zfr1">Exact Sciences</a><p class="css-16ty995">EXAS</p></div><button class="css-1cjm6w8"><span>+0.74%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Becton, Dickinson and Co." href="../stocks/bdx.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="BDX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/BDX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/bdx.html" class="css-112zfr1">Becton, Dickinson and Co.</a><p class="css-16ty995">BDX</p></div><button class="css-1cjm6w8"><span>+0.58%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Johnson &amp; Johnson" href="../stocks/jnj.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="JNJ logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/JNJ@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/jnj.html" class="css-112zfr1">Johnson &amp; Johnson</a><p class="css-16ty995">JNJ</p></div><button class="css-1cjm6w8"><span>+0.27%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Merck" href="../stocks/mrk.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="MRK logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/MRK@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/mrk.html" class="css-112zfr1">Merck</a><p class="css-16ty995">MRK</p></div><button class="css-1cjm6w8"><span>+0.16%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="AbbVie" href="../stocks/abbv.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="ABBV logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/ABBV@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/abbv.html" class="css-112zfr1">AbbVie</a><p class="css-16ty995">ABBV</p></div><button class="css-1cjm6w8"><span>+0.15%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="bluebird bio" href="../stocks/blue.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="BLUE logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/BLUE@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/blue.html" class="css-112zfr1">bluebird bio</a><p class="css-16ty995">BLUE</p></div></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Pfizer" href="../stocks/pfe.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="PFE logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/PFE@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/pfe.html" class="css-112zfr1">Pfizer</a><p class="css-16ty995">PFE</p></div><style data-emotion="css pt9qiw">.css-pt9qiw{border-radius:100px;font:var(--font-body-1-heavy);height:48px;min-width:96px;padding:0 16px;color:var(--pw-core-color-red-600);-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background-color:var(--pw-core-color-greyscale-300);border:0;border-radius:100px;box-sizing:border-box;cursor:pointer;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;margin-left:auto;}.css-pt9qiw:focus{background-color:var(--pw-core-color-red-100);}.css-pt9qiw >span{display:block;}.css-pt9qiw:disabled{cursor:default;}</style><button class="css-pt9qiw"><span>-0.04%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Sanofi" href="../stocks/sny.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="SNY logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/SNY@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/sny.html" class="css-112zfr1">Sanofi</a><p class="css-16ty995">SNY</p></div><button class="css-pt9qiw"><span>-0.06%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Bristol-Myers" href="../stocks/bmy.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="BMY logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/BMY@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/bmy.html" class="css-112zfr1">Bristol-Myers</a><p class="css-16ty995">BMY</p></div><button class="css-pt9qiw"><span>-0.08%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Abbott Labs" href="../stocks/abt.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="ABT logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/ABT@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/abt.html" class="css-112zfr1">Abbott Labs</a><p class="css-16ty995">ABT</p></div><button class="css-pt9qiw"><span>-0.15%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Amgen" href="../stocks/amgn.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="AMGN logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/AMGN@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/amgn.html" class="css-112zfr1">Amgen</a><p class="css-16ty995">AMGN</p></div><button class="css-pt9qiw"><span>-0.22%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Atara Biotherapeutics" href="../stocks/atra.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="ATRA logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/ATRA@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/atra.html" class="css-112zfr1">Atara Biotherapeutics</a><p class="css-16ty995">ATRA</p></div><button class="css-pt9qiw"><span>-0.25%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Incyte" href="../stocks/incy.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="INCY logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/INCY@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/incy.html" class="css-112zfr1">Incyte</a><p class="css-16ty995">INCY</p></div><button class="css-pt9qiw"><span>-0.28%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Gilead Sciences" href="../stocks/gild.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="GILD logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/GILD@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/gild.html" class="css-112zfr1">Gilead Sciences</a><p class="css-16ty995">GILD</p></div><button class="css-pt9qiw"><span>-0.32%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Novartis" href="../stocks/nvs.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="NVS logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/NVS@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/nvs.html" class="css-112zfr1">Novartis</a><p class="css-16ty995">NVS</p></div><button class="css-pt9qiw"><span>-0.43%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Takeda Pharmaceutical" href="../stocks/tak.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="TAK logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/TAK@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/tak.html" class="css-112zfr1">Takeda Pharmaceutical</a><p class="css-16ty995">TAK</p></div><button class="css-pt9qiw"><span>-0.54%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Exelixis" href="../stocks/exel.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="EXEL logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/EXEL@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/exel.html" class="css-112zfr1">Exelixis</a><p class="css-16ty995">EXEL</p></div><button class="css-pt9qiw"><span>-1.34%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Regeneron Pharmaceuticals" href="../stocks/regn.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="REGN logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/REGN@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/regn.html" class="css-112zfr1">Regeneron Pharmaceuticals</a><p class="css-16ty995">REGN</p></div><button class="css-pt9qiw"><span>-1.35%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Dynavax Technologies" href="../stocks/dvax.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="DVAX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/DVAX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/dvax.html" class="css-112zfr1">Dynavax Technologies</a><p class="css-16ty995">DVAX</p></div><button class="css-pt9qiw"><span>-1.67%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Nektar Therapeutics" href="../stocks/nktr.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="NKTR logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/NKTR@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/nktr.html" class="css-112zfr1">Nektar Therapeutics</a><p class="css-16ty995">NKTR</p></div><button class="css-pt9qiw"><span>-1.68%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Moderna" href="../stocks/mrna.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="MRNA logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/MRNA@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/mrna.html" class="css-112zfr1">Moderna</a><p class="css-16ty995">MRNA</p></div><button class="css-pt9qiw"><span>-1.90%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Agios Pharmaceuticals" href="../stocks/agio.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="AGIO logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/AGIO@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/agio.html" class="css-112zfr1">Agios Pharmaceuticals</a><p class="css-16ty995">AGIO</p></div><button class="css-pt9qiw"><span>-2.24%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Novavax" href="../stocks/nvax.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="NVAX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/NVAX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/nvax.html" class="css-112zfr1">Novavax</a><p class="css-16ty995">NVAX</p></div><button class="css-pt9qiw"><span>-2.55%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Vaxart" href="../stocks/vxrt.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="VXRT logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/VXRT@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/vxrt.html" class="css-112zfr1">Vaxart</a><p class="css-16ty995">VXRT</p></div><button class="css-pt9qiw"><span>-2.86%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Inovio Pharmaceuticals" href="../stocks/ino.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="INO logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/INO@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/ino.html" class="css-112zfr1">Inovio Pharmaceuticals</a><p class="css-16ty995">INO</p></div><button class="css-pt9qiw"><span>-3.21%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Karyopharm Therapeutics" href="../stocks/kpti.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="KPTI logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/KPTI@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/kpti.html" class="css-112zfr1">Karyopharm Therapeutics</a><p class="css-16ty995">KPTI</p></div><button class="css-pt9qiw"><span>-8.85%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Heat Biologics" href="../stocks/htbx.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="HTBX logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/HTBX@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/htbx.html" class="css-112zfr1">Heat Biologics</a><p class="css-16ty995">HTBX</p></div><button class="css-pt9qiw"><span>-46.97%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div></section><div class="css-1gwnpnb"><h2>ETFs</h2><div style="margin-left:auto" class="css-79elbk"><button aria-label="Sort" class="css-jjef33">Sort by <svg data-testid="ArrowDownIcon" color="inherit" width="20" height="20" viewBox="0 0 24 24" class="css-107d1c9"><path d="M4.99976 9.03436C5.00391 9.09486 5.00341 9.11026 5.01371 9.17016C5.03696 9.30487 5.08801 9.43442 5.16301 9.54873C5.20091 9.60653 5.24502 9.65698 5.29207 9.70739L11.2923 15.7076C11.3367 15.749 11.3468 15.7606 11.3952 15.7973C11.4496 15.8386 11.5083 15.8743 11.57 15.9036C11.8395 16.0318 12.1594 16.0318 12.429 15.9036C12.4907 15.8743 12.5493 15.8386 12.6037 15.7973C12.6521 15.7606 12.6623 15.749 12.7066 15.7076L18.7068 9.70739C18.7482 9.66303 18.7598 9.65288 18.7965 9.60448C18.893 9.47738 18.9581 9.32737 18.9853 9.17016C19.0046 9.05791 19.0046 8.94255 18.9853 8.8303C18.9698 8.74054 18.942 8.65299 18.9029 8.57074C18.7543 8.25832 18.4461 8.04081 18.102 8.00541C17.966 7.99146 17.8275 8.00571 17.6972 8.04707C17.5886 8.08152 17.4862 8.13457 17.3955 8.20337C17.347 8.24012 17.3369 8.25167 17.2926 8.29308L11.9995 13.5862L6.70633 8.29308L6.65643 8.24647C6.60942 8.20822 6.59847 8.19732 6.54767 8.16402C6.45247 8.10157 6.34661 8.05557 6.23601 8.02861C6.1475 8.00706 6.0561 7.99766 5.9651 8.00076C5.61933 8.01256 5.29707 8.20857 5.12751 8.51009C5.07171 8.60934 5.03306 8.71809 5.01371 8.8303C5.00341 8.8902 5.00391 8.9056 4.99976 8.9661C4.99976 8.98886 4.99976 9.01161 4.99976 9.03436Z"></path></svg></button></div></div><section role="list" class="css-xw6udu"><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Loncar Cancer Immunotherapy ETF" href="../stocks/cncr.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="CNCR logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/CNCR@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/cncr.html" class="css-112zfr1">Loncar Cancer Immunotherapy ETF</a><p class="css-16ty995">CNCR</p></div><button class="css-1cjm6w8"><span>+1.58%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Health Care Select Sector SPDR Fund" href="../stocks/xlv.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="XLV logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/XLV@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/xlv.html" class="css-112zfr1">Health Care Select Sector SPDR Fund</a><p class="css-16ty995">XLV</p></div><button class="css-pt9qiw"><span>-0.37%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="Vanguard Health Care ETF" href="../stocks/vht.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="VHT logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/VHT@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/vht.html" class="css-112zfr1">Vanguard Health Care ETF</a><p class="css-16ty995">VHT</p></div><button class="css-pt9qiw"><span>-0.50%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="SPDR S&amp;P Biotech ETF" href="../stocks/xbi.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="XBI logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/XBI@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/xbi.html" class="css-112zfr1">SPDR S&amp;P Biotech ETF</a><p class="css-16ty995">XBI</p></div><button class="css-pt9qiw"><span>-0.83%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div><div role="listitem" tabindex="0" class="css-9iapl"><div><article class="css-15lcc24"><a aria-label="iShares Genomics Immunology and Healthcare ETF" href="../stocks/idna.html"><div class="css-qeujau"><div data-logo="true" class="css-1atggoe"><img alt="IDNA logo" loading="lazy" src="https://universal.hellopublic.com/companyLogos/IDNA@2x.png" class="css-1dan62f"/></div></div></a><div class="css-1w41jg1"><a href="../stocks/idna.html" class="css-112zfr1">iShares Genomics Immunology and Healthcare ETF</a><p class="css-16ty995">IDNA</p></div><button class="css-pt9qiw"><span>-1.17%</span><span class="css-39e5zc">Daily (%)</span></button></article></div></div></section><style data-emotion="css 1jo5pir">.css-1jo5pir{color:var(--pw-core-color-greyscale-600);font-size:14px;line-height:20px;margin-top:40px;}</style><div class="css-1jo5pir">Note: This Public Theme is based on data from one or more third-party data providers. This Theme is provided for informational purposes only by Public Holdings, Inc., and is not investment advice or an investment recommendation. You should not buy or sell anything included in this Public Theme without first determining it is appropriate for your portfolio or investment strategy. Investors should consider the investment objectives and unique risk profile of an Exchange Traded Product (“ETP”) and read the ETP’s prospectus carefully before investing.</div><style data-emotion="css szycb">.css-szycb{margin-bottom:40px;margin-top:40px;}</style><style data-emotion="css 1wl8wdp">.css-1wl8wdp{background:url(../_next/static/images/da5b8d23f198d1d8917adc7b443dbd31-banner-sm-bg@2x.jpg);-webkit-background-position:center;background-position:center;-webkit-background-size:cover;background-size:cover;border-radius:24px;box-sizing:border-box;cursor:pointer;margin:16px 0;max-width:705px;overflow:hidden;padding:24px 22px;position:relative;margin-bottom:40px;margin-top:40px;}@media (min-width:400px){.css-1wl8wdp{background-image:url(../_next/static/images/392a1929885f9b9d6ad46e183be82ee0-banner-md-bg@2x.jpg);}}@media (min-width:560px){.css-1wl8wdp{padding:38px 38px 32px;}}@media (min-width: 760px){.css-1wl8wdp{display:none;}}</style><div class="css-1wl8wdp" role="button" tabindex="0"><svg width="105" height="20" viewBox="0 0 126 24" fill="none"><path d="M83.5876 18.5712C83.9239 18.5731 84.2531 18.4756 84.5338 18.2908C84.8145 18.1061 85.034 17.8424 85.1646 17.5332C85.2952 17.224 85.331 16.8831 85.2676 16.5536C85.2041 16.2241 85.0442 15.9207 84.808 15.6819C84.5719 15.4431 84.2701 15.2794 83.9407 15.2117C83.6114 15.144 83.2694 15.1752 82.9579 15.3014C82.6463 15.4276 82.3793 15.6432 82.1904 15.9208C82.0016 16.1984 81.8995 16.5257 81.8969 16.8612C81.8952 17.0843 81.9377 17.3056 82.0218 17.5123C82.1058 17.7191 82.23 17.9073 82.387 18.0661C82.544 18.2249 82.7309 18.3512 82.9369 18.4379C83.1429 18.5246 83.3641 18.5699 83.5876 18.5712Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M92.2184 18.6362C94.2124 18.6362 96.0122 17.6193 97.0964 15.758L95.3404 14.6761C95.0469 15.246 94.5992 15.7225 94.0481 16.0515C93.497 16.3805 92.8646 16.5488 92.2226 16.5373C90.4228 16.5373 88.9262 15.3465 88.9262 12.9874C88.9262 10.5434 90.5305 9.39635 92.2878 9.39635C93.4797 9.39635 94.4986 9.96209 95.3447 10.9762L96.9036 9.63396C95.9286 8.3356 94.2109 7.29748 92.2864 7.29748C89.5101 7.29748 86.7593 9.39635 86.7593 12.9874C86.7537 16.5373 89.4421 18.6362 92.2184 18.6362Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M112.795 9.15309L113.403 9.28321V7.36112H111.299V18.3109H113.533V11.5575C113.533 10.2365 114.356 9.28462 115.571 9.28462C116.763 9.28462 117.609 10.2365 117.609 11.5575V18.3081H119.756V11.5575C119.756 10.2365 120.606 9.28462 121.75 9.28462C122.894 9.28462 123.68 10.1502 123.68 11.5575V18.3081H126V11.4302C126 8.8985 124.441 7.18716 122.293 7.18716C120.926 7.18716 119.821 7.85755 119.033 8.93952C118.448 7.85755 117.364 7.18716 116.019 7.18716C115.351 7.18154 114.695 7.36273 114.125 7.7102C113.555 8.05767 113.094 8.55753 112.795 9.15309Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M103.559 7.18857C100.328 7.18857 97.856 9.5689 97.856 12.8799C97.856 16.1908 100.328 18.5712 103.559 18.5712C106.875 18.5712 109.152 16.1668 109.152 12.8799C109.152 9.59294 106.875 7.18857 103.559 7.18857ZM103.623 16.4723C101.585 16.4723 100.024 14.9165 100.024 12.8148C100.024 10.7131 101.583 9.28745 103.623 9.28745C105.531 9.28745 106.984 10.7159 106.984 12.8148C106.984 14.9137 105.531 16.4723 103.623 16.4723Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M74.828 18.5712C75.8186 18.5553 76.7879 18.2814 77.6398 17.7765C78.4917 17.2717 79.1966 16.5534 79.6847 15.693L78.0223 14.611C77.7188 15.1879 77.2592 15.6681 76.6958 15.9972C76.1323 16.3262 75.4876 16.4908 74.835 16.4723C73.1443 16.4723 71.6038 15.2163 71.6038 12.8799C71.6038 10.4133 73.1443 9.28745 74.835 9.28745C76.0935 9.28745 77.1125 9.80651 78.0223 10.8885L79.4976 9.5689C78.9838 8.8385 78.3025 8.24133 77.5103 7.82725C76.7182 7.41317 75.8384 7.19418 74.9442 7.18857C72.1254 7.18857 69.3491 9.28744 69.3491 12.8799C69.3491 16.4723 72.0531 18.5712 74.828 18.5712Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M66.1987 5.43622C66.5357 5.43789 66.8657 5.33957 67.1467 5.15372C67.4276 4.96788 67.6469 4.7029 67.7767 4.39243C67.9065 4.08197 67.9409 3.74001 67.8755 3.41C67.8102 3.07998 67.648 2.77679 67.4097 2.53892C67.1713 2.30106 66.8675 2.13924 66.5368 2.07403C66.2062 2.00881 65.8635 2.04313 65.5524 2.17264C65.2413 2.30215 64.9758 2.521 64.7896 2.8014C64.6034 3.0818 64.5048 3.4111 64.5065 3.7475C64.5037 3.97005 64.5455 4.19093 64.6295 4.3971C64.7135 4.60327 64.8381 4.79057 64.9958 4.94795C65.1535 5.10534 65.3412 5.22962 65.5477 5.31348C65.7543 5.39733 65.9757 5.43907 66.1987 5.43622Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M67.2389 7.53508H65.0918V18.3109H67.2389V7.53508Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M62.2291 1.865H59.8879V18.3109H62.2291V1.865Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M52.5596 7.18857C50.934 7.18857 49.7408 7.85897 49.069 8.94094V1.86925H46.6839V18.3109H49.069V16.9475C49.7408 17.9644 50.934 18.5712 52.5596 18.5712C55.6774 18.5712 57.85 16.1668 57.85 12.8799C57.85 9.76408 55.5513 7.18857 52.5596 7.18857ZM52.3711 16.3662C50.2254 16.3662 48.7728 14.9165 48.7728 12.8827C48.7728 10.8913 50.2254 9.39918 52.3711 9.39918C54.3013 9.39918 55.6887 10.7838 55.6887 12.8827C55.6816 14.9137 54.2942 16.3662 52.3711 16.3662Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M38.878 18.4623C40.0273 18.4623 40.9811 17.9644 41.6968 16.9475V18.3109H43.9303V7.53508H41.6316V13.7667C41.6316 15.3465 40.6778 16.3634 39.1161 16.3634C37.7938 16.3634 37.0781 15.2164 37.0781 13.7667V7.53508H34.7355V14.1344C34.7355 16.6491 36.2973 18.4623 38.878 18.4623Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M27.6028 7.18857C26.0438 7.18857 24.8491 7.85897 23.8727 8.94094V7.53508H21.5967V22.165H23.8727V16.9475C24.8491 17.9644 26.041 18.5712 27.6028 18.5712C30.7036 18.5712 32.9371 15.9957 32.9371 12.8799C32.9371 9.5689 30.7036 7.18857 27.6028 7.18857ZM27.2995 16.3662C25.0872 16.3662 23.765 14.9165 23.765 12.8827C23.765 10.8913 25.0872 9.39918 27.2995 9.39918C29.4026 9.39918 30.7007 10.8913 30.7007 12.8827C30.7036 14.9137 29.4026 16.3662 27.2995 16.3662Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M7.19935 14.396C11.1754 14.396 14.3987 11.1734 14.3987 7.19802C14.3987 3.22266 11.1754 0 7.19935 0C3.22326 0 0 3.22266 0 7.19802C0 11.1734 3.22326 14.396 7.19935 14.396Z" fill="var(--pw-core-color-greyscale-100)"></path><path d="M3.59968 24C4.31066 24 5.00571 23.7895 5.59717 23.395C6.18863 23.0005 6.65002 22.4398 6.92312 21.7835C7.19622 21.1271 7.26882 20.4047 7.13176 19.7072C6.99469 19.0096 6.6541 18.3683 6.15294 17.8641C5.65178 17.3599 5.0125 17.0153 4.31573 16.8739C3.61897 16.7325 2.89592 16.8005 2.23778 17.0695C1.57964 17.3384 1.0159 17.7962 0.617646 18.385C0.219396 18.9739 0.00447861 19.6675 0 20.3783C0.000352998 21.3348 0.378999 22.2524 1.05334 22.9308C1.72769 23.6093 2.64302 23.9936 3.59968 24Z" fill="var(--pw-core-color-greyscale-100)"></path></svg><style data-emotion="css 6929f2">.css-6929f2{color:var(--pw-core-color-greyscale-100);font-size:23px;font-weight:600;line-height:120%;margin:15px 0;max-width:254px;}@media (min-width:560px){.css-6929f2{font-size:24px;}}</style><div class="css-6929f2">Own your future.<br/>Build your portfolio.</div><style data-emotion="css shxu4o">.css-shxu4o{background:rgba(255,255,255,0.2);-webkit-backdrop-filter:blur(54px);backdrop-filter:blur(54px);color:var(--pw-core-color-greyscale-100);}</style><style data-emotion="css wzufl6">.css-wzufl6{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;border:0;border-radius:100px;box-sizing:border-box;-webkit-column-gap:4px;column-gap:4px;cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;background-color:var(--pw-core-color-blue-600);color:var(--pw-core-color-greyscale-100);--button-icon-size:12px;--button-icon-margin:-4px;font:var(--font-body-1-heavy);height:48px;min-width:92px;padding:0 22px;background:rgba(255,255,255,0.2);-webkit-backdrop-filter:blur(54px);backdrop-filter:blur(54px);color:var(--pw-core-color-greyscale-100);}.css-wzufl6:disabled,.css-wzufl6:disabled:hover{cursor:default;}.css-wzufl6 svg{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;height:var(--button-icon-size);width:var(--button-icon-size);}.css-wzufl6:focus,.css-wzufl6:hover{-webkit-filter:brightness(90%);filter:brightness(90%);}.css-wzufl6:disabled,.css-wzufl6:disabled:hover{background-color:var(--pw-core-color-greyscale-200);color:var(--pw-core-color-greyscale-400);-webkit-filter:none;filter:none;}</style><button class="css-wzufl6"><style data-emotion="css k008qs">.css-k008qs{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;}</style><span class="css-k008qs">Download the app</span><style data-emotion="css 9whvzf">.css-9whvzf{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-right:var(--button-icon-margin);opacity:1;}</style><span class="css-9whvzf"><svg data-testid="ArrowRightIcon" color="inherit" width="18" height="18" viewBox="0 0 24 24" class="css-107d1c9"><path d="M9.03414 19C9.09465 18.9958 9.11005 18.9964 9.16995 18.986C9.30466 18.9628 9.43421 18.9117 9.54852 18.8367C9.60632 18.7988 9.65677 18.7547 9.70717 18.7077L15.7074 12.7074C15.7488 12.6631 15.7604 12.653 15.7971 12.6045C15.8384 12.5501 15.874 12.4915 15.9034 12.4298C16.0316 12.1602 16.0316 11.8403 15.9034 11.5708C15.874 11.5091 15.8384 11.4504 15.7971 11.396C15.7604 11.3476 15.7488 11.3375 15.7074 11.2932L9.70717 5.29291C9.66282 5.25151 9.65267 5.23991 9.60427 5.20321C9.47716 5.10675 9.32716 5.04165 9.16995 5.0145C9.05769 4.9952 8.94234 4.9952 8.83008 5.0145C8.74033 5.03 8.65278 5.0578 8.57052 5.0969C8.25811 5.24546 8.0406 5.55362 8.0052 5.89774C7.99125 6.03374 8.0055 6.17225 8.04685 6.30256C8.0813 6.41111 8.13436 6.51356 8.20316 6.60427C8.23991 6.65272 8.25146 6.66282 8.29286 6.70717L13.586 12.0003L8.29286 17.2934L8.24626 17.3433C8.20801 17.3903 8.19711 17.4013 8.16381 17.4521C8.10135 17.5473 8.05535 17.6531 8.0284 17.7637C8.00685 17.8523 7.99745 17.9437 8.00055 18.0347C8.01235 18.3804 8.20836 18.7027 8.50987 18.8722C8.60913 18.928 8.71788 18.9667 8.83008 18.986C8.88999 18.9964 8.90539 18.9958 8.96589 19C8.98864 19 9.01139 19 9.03414 19Z"></path></svg></span></button><style data-emotion="css w9zmaf">.css-w9zmaf{display:none;height:192px;object-fit:cover;position:absolute;right:35px;top:18px;width:161px;}@media (min-width:690px){.css-w9zmaf{display:block;}}</style><img src="../_next/static/images/debd9660fbcf4bf5a0916e732dee6367-banner-md-glass@2x.png" width="auto" height="192" alt="" class="css-w9zmaf"/></div></main><aside><style data-emotion="css 1p0dr8w">.css-1p0dr8w{max-width:336px;}</style><div class="css-1p0dr8w"><style data-emotion="css zhxjkv">.css-zhxjkv{background:url(../_next/static/images/e69520615a1a5fbde2a654bb84f49523-all-assets@2x.jpeg);border-radius:12px;-webkit-background-size:100% auto;background-size:100% auto;box-sizing:border-box;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;height:214px;padding:0 16px 38px 0;width:100%;}</style><div class="css-zhxjkv"></div><style data-emotion="css dsd0po">.css-dsd0po{background:var(--pw-core-color-greyscale-100);border-radius:12px;box-sizing:border-box;margin-top:-22px;padding:24px 24px 32px;}</style><div class="css-dsd0po"><style data-emotion="css jg2kwt">.css-jg2kwt{font:var(--font-h2);margin:0 0 20px 0;}</style><h2 class="css-jg2kwt">Invest in everything on Public</h2><style data-emotion="css wy151o">.css-wy151o{font:var(--font-body-1-light);margin-bottom:20px;}</style><div class="css-wy151o">Public is an all-in-one investing platform where you can build a multi-asset portfolio that includes everything from stocks and options to bonds, crypto, and a High-Yield Cash Account.</div><style data-emotion="css 8bz49y">.css-8bz49y{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;border:0;border-radius:100px;box-sizing:border-box;-webkit-column-gap:4px;column-gap:4px;cursor:pointer;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;outline:none;position:relative;display:-webkit-inline-box;display:-webkit-inline-flex;display:-ms-inline-flexbox;display:inline-flex;width:100%;background-color:var(--pw-core-color-blue-600);color:var(--pw-core-color-greyscale-100);--button-icon-size:12px;--button-icon-margin:-4px;font:var(--font-body-1-heavy);height:48px;min-width:92px;padding:0 22px;}.css-8bz49y:disabled,.css-8bz49y:disabled:hover{cursor:default;}.css-8bz49y svg{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;height:var(--button-icon-size);width:var(--button-icon-size);}.css-8bz49y:focus,.css-8bz49y:hover{-webkit-filter:brightness(90%);filter:brightness(90%);}.css-8bz49y:disabled,.css-8bz49y:disabled:hover{background-color:var(--pw-core-color-greyscale-200);color:var(--pw-core-color-greyscale-400);-webkit-filter:none;filter:none;}</style><a class="css-8bz49y" href="../signup.html"><span class="css-k008qs">Sign Up</span></a></div></div></aside></div><footer class="page-footer_footer__hDjNG"><div class="page-footer_footerContainer__p7Hox"><div class="page-footer_topContainer__umRXr"><div><div class="page-footer_navTitle__yziUh">Products</div><ul><li><a href="../stocks.html">Stocks</a></li><li><a href="../etfs.html">ETFs</a></li><li><a href="../invest/crypto.html">Crypto<!-- --> <span class="page-footer_bakkt__DKEFk">Offered by Bakkt Crypto</span></a></li><li><a href="../invest/options.html">Options</a></li><li><a href="../invest/bonds.html">Bonds</a></li><li><a href="../invest/treasuries.html">Treasuries</a></li><li><a href="../high-yield-cash-account.html">High-Yield Cash Account</a></li><li><a href="../premium.html">Premium</a></li><li><a href="../alpha.html">Alpha</a></li></ul></div><div><div class="page-footer_navTitle__yziUh">Resources</div><ul><li><a href="../about-us.html">About Us</a></li><li><a href="../learn.html">Learn</a></li><li><a href="../careers.html">Careers</a></li><li><a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf">Fee Schedule</a></li></ul></div><div><div class="page-footer_navTitle__yziUh">Quick Links</div><ul><li><a href="../themes.html">Investment Themes</a></li><li><a href="../glossary/investing.html">Investing Glossary</a></li><li><a href="../transfer-account.html">Transfer your Portfolio</a></li><li><a href="../live.html">Public Live</a></li><li><a href="../talks.html">Public Talks</a></li><li><a href="../treasury-yield-curve.html">Treasury Yield Curve</a></li><li><a href="../tools/high-yield-savings-calculator.html">High Yield Savings Calculator</a></li></ul></div><div><div class="page-footer_navTitle__yziUh">Contact Us</div><ul><li><a href="https://help.public.com/en">Help &amp; Support</a></li><li><a href="mailto:support@public.com">support@public.com</a></li><li><a href="mailto:press@public.com">press@public.com</a></li></ul><div class="page-footer_social__w0kqZ"><ul><li><a href="https://twitter.com/public" target="_blank" rel="noopener noreferrer nofollow" aria-label="Twitter"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="TwitterIcon" color="inherit" aria-label="Twitter" width="28" height="28" viewBox="0 0 24 24" class="css-107d1c9"><path d="M21.4568 5.53571C20.7408 5.87054 19.963 6.11161 19.1605 6.20536C19.9877 5.66964 20.6173 4.82589 20.9136 3.82143C20.1482 4.31696 19.284 4.67857 18.3827 4.86607C17.6543 4.02232 16.6173 3.5 15.4692 3.5C13.2593 3.5 11.4815 5.44196 11.4815 7.82589C11.4815 8.16071 11.5185 8.49554 11.5803 8.81696C8.27161 8.62946 5.32099 6.91518 3.35803 4.29018C3.01235 4.93304 2.81482 5.66964 2.81482 6.47321C2.81482 7.97321 3.51852 9.29911 4.5926 10.0759C3.93827 10.0491 3.32099 9.84821 2.79012 9.52679C2.79012 9.54018 2.79012 9.56696 2.79012 9.58036C2.79012 11.683 4.1605 13.4241 5.98766 13.8259C5.65433 13.9196 5.2963 13.9732 4.93828 13.9732C4.67902 13.9732 4.4321 13.9464 4.18519 13.9062C4.69136 15.6205 6.1605 16.8661 7.91359 16.9062C6.54322 18.0714 4.82716 18.7545 2.96296 18.7545C2.62963 18.7545 2.32099 18.7411 2 18.7009C3.76543 19.933 5.8642 20.6429 8.12346 20.6429C15.4568 20.6429 19.4692 14.0536 19.4692 8.33482C19.4692 8.14732 19.4692 7.95982 19.4568 7.77232C20.2346 7.15625 20.9136 6.39286 21.4568 5.53571Z"></path></svg></a></li><li><a href="https://www.instagram.com/publicapp" target="_blank" rel="noopener noreferrer nofollow" aria-label="Instagram"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="InstagramIcon" color="inherit" aria-label="Instagram" width="28" height="28" viewBox="0 0 28 28" class="css-107d1c9"><path fill-rule="evenodd" clip-rule="evenodd" d="M14 18.6667C16.5773 18.6667 18.6667 16.5773 18.6667 14C18.6667 11.4227 16.5773 9.33333 14 9.33333C11.4227 9.33333 9.33333 11.4227 9.33333 14C9.33333 16.5773 11.4227 18.6667 14 18.6667ZM14 16.9167C15.6108 16.9167 16.9167 15.6108 16.9167 14C16.9167 12.3892 15.6108 11.0833 14 11.0833C12.3892 11.0833 11.0833 12.3892 11.0833 14C11.0833 15.6108 12.3892 16.9167 14 16.9167Z"></path><path d="M19.8333 9.33333C20.4777 9.33333 21 8.811 21 8.16667C21 7.52233 20.4777 7 19.8333 7C19.189 7 18.6667 7.52233 18.6667 8.16667C18.6667 8.811 19.189 9.33333 19.8333 9.33333Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M7 3.5C5.067 3.5 3.5 5.067 3.5 7V21C3.5 22.933 5.067 24.5 7 24.5H21C22.933 24.5 24.5 22.933 24.5 21V7C24.5 5.067 22.933 3.5 21 3.5H7ZM21 5.25H7C6.0335 5.25 5.25 6.0335 5.25 7V21C5.25 21.9665 6.0335 22.75 7 22.75H21C21.9665 22.75 22.75 21.9665 22.75 21V7C22.75 6.0335 21.9665 5.25 21 5.25Z"></path></svg></a></li><li><a href="https://www.facebook.com/PublicHello" target="_blank" rel="noopener noreferrer nofollow" aria-label="Facebook"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="FacebookIcon" color="inherit" aria-label="Facebook" width="28" height="28" viewBox="0 0 24 24" class="css-107d1c9"><path d="M16 3C16 3 15.75 3 14.6667 3C12.2708 3 10.6563 4.38616 10.6667 6.85714V9.42856H8V12H10.6563L10.6667 21H13.3333V12H15.6L16 9.42856H13.3333V7.21875C13.3333 5.57143 14.0956 5.57143 15.3646 5.57143H16V3Z"></path></svg></a></li><li><a href="https://www.linkedin.com/company/publichello" target="_blank" rel="noopener noreferrer nofollow" aria-label="LinkedIn"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="LinkedInIcon" color="inherit" width="28" height="28" viewBox="0 0 24 24" class="css-107d1c9"><path fill-rule="evenodd" clip-rule="evenodd" d="M7.04328 8.52936H3.22571V19.9996H7.04328V8.52936Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M7.29475 4.98125C7.26997 3.8566 6.46573 3 5.15976 3C3.8538 3 3 3.8566 3 4.98125C3 6.0826 3.82856 6.96387 5.11021 6.96387H5.13461C6.46573 6.96387 7.29475 6.0826 7.29475 4.98125Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M20.811 13.423C20.811 9.89984 18.9277 8.2601 16.4156 8.2601C14.3887 8.2601 13.4812 9.37341 12.9745 10.1544V8.52975H9.15649C9.20681 9.60606 9.15649 20 9.15649 20H12.9745V13.5941C12.9745 13.2512 12.9993 12.9093 13.1002 12.6638C13.3762 11.979 14.0044 11.2699 15.059 11.2699C16.441 11.2699 16.9934 12.3217 16.9934 13.8631V19.9997H20.8109L20.811 13.423Z"></path></svg></a></li><li><a href="https://medium.com/the-public-blog/" target="_blank" rel="noopener noreferrer nofollow" aria-label="Blog"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="BlogIcon" color="inherit" viewBox="0 0 1043.63 592.71" width="28" height="28" class="css-107d1c9"><g><path d="M588.67 296.36c0 163.67-131.78 296.35-294.33 296.35S0 460 0 296.36 131.78 0 294.34 0s294.33 132.69 294.33 296.36"></path><path d="M911.56 296.36c0 154.06-65.89 279-147.17 279s-147.17-124.94-147.17-279 65.88-279 147.16-279 147.17 124.9 147.17 279"></path><path d="M1043.63 296.36c0 138-23.17 249.94-51.76 249.94s-51.75-111.91-51.75-249.94 23.17-249.94 51.75-249.94 51.76 111.9 51.76 249.94"></path></g></svg></a></li><li><a href="https://www.tiktok.com/@public" target="_blank" rel="noopener noreferrer nofollow" aria-label="TikTok"><style data-emotion="css 107d1c9">.css-107d1c9{fill:currentColor;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;}</style><svg data-testid="TikTokIcon" color="inherit" width="22" height="22" viewBox="0 0 22 22" class="css-107d1c9"><path d="M15.6495 0H11.9418V14.9855C11.9418 16.771 10.5158 18.2377 8.74125 18.2377C6.96665 18.2377 5.54064 16.771 5.54064 14.9855C5.54064 13.2319 6.93496 11.7971 8.6462 11.7333V7.97103C4.87517 8.03477 1.83301 11.1275 1.83301 14.9855C1.83301 18.8754 4.93854 22 8.77295 22C12.6073 22 15.7128 18.8435 15.7128 14.9855V7.30143C17.1072 8.32174 18.8184 8.92754 20.6247 8.95944V5.1971C17.8361 5.10145 15.6495 2.80579 15.6495 0Z"></path></svg></a></li></ul></div><ul class="page-footer_appStore__WCUf_"><li><a href="https://public.sng.link/Ag0a8/f14v?_ios_dl=matador%3A%2F%2F&amp;_android_dl=public%3A%2F%2F&amp;_smtype=3" target="_blank" rel="noopener noreferrer nofollow" aria-label="App Store"><svg width="144" height="49" viewBox="0 0 165 56" fill="none" aria-label="App Store"><path d="M151.806 0.000179188H13.1423C12.6369 0.000179188 12.1375 0.000179188 11.6334 0.00293592C11.2114 0.00569266 10.7927 0.013701 10.3667 0.0204412C9.44115 0.0313328 8.51777 0.112759 7.60459 0.264013C6.6927 0.418559 5.80937 0.709923 4.98448 1.12825C4.1606 1.55012 3.4078 2.09829 2.75339 2.75288C2.09554 3.40563 1.54717 4.16012 1.12937 4.98734C0.710411 5.81291 0.419907 6.69758 0.267886 7.61081C0.11442 8.52288 0.0318381 9.44548 0.0208823 10.3703C0.00809102 10.7929 0.00674022 11.2169 0 11.6396V43.4995C0.00674022 43.9275 0.00809102 44.3421 0.0208823 44.7703C0.0318414 45.695 0.114423 46.6176 0.267886 47.5296C0.419487 48.4434 0.710009 49.3286 1.12937 50.1544C1.54698 50.979 2.09542 51.7304 2.75339 52.3795C3.40532 53.037 4.15861 53.5856 4.98448 54.0042C5.80936 54.4237 6.6926 54.7168 7.60459 54.8737C8.51793 55.0237 9.44121 55.1052 10.3667 55.1174C10.7927 55.1268 11.2114 55.1321 11.6334 55.1321C12.1375 55.1349 12.6369 55.1349 13.1423 55.1349H151.806C152.302 55.1349 152.805 55.1349 153.3 55.1321C153.72 55.1321 154.151 55.1268 154.571 55.1174C155.495 55.1059 156.416 55.0244 157.328 54.8737C158.243 54.7157 159.129 54.4226 159.958 54.0042C160.783 53.5853 161.536 53.0368 162.187 52.3795C162.843 51.7279 163.393 50.977 163.816 50.1544C164.232 49.328 164.52 48.4428 164.669 47.5296C164.823 46.6175 164.908 45.6951 164.925 44.7703C164.93 44.3421 164.93 43.9275 164.93 43.4995C164.941 42.9988 164.941 42.5008 164.941 41.9919V13.1445C164.941 12.6397 164.941 12.139 164.93 11.6396C164.93 11.2169 164.93 10.7929 164.925 10.3702C164.908 9.44534 164.823 8.52295 164.669 7.61076C164.519 6.69806 164.232 5.81345 163.816 4.98728C162.965 3.32921 161.616 1.97955 159.958 1.12813C159.129 0.710821 158.243 0.419534 157.328 0.263889C156.417 0.111969 155.495 0.030514 154.571 0.0202482C154.151 0.0135218 153.72 0.00544455 153.3 0.00275674C152.805 0 152.302 0 151.806 0V0.000179188Z" fill="white"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M102.936 40.0773C100.683 40.0773 99.0336 38.9628 98.8438 37.2654L96.2216 37.2653C96.3872 40.3613 98.9501 42.3198 102.746 42.3198C106.803 42.3198 109.353 40.3142 109.353 37.1119C109.353 34.6082 107.895 33.1975 104.383 32.367L102.497 31.904C100.291 31.3589 99.389 30.6468 99.389 29.4367C99.389 27.9183 100.801 26.8751 102.864 26.8751C104.928 26.8751 106.34 27.9062 106.495 29.6143H109.081C108.997 26.6611 106.518 24.6326 102.9 24.6326C99.2463 24.6326 96.6726 26.6611 96.6726 29.6143C96.6726 31.9996 98.1318 33.4695 101.275 34.2287L103.493 34.7631C105.711 35.3082 106.648 36.1037 106.648 37.4323C106.648 38.9628 105.095 40.0773 102.936 40.0773ZM58.3107 37.408H51.7863L50.2195 42.0344H47.4561L53.6358 24.9178H56.507L62.6867 42.0344H59.8762L58.3107 37.408ZM52.4639 35.2747H57.6355L55.086 27.7664H55.0146L52.4639 35.2747ZM70.8268 42.164C73.9591 42.164 76.0347 39.6725 76.0347 35.7944C76.0347 31.9272 73.9469 29.4235 70.7796 29.4235C69.1499 29.371 67.6231 30.2186 66.806 31.6297H66.7589V29.5541H64.2795V46.1618H66.841V39.9807H66.9003C67.6827 41.4007 69.2077 42.2487 70.8268 42.164ZM73.4025 35.7948C73.4025 33.2682 72.0968 31.6072 70.1047 31.6072C68.1475 31.6072 66.8311 33.3032 66.8311 35.7948C66.8311 38.3092 68.1475 39.9932 70.1047 39.9932C72.0969 39.9932 73.4025 38.3442 73.4025 35.7948H73.4025ZM84.5584 42.164C87.6907 42.164 89.767 39.6725 89.767 35.7944C89.767 31.9272 87.6786 29.4235 84.5113 29.4235C82.8815 29.371 81.3548 30.2186 80.5377 31.6297H80.4906V29.5541H78.0112V46.1618H80.5727V39.9807H80.632C81.4143 41.4007 82.9394 42.2487 84.5584 42.164ZM87.133 35.7945C87.133 33.268 85.8273 31.6069 83.8351 31.6069C81.878 31.6069 80.5615 33.3029 80.5615 35.7945C80.5615 38.309 81.878 39.9929 83.8351 39.9929C85.8273 39.9929 87.133 38.344 87.133 35.7945ZM114.883 26.6035V29.5568H117.256V31.5853H114.883V38.465C114.883 39.5338 115.358 40.0318 116.401 40.0318C116.683 40.0269 116.964 40.0071 117.244 39.9726V41.989C116.775 42.0766 116.298 42.1163 115.821 42.1074C113.294 42.1074 112.309 41.1584 112.309 38.7382V31.5853H110.495V29.5568H112.309V26.6035H114.883ZM124.55 29.4021C120.944 29.4021 118.632 31.8694 118.632 35.7959C118.632 39.7331 120.921 42.1897 124.55 42.1897C128.181 42.1897 130.47 39.7331 130.47 35.7959C130.47 31.8694 128.169 29.4021 124.55 29.4021ZM127.862 35.7972C127.862 33.1038 126.628 31.5141 124.552 31.5141C122.476 31.5141 121.242 33.1159 121.242 35.7972C121.242 38.5015 122.476 40.0791 124.552 40.0791C126.628 40.0791 127.862 38.5015 127.862 35.7972ZM135.024 29.5544H132.581L132.581 42.0337H135.143V34.6317C135.057 33.8829 135.304 33.1342 135.817 32.5822C136.33 32.0302 137.059 31.73 137.812 31.7606C138.201 31.7492 138.59 31.8015 138.963 31.9154V29.5194C138.675 29.4548 138.38 29.4228 138.085 29.4238C136.677 29.3701 135.424 30.3111 135.083 31.6785H135.024V29.5544ZM150.776 38.3696C150.431 40.635 148.225 42.1897 145.402 42.1897C141.772 42.1897 139.519 39.7574 139.519 35.8551C139.519 31.9408 141.784 29.4021 145.295 29.4021C148.747 29.4021 150.918 31.7739 150.918 35.5576V36.4353H142.104V36.5901C142.022 37.5191 142.343 38.4388 142.985 39.1151C143.627 39.7914 144.529 40.1591 145.461 40.1248C146.704 40.2413 147.876 39.5275 148.343 38.3696L150.776 38.3696ZM148.355 34.6443H142.116C142.114 33.8018 142.449 32.9932 143.045 32.3985C143.642 31.8037 144.452 31.472 145.294 31.477C146.13 31.4591 146.936 31.7906 147.517 32.3919C148.098 32.9931 148.402 33.8095 148.355 34.6443Z" fill="black"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M81.4541 11.6311H82.679V20.2607H81.4541V11.6311ZM55.0418 13.1626C54.2922 12.371 53.2271 11.9573 52.1396 12.0353H49.1689V20.2598H52.1396C54.5894 20.2598 56.0095 18.7495 56.0095 16.1219C56.1466 15.0403 55.7915 13.9543 55.0418 13.1626ZM52.0009 19.0977H50.4502V13.1986H52.0009C52.7739 13.1557 53.5256 13.4605 54.0505 14.0296C54.5754 14.5988 54.8184 15.3727 54.7132 16.1397C54.8267 16.9099 54.5871 17.6903 54.0609 18.2641C53.5347 18.838 52.778 19.1441 52.0009 19.0977ZM57.4514 17.1558C57.3449 16.0433 57.8784 14.9666 58.828 14.3773C59.7776 13.7881 60.9792 13.7881 61.9288 14.3773C62.8784 14.9666 63.4118 16.0433 63.3054 17.1558C63.4138 18.2695 62.8809 19.3482 61.9304 19.9388C60.98 20.5293 59.7768 20.5293 58.8263 19.9388C57.8759 19.3482 57.3429 18.2695 57.4514 17.1558ZM60.3795 15.0227C61.4402 15.0227 62.0446 15.8095 62.0446 17.1549H62.0446C62.0446 18.5056 61.4402 19.2917 60.3795 19.2917C59.3148 19.2917 58.7158 18.511 58.7158 17.1549C58.7158 15.8095 59.3148 15.0227 60.3795 15.0227ZM71.0864 20.2606H69.8158L68.533 15.6894H68.4361L67.1586 20.2606H65.9001L64.1892 14.0539H65.4316L66.5435 18.79H66.635L67.9111 14.0539H69.0862L70.3623 18.79H70.4592L71.5656 14.0539H72.7906L71.0864 20.2606ZM75.4106 14.0539H74.2315L74.2314 20.2606H75.4564V16.6296C75.4124 16.2166 75.551 15.8049 75.8359 15.5026C76.1208 15.2003 76.5234 15.0374 76.9384 15.0567C77.8443 15.0567 78.2777 15.5528 78.2777 16.5502V20.2606H79.5026V16.2426C79.5924 15.6358 79.4014 15.021 78.9835 14.5719C78.5655 14.1228 77.9661 13.8881 77.3543 13.9341C76.5643 13.8699 75.8204 14.314 75.5021 15.0399H75.4106V14.0539ZM85.7591 14.3751C84.8094 14.9644 84.2759 16.0411 84.3822 17.1536C84.2739 18.2674 84.807 19.3461 85.7575 19.9366C86.708 20.5271 87.9112 20.5271 88.8617 19.9366C89.8122 19.3461 90.3453 18.2674 90.2369 17.1536C90.3433 16.0411 89.8097 14.9644 88.8601 14.3751C87.9104 13.7858 86.7088 13.7858 85.7591 14.3751ZM88.9782 17.1549C88.9782 15.8095 88.3738 15.0227 87.3131 15.0227C86.2484 15.0227 85.6494 15.8095 85.6494 17.1549C85.6494 18.511 86.2484 19.2917 87.3131 19.2917C88.3738 19.2917 88.9782 18.5056 88.9782 17.1549ZM93.8368 16.6542C92.3602 16.7457 91.5283 17.3898 91.5283 18.507C91.5304 19.0368 91.7565 19.5409 92.1506 19.8948C92.5448 20.2487 93.0703 20.4193 93.5972 20.3645C94.3488 20.3993 95.061 20.027 95.4615 19.39H95.5584V20.2623H96.7376V16.0215C96.7376 14.7104 95.86 13.9358 94.3039 13.9358C92.8959 13.9358 91.8931 14.6196 91.7679 15.6857H92.9538C93.0898 15.2469 93.5636 14.9958 94.2474 14.9958C95.0846 14.9958 95.518 15.366 95.518 16.0215V16.5572L93.8368 16.6542ZM95.5169 17.9752V17.4563L94.0012 17.5532C93.1465 17.6104 92.7588 17.9012 92.7588 18.4483C92.7588 19.0069 93.2434 19.332 93.9097 19.332C94.3042 19.372 94.698 19.2501 95.0009 18.9943C95.3039 18.7385 95.4901 18.3708 95.5169 17.9752ZM100.921 13.9511C99.3529 13.9511 98.3447 15.1935 98.3447 17.1547C98.3447 19.1206 99.3422 20.3631 100.921 20.363C101.722 20.3925 102.472 19.9754 102.87 19.2801H102.967V20.2607H104.141V11.6311H102.916V15.04H102.824C102.455 14.3389 101.713 13.9146 100.921 13.9511ZM99.6143 17.1562C99.6143 18.4727 100.235 19.2648 101.273 19.2648C102.305 19.2648 102.943 18.4612 102.943 17.1616C102.943 15.868 102.298 15.053 101.273 15.053C100.242 15.053 99.6143 15.8505 99.6143 17.1562H99.6143ZM110.587 14.3773C109.637 14.9666 109.104 16.0433 109.21 17.1558C109.102 18.2695 109.635 19.3482 110.585 19.9388C111.536 20.5293 112.739 20.5293 113.689 19.9388C114.64 19.3482 115.173 18.2695 115.064 17.1558C115.171 16.0433 114.637 14.9666 113.688 14.3773C112.738 13.7881 111.536 13.7881 110.587 14.3773ZM113.806 17.1549C113.806 15.8095 113.202 15.0227 112.141 15.0227C111.076 15.0227 110.478 15.8095 110.478 17.1549C110.478 18.511 111.077 19.2917 112.141 19.2917C113.202 19.2917 113.806 18.5056 113.806 17.1549ZM117.883 14.0535H116.704V20.2602H117.929V16.6292C117.885 16.2161 118.024 15.8045 118.309 15.5022C118.594 15.1998 118.996 15.037 119.411 15.0563C120.317 15.0563 120.751 15.5523 120.751 16.5498V20.2601H121.975V16.2422C122.065 15.6353 121.874 15.0206 121.456 14.5715C121.038 14.1224 120.439 13.8877 119.827 13.9337C119.037 13.8695 118.293 14.3135 117.975 15.0395H117.883V14.0535ZM128.904 12.509V14.0826H130.249V15.1143H128.904V18.3059C128.904 18.956 129.172 19.2407 129.782 19.2407C129.938 19.2402 130.094 19.2308 130.249 19.2124V20.2327C130.029 20.2721 129.806 20.293 129.582 20.2953C128.22 20.2953 127.678 19.8161 127.678 18.6195V15.1143H126.692V14.0825H127.678V12.509H128.904ZM133.129 11.6311H131.915L131.915 20.2607H133.14V16.6358C133.102 16.2098 133.254 15.7889 133.555 15.4856C133.857 15.1822 134.277 15.0273 134.703 15.0622C135.568 15.0622 136.03 15.5643 136.03 16.5557V20.2607H137.256V16.2535C137.337 15.6497 137.145 15.0413 136.732 14.5938C136.318 14.1464 135.727 13.9065 135.119 13.9396C134.317 13.8745 133.56 14.3192 133.226 15.0515H133.129V11.6311ZM144.4 18.5836C144.057 19.7544 142.924 20.5108 141.711 20.3792C140.883 20.4011 140.088 20.058 139.536 19.4411C138.984 18.8242 138.731 17.9958 138.844 17.1756C138.734 16.3532 138.986 15.5235 139.535 14.9013C140.084 14.2792 140.876 13.9259 141.706 13.933C143.433 13.933 144.474 15.1128 144.474 17.0619V17.4893H140.092V17.5579C140.053 18.0185 140.21 18.4741 140.525 18.8126C140.84 19.1511 141.282 19.3412 141.745 19.336C142.344 19.408 142.927 19.1107 143.221 18.5836L144.4 18.5836ZM143.227 16.585H140.092C140.086 16.157 140.254 15.7449 140.556 15.4422C140.859 15.1395 141.271 14.9718 141.699 14.9772C142.121 14.9675 142.528 15.1366 142.819 15.4428C143.11 15.749 143.258 16.1638 143.227 16.585Z" fill="black"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M32.137 10.8181C32.2758 12.6302 31.7027 14.4251 30.5395 15.8214C29.411 17.2251 27.701 18.0336 25.9001 18.015C25.7855 16.2551 26.3753 14.5218 27.5394 13.1969C28.7183 11.8541 30.3599 11.0048 32.137 10.8181ZM37.8338 21.4657C35.7621 22.7393 34.4873 24.9854 34.4559 27.4171C34.4589 30.1682 36.1065 32.651 38.6403 33.7227C38.153 35.3058 37.4184 36.8018 36.4638 38.1554C35.1818 40.0731 33.8377 41.9466 31.7043 41.9812C30.6897 42.0047 30.0048 41.7129 29.2911 41.4089C28.5467 41.0918 27.771 40.7613 26.5571 40.7613C25.2698 40.7613 24.4593 41.1024 23.6777 41.4313C23.0022 41.7156 22.3482 41.9909 21.4266 42.0291C19.3948 42.1043 17.8421 39.9823 16.5135 38.0826C13.8581 34.203 11.7904 27.1494 14.5624 22.3499C15.8642 20.0107 18.2981 18.5263 20.9737 18.4399C22.1261 18.4162 23.2318 18.8603 24.2012 19.2497C24.9426 19.5475 25.6042 19.8133 26.146 19.8133C26.6223 19.8133 27.2655 19.558 28.0151 19.2605C29.1959 18.7918 30.6407 18.2184 32.113 18.373C34.4008 18.4446 36.5209 19.5907 37.8338 21.4657Z" fill="black"></path></svg></a></li><li><a href="https://public.sng.link/Ag0a8/f14v?_ios_dl=matador%3A%2F%2F&amp;_android_dl=public%3A%2F%2F&amp;_smtype=3" target="_blank" rel="noopener noreferrer nofollow" aria-label="Google Play"><svg width="144" height="49" viewBox="0 0 165 56" fill="none" aria-label="Google Play"><path d="M151.806 0.000179188H13.1423C12.6369 0.000179188 12.1375 0.000179188 11.6334 0.00293592C11.2114 0.00569266 10.7927 0.013701 10.3667 0.0204412C9.44115 0.0313328 8.51777 0.112759 7.60459 0.264013C6.6927 0.418559 5.80937 0.709923 4.98448 1.12825C4.1606 1.55012 3.4078 2.09829 2.75339 2.75288C2.09554 3.40563 1.54717 4.16012 1.12937 4.98734C0.710411 5.81291 0.419907 6.69758 0.267886 7.61081C0.11442 8.52288 0.0318381 9.44548 0.0208823 10.3703C0.00809102 10.7929 0.00674022 11.2169 0 11.6396V43.4995C0.00674022 43.9275 0.00809102 44.3421 0.0208823 44.7703C0.0318414 45.695 0.114423 46.6176 0.267886 47.5296C0.419487 48.4434 0.710009 49.3286 1.12937 50.1544C1.54698 50.979 2.09542 51.7304 2.75339 52.3795C3.40532 53.037 4.15861 53.5856 4.98448 54.0042C5.80936 54.4237 6.6926 54.7168 7.60459 54.8737C8.51793 55.0237 9.44121 55.1052 10.3667 55.1174C10.7927 55.1268 11.2114 55.1321 11.6334 55.1321C12.1375 55.1349 12.6369 55.1349 13.1423 55.1349H151.806C152.302 55.1349 152.805 55.1349 153.3 55.1321C153.72 55.1321 154.151 55.1268 154.571 55.1174C155.495 55.1059 156.416 55.0244 157.328 54.8737C158.243 54.7157 159.129 54.4226 159.958 54.0042C160.783 53.5853 161.536 53.0368 162.187 52.3795C162.843 51.7279 163.393 50.977 163.816 50.1544C164.232 49.328 164.52 48.4428 164.669 47.5296C164.823 46.6175 164.908 45.6951 164.925 44.7703C164.93 44.3421 164.93 43.9275 164.93 43.4995C164.941 42.9988 164.941 42.5008 164.941 41.9919V13.1445C164.941 12.6397 164.941 12.139 164.93 11.6396C164.93 11.2169 164.93 10.7929 164.925 10.3702C164.908 9.44534 164.823 8.52295 164.669 7.61076C164.519 6.69806 164.232 5.81345 163.816 4.98728C162.965 3.32921 161.616 1.97955 159.958 1.12813C159.129 0.710821 158.243 0.419534 157.328 0.263889C156.417 0.111969 155.495 0.030514 154.571 0.0202482C154.151 0.0135218 153.72 0.00544455 153.3 0.00275674C152.805 0 152.302 0 151.806 0V0.000179188Z" fill="white"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M57.183 31.6094V33.8086H62.4612C62.3784 34.8444 61.9478 35.8218 61.2394 36.582C60.1716 37.6697 58.6938 38.2555 57.1708 38.1948C53.9319 38.1948 51.3062 35.5691 51.3062 32.3302C51.3062 29.0913 53.9319 26.4657 57.1708 26.4657C58.6587 26.4414 60.0955 27.0082 61.1661 28.0418L62.7177 26.4901C61.2576 25.0116 59.261 24.1873 57.183 24.2054C54.225 24.0902 51.4411 25.6027 49.9279 28.1469C48.4147 30.6911 48.4147 33.8594 49.9279 36.4036C51.4411 38.9478 54.225 40.4603 57.183 40.3451C59.2989 40.4408 61.3527 39.6166 62.8155 38.0848C64.0955 36.6785 64.7789 34.8297 64.7215 32.9289C64.7254 32.4658 64.6845 32.0035 64.5993 31.5483L57.183 31.6094ZM70.7312 30.0088C67.865 30.0155 65.5463 32.3433 65.5508 35.2095C65.5553 38.0757 67.8812 40.3962 70.7474 40.3939C73.6136 40.3917 75.936 38.0675 75.936 35.2013C75.9561 33.8139 75.4121 32.4776 74.4286 31.4987C73.4451 30.5198 72.1063 29.9821 70.7189 30.0088H70.7312ZM76.9375 35.2176C76.9285 32.353 79.2411 30.0222 82.1057 30.0088C83.493 29.9821 84.8318 30.5198 85.8153 31.4987C86.7988 32.4776 87.3428 33.8139 87.3227 35.2013C87.3227 38.066 85.0028 40.3894 82.1382 40.3939C79.2736 40.3983 76.9465 38.0821 76.9375 35.2176ZM79.0428 36.5696C79.6007 37.7375 80.8158 38.4456 82.107 38.3553C82.9174 38.3365 83.6858 37.9912 84.2379 37.3977C84.7901 36.8041 85.079 36.0128 85.0393 35.2031C85.0361 33.9088 84.2421 32.748 83.037 32.2758C81.8319 31.8037 80.4606 32.1161 79.5791 33.0638C78.6975 34.0115 78.4848 35.4017 79.0428 36.5696ZM67.6597 36.5781C68.2215 37.7452 69.4402 38.4498 70.732 38.3544H70.7198C71.5302 38.3356 72.2987 37.9903 72.8508 37.3968C73.4029 36.8033 73.6919 36.0119 73.6521 35.2022C73.6486 33.9069 72.853 32.7456 71.6464 32.2745C70.4397 31.8033 69.0677 32.1184 68.1875 33.0686C67.3072 34.0189 67.0978 35.4109 67.6597 36.5781ZM108.093 30.0104C110.118 30.085 111.888 31.4022 112.54 33.3214L112.796 33.8712L105.844 36.7424C106.28 37.7347 107.278 38.3598 108.361 38.3185C109.407 38.3212 110.377 37.7735 110.915 36.8768L112.686 38.0986C111.722 39.5421 110.097 40.4049 108.361 40.3955C106.981 40.4158 105.653 39.874 104.68 38.8947C103.708 37.9153 103.175 36.5827 103.205 35.2029C103.121 33.8547 103.598 32.5317 104.524 31.548C105.45 30.5643 106.742 30.0077 108.093 30.0104ZM105.451 35.0569C105.401 34.2935 105.661 33.542 106.171 32.972C106.681 32.402 107.4 32.0613 108.164 32.0268C108.969 31.9738 109.729 32.4064 110.094 33.1265L105.451 35.0569ZM102.094 40.0902H99.8088V24.8179H102.094V40.0902ZM96.0714 31.1706H95.9859C95.2894 30.3919 94.2938 29.9475 93.2491 29.9488C90.4758 30.0833 88.2964 32.371 88.2964 35.1475C88.2964 37.9241 90.4758 40.2117 93.2491 40.3462C94.2972 40.3639 95.2993 39.9165 95.9859 39.1244H96.0592V39.8697C96.0592 41.8612 94.9963 42.9242 93.2858 42.9242C92.1205 42.8969 91.0874 42.168 90.6711 41.0793L88.6796 41.9101C89.4465 43.7756 91.2689 44.9888 93.2858 44.9768C95.9615 44.9768 98.1729 43.4007 98.1729 39.5643V30.3154H96.0714V31.1706ZM93.4522 38.3547L93.456 38.3551H93.4437L93.4522 38.3547ZM95.511 37.3749C94.9866 37.9683 94.2431 38.322 93.4522 38.3547C91.8204 38.209 90.5693 36.8416 90.5693 35.2028C90.5693 33.5628 91.8223 32.1946 93.456 32.0506C94.2454 32.0911 94.985 32.4487 95.5072 33.0421C96.0293 33.6356 96.2897 34.4147 96.2294 35.2028C96.2968 35.9946 96.0372 36.7795 95.511 37.3749ZM123.244 24.8156H117.782V40.088H120.067V34.2967H123.256C125.031 34.4242 126.728 33.5496 127.654 32.0302C128.581 30.5109 128.581 28.6014 127.654 27.0821C126.728 25.5627 125.031 24.6881 123.256 24.8156H123.244ZM120.055 32.1469H123.244L123.293 32.1835C124.74 32.1835 125.914 31.0102 125.914 29.5628C125.914 28.1154 124.74 26.9421 123.293 26.9421H120.055V32.1469ZM137.331 29.9498C135.631 29.8482 134.033 30.7648 133.263 32.2834L135.291 33.1264C135.699 32.3734 136.514 31.9326 137.368 32.0024C137.954 31.9339 138.543 32.1037 139.002 32.4736C139.462 32.8435 139.753 33.3825 139.812 33.9694V34.1283C139.078 33.7398 138.259 33.5383 137.429 33.5418C135.242 33.5418 133.031 34.7636 133.031 36.975C133.074 37.9277 133.501 38.8222 134.215 39.455C134.928 40.0879 135.867 40.4052 136.818 40.335C137.99 40.4191 139.115 39.8569 139.75 38.8688H139.824V40.0906H142.023V34.2138C142.023 31.5381 139.995 29.9864 137.392 29.9864L137.331 29.9498ZM135.27 37.0227C135.27 37.939 136.308 38.3178 137.053 38.3178L137.114 38.3544C138.491 38.3209 139.632 37.2786 139.79 35.9109C139.156 35.557 138.439 35.3798 137.713 35.3977C136.565 35.3977 135.27 35.8009 135.27 37.0227ZM150.039 30.3164L147.425 36.9385H147.351L144.639 30.3164H142.195L146.264 39.5775L143.942 44.7213H146.325L152.58 30.3164H150.039ZM131.785 40.0902H129.5V24.8179H131.785V40.0902Z" fill="black"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M83.4092 12.9297C81.9678 14.4554 81.9678 16.8409 83.4092 18.3666C84.8961 19.8453 87.2981 19.8453 88.785 18.3666C90.2325 16.8433 90.2325 14.4529 88.785 12.9297C88.0739 12.2134 87.1064 11.8105 86.0971 11.8105C85.0878 11.8105 84.1202 12.2134 83.4092 12.9297ZM55.8737 18.3903C56.5008 17.7355 56.832 16.8523 56.7901 15.9467C56.7901 15.7623 56.7738 15.5783 56.7412 15.3969H53.1858V16.2766H55.8371C55.819 16.8307 55.6021 17.3597 55.2262 17.7671C54.3888 18.5766 53.1466 18.8028 52.0776 18.3405C51.0086 17.8781 50.3227 16.8181 50.339 15.6535C50.3124 14.8828 50.601 14.1345 51.1381 13.5812C51.6753 13.0279 52.4147 12.7174 53.1858 12.7212C53.9529 12.6793 54.6951 13.0006 55.1895 13.5886L55.8371 12.9411C55.5243 12.5813 55.1307 12.3008 54.6886 12.1225C54.2137 11.9193 53.7023 11.8153 53.1858 11.8171C52.1724 11.7945 51.1949 12.1925 50.4857 12.9167C49.394 14.0154 49.0675 15.6615 49.6569 17.0938C50.2464 18.5261 51.637 19.4655 53.1858 19.4777C54.1956 19.5136 55.173 19.1182 55.8737 18.3903ZM59.0874 12.8936H62.3863V11.9895H58.11V19.3202H62.3863V18.4161H59.0874V16.0947H62.093V15.215H59.0874V12.8936ZM66.392 19.3202H65.4512V12.8936H63.3986V11.9895H68.4935V12.8936H66.392V19.3202ZM72.0859 11.9893V19.32H73.0267V11.9893H72.0859ZM77.2082 19.32H76.2674V12.8934H74.2148V11.9893H79.2486V12.8934H77.2082V19.32ZM84.1071 17.7543C85.2083 18.851 86.9889 18.851 88.0901 17.7543C89.1716 16.5621 89.1716 14.7436 88.0901 13.5514C86.9889 12.4547 85.2083 12.4547 84.1071 13.5514C83.0255 14.7436 83.0255 16.5621 84.1071 17.7543ZM91.1992 11.9893V19.32H92.1522V13.3454L95.8787 19.32H96.8561V11.9893H95.9153V17.695L92.3477 11.9893H91.1992Z" fill="black"></path><path d="M83.4092 18.3666L83.3203 18.4506L83.323 18.4532L83.4092 18.3666ZM83.4092 12.9297L83.3224 12.8436L83.3203 12.8458L83.4092 12.9297ZM88.785 18.3666L88.8712 18.4533L88.8736 18.4508L88.785 18.3666ZM88.785 12.9297L88.8736 12.8455L88.8717 12.8436L88.785 12.9297ZM56.7901 15.9467L56.6678 15.9466L56.668 15.9523L56.7901 15.9467ZM55.8737 18.3903L55.9618 18.475L55.962 18.4748L55.8737 18.3903ZM56.7412 15.3969L56.8615 15.3753L56.8434 15.2747H56.7412V15.3969ZM53.1858 15.3969V15.2747H53.0636V15.3969H53.1858ZM53.1858 16.2766H53.0636V16.3987H53.1858V16.2766ZM55.8371 16.2766L55.9592 16.2806L55.9633 16.1544H55.8371V16.2766ZM55.2262 17.7671L55.3112 17.8551L55.316 17.85L55.2262 17.7671ZM52.0776 18.3405L52.1261 18.2283L52.0776 18.3405ZM50.339 15.6535L50.4614 15.6552L50.4611 15.6492L50.339 15.6535ZM51.1381 13.5812L51.2258 13.6663L51.1381 13.5812ZM53.1858 12.7212L53.1852 12.8436L53.1925 12.8432L53.1858 12.7212ZM55.1895 13.5886L55.096 13.6673L55.1817 13.7692L55.2759 13.675L55.1895 13.5886ZM55.8371 12.9411L55.9235 13.0275L56.004 12.9469L55.9293 12.8609L55.8371 12.9411ZM54.6886 12.1225L54.6405 12.2348L54.6429 12.2358L54.6886 12.1225ZM53.1858 11.8171L53.1831 11.9392L53.1862 11.9392L53.1858 11.8171ZM50.4857 12.9167L50.5723 13.0028L50.5729 13.0022L50.4857 12.9167ZM49.6569 17.0938L49.7699 17.0473L49.6569 17.0938ZM53.1858 19.4777L53.1902 19.3555L53.1868 19.3555L53.1858 19.4777ZM62.3863 12.8936V13.0158H62.5084V12.8936H62.3863ZM59.0874 12.8936V12.7715H58.9652V12.8936H59.0874ZM62.3863 11.9895H62.5084V11.8673H62.3863V11.9895ZM58.11 11.9895V11.8673H57.9878V11.9895H58.11ZM58.11 19.3202H57.9878V19.4424H58.11V19.3202ZM62.3863 19.3202V19.4424H62.5084V19.3202H62.3863ZM62.3863 18.4161H62.5084V18.2939H62.3863V18.4161ZM59.0874 18.4161H58.9652V18.5383H59.0874V18.4161ZM59.0874 16.0947V15.9725H58.9652V16.0947H59.0874ZM62.093 16.0947V16.2169H62.2152V16.0947H62.093ZM62.093 15.215H62.2152V15.0929H62.093V15.215ZM59.0874 15.215H58.9652V15.3372H59.0874V15.215ZM65.4512 19.3202H65.3291V19.4424H65.4512V19.3202ZM66.392 19.3202V19.4424H66.5142V19.3202H66.392ZM65.4512 12.8936H65.5734V12.7715H65.4512V12.8936ZM63.3986 12.8936H63.2765V13.0158H63.3986V12.8936ZM63.3986 11.9895V11.8673H63.2765V11.9895H63.3986ZM68.4935 11.9895H68.6157V11.8673H68.4935V11.9895ZM68.4935 12.8936V13.0158H68.6157V12.8936H68.4935ZM66.392 12.8936V12.7715H66.2698V12.8936H66.392ZM72.0859 19.32H71.9638V19.4422H72.0859V19.32ZM72.0859 11.9893V11.8671H71.9638V11.9893H72.0859ZM73.0267 19.32V19.4422H73.1489V19.32H73.0267ZM73.0267 11.9893H73.1489V11.8671H73.0267V11.9893ZM76.2674 19.32H76.1453V19.4422H76.2674V19.32ZM77.2082 19.32V19.4422H77.3304V19.32H77.2082ZM76.2674 12.8934H76.3896V12.7712H76.2674V12.8934ZM74.2148 12.8934H74.0927V13.0156H74.2148V12.8934ZM74.2148 11.9893V11.8671H74.0927V11.9893H74.2148ZM79.2486 11.9893H79.3708V11.8671H79.2486V11.9893ZM79.2486 12.8934V13.0156H79.3708V12.8934H79.2486ZM77.2082 12.8934V12.7712H77.086V12.8934H77.2082ZM88.0901 17.7543L88.1764 17.841L88.1806 17.8364L88.0901 17.7543ZM84.1071 17.7543L84.0164 17.8365L84.0208 17.8409L84.1071 17.7543ZM88.0901 13.5514L88.1807 13.4692L88.1763 13.4648L88.0901 13.5514ZM84.1071 13.5514L84.0207 13.4647L84.0166 13.4693L84.1071 13.5514ZM91.1992 19.32H91.077V19.4422H91.1992V19.32ZM91.1992 11.9893V11.8671H91.077V11.9893H91.1992ZM92.1522 19.32V19.4422H92.2744V19.32H92.1522ZM92.1522 13.3454L92.2559 13.2808L92.03 12.9187V13.3454H92.1522ZM95.8787 19.32L95.775 19.3846L95.8109 19.4422H95.8787V19.32ZM96.8561 19.32V19.4422H96.9783V19.32H96.8561ZM96.8561 11.9893H96.9783V11.8671H96.8561V11.9893ZM95.9153 11.9893V11.8671H95.7931V11.9893H95.9153ZM95.9153 17.695L95.8117 17.7598L96.0375 18.1209V17.695H95.9153ZM92.3477 11.9893L92.4513 11.9245L92.4154 11.8671H92.3477V11.9893ZM83.498 18.2827C82.1011 16.8041 82.1011 14.4922 83.498 13.0136L83.3203 12.8458C81.8345 14.4186 81.8345 16.8777 83.3203 18.4505L83.498 18.2827ZM88.6989 18.28C87.2596 19.7112 84.9346 19.7112 83.4953 18.28L83.323 18.4532C84.8576 19.9793 87.3366 19.9793 88.8712 18.4532L88.6989 18.28ZM88.6965 13.0138C90.0992 14.4899 90.0992 16.8063 88.6965 18.2824L88.8736 18.4508C90.3659 16.8803 90.3659 14.4159 88.8736 12.8455L88.6965 13.0138ZM86.0971 11.9327C87.0738 11.9327 88.0102 12.3226 88.6983 13.0157L88.8717 12.8436C88.1377 12.1042 87.1389 11.6884 86.0971 11.6884V11.9327ZM83.4959 13.0157C84.184 12.3226 85.1203 11.9327 86.0971 11.9327V11.6884C85.0552 11.6884 84.0565 12.1042 83.3225 12.8436L83.4959 13.0157ZM56.668 15.9523C56.7084 16.8246 56.3895 17.6752 55.7855 18.3057L55.962 18.4748C56.6122 17.7959 56.9556 16.8801 56.9121 15.941L56.668 15.9523ZM56.6209 15.4185C56.6523 15.5928 56.668 15.7695 56.6679 15.9466L56.9123 15.9467C56.9123 15.7551 56.8953 15.5639 56.8615 15.3753L56.6209 15.4185ZM53.1858 15.5191H56.7412V15.2747H53.1858V15.5191ZM53.308 16.2766V15.3969H53.0636V16.2766H53.308ZM55.8371 16.1544H53.1858V16.3987H55.8371V16.1544ZM55.316 17.85C55.7118 17.421 55.9401 16.864 55.9592 16.2806L55.715 16.2726C55.6978 16.7973 55.4925 17.2984 55.1364 17.6843L55.316 17.85ZM52.0291 18.4526C53.1434 18.9346 54.4382 18.6988 55.3111 17.855L55.1413 17.6793C54.3393 18.4545 53.1498 18.6711 52.1261 18.2283L52.0291 18.4526ZM50.2169 15.6517C50.1998 16.8657 50.9148 17.9707 52.0291 18.4526L52.1261 18.2283C51.1023 17.7856 50.4455 16.7704 50.4612 15.6552L50.2169 15.6517ZM51.0505 13.4961C50.4902 14.0733 50.1892 14.8538 50.2169 15.6577L50.4611 15.6492C50.4357 14.9118 50.7118 14.1958 51.2258 13.6663L51.0505 13.4961ZM53.1864 12.599C52.382 12.595 51.6108 12.919 51.0505 13.4961L51.2258 13.6663C51.7398 13.1369 52.4473 12.8397 53.1852 12.8433L53.1864 12.599ZM55.2831 13.51C54.7639 12.8925 53.9846 12.5552 53.1791 12.5992L53.1925 12.8432C53.9213 12.8033 54.6263 13.1086 55.096 13.6673L55.2831 13.51ZM55.7507 12.8547L55.1031 13.5022L55.2759 13.675L55.9235 13.0275L55.7507 12.8547ZM54.6429 12.2358C55.0671 12.4069 55.4447 12.6761 55.7449 13.0213L55.9293 12.8609C55.6038 12.4866 55.1943 12.1947 54.7343 12.0092L54.6429 12.2358ZM53.1862 11.9392C53.6861 11.9376 54.181 12.0382 54.6405 12.2348L54.7367 12.0102C54.2465 11.8004 53.7186 11.6931 53.1854 11.6949L53.1862 11.9392ZM50.5729 13.0022C51.2586 12.3022 52.2035 11.9174 53.1831 11.9392L53.1885 11.6949C52.1414 11.6716 51.1313 12.0829 50.3984 12.8312L50.5729 13.0022ZM49.7699 17.0473C49.1991 15.6605 49.5154 14.0667 50.5723 13.0028L50.399 12.8305C49.2727 13.9642 48.9358 15.6626 49.5439 17.1403L49.7699 17.0473ZM53.1868 19.3555C51.6871 19.3437 50.3406 18.4342 49.7699 17.0473L49.5439 17.1403C50.1521 18.6181 51.5869 19.5873 53.1848 19.5998L53.1868 19.3555ZM55.7857 18.3055C55.109 19.0085 54.1652 19.3903 53.1902 19.3555L53.1815 19.5998C54.2259 19.6369 55.2369 19.228 55.9618 18.475L55.7857 18.3055ZM62.3863 12.7715H59.0874V13.0158H62.3863V12.7715ZM62.2641 11.9895V12.8936H62.5084V11.9895H62.2641ZM58.11 12.1117H62.3863V11.8673H58.11V12.1117ZM58.2322 19.3202V11.9895H57.9878V19.3202H58.2322ZM62.3863 19.1981H58.11V19.4424H62.3863V19.1981ZM62.2641 18.4161V19.3202H62.5084V18.4161H62.2641ZM59.0874 18.5383H62.3863V18.2939H59.0874V18.5383ZM58.9652 16.0947V18.4161H59.2096V16.0947H58.9652ZM62.093 15.9725H59.0874V16.2169H62.093V15.9725ZM61.9708 15.215V16.0947H62.2152V15.215H61.9708ZM59.0874 15.3372H62.093V15.0929H59.0874V15.3372ZM58.9652 12.8936V15.215H59.2096V12.8936H58.9652ZM65.4512 19.4424H66.392V19.1981H65.4512V19.4424ZM65.3291 12.8936V19.3202H65.5734V12.8936H65.3291ZM63.3986 13.0158H65.4512V12.7715H63.3986V13.0158ZM63.2765 11.9895V12.8936H63.5208V11.9895H63.2765ZM68.4935 11.8673H63.3986V12.1117H68.4935V11.8673ZM68.6157 12.8936V11.9895H68.3713V12.8936H68.6157ZM66.392 13.0158H68.4935V12.7715H66.392V13.0158ZM66.5142 19.3202V12.8936H66.2698V19.3202H66.5142ZM72.2081 19.32V11.9893H71.9638V19.32H72.2081ZM73.0267 19.1978H72.0859V19.4422H73.0267V19.1978ZM72.9045 11.9893V19.32H73.1489V11.9893H72.9045ZM72.0859 12.1114H73.0267V11.8671H72.0859V12.1114ZM76.2674 19.4422H77.2082V19.1978H76.2674V19.4422ZM76.1453 12.8934V19.32H76.3896V12.8934H76.1453ZM74.2148 13.0156H76.2674V12.7712H74.2148V13.0156ZM74.0927 11.9893V12.8934H74.337V11.9893H74.0927ZM79.2486 11.8671H74.2148V12.1114H79.2486V11.8671ZM79.3708 12.8934V11.9893H79.1264V12.8934H79.3708ZM77.2082 13.0156H79.2486V12.7712H77.2082V13.0156ZM77.3304 19.32V12.8934H77.086V19.32H77.3304ZM88.0039 17.6677C86.9503 18.7169 85.2468 18.7169 84.1933 17.6677L84.0208 17.8409C85.1697 18.985 87.0274 18.985 88.1763 17.8409L88.0039 17.6677ZM87.9996 13.6335C89.0389 14.7791 89.0389 16.5265 87.9996 17.6722L88.1806 17.8364C89.3043 16.5976 89.3043 14.7081 88.1806 13.4693L87.9996 13.6335ZM84.1933 13.6379C85.2468 12.5888 86.9503 12.5888 88.0039 13.6379L88.1763 13.4648C87.0274 12.3207 85.1697 12.3207 84.0208 13.4648L84.1933 13.6379ZM84.1976 17.6722C83.1583 16.5265 83.1583 14.7791 84.1976 13.6335L84.0166 13.4693C82.8928 14.7081 82.8928 16.5976 84.0166 17.8364L84.1976 17.6722ZM91.3214 19.32V11.9893H91.077V19.32H91.3214ZM92.1522 19.1978H91.1992V19.4422H92.1522V19.1978ZM92.03 13.3454V19.32H92.2744V13.3454H92.03ZM95.9823 19.2553L92.2559 13.2808L92.0485 13.4101L95.775 19.3846L95.9823 19.2553ZM96.8561 19.1978H95.8787V19.4422H96.8561V19.1978ZM96.7339 11.9893V19.32H96.9783V11.9893H96.7339ZM95.9153 12.1114H96.8561V11.8671H95.9153V12.1114ZM96.0375 17.695V11.9893H95.7931V17.695H96.0375ZM92.2441 12.054L95.8117 17.7598L96.0189 17.6302L92.4513 11.9245L92.2441 12.054ZM91.1992 12.1114H92.3477V11.8671H91.1992V12.1114Z" fill="black"></path><path d="M11.6055 12.648C11.2072 13.1259 11.0062 13.7376 11.0434 14.3585V41.3844C11.0062 42.0054 11.2072 42.6171 11.6055 43.0949L11.691 43.1805L26.8289 28.0548V27.7004L11.691 12.5625L11.6055 12.648Z" fill="url(#GooglePlayIcon_paint0_linear)"></path><path d="M31.8374 33.1011L26.8281 28.0551V27.7008L31.8374 22.6426L31.9474 22.7037L37.9464 26.1125C39.6569 27.0777 39.6569 28.666 37.9464 29.6434L31.9718 33.04L31.8374 33.1011Z" fill="url(#GooglePlayIcon_paint1_linear)"></path><path d="M31.9849 33.027L26.8289 27.8711L11.6055 43.0946C12.3248 43.7269 13.3922 43.7576 14.1468 43.1679L31.9971 33.027" fill="url(#GooglePlayIcon_paint2_linear)"></path><path d="M31.9854 22.7156L14.1351 12.5748C13.3805 11.985 12.313 12.0158 11.5938 12.6481L26.8294 27.8716L31.9854 22.7156Z" fill="url(#GooglePlayIcon_paint3_linear)"></path><path opacity="0.2" d="M31.8382 32.9189L14.1346 42.9987C13.4101 43.5403 12.4155 43.5403 11.691 42.9987L11.6055 43.0842L11.691 43.1697C12.4141 43.7155 13.4115 43.7155 14.1346 43.1697L31.9849 33.0289L31.8382 32.9189Z" fill="black"></path><path opacity="0.12" fill-rule="evenodd" clip-rule="evenodd" d="M31.8357 32.9171L37.9446 29.4594C38.5759 29.1478 39.0271 28.5612 39.1664 27.8711C39.1034 28.634 38.6374 29.305 37.9446 29.6305L31.9456 33.027L31.8357 32.9171ZM11.0408 41.4502C11.061 41.9878 11.2582 42.5062 11.6055 42.9229L11.691 43.0206L11.6055 43.1062C11.2189 42.6423 11.0182 42.0523 11.0408 41.4502ZM11.0408 41.4502C11.0415 41.432 11.0423 41.4138 11.0434 41.3956V41.2124C11.0387 41.2919 11.0378 41.3713 11.0408 41.4502Z" fill="black"></path><path opacity="0.25" d="M14.1346 12.747L37.9472 26.2844C38.5785 26.596 39.0297 27.1826 39.169 27.8727C39.106 27.1099 38.64 26.4388 37.9472 26.1134L14.1346 12.576C12.4241 11.6108 11.0312 12.4171 11.0312 14.372V14.5553C11.0679 12.5882 12.4363 11.7818 14.1346 12.747Z" fill="white"></path><defs><linearGradient id="GooglePlayIcon_paint0_linear" x1="20.1986" y1="-5.79969" x2="-4.04097" y2="0.646869" gradientUnits="userSpaceOnUse"><stop stop-color="#00A0FF"></stop><stop offset="0.01" stop-color="#00A1FF"></stop><stop offset="0.26" stop-color="#00BEFF"></stop><stop offset="0.51" stop-color="#00D2FF"></stop><stop offset="0.76" stop-color="#00DFFF"></stop><stop offset="1" stop-color="#00E3FF"></stop></linearGradient><linearGradient id="GooglePlayIcon_paint1_linear" x1="40.1822" y1="15.4092" x2="10.6272" y2="15.4092" gradientUnits="userSpaceOnUse"><stop stop-color="#FFE000"></stop><stop offset="0.41" stop-color="#FFBD00"></stop><stop offset="0.78" stop-color="#FFA500"></stop><stop offset="1" stop-color="#FF9C00"></stop></linearGradient><linearGradient id="GooglePlayIcon_paint2_linear" x1="11.1582" y1="19.9631" x2="-8.31277" y2="52.715" gradientUnits="userSpaceOnUse"><stop stop-color="#FF3A44"></stop><stop offset="1" stop-color="#C31162"></stop></linearGradient><linearGradient id="GooglePlayIcon_paint3_linear" x1="-0.281989" y1="8.44029" x2="8.40892" y2="23.0656" gradientUnits="userSpaceOnUse"><stop stop-color="#32A071"></stop><stop offset="0.07" stop-color="#2DA771"></stop><stop offset="0.48" stop-color="#15CF74"></stop><stop offset="0.8" stop-color="#06E775"></stop><stop offset="1" stop-color="#00F076"></stop></linearGradient></defs></svg></a></li></ul></div><div><svg width="126" height="24" viewBox="0 0 126 24" fill="none" style="height:38px;margin-bottom:30px;object-position:top left;width:200px"><path d="M83.5876 18.5712C83.9239 18.5731 84.2531 18.4756 84.5338 18.2908C84.8145 18.1061 85.034 17.8424 85.1646 17.5332C85.2952 17.224 85.331 16.8831 85.2676 16.5536C85.2041 16.2241 85.0442 15.9207 84.808 15.6819C84.5719 15.4431 84.2701 15.2794 83.9407 15.2117C83.6114 15.144 83.2694 15.1752 82.9579 15.3014C82.6463 15.4276 82.3793 15.6432 82.1904 15.9208C82.0016 16.1984 81.8995 16.5257 81.8969 16.8612C81.8952 17.0843 81.9377 17.3056 82.0218 17.5123C82.1058 17.7191 82.23 17.9073 82.387 18.0661C82.544 18.2249 82.7309 18.3512 82.9369 18.4379C83.1429 18.5246 83.3641 18.5699 83.5876 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M92.2184 18.6362C94.2124 18.6362 96.0122 17.6193 97.0964 15.758L95.3404 14.6761C95.0469 15.246 94.5992 15.7225 94.0481 16.0515C93.497 16.3805 92.8646 16.5488 92.2226 16.5373C90.4228 16.5373 88.9262 15.3465 88.9262 12.9874C88.9262 10.5434 90.5305 9.39635 92.2878 9.39635C93.4797 9.39635 94.4986 9.96209 95.3447 10.9762L96.9036 9.63396C95.9286 8.3356 94.2109 7.29748 92.2864 7.29748C89.5101 7.29748 86.7593 9.39635 86.7593 12.9874C86.7537 16.5373 89.4421 18.6362 92.2184 18.6362Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M112.795 9.15309L113.403 9.28321V7.36112H111.299V18.3109H113.533V11.5575C113.533 10.2365 114.356 9.28462 115.571 9.28462C116.763 9.28462 117.609 10.2365 117.609 11.5575V18.3081H119.756V11.5575C119.756 10.2365 120.606 9.28462 121.75 9.28462C122.894 9.28462 123.68 10.1502 123.68 11.5575V18.3081H126V11.4302C126 8.8985 124.441 7.18716 122.293 7.18716C120.926 7.18716 119.821 7.85755 119.033 8.93952C118.448 7.85755 117.364 7.18716 116.019 7.18716C115.351 7.18154 114.695 7.36273 114.125 7.7102C113.555 8.05767 113.094 8.55753 112.795 9.15309Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M103.559 7.18857C100.328 7.18857 97.856 9.5689 97.856 12.8799C97.856 16.1908 100.328 18.5712 103.559 18.5712C106.875 18.5712 109.152 16.1668 109.152 12.8799C109.152 9.59294 106.875 7.18857 103.559 7.18857ZM103.623 16.4723C101.585 16.4723 100.024 14.9165 100.024 12.8148C100.024 10.7131 101.583 9.28745 103.623 9.28745C105.531 9.28745 106.984 10.7159 106.984 12.8148C106.984 14.9137 105.531 16.4723 103.623 16.4723Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M74.828 18.5712C75.8186 18.5553 76.7879 18.2814 77.6398 17.7765C78.4917 17.2717 79.1966 16.5534 79.6847 15.693L78.0223 14.611C77.7188 15.1879 77.2592 15.6681 76.6958 15.9972C76.1323 16.3262 75.4876 16.4908 74.835 16.4723C73.1443 16.4723 71.6038 15.2163 71.6038 12.8799C71.6038 10.4133 73.1443 9.28745 74.835 9.28745C76.0935 9.28745 77.1125 9.80651 78.0223 10.8885L79.4976 9.5689C78.9838 8.8385 78.3025 8.24133 77.5103 7.82725C76.7182 7.41317 75.8384 7.19418 74.9442 7.18857C72.1254 7.18857 69.3491 9.28744 69.3491 12.8799C69.3491 16.4723 72.0531 18.5712 74.828 18.5712Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M66.1987 5.43622C66.5357 5.43789 66.8657 5.33957 67.1467 5.15372C67.4276 4.96788 67.6469 4.7029 67.7767 4.39243C67.9065 4.08197 67.9409 3.74001 67.8755 3.41C67.8102 3.07998 67.648 2.77679 67.4097 2.53892C67.1713 2.30106 66.8675 2.13924 66.5368 2.07403C66.2062 2.00881 65.8635 2.04313 65.5524 2.17264C65.2413 2.30215 64.9758 2.521 64.7896 2.8014C64.6034 3.0818 64.5048 3.4111 64.5065 3.7475C64.5037 3.97005 64.5455 4.19093 64.6295 4.3971C64.7135 4.60327 64.8381 4.79057 64.9958 4.94795C65.1535 5.10534 65.3412 5.22962 65.5477 5.31348C65.7543 5.39733 65.9757 5.43907 66.1987 5.43622Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M67.2389 7.53508H65.0918V18.3109H67.2389V7.53508Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M62.2291 1.865H59.8879V18.3109H62.2291V1.865Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M52.5596 7.18857C50.934 7.18857 49.7408 7.85897 49.069 8.94094V1.86925H46.6839V18.3109H49.069V16.9475C49.7408 17.9644 50.934 18.5712 52.5596 18.5712C55.6774 18.5712 57.85 16.1668 57.85 12.8799C57.85 9.76408 55.5513 7.18857 52.5596 7.18857ZM52.3711 16.3662C50.2254 16.3662 48.7728 14.9165 48.7728 12.8827C48.7728 10.8913 50.2254 9.39918 52.3711 9.39918C54.3013 9.39918 55.6887 10.7838 55.6887 12.8827C55.6816 14.9137 54.2942 16.3662 52.3711 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M38.878 18.4623C40.0273 18.4623 40.9811 17.9644 41.6968 16.9475V18.3109H43.9303V7.53508H41.6316V13.7667C41.6316 15.3465 40.6778 16.3634 39.1161 16.3634C37.7938 16.3634 37.0781 15.2164 37.0781 13.7667V7.53508H34.7355V14.1344C34.7355 16.6491 36.2973 18.4623 38.878 18.4623Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M27.6028 7.18857C26.0438 7.18857 24.8491 7.85897 23.8727 8.94094V7.53508H21.5967V22.165H23.8727V16.9475C24.8491 17.9644 26.041 18.5712 27.6028 18.5712C30.7036 18.5712 32.9371 15.9957 32.9371 12.8799C32.9371 9.5689 30.7036 7.18857 27.6028 7.18857ZM27.2995 16.3662C25.0872 16.3662 23.765 14.9165 23.765 12.8827C23.765 10.8913 25.0872 9.39918 27.2995 9.39918C29.4026 9.39918 30.7007 10.8913 30.7007 12.8827C30.7036 14.9137 29.4026 16.3662 27.2995 16.3662Z" fill="var(--pw-core-color-greyscale-1000)"></path><path d="M7.19935 14.396C11.1754 14.396 14.3987 11.1734 14.3987 7.19802C14.3987 3.22266 11.1754 0 7.19935 0C3.22326 0 0 3.22266 0 7.19802C0 11.1734 3.22326 14.396 7.19935 14.396Z" fill="var(--pw-core-color-blue-600-day)"></path><path d="M3.59968 24C4.31066 24 5.00571 23.7895 5.59717 23.395C6.18863 23.0005 6.65002 22.4398 6.92312 21.7835C7.19622 21.1271 7.26882 20.4047 7.13176 19.7072C6.99469 19.0096 6.6541 18.3683 6.15294 17.8641C5.65178 17.3599 5.0125 17.0153 4.31573 16.8739C3.61897 16.7325 2.89592 16.8005 2.23778 17.0695C1.57964 17.3384 1.0159 17.7962 0.617646 18.385C0.219396 18.9739 0.00447861 19.6675 0 20.3783C0.000352998 21.3348 0.378999 22.2524 1.05334 22.9308C1.72769 23.6093 2.64302 23.9936 3.59968 24Z" fill="var(--pw-core-color-blue-600-day)"></path></svg><div class="page-footer_public__krJ86"><div style="margin-bottom:12px">Check the background of this firm on<!-- --> <a href="https://brokercheck.finra.org/" target="_blank" rel="noopener noreferrer nofollow">FINRA’s BrokerCheck</a>.</div><div style="display:block;font-size:12px"><a rel="noopener noreferrer nofollow" href="https://files.brokercheck.finra.org/crs_127818.pdf">Open to the Public Investing, Inc. Customer Relationship Summary</a></div></div></div></div></div><div class="page-footer_bottomContainer__EfadX" style="padding-bottom:0px"><div class="page-footer_subNavWrapper__8L4JP"><div class="page-footer_footerContainer__p7Hox"><ul class="page-footer_subNav__Ivgmr"><li><a href="../disclosures.html">Disclosures</a></li><li><a href="../privacy-policy.html">Privacy Policy</a></li><li><a href="../terms-of-service.html">Terms of Service</a></li><li><a href="../wp-content/uploads/2021/10/Fractional-Shares-Disclosure.pdf">Fractional Shares Disclosure</a></li><li><a href="../markets/top-gainers.html">Markets</a></li><li><a href="../directory/stocks.html">Stocks Directory</a></li><li><a href="../directory/etfs.html">ETFs Directory</a></li><li><a href="../directory/stocks-options-chain.html">Options Chain</a></li><li><a href="../directory/otc-stocks.html">OTC Stocks</a></li><li><a href="../how-to-buy/crypto.html">How to buy Crypto</a></li><li><a href="../treasuries/6-month-tbills.html">Buy T-bills</a></li></ul></div></div><div class="page-footer_footerContainer__p7Hox"><div class="page-footer-copyright_copyright__t2fcx"><p>© Copyright <!-- -->2025<!-- --> Public Holdings, Inc. All Rights Reserved.</p><p>Market data powered by<!-- --> <a href="https://xignite.com/" target="_blank" rel="noopener noreferrer nofollow">Xignite</a>.</p><p><b>All investments</b> involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.</p><p><b>Stocks, ETFs, Options, Bonds.</b><br/>Self-directed brokerage accounts and brokerage services for US-listed, registered securities, options, and Bonds, except for treasury securities offered through Jiko Securities, Inc., are offered to self-directed customers by Open to the Public Investing, Inc. (“Public Investing”), a registered broker-dealer and member of<!-- --> <a href="https://www.finra.org" target="_blank" rel="noopener noreferrer nofollow">FINRA</a> <!-- -->&amp;<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a>. Additional information about your broker can be found by clicking<!-- --> <a href="https://brokercheck.finra.org/" target="_blank" rel="noopener noreferrer nofollow">here</a>. Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Public Investing is not registered. Securities products offered by Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a> <!-- -->limits. Additional information can be found<!-- --> <a href="https://help.public.com/en/articles/6594797-frequently-asked-questions-sipc" target="_blank" rel="noopener noreferrer nofollow">here</a>.</p><p><b>Options.</b><br/>Certain requirements must be met in order to trade options. Options can be risky and are not suitable for all investors. Options transactions are often complex, and investors can rapidly lose the entire amount of their investment or more in a short period of time. Investors should consider their investment objectives and risks carefully before investing in options. Refer to the<!-- --> <a href="https://www.theocc.com/company-information/documents-and-archives/options-disclosure-document" rel="noopener noreferrer nofollow" target="_blank">Characteristics and Risks of Standardized Options</a> <!-- -->before considering any options transaction. Supporting documentation for any claims, if applicable, will be furnished upon request. Tax considerations with options transactions are unique and investors considering options should consult their tax advisor as to how taxes affect the outcome of each options strategy.</p><p><b>Options Order Flow Rebates.</b><br/>If you are enrolled in our Options Order Flow Rebate Program, Public Investing will share a percentage of our estimated order flow revenue for each completed options trade as a rebate to help reduce your trading costs. Rebate rates vary monthly from $0.06-$0.18 and depend on your current and prior month’s options trading volume. This rebate will be deducted from your cost to place the trade and will be reflected on your trade confirmation. To learn more, see our<!-- --> <a href="../disclosures/Options-Order-Flow-Rebate-Program-TCs-06.03.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Options Rebate Program Terms &amp; Conditions</a>,<!-- --> <a href="https://help.public.com/en/articles/8609726-what-are-order-flow-rebates" rel="noopener noreferrer nofollow" target="_blank">Order Rebate FAQ</a> <!-- -->and<!-- --> <a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Fee Schedule</a>.</p><p><b>Bonds.</b><br/>“Bonds” shall refer to corporate debt securities and U.S. government securities offered on the Public platform through a self-directed brokerage account held at Public Investing and custodied at Apex Clearing. For purposes of this section, Bonds exclude treasury securities held in treasury accounts with Jiko Securities, Inc. as explained under the “ Treasury Accounts” section.<br/><br/>Investments in Bonds are subject to various risks including risks related to interest rates, credit quality, market valuations, liquidity, prepayments, early redemption, corporate events, tax ramifications and other factors. The value of Bonds fluctuate and any investments sold prior to maturity may result in gain or loss of principal. In general, when interest rates go up, Bond prices typically drop, and vice versa. Bonds with higher yields or offered by issuers with lower credit ratings generally carry a higher degree of risk. All fixed income securities are subject to price change and availability, and yield is subject to change. Bond ratings, if provided, are third party opinions on the overall bond&#x27;s credit worthiness at the time the rating is assigned. Ratings are not recommendations to purchase, hold, or sell securities, and they do not address the market value of securities or their suitability for investment purposes.<br/><br/><em>A Bond Account is a self-directed brokerage account with Public Investing. Deposits into this account are used to purchase 10 investment-grade and high-yield bonds. The Bond Account’s yield is the average, annualized yield to worst (YTW) across all ten bonds in the Bond Account, before fees. A bond’s yield is a function of its market price, which can fluctuate; therefore a bond’s YTW is not “locked in” until the bond is purchased, and your yield at time of purchase may be different from the yield shown here. The “locked in” YTW is not guaranteed; you may receive less than the YTW of the bonds in the Bond Account if you sell any of the bonds before maturity or if the issuer defaults on the bond. Public Investing charges a markup on each bond trade. See our<!-- --> <a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Fee Schedule</a></em>. <br/><br/><em>Bond Accounts are not recommendations of individual bonds or default allocations. The bonds in the Bond Account have not been selected based on your needs or risk profile. You should evaluate each bond before investing in a Bond Account. The bonds in your Bond Account will not be rebalanced and allocations will not be updated, except for Corporate Actions.</em><br/><br/>Fractional Bonds also carry additional risks including that they are only available on Public and cannot be transferred to other brokerages. Read more about the risks associated with<!-- --> <a href="../disclosures/Open-to-the-Public-Investing-Inc.-Fixed-Income-Disclosure.pdf" rel="noopener noreferrer nofollow" target="_blank">fixed income</a> <!-- -->and<!-- --> <a href="../disclosures/OTTP-Apex-Fractional-Bond-Disclosure-1.pdf" rel="noopener noreferrer nofollow" target="_blank">fractional bonds</a>. See<!-- --> <a href="../disclosures/Bond-Account-Disclosure-1.pdf" rel="noopener noreferrer nofollow" target="_blank">Bond Account Disclosures</a> <!-- -->to learn more.<br/><br/><b id="disclosures-hyca">High-Yield Cash Account.</b><br/>A High-Yield Cash Account is a secondary brokerage account with Public Investing. Funds in your High-Yield Cash Account are automatically deposited into partner banks (“Partner Banks”), where that cash earns interest and is eligible for FDIC insurance. See<!-- --> <a href="../disclosures/APEX-High-Yield-Cash-Account-Bank-Partners-List-01.06.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">here</a> <!-- -->for a list of current Partner Banks. Your Annual Percentage Yield is variable and may change at the discretion of the Partner Banks or Public Investing. Apex Clearing and Public Investing receive administrative fees for operating this program, which reduce the amount of interest paid on swept cash. Neither Public Investing nor any of its affiliates is a bank.<!-- --> <a href="../disclosures/HIGH-YIELD-CASH-ACCOUNT-TERMS-AND-CONDITIONS-Effective-October-3-2024.pdf" rel="noopener noreferrer nofollow" target="_blank">Learn more</a>.</p><p><b>Cryptocurrency.</b><br/>Cryptocurrency trading, execution, and custody services are provided by Bakkt Crypto Solutions, LLC (NMLS ID 1828849) (“Bakkt”). Cryptocurrency is highly speculative, involves a high degree of risk, and has the potential for loss of the entire amount of an investment. Cryptocurrencies offered by Bakkt are not securities and are not FDIC insured or protected by<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a>. Your cryptocurrency assets are held in your Bakkt account. Bakkt is a licensed virtual currency business by the New York State Department of Financial Services and a licensed money transmitter, but is not a registered broker-dealer or a<!-- --> <a href="https://www.finra.org" target="_blank" rel="noopener noreferrer nofollow">FINRA</a> <!-- -->member. Your Bakkt Crypto account is separate from your brokerage account with Public Investing, which holds US-listed stocks and ETFs. Please review the<!-- --> <a href="https://public.com/disclosures/bakkt-crypto-risk-disclosure" target="_blank" rel="noopener noreferrer nofollow">Risk Disclosures</a> <!-- -->before trading.</p><p><b>Treasury Accounts.</b><br/>Investing services in treasury accounts offering 6 month US Treasury Bills on the Public platform are through Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of<!-- --> <a href="https://www.finra.org" target="_blank" rel="noopener noreferrer nofollow">FINRA</a> <!-- -->&amp;<!-- --> <a href="https://www.sipc.org" target="_blank" rel="noopener noreferrer nofollow">SIPC</a>. See JSI’s<!-- --> <a href="https://brokercheck.finra.org/firm/summary/287507" target="_blank" rel="noopener noreferrer nofollow">FINRA BrokerCheck</a> <!-- -->and<!-- --> <a href="https://jiko.io/docs/JikoSecuritiesFormCRS.pdf" target="_blank" rel="noopener noreferrer nofollow">Form CRS</a> <!-- -->for further information. JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). T-bills are purchased at a discount to the par value and the T-bill’s yield represents the difference in price between the “par value” and the “discount price.” Aggregate funds in your Treasury Account in excess of the T-bill purchases will remain in your Treasury Account as cash. The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability - yield is subject to change. Past performance is not indicative of future performance. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. Although T-bills are considered safer than many other financial instruments, you could lose all or a part of your investment. See<!-- --> <a href="../disclosures/treasuries_risk_disclosure.pdf" target="_blank" rel="noopener noreferrer nofollow">Jiko U.S. Treasuries Risk Disclosures</a> <!-- -->for further details.<br/><br/><b>Investments in T-bills: Not FDIC Insured; No Bank Guarantee; May Lose Value.</b><br/><br/>Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.<br/><br/><b>Commission-free</b> trading refers to $0 commissions charged on trades of US listed registered securities placed during the US Markets Regular Trading Hours in self-directed brokerage accounts offered by Public Investing. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see<!-- --> <a href="../disclosures/Public-Fee-Schedule-07.01.2025.pdf" rel="noopener noreferrer nofollow" target="_blank">Public’s Investing’s Fee Schedule</a> <!-- -->to learn more.<br/><br/><b>Fractional shares</b> are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our<!-- --> <a href="https://public.com//disclosures/public-fractional-shares-disclosure" rel="noopener noreferrer nofollow" target="_blank">Fractional Share Disclosure</a> <!-- -->to learn more.</p><p><b>Investment Plans.</b> Investment Plans (“Plans”) shown in our marketplace are for informational purposes only and are meant as helpful starting points as you discover, research and create a Plan that meets your specific investing needs. Plans are self-directed purchases of individually-selected assets, which may include stocks, ETFs and cryptocurrency. Plans are not recommendations of a Plan overall or its individual holdings or default allocations. Plans are created using defined, objective criteria based on generally accepted investment theory; they are not based on your needs or risk profile. You are responsible for establishing and maintaining allocations among assets within your Plan. Plans involve continuous investments, regardless of market conditions. Diversification does not eliminate risk. See our<!-- --> <a href="../disclosures/investment-plans.html" target="_blank" rel="noopener noreferrer nofollow">Investment Plans Terms and Conditions</a> <!-- -->and<!-- --> <a href="../disclosures/sponsored-content-disclosure.html" target="_blank" rel="noopener noreferrer nofollow">Sponsored Content and Conflicts of Interest Disclosure</a>.</p><p><b>Alpha.</b><br/>Alpha is an experiment brought to you by Public Holdings, Inc. (“Public”). Alpha is an AI research tool powered by GPT-4, a generative large language model. Alpha is experimental technology and may give inaccurate or inappropriate responses. Output from Alpha should not be construed as investment research or recommendations, and should not serve as the basis for any investment decision. All Alpha output is provided “as is.” Public makes no representations or warranties with respect to the accuracy, completeness, quality, timeliness, or any other characteristic of such output. Your use of Alpha output is at your sole risk. Please independently evaluate and verify the accuracy of any such output for your own use case.</p><p><b>Market Data.</b><br/>Quotes and other market data for Public’s product offerings are obtained from third party sources believed to be reliable, but Public makes no representation or warranty regarding the quality, accuracy, timeliness, and/or completeness of this information. Such information is time sensitive and subject to change based on market conditions and other factors. You assume full responsibility for any trading decisions you make based upon the market data provided, and Public is not liable for any loss caused directly or indirectly by your use of such information. Market data is provided solely for informational and/or educational purposes only. It is not intended as a recommendation and does not represent a solicitation or an offer to buy or sell any particular security.</p><div class="page-footer-copyright_disclosures__VYLbz"><a href="../disclosures.html" target="_blank" rel="nofollow">View Full Disclosures</a></div></div></div></div></footer><section class="Toastify" aria-live="polite" aria-atomic="false" aria-relevant="additions text" aria-label="Notifications Alt+T"></section></div><div id="drawer-root"></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"theme":{"themeId":"b6a2f00a-f413-4d26-8993-b56ea7d40863","name":"Fighting Disease","description":"Companies leading the charge to cure existing and emerging diseases.","detailedDescription":"As humans have evolved so has our capacity to fend off and prevent diseases that threaten our wellbeing. From existing diseases like cancer—which stands to affect nearly 40% of people at some point in their lifetimes—to viruses like COVID-19, public companies remain tireless in their pursuit for a cure. This theme includes disease-fighting public companies like Eli Lilly, Exelixis, Moderna, and Pfizer.","imageUrl":"https://prod-api.154310543964.hellopublic.com/static/themes/images/j7tsYLk5nOprVqlmnjpe0nxuopq0DIO5.jpg","followersCount":1144,"shareUrl":"https://public.com/themes/fighting-disease","assetCount":36,"following":false},"themeDetails":{"theme":{"themeId":"b6a2f00a-f413-4d26-8993-b56ea7d40863","name":"Fighting Disease","description":"Companies leading the charge to cure existing and emerging diseases.","detailedDescription":"As humans have evolved so has our capacity to fend off and prevent diseases that threaten our wellbeing. From existing diseases like cancer—which stands to affect nearly 40% of people at some point in their lifetimes—to viruses like COVID-19, public companies remain tireless in their pursuit for a cure. This theme includes disease-fighting public companies like Eli Lilly, Exelixis, Moderna, and Pfizer.","imageUrl":"https://prod-api.154310543964.hellopublic.com/static/themes/images/j7tsYLk5nOprVqlmnjpe0nxuopq0DIO5.jpg","followersCount":1144,"shareUrl":"https://public.com/themes/fighting-disease","assetCount":36,"following":false},"entities":[{"instrument":{"symbol":"SYRS","name":"Syros Pharmaceuticals","displayName":"Syros Pharmaceuticals","availableForFractional":false,"availableForTrade":true,"safetyLabel":"LOW_MARKET_CAP","trading":"LIQUIDATION_ONLY","optionsTrading":"LIQUIDATION_ONLY","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"HTBX","name":"Heat Biologics","displayName":"Heat Biologics","availableForFractional":false,"availableForTrade":false,"safetyLabel":null,"trading":"DISABLED","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"DISABLED","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":"CORPORATE_ACTION","newSymbol":"NHWK","newSymbolDate":"2022-05-03","nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"BLUE","name":"bluebird bio","displayName":"bluebird bio","availableForFractional":false,"availableForTrade":false,"safetyLabel":null,"trading":"DISABLED","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"DISABLED","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":"CORPORATE_ACTION","newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"EXAS","name":"Exact Sciences","displayName":"Exact Sciences","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"CNCR","name":"Loncar Cancer Immunotherapy ETF","displayName":"Loncar Cancer Immunotherapy ETF","availableForFractional":false,"availableForTrade":false,"safetyLabel":null,"trading":"DISABLED","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"DISABLED","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":"CORPORATE_ACTION","newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"MRK","name":"Merck","displayName":"Merck","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"JNJ","name":"Johnson \u0026 Johnson","displayName":"Johnson \u0026 Johnson","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"991ac2c0-10e3-49d8-b22a-4242809b1e0a","name":"Band-Aid","description":"Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson \u0026 Johnson's line of adhesive bandages.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/CwQJW5U6T8qn3gTGSJ8NAQ-thumbnail-300x300.png"},{"id":"c0f1df33-fd89-4694-a64c-bbc8e08150c6","name":"Johnson's Baby","description":"Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson \u0026 Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are \"exceptionally pure and safe\" since at least the 1980s.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/GF2PYlfLR7erH4K6Y06wfw-thumbnail-300x300.png"},{"id":"2ebdeee4-cf0d-4e2f-9c79-b046219f40c8","name":"Aveeno","description":"Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson \u0026 Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as \"active naturals\". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/o-Da42b-RnGPugGo9fqsQg-thumbnail-300x300.png"},{"id":"fc95f1ae-7e45-405e-abe8-8c7e693ba6d3","name":"Neutrogena","description":"Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson \u0026 Johnson conglomerate, which bought the independent company in 1994.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/cNboxYyWSH2QkyiD_hwQIg-thumbnail-300x300.png"},{"id":"d1a06e37-95db-44c7-af85-6abb70098f3b","name":"Clean \u0026 Clear","description":"Clean \u0026 Clear is a line of dermatology products owned by Johnson \u0026 Johnson.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/EfFq5FJeSkSy2FxvfZM7uw-thumbnail-300x300.png"},{"id":"2b4670e8-2026-4eb0-8cf9-eeb8d9fe9594","name":"Listerine","description":"Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan \"Kills germs that cause bad breath\". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/b91I8WMrR6eS597Ijmfnfg-thumbnail-300x300.png"},{"id":"6bb90554-3714-40d1-9389-9b0ba059ce30","name":"Acuvue","description":"Acuvue (from \"Accurate view\") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson \u0026 Johnson (J\u0026J).","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/HRg_EuzuQLikpv8s1hoaMw-thumbnail-300x300.png"}]},{"instrument":{"symbol":"NVS","name":"Novartis","displayName":"Novartis","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"INO","name":"Inovio Pharmaceuticals","displayName":"Inovio Pharmaceuticals","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"ADAP","name":"Adaptimmune Therapeutics","displayName":"Adaptimmune Therapeutics","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"AMGN","name":"Amgen","displayName":"Amgen","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"PFE","name":"Pfizer","displayName":"Pfizer","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"ffb43038-b3d2-4497-9554-e92419796323","name":"Viagra","description":"Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/rf3apah-STiWyE-CZoyjfw-thumbnail-300x300.png"},{"id":"234b3335-b8fe-473f-b3fb-7c171adbae82","name":"Lipitor","description":"Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/_FLhgMqmS5uobmmLP67-Gw-thumbnail-300x300.png"}]},{"instrument":{"symbol":"AGIO","name":"Agios Pharmaceuticals","displayName":"Agios Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"ABT","name":"Abbott Labs","displayName":"Abbott Labs","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"0a0ac13a-8169-43ec-b4e5-fa585d338059","name":"St. Jude Medical","description":"St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.","imageUrl":null}]},{"instrument":{"symbol":"BDX","name":"Becton, Dickinson and Co.","displayName":"Becton, Dickinson and Co.","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"LLY","name":"Eli Lilly","displayName":"Eli Lilly","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"ec3556ba-e79c-48e8-9ed1-e77000e792af","name":"Cialis","description":"Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/NE3e8MaGRpWGaIVfh2dyOA-thumbnail-300x300.png"},{"id":"f0b9c23d-1faf-48ed-b14b-278aaf2be224","name":"Cymbalta","description":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/W4Hje2KxTJSKQx2cWRmXCw-thumbnail-300x300.png"},{"id":"8bfcfab4-31f4-48ce-9850-ae6cf2e67793","name":"Gemzar","description":"Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/sdJ66TnJSuSW_ZR8LtCOPA-thumbnail-300x300.png"},{"id":"ef47a1fc-917d-485e-92c7-29179d2d2b2a","name":"Methadone","description":"Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/hNwNMQUTReeWrrzWD4Gw6Q-thumbnail-300x300.png"},{"id":"e7579738-4aea-491d-8933-ab78dd6af1d4","name":"Prozac","description":"Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/xMWfDQuxRLqCugqvTgLeGQ-thumbnail-300x300.png"}]},{"instrument":{"symbol":"NVAX","name":"Novavax","displayName":"Novavax","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"XBI","name":"SPDR S\u0026P Biotech ETF","displayName":"SPDR S\u0026P Biotech ETF","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"SNY","name":"Sanofi","displayName":"Sanofi","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"NKTR","name":"Nektar Therapeutics","displayName":"Nektar Therapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"VHT","name":"Vanguard Health Care ETF","displayName":"Vanguard Health Care ETF","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"XLV","name":"Health Care Select Sector SPDR Fund","displayName":"Health Care Select Sector SPDR Fund","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"DVAX","name":"Dynavax Technologies","displayName":"Dynavax Technologies","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"ABBV","name":"AbbVie","displayName":"AbbVie","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"VXRT","name":"Vaxart","displayName":"Vaxart","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"LIQUIDATION_ONLY","optionsTrading":"LIQUIDATION_ONLY","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"IDNA","name":"iShares Genomics Immunology and Healthcare ETF","displayName":"iShares Genomics Immunology and Healthcare ETF","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"BMY","name":"Bristol-Myers","displayName":"Bristol-Myers","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"AZN","name":"AstraZeneca","displayName":"AstraZeneca","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[{"id":"175fe1d9-21d7-4dd7-8e54-c3fca29aada9","name":"MedImmune","description":"MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.","imageUrl":null}]},{"instrument":{"symbol":"INCY","name":"Incyte","displayName":"Incyte","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"KPTI","name":"Karyopharm Therapeutics","displayName":"Karyopharm Therapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"EXEL","name":"Exelixis","displayName":"Exelixis","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"GILD","name":"Gilead Sciences","displayName":"Gilead Sciences","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"MRNA","name":"Moderna","displayName":"Moderna","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"REGN","name":"Regeneron Pharmaceuticals","displayName":"Regeneron Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"ATRA","name":"Atara Biotherapeutics","displayName":"Atara Biotherapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"LIQUIDATION_ONLY","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]},{"instrument":{"symbol":"TAK","name":"Takeda Pharmaceutical","displayName":"Takeda Pharmaceutical","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null},"brands":[]}]},"universalThemesSeo":{"404866be-d726-4025-8d80-eb93f8737ca7":{"title":"Invest in companies that help you stay at home","description":"Invest in companies that help you stay at home, socially distant stocks \u0026 ETFs. #StayHome  Public offers commission-free trading and much more."},"ff0bb2e1-d3fc-499f-885a-fed54faaca08":{"title":"Invest in diverse \u0026 inclusive companies","description":"Invest in diverse \u0026 inclusivity-focused companies.  Public offers commission-free trading and much more."},"6b636830-4b33-4463-9374-530df175099a":{"title":"Invest in online sports \u0026 e-gaming companies","description":"Invest in online sports \u0026 e-gaming companies leading the charge in e-sports.  Public offers commission-free trading and much more."},"ceca1ad1-1c87-408d-a8a3-9b4255f1ffd3":{"title":"Invest in American companies","description":"Invest in American companies creating products that are \"made in America.\" Public offers commission-free trading and much more."},"97eebf4d-7db4-459e-bfd9-c051349741b0":{"title":"Invest in entertainment companies","description":"Invest in entertainment companies creating original content and distributing through streaming and traditional media outlets. Public offers commission-free trading and much more."},"7fdc398e-82fb-427a-82b1-16081d91ad31":{"title":"Invest in dividend paying companies","description":"Invest in dividend paying companies. Cash-rich companies that pay out regular dividends to investors.  Public offers commission-free trading and much more."},"33501ded-1571-4771-a8f1-4e2d13f7d154":{"title":"Invest in exchange-traded funds (ETFs)","description":"Invest in exchange-traded funds (ETFs). See a list of popular ETFs available in slices or fractional shares.  Public offers commission-free trading and much more."},"b6a2f00a-f413-4d26-8993-b56ea7d40863":{"title":"Invest in biomedical companies","description":"Invest in biomedical companies leading the charge to cure existing and emerging diseases.  Public offers commission-free trading and much more."},"f8c1f55a-66a8-47c6-9630-c9b7681390d8":{"title":"Invest in food delivery companies","description":"Invest in food deliver companies bringing the food you crave right to your face.  Public offers commission-free trading and much more."},"89550b52-5f22-4d85-b496-e223ca665aa3":{"title":"Invest in women-lead companies","description":"Invest in women-lead companies.  Public offers commission-free trading and much more."},"56cc8582-47c5-4f28-a19b-c236771c55ba":{"title":"Invest in e-commerce companies","description":"Invest in e-commerce companies that make it possible to shop from home in your pajamas.  Public offers commission-free trading and much more."},"de697c24-50f2-4c76-9ad0-047a850c3985":{"title":"Invest in sustainable \u0026 renewable energy companies","description":"Invest in sustainable and renewable energy companies.  Public offers commission-free trading and much more."},"4ce0e525-91dd-4573-8279-d5df93d33599":{"title":"Invest in plant-based food companies","description":"Invest in plant-based food companies that are innovating for a better-tasting green food future.  Public offers commission-free trading and much more."},"c11fb986-0bef-4152-8dcd-00dfd61e92c8":{"title":"Invest in recycling technology companies","description":"Invest in recycling technology companies foused on converting waste materials into reusable products.  Public offers commission-free trading and much more."},"707451b9-c565-425e-a21e-8c8c3fec181a":{"title":"Invest in cannabis companies","description":"Invest in cannabis companies. Cannabis (or Cannabiz) is growing rapidly, these companies offer you a chance to be a part.  Public offers commission-free trading and much more."},"1ff640fa-1f33-4a2d-a064-7dfc869f5308":{"title":"Invest in green companies","description":"Invest in green companies and those actively working to lower their carbon footprint.  Public offers commission-free trading and much more."},"37570678-4725-4b20-983f-1696ab16704b":{"title":"Invest in artificial intelligence \u0026 machine learning companies","description":"Invest in artificial intelligence \u0026 machine learning companies pushing the boundaries of AI, automation, and machine learning.  Public offers commission-free trading and much more."},"18d99fa8-7f86-486a-a364-f3074432496b":{"title":"Invest in SAAS \u0026 cloud companies","description":"Invest in software-as-a-service (SAAS) \u0026 cloud computing companies powering the present \u0026 future of business.  Public offers commission-free trading and much more."},"85f91c15-5859-4d1a-b8a0-1e4bf7617928":{"title":"Invest in virtual \u0026 augmented reality companies","description":"Invest in virtual (VR) \u0026 augmented (AR) reality companies.  VR \u0026 AR is a growing a tech sector. Public offers commission-free trading and much more."},"4f307f38-d692-4e35-8338-3e01259e8336":{"title":"Invest in media companies","description":"Invest in media companies that are behind the headlines and stories you read on your phone, TV, and everywhere else.  Public offers commission-free trading and much more."},"f7108117-fa99-422d-9642-e3d58e0b53ec":{"title":"Invest in space technology companies","description":"Invest in space technology companies that are poised to lead exploration of the final frontier.  Public offers commission-free trading and much more."},"5ba5f619-9c46-49cb-9cce-05f702105fec":{"title":"Invest in self-driving car technology companies","description":"Invest in self-driving car technology companies that are pioneering the self-driving car movement and networks that power them.  Public offers commission-free trading and much more."},"b4f9ba56-f8e2-4a17-85eb-7757c44f8f98":{"title":"Invest in social cause companies","description":"Invest in companies focused on creating a more conscientious, fair, and sustainable future.  Public offers commission-free trading and much more."},"fe6aa965-1c1a-4f6f-b6c1-90aa590f4496":{"title":"Invest in wearable technology companies","description":"Invest in wearable technology companies that are creating internet-enabled wearable devices.  Public offers commission-free trading and much more."},"2a206e44-2387-4810-807d-8d10034a186a":{"title":"Invest in biotechnology \u0026 genetic engineering companies","description":"Invest in biotechnology \u0026 genetic engineering companies.  Public offers commission-free trading and much more."},"a2a014d4-d9f3-4fc3-bf28-1d51d96c1a93":{"title":"Invest in payment processing companies","description":"Invest in companies behind payment processing and transactions.  Public offers commission-free trading and much more."},"c85cb917-b178-406f-a1c3-2fe925becb53":{"title":"Invest in large tech companies","description":"Invest in large tech companies that are some of the biggest companies in the world.  Public offers commission-free trading and much more."},"fdc1b410-e77e-4bb3-be55-3591d7856761":{"title":"Invest in blockchain technology companies","description":"Invest in blockchain technology companies that are leading the future of data security and the blockchain.  Public offers commission-free trading and much more."},"a08c9f31-cd53-4b01-82f3-fb7caa930acb":{"title":"Invest in health \u0026 wellness companies","description":"Invest in ahealth \u0026 wellness companies that are leaders in the active lifestyle community.  Public offers commission-free trading and much more."},"20386349-2797-4294-8692-8cb8f44866ed":{"title":"Invest in home \u0026 garden companies","description":"Invest in home \u0026 garden companies that are leading the way to help people improve their homes.  Public offers commission-free trading and much more."},"d323ee49-661c-4652-b944-bcf693a783e0":{"title":"Invest in privacy \u0026 security companies","description":"Invest in privacy and security companies that are devoted to keeping your information safe \u0026 secure.  Public offers commission-free trading and much more."},"a2fde2b2-70e9-46c1-8867-34684476206a":{"title":"Invest in household goods companies","description":"Invest in household goods companies that are likely found in almost any home pantry.  Public offers commission-free trading and much more."},"84f39b66-47a7-44c1-bbab-4f1f3cd8777f":{"title":"Invest in water technology companies","description":"Invest in water technology companies responsible for supplying and purifying drinking water.  Public offers commission-free trading and much more."},"ed06c94c-1b5e-41b2-a7de-2857c7b1c6d6":{"title":"Invest in telecom, communications, \u0026 I.T. companies","description":"Invest in telecom, communications, and information technology companies powering how we communicate.  Public offers commission-free trading and much more."},"35dee11e-1aa4-4d26-86e9-f312fae328d9":{"title":"Invest in Chinese companies","description":"Invest in Chinese companies. China is the world's second-largest economy and these companies are major players in it.  Public offers commission-free trading and much more."},"cc537995-40ac-44e6-b46f-3de00eeeacfc":{"title":"Invest in small businesses","description":"Invest in small businesses and the companies that power the small business economy.  Public offers commission-free trading and much more."},"af6fcef0-3a9c-4ec1-802f-a98c88b99956":{"title":"Invest in creative companies","description":"Invest in creative companies that are widely recognized for their design and creative output.  Public offers commission-free trading and much more."},"cNNSTHmE3jYrXlLbUEFqhawGn4GndJvr":{"title":"Invest in cryptocurrency \u0026 blockchain companies","description":""},"Y0wjKD4Ph4kyUYeBoLwNHW2OgmyxizYK":{"title":"Invest in SPACs","description":""},"MLDbQ7kMv18aMPSrkD35s9UXnibRuCDy":{"title":"Invest in education tech companies","description":""},"2KTdBiugykLbR5Oj9kmk5qHQhiseGLJM":{"title":"Invest in the top 20 most popular stocks","description":""},"jHoxWfr2cD9dJevSO0BDWJbfgGVDqZSW":{"title":"Invest in the business of sports \u0026 eSports","description":""}},"instruments":[{"instrument":{"symbol":"BDX","name":"Becton, Dickinson and Co.","displayName":"Becton, Dickinson and Co.","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"BDX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":182.58,"high":185.35,"low":181.33,"volume":4,"volumeDate":"2025-07-25","last":183.63,"open":182.28,"gainPercentage":0.575,"gainValue":1.05,"ask":186,"bid":182.88,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":52629643400,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":3239022.9355,"highPriceLast52Weeks":251.985,"lowPriceLast52Weeks":163.33,"companyName":"Becton, Dickinson \u0026 Co.","longBusinessDescription":"Becton, Dickinson \u0026 Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.","dividendRate":4.07,"salesOrRevenue":20178000000,"oneYearAnnualRevenueGrowthRate":4.16064422878381,"threeYearAnnualRevenueGrowthRate":1.8189,"fiveYearAnnualRevenueGrowthRate":4.7174,"earningsGrowth":15.1177,"totalDebt":20919000000,"totalAssets":57286000000,"floatAsPercentOfSharesOutstanding":99.8182,"dividendYield":2.22,"betaTwelveMonth":0.4737,"salesOrRevenueTtm":20867000000,"ebitdaTtm":4955000000,"debtToEquityRatioQuarterly":76.3440434214175,"totalEnterpriseValue":88780269900,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":5.27692307692308,"fiveYearAverageDebtEquityRatio":66.93,"currentRatio":1.1267715511637,"peratio":35.04},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":234.89,"totalRatings":22,"strongSellRatings":0,"sellRatings":0,"holdRatings":10,"buyRatings":6,"strongBuyRatings":6,"lastUpdated":"2025-06-03T12:31:40Z"},"earningEstimates":[{"actual":2.59,"estimate":2.46,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2021-11-04T10:16:54Z","audioUrl":"https://files.quartr.com/audio-files/5c479-2022-10-19-04-23-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/787fd-2021-11-04-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c64d7-2023-01-25-10-25-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":3.64,"estimate":2.85,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-02-03T11:44:09Z","audioUrl":"https://files.quartr.com/audio-files/723ae-2022-10-19-10-24-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/06273-2022-02-03-02-49-44-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/18ac7-2023-01-25-12-04-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-03T02:44:49Z","earningsSummary":null},{"actual":3.18,"estimate":2.99,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-05-05T10:42:37Z","audioUrl":"https://files.quartr.com/audio-files/0d81d-2022-10-28-05-36-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a1fcb-2022-05-05-12-04-33-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b7de4-2023-01-25-02-37-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-05T12:33:04Z","earningsSummary":null},{"actual":2.66,"estimate":2.5,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-08-04T10:44:17Z","audioUrl":"https://files.quartr.com/audio-files/496d6-2022-08-04-05-32-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2e489-2022-08-04-11-23-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4a9dc-2022-08-04-11-18-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T00:55:00Z","earningsSummary":null},{"actual":2.75,"estimate":2.74,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2022-11-10T11:32:53Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_10T13_00_00_00_00_Becton_Dickinson_and_Co_Earnings_Call_Q4_2022.5W2NX36B1SAC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/564db-2022-11-10-12-10-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6e2cf-2022-11-10-12-56-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-10T13:45:00Z","earningsSummary":null},{"actual":2.98,"estimate":2.68,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-02-02T11:37:41Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T13_00_00_00_00_Becton_Dickinson_and_Co_Earnings_Call_Q1_2023.PTIVJD2NMRSU_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/bcc7f-2023-02-02-12-41-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/d4dbf-2023-02-02-12-39-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T13:00:00Z","earningsSummary":{"summary":"Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.\nWhile facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.\nStrategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.","headline":"BDX surpasses Q1 expectations, eyes growth amid market challenges","lastUpdated":"2024-05-07T11:25:30.309302Z"}},{"actual":2.86,"estimate":2.74,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-05-04T10:31:40Z","audioUrl":"https://files.quartr.com/audio-files/1a2ae-2023-05-04-05-14-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/edfb7-2023-05-04-10-21-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/63223-2023-05-04-10-47-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:00:00Z","earningsSummary":{"summary":"Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.\nThe company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.\nOpportunities for BDX include leveraging M\u0026A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.\nOverall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.","headline":"BDX reports strong Q2 performance, raises guidance for growth","lastUpdated":"2024-05-07T13:55:08.112348Z"}},{"actual":2.96,"estimate":2.91,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-08-03T10:33:16Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T12_00_00_00_00_Becton__Dickinson_and_Company_Q3_2023.K92J5IOZS6VW_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/25389-2023-08-03-11-06-02.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/86e80-2023-08-03-11-06-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T12:00:00Z","earningsSummary":{"summary":"BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.\nThe company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.\nDespite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.","headline":"BDX reports robust Q3 earnings, focuses on Alaris system growth","lastUpdated":"2024-05-07T11:56:58.128502Z"}},{"actual":3.42,"estimate":3.43,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2023-11-09T11:34:02Z","audioUrl":"https://files.quartr.com/audio-files/03656-2023-11-09-02-14-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a8564-2023-11-09-12-46-25.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/fa15c-2023-11-09-11-19-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-09T13:00:00Z","earningsSummary":{"summary":"BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches\nChallenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement\nFocus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation\nConfidence in achieving operating margin guidance and strong performance in FY '24","headline":"BD reports strong Q4 earnings, eyes growth amid challenges","lastUpdated":"2024-05-07T12:15:47.721691Z"}},{"actual":2.68,"estimate":2.4,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-02-01T11:30:38Z","audioUrl":"https://files.quartr.com/audio-files/fa592-2024-02-01-02-28-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/360db-2024-02-01-11-30-36.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d0e0a-2024-02-01-11-51-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-01T13:00:00Z","earningsSummary":{"summary":"BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.\nRaised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.\nOpportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.","headline":"Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities","lastUpdated":"2024-05-07T10:33:24.441575Z"}},{"actual":3.17,"estimate":2.97,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-05-02T10:30:57Z","audioUrl":"https://files.quartr.com/audio-files/362c8-2024-05-02-01-26-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6647e-2024-05-02-10-32-35.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/82c47-2024-05-02-10-57-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T12:00:00Z","earningsSummary":{"summary":"Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.","headline":"BDX reports robust Q2 earnings, focuses on innovation and growth","lastUpdated":"2024-05-07T10:16:12.396760Z"}},{"actual":3.5,"estimate":3.31,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-08-01T10:31:34Z","audioUrl":"https://files.quartr.com/audio-files/93a34-2024-08-01-01-55-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f81d8-2024-08-01-10-14-36.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/fd9eb-2024-08-01-10-26-35.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:00:00Z","earningsSummary":{"summary":"Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.","headline":"BDX excels in Q3 with strong revenue growth and operational efficiency","lastUpdated":"2024-08-01T16:37:42.174325Z"}},{"actual":3.81,"estimate":3.77,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2024-11-07T11:32:34Z","audioUrl":"https://files.quartr.com/audio-files/d78d3-2024-11-07-02-36-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f0773-2024-11-07-11-14-44.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2b382-2024-11-07-11-09-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-07T13:00:00Z","earningsSummary":{"summary":"BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.\nThe company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.\nWhile facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.","headline":"BDX reports robust Q4 earnings, eyes growth amid market complexities","lastUpdated":"2024-11-07T18:28:36.259665Z"}},{"actual":3.43,"estimate":2.99,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-02-05T22:56:02Z","audioUrl":"https://files.quartr.com/audio-files/d7971-2025-02-06-02-41-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0c806-2025-02-06-12-52-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f8c89-2025-02-06-12-57-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-06T13:00:00Z","earningsSummary":{"summary":"BDX's Q1 performance surpassed expectations, showcasing strong financial growth and a commitment to shareholder returns. The decision to separate business segments reflects a strategic move to enhance value and drive innovation.","headline":"Becton, Dickinson and Co. exceeds Q1 goals, plans strategic separation","lastUpdated":"2025-02-06T15:52:10.827193Z"}},{"actual":3.35,"estimate":3.28,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-05-01T10:34:30Z","audioUrl":"https://files.quartr.com/audio-files/55dca-2025-05-01-01-00-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e1156-2025-05-01-11-06-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9357a-2025-05-01-10-32-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T12:00:00Z","earningsSummary":{"summary":"BD's Q2 performance showed mixed results with revenue growth slightly below expectations but strong EPS. The company faces challenges in Life Sciences and Diagnostics but is taking strategic actions to drive growth and address market dynamics.","headline":"Becton, Dickinson and Co. reports Q2 results, adjusts guidance amid challenges","lastUpdated":"2025-05-01T15:42:24.603812Z"}},{"actual":null,"estimate":3.41,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:26Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q4 2021","quarter":"Q4","hash":"b97aafa70103b82366ee0625cf0099d205c8c993fad5e429112b80708fb40b76"},{"date":"2022-02-03","title":"Earnings data Q1 2022","quarter":"Q1","hash":"de56dd3001946435430c3102e4550beafc5dd8c980ea2ed254a6244e505464c1"},{"date":"2022-05-05","title":"Earnings data Q2 2022","quarter":"Q2","hash":"da5bf0bde4a0606571b8edb549ec386247050f8cec0137561e2c18f7b28670d1"},{"date":"2022-08-04","title":"Earnings data Q3 2022","quarter":"Q3","hash":"936eb217d813eff12453d9c7f8588082635995f06656b759c37f8be7e82799b6"},{"date":"2022-11-10","title":"Earnings data Q4 2022","quarter":"Q4","hash":"9fb63132b1a3d70ffaf9ee0229857b7a602f7b6b564a835e90c09089073a5001"},{"date":"2023-02-02","title":"Earnings data Q1 2023","quarter":"Q1","hash":"8ad369a8e8029f37e447fddfcdb866cd90459a054e28fe4fd763639d9c5dbd16"},{"date":"2023-05-04","title":"Earnings data Q2 2023","quarter":"Q2","hash":"0f0102f20724624c8dfd97da5367c17e9d6ab8129e02aa855bfb871dca4776e7"},{"date":"2023-08-03","title":"Earnings data Q3 2023","quarter":"Q3","hash":"9e4adbcb265017a378957c02e7c59638f734421af4e16319b2391338091072ba"},{"date":"2023-11-09","title":"Earnings data Q4 2023","quarter":"Q4","hash":"5fdeef154536b4cc094ba0b64f0a6725f6dc8b9940c4eef4d0ce2fa55d4cc237"},{"date":"2024-02-01","title":"Earnings data Q1 2024","quarter":"Q1","hash":"b48f2b59551b247980fb53da1e6b12a1d8b0c5a7f416ed8a644a6780a6cb5969"},{"date":"2024-05-02","title":"Earnings data Q2 2024","quarter":"Q2","hash":"4be65b04fb09361772636ed650f91070458a00c8dbe0aab01c455b1e7d7f32ee"},{"date":"2024-08-01","title":"Earnings data Q3 2024","quarter":"Q3","hash":"d429130722403c4b0a83016a57449a13572e5a34aab26ba1d4e0c0a7c3067e61"},{"date":"2024-11-07","title":"Earnings data Q4 2024","quarter":"Q4","hash":"82179b8c3af9997a5600ae1b54f3a1885167ca726061faa010069d67be02a3a1"},{"date":"2025-02-05","title":"Earnings data Q1 2025","quarter":"Q1","hash":"39b9f28394d3ca7d3ca0efec6797d66f83dcf8dd596836b12529157395957810"},{"date":"2025-05-01","title":"Earnings data Q2 2025","quarter":"Q2","hash":"684ea103f29fcf95b2d497319e6c059ab4b28017b04fff743822c14c8ab171c7"},{"date":"2025-08-07","title":"Earnings data Q3 2025","quarter":"Q3","hash":"27c2410b16549b3497922af8f9a621eaa699aebb64ab9a4f4cad0a32df7f2f79"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Becton, Dickinson and Co.","companyDescription":"Becton, Dickinson \u0026 Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":5272000000,"changePercentage":4.5,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3015000000,"changePercentage":10,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":2257000000,"changePercentage":-2.04,"valueToRevenueRatio":0.42811077389984825},{"financialKey":"OPERATING_EXPENSES","value":1610000000,"changePercentage":9.6,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":1575000000,"changePercentage":5.56,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":35000000,"changePercentage":252.17,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":647000000,"changePercentage":-22.51,"valueToRevenueRatio":0.12272382397572079},{"financialKey":"EBITDA","value":1255000000,"changePercentage":-10.74,"valueToRevenueRatio":0.23805007587253416},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":608000000,"changePercentage":6.48,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":308000000,"changePercentage":-42.64,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.0704,"changePercentage":-42.12,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":54467000000,"changePercentage":0.57,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":8666000000,"changePercentage":-16.19,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":763000000,"changePercentage":-76.31,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":3029000000,"changePercentage":18.37,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":3723000000,"changePercentage":15.3,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":1151000000,"changePercentage":-13.46,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":45801000000,"changePercentage":4.53,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":6646000000,"changePercentage":0.83,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":36579000000,"changePercentage":5.03,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":2576000000,"changePercentage":7.38,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":29226000000,"changePercentage":2.51,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":7691000000,"changePercentage":4.97,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":1604000000,"changePercentage":-20.44,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":6087000000,"changePercentage":14.61,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":21535000000,"changePercentage":1.67,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":17666000000,"changePercentage":10.45,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":3869000000,"changePercentage":-25.41,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":25241000000,"changePercentage":-1.58,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":25241000000,"changePercentage":-1.58,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":54467000000,"changePercentage":0.57,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":19270000000,"changePercentage":6.99,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":18507000000,"changePercentage":25.13,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":88.0682,"changePercentage":-0.76,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":308000000,"changePercentage":-42.64,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":164000000,"changePercentage":-68.16,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":940000000,"changePercentage":-14.93,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-776000000,"changePercentage":-31.53,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-192000000,"changePercentage":81.82,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":129000000,"changePercentage":-3.73,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":2000000,"changePercentage":100.25,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":5000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-328000000,"changePercentage":12.53,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-39000000,"changePercentage":-102.29,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-1000000,"changePercentage":-100.05,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":298000000,"changePercentage":8.36,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-5000000,"changePercentage":-162.5,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":1000000,"changePercentage":125,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-66000000,"changePercentage":-105.69,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":35000000,"changePercentage":-90.81,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:37Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":1.04,"priorDividend":0.95,"dividendYieldPercentage":2.37,"announcementDate":"2025-07-22","exDividendDate":"2025-09-08","payableDate":"2025-09-30","recordDate":"2025-09-08","updatedAt":"2025-07-22T20:28:14Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2024-05-08T12:55:06Z","bearsSay":["Becton Dickinson is currently facing headwinds in its first quarter due to weakening margins, concerns about their performance in China, and inventory reductions. This has led to a lower expected EPS for the quarter, which may continue into FY'24. While the company has a history of conservative guidance and strong execution, recent events have caused uncertainty and a potential for reduced growth in China, making investors cautious."],"bullsSay":["Becton Dickinson is expected to continue generating strong free cash flow in FY'24 despite FX headwinds, giving investors confidence in the company's management team and their conservative guidance approach. The company is also ramping up manufacturing to support additional revenue from Alaris, with expectations of steady revenue growth throughout the year. Management's guidance for base organic growth and EPS in FY'24 reinforces our positive outlook on the company's ability to deliver strong performance."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"BD Medical","dataPoints":[{"key":"21 Q3","value":2375},{"key":"21 Q4","value":2532},{"key":"22 Q1","value":2397},{"key":"22 Q2","value":2416},{"key":"22 Q3","value":2191},{"key":"22 Q4","value":2377},{"key":"23 Q1","value":2154},{"key":"23 Q2","value":2360},{"key":"23 Q3","value":2434},{"key":"23 Q4","value":2554},{"key":"24 Q1","value":2230},{"key":"24 Q2","value":2449},{"key":"24 Q3","value":2558},{"key":"24 Q4","value":2837},{"key":"25 Q1","value":2615},{"key":"25 Q1","value":2760}]},{"title":"BD Life Sciences","dataPoints":[{"key":"21 Q3","value":1433},{"key":"21 Q4","value":1532},{"key":"22 Q1","value":1483},{"key":"22 Q2","value":1485},{"key":"22 Q3","value":1309},{"key":"22 Q4","value":1287},{"key":"23 Q1","value":1302},{"key":"23 Q2","value":1275},{"key":"23 Q3","value":1226},{"key":"23 Q4","value":1330},{"key":"24 Q1","value":1288},{"key":"24 Q2","value":1304},{"key":"24 Q3","value":1260},{"key":"24 Q4","value":1340},{"key":"25 Q1","value":1297},{"key":"25 Q1","value":1247}]},{"title":"BD Interventional","dataPoints":[{"key":"21 Q3","value":1082},{"key":"21 Q4","value":1071},{"key":"22 Q1","value":1115},{"key":"22 Q2","value":1111},{"key":"22 Q3","value":1142},{"key":"22 Q4","value":1097},{"key":"23 Q1","value":1129},{"key":"23 Q2","value":1186},{"key":"23 Q3","value":1218},{"key":"23 Q4","value":1203},{"key":"24 Q1","value":1188},{"key":"24 Q2","value":1292},{"key":"24 Q3","value":1240},{"key":"24 Q4","value":1260},{"key":"25 Q1","value":1257},{"key":"25 Q1","value":1264}]},{"title":"Other","dataPoints":[{"key":"24 Q3","value":-67}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":44.19},{"key":"21 Q4","value":44.53},{"key":"22 Q1","value":48.5},{"key":"22 Q2","value":46},{"key":"22 Q3","value":44.54},{"key":"22 Q4","value":43.6},{"key":"23 Q1","value":46.49},{"key":"23 Q2","value":46.35},{"key":"23 Q3","value":43.05},{"key":"23 Q4","value":33.43},{"key":"24 Q1","value":43.07},{"key":"24 Q2","value":45.66},{"key":"24 Q3","value":46.24},{"key":"24 Q4","value":46.25},{"key":"25 Q1","value":43.25},{"key":"25 Q1","value":42.8}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":12.84},{"key":"21 Q4","value":9.63},{"key":"22 Q1","value":16.33},{"key":"22 Q2","value":13.04},{"key":"22 Q3","value":11.58},{"key":"22 Q4","value":10.29},{"key":"23 Q1","value":12.75},{"key":"23 Q2","value":13},{"key":"23 Q3","value":11.21},{"key":"23 Q4","value":6.84},{"key":"24 Q1","value":9.3},{"key":"24 Q2","value":14.54},{"key":"24 Q3","value":12.08},{"key":"24 Q4","value":11.95},{"key":"25 Q1","value":8.8},{"key":"25 Q1","value":10.35}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":10.73},{"key":"21 Q4","value":5.16},{"key":"22 Q1","value":13.55},{"key":"22 Q2","value":9.05},{"key":"22 Q3","value":7.75},{"key":"22 Q4","value":6.02},{"key":"23 Q1","value":11.1},{"key":"23 Q2","value":9.54},{"key":"23 Q3","value":8.34},{"key":"23 Q4","value":2.12},{"key":"24 Q1","value":5.97},{"key":"24 Q2","value":10.64},{"key":"24 Q3","value":9.75},{"key":"24 Q4","value":7.74},{"key":"25 Q1","value":5.86},{"key":"25 Q1","value":5.84}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling and administrative","dataPoints":[{"key":"21 Q3","value":1237},{"key":"21 Q4","value":1332},{"key":"22 Q1","value":1223},{"key":"22 Q2","value":1232},{"key":"22 Q3","value":1149},{"key":"22 Q4","value":1182},{"key":"23 Q1","value":1187},{"key":"23 Q2","value":1205},{"key":"23 Q3","value":1190},{"key":"23 Q4","value":1137},{"key":"24 Q1","value":1213},{"key":"24 Q2","value":1193},{"key":"24 Q3","value":1196},{"key":"24 Q4","value":1256},{"key":"25 Q1","value":1318},{"key":"25 Q1","value":1273}]},{"title":"Research and development","dataPoints":[{"key":"21 Q3","value":344},{"key":"21 Q4","value":387},{"key":"22 Q1","value":329},{"key":"22 Q2","value":343},{"key":"22 Q3","value":315},{"key":"22 Q4","value":300},{"key":"23 Q1","value":313},{"key":"23 Q2","value":337},{"key":"23 Q3","value":306},{"key":"23 Q4","value":281},{"key":"24 Q1","value":290},{"key":"24 Q2","value":299},{"key":"24 Q3","value":299},{"key":"24 Q4","value":302},{"key":"25 Q1","value":343},{"key":"25 Q1","value":302}]},{"title":"Acquisition-related integration and restructuring","dataPoints":[{"key":"21 Q3","value":24},{"key":"21 Q4","value":59},{"key":"22 Q1","value":34},{"key":"22 Q2","value":28},{"key":"22 Q3","value":55},{"key":"22 Q4","value":74},{"key":"23 Q1","value":44},{"key":"23 Q2","value":62},{"key":"23 Q3","value":70},{"key":"23 Q4","value":138},{"key":"24 Q1","value":75},{"key":"24 Q2","value":101},{"key":"24 Q3","value":112},{"key":"24 Q4","value":170},{"key":"25 Q1","value":92},{"key":"25 Q1","value":90}]},{"title":"Other operating expense, net","dataPoints":[{"key":"21 Q3","value":-72},{"key":"21 Q4","value":14},{"key":"22 Q1","value":21},{"key":"22 Q2","value":49},{"key":"22 Q3","value":11},{"key":"22 Q4","value":30},{"key":"23 Q1","value":3},{"key":"23 Q2","value":4},{"key":"23 Q3","value":-13},{"key":"23 Q4","value":-203},{"key":"24 Q1","value":11},{"key":"24 Q2","value":-23},{"key":"24 Q3","value":98},{"key":"24 Q4","value":137},{"key":"25 Q1","value":28},{"key":"25 Q1","value":45}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":26.85},{"key":"21 Q4","value":7.34},{"key":"22 Q1","value":-6.02},{"key":"22 Q2","value":2.12},{"key":"22 Q3","value":-5.07},{"key":"22 Q4","value":-7.28},{"key":"23 Q1","value":-8.21},{"key":"23 Q2","value":-3.81},{"key":"23 Q3","value":5.08},{"key":"23 Q4","value":6.85},{"key":"24 Q1","value":2.64},{"key":"24 Q2","value":4.65},{"key":"24 Q3","value":2.32},{"key":"24 Q4","value":6.88},{"key":"25 Q1","value":9.84},{"key":"25 Q1","value":4.48}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":17.83},{"key":"21 Q4","value":-8.2},{"key":"22 Q1","value":7.85},{"key":"22 Q2","value":-8.88},{"key":"22 Q3","value":-0.2},{"key":"22 Q4","value":-11.5},{"key":"23 Q1","value":-3.73},{"key":"23 Q2","value":-2.66},{"key":"23 Q3","value":1.5},{"key":"23 Q4","value":-14.69},{"key":"24 Q1","value":2.71},{"key":"24 Q2","value":-2.36},{"key":"24 Q3","value":9.79},{"key":"24 Q4","value":37.84},{"key":"25 Q1","value":12.08},{"key":"25 Q1","value":8.92}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":289.522},{"key":"21 Q4","value":285.985},{"key":"22 Q1","value":284.685},{"key":"22 Q2","value":285.243},{"key":"22 Q3","value":285.441},{"key":"22 Q4","value":284.662},{"key":"23 Q1","value":283.887},{"key":"23 Q2","value":284.292},{"key":"23 Q3","value":286.317},{"key":"23 Q4","value":290.59},{"key":"24 Q1","value":290.113},{"key":"24 Q2","value":289.518},{"key":"24 Q3","value":289.562},{"key":"24 Q4","value":289.607},{"key":"25 Q1","value":289.505},{"key":"25 Q1","value":287.293}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":69426.507},{"key":"21 Q4","value":70167.278},{"key":"22 Q1","value":68229.885},{"key":"22 Q2","value":73471.18},{"key":"22 Q3","value":72292.786},{"key":"22 Q4","value":70664.78},{"key":"23 Q1","value":66831.826},{"key":"23 Q2","value":69360.994},{"key":"23 Q3","value":72522.092},{"key":"23 Q4","value":78296.57},{"key":"24 Q1","value":71506.182},{"key":"24 Q2","value":69305.977},{"key":"24 Q3","value":68219.07},{"key":"24 Q4","value":67876.351},{"key":"25 Q1","value":66846.705},{"key":"25 Q1","value":66655.711}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":3.55},{"key":"21 Q4","value":3.42},{"key":"22 Q1","value":3.41},{"key":"22 Q2","value":3.66},{"key":"22 Q3","value":3.89},{"key":"22 Q4","value":3.71},{"key":"23 Q1","value":3.64},{"key":"23 Q2","value":3.6},{"key":"23 Q3","value":3.72},{"key":"23 Q4","value":3.85},{"key":"24 Q1","value":3.8},{"key":"24 Q2","value":3.43},{"key":"24 Q3","value":3.42},{"key":"24 Q4","value":3.12},{"key":"25 Q1","value":3.23},{"key":"25 Q1","value":3.16}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T14:57:06Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.51,"sell":0.49,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"INCY","name":"Incyte","displayName":"Incyte","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"INCY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":70.69,"high":71.29,"low":70.33,"volume":1680116,"volumeDate":"2025-07-24","last":70.49,"open":70.81,"gainPercentage":-0.283,"gainValue":-0.2,"ask":82.8,"bid":70.15,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":13644749300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1850196.2742,"highPriceLast52Weeks":83.95,"lowPriceLast52Weeks":53.56,"companyName":"Incyte Corp.","longBusinessDescription":"Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.","dividendRate":0,"salesOrRevenue":4241216999.9999995,"oneYearAnnualRevenueGrowthRate":14.7624409136257,"threeYearAnnualRevenueGrowthRate":12.4349,"fiveYearAnnualRevenueGrowthRate":14.5635,"earningsGrowth":-88.7834,"totalDebt":60337000,"totalAssets":5482313000,"floatAsPercentOfSharesOutstanding":98.6072,"dividendYield":0,"betaTwelveMonth":0.6345,"salesOrRevenueTtm":4413226000,"ebitdaTtm":296130000,"debtToEquityRatioQuarterly":1.17568532565085,"totalEnterpriseValue":12443552100,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":35.1508771929825,"fiveYearAverageDebtEquityRatio":1.27,"currentRatio":2.03885449546297,"peratio":218.1},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":82.46,"totalRatings":35,"strongSellRatings":0,"sellRatings":2,"holdRatings":14,"buyRatings":7,"strongBuyRatings":12,"lastUpdated":"2025-06-16T17:23:59Z"},"earningEstimates":[{"actual":1.18,"estimate":0.73,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T11:46:26Z","audioUrl":"https://files.quartr.com/audio-files/35dd4-2022-10-19-04-13-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/505e5-2025-03-21-10-34-44.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8965d-2023-01-25-10-22-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":0.1,"estimate":0.86,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-08T12:09:22Z","audioUrl":"https://files.quartr.com/audio-files/aa1c0-2022-10-19-10-46-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b9571-2025-03-21-10-56-43.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/613e1-2023-01-25-12-01-24.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-08T09:30:00Z","earningsSummary":null},{"actual":0.55,"estimate":0.68,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-03T11:33:22Z","audioUrl":"https://files.quartr.com/audio-files/3eb23-2022-10-28-04-07-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fe228-2022-05-03-10-45-39-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c1bf2-2023-01-25-01-55-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-03T10:39:45Z","earningsSummary":null},{"actual":1.01,"estimate":0.75,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-02T11:27:51Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_02_14_00_Q2_2022_Incyte_Corp_Earnings_Call.HNSCCP1E9NW6_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1fb92-2022-08-02-01-49-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5a341-2022-08-02-11-12-27.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-02T02:00:00Z","earningsSummary":null},{"actual":0.6,"estimate":0.74,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T11:04:10Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_01T12_00_00_00_00_Incyte_Corp_Earnings_Call_Q3_2022.ZRY65V2BUX6P_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fdd83-2022-11-01-12-38-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d0b53-2022-11-01-11-54-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T12:00:00Z","earningsSummary":null},{"actual":0.62,"estimate":0.58,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-07T12:03:34Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_07T13_00_00_00_00_Incyte_Corp_Earnings_Call_Q4_2022.BGLKTE89UKLA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/943cf-2023-02-07-12-45-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/bbca7-2023-02-07-12-57-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-07T13:00:00Z","earningsSummary":{"summary":"Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.\nWhile facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.\nOpportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.\nOverall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.","headline":"Incyte reports robust revenue growth and strategic focus on pediatric market","lastUpdated":"2024-05-06T03:40:15.814272Z"}},{"actual":0.37,"estimate":0.75,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-02T11:04:27Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_02T12_00_00_00_00_Incyte_Corporation_Q1_2023.65BFSOJ4CRCG_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ed4ce-2023-05-02-11-59-42.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e3eb1-2023-05-02-11-47-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-02T12:00:00Z","earningsSummary":{"summary":"Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.\nFocusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.\nChallenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.","headline":"Incyte (INCY) reports robust Q1 growth, eyes international expansion","lastUpdated":"2024-05-06T21:58:23.634225Z"}},{"actual":0.99,"estimate":0.87,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T11:01:29Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_01T12_00_00_00_00_Incyte_Corporation_Q2_2023.AW9POKTEPTRA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dec78-2023-08-01-11-14-42.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5bbed-2023-08-01-11-16-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T12:00:00Z","earningsSummary":{"summary":"Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.\nThe company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.\nWhile facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M\u0026A and growth opportunities signals a proactive approach to driving future expansion.","headline":"Incyte excels in Q2 with strong revenue growth and strategic advancements","lastUpdated":"2024-05-07T00:58:25.403060Z"}},{"actual":1.1,"estimate":1.02,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-31T11:01:13Z","audioUrl":"https://files.quartr.com/audio-files/335eb-2023-10-31-01-55-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4bffb-2023-10-31-11-13-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/be8f1-2023-10-31-11-09-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-31T12:00:00Z","earningsSummary":{"summary":"Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.","headline":"Incyte reports strong Q3 earnings, focuses on pipeline expansion","lastUpdated":"2024-05-06T01:41:00.799922Z"}},{"actual":1.06,"estimate":1.16,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-13T12:05:07Z","audioUrl":"https://files.quartr.com/audio-files/3a29a-2024-02-13-02-02-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bcfca-2024-02-13-12-46-50.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9cb63-2024-02-13-12-45-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-13T13:00:00Z","earningsSummary":{"summary":"Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.\nThe company's focus on innovative clinical programs and R\u0026D advancements positions it well for future growth and market expansion.\nChallenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.","headline":"Incyte reports robust 2023 earnings, eyes global growth opportunities","lastUpdated":"2024-05-07T07:13:47.377824Z"}},{"actual":0.64,"estimate":0.84,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-30T11:08:07Z","audioUrl":"https://files.quartr.com/audio-files/341fa-2024-04-30-01-56-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/98b9a-2024-04-30-11-50-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4b3c9-2024-04-30-11-39-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-30T12:00:00Z","earningsSummary":{"summary":"Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.\nThe company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.\nStrategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.\nOpportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.","headline":"Incyte reports strong Q1 growth, eyes oncology opportunities ahead","lastUpdated":"2024-05-06T03:23:25.969018Z"}},{"actual":-1.82,"estimate":-1.55,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-30T11:07:26Z","audioUrl":"https://files.quartr.com/audio-files/5da64-2024-07-30-01-18-07.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/111a5-2024-07-30-11-59-57.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/60b33-2024-07-30-11-45-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-30T12:00:00Z","earningsSummary":{"summary":"Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.","headline":"Incyte reports robust Q2 earnings, raises guidance on key products","lastUpdated":"2024-07-30T16:42:10.223272Z"}},{"actual":1.07,"estimate":1.09,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-29T11:00:35Z","audioUrl":"https://files.quartr.com/audio-files/c2956-2024-10-29-01-53-15.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/3da78-2024-10-29-12-03-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e36ad-2024-10-29-11-24-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-29T12:00:00Z","earningsSummary":{"summary":"Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.","headline":"Incyte reports robust Q3 earnings, eyes high-impact launches by 2030","lastUpdated":"2024-10-29T16:12:36.720349Z"}},{"actual":1.43,"estimate":1.55,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-10T12:00:35Z","audioUrl":"https://files.quartr.com/audio-files/c6d12-2025-02-10-02-37-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9327c-2025-02-10-01-45-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b7e76-2025-02-10-12-11-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-10T13:00:00Z","earningsSummary":{"summary":"Incyte's strong financial performance in 2024, driven by key products and new approvals, sets a positive foundation for growth in 2025.\nBalancing revenue growth with cost management will be crucial for Incyte in navigating challenges and seizing opportunities in the competitive pharmaceutical landscape.\nWith a focus on innovation, market expansion, and efficient operations, Incyte aims to leverage its strengths to overcome challenges and capitalize on growth prospects in 2025.","headline":"Incyte reports robust 2024 earnings, eyes growth amid challenges","lastUpdated":"2025-02-10T17:31:53.121810Z"}},{"actual":1.16,"estimate":1.03,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-29T11:00:54Z","audioUrl":"https://files.quartr.com/audio-files/752e7-2025-04-29-01-17-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c0b18-2025-04-29-11-04-54.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6d946-2025-04-29-11-21-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-29T12:00:00Z","earningsSummary":{"summary":"Incyte's Q1 2025 performance reflects strong revenue growth and product success, underpinned by strategic initiatives and a robust cash position. While facing challenges in cost management and market dynamics, the company's focus on innovation and guidance raise confidence in its future prospects. Opportunities lie in advancing its pipeline, expanding market presence, and capitalizing on emerging trends to drive long-term growth and value creation. Overall, Incyte's performance highlights resilience, strategic foresight, and a commitment to delivering innovative therapies for patients in need.","headline":"Incyte excels in Q1 2025 with robust revenue growth and strategic focus","lastUpdated":"2025-04-29T15:42:03.568366Z"}},{"actual":null,"estimate":1.34,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:08Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-29T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"618bae1b0dcfebf7aa6b1ffc206213c86d639bd1599eff8e0b4f263c4575f32f"},{"date":"2022-02-08","title":"Earnings data Q4 2021","quarter":"Q4","hash":"dfd859556d24f4c5c661126df195ad4f094b965c93f49f8d442560646c5f1d53"},{"date":"2022-05-03","title":"Earnings data Q1 2022","quarter":"Q1","hash":"57c8c5e619543edac05ea12db8821b6071e19ba5d780e7b47656954f22e21a22"},{"date":"2022-08-02","title":"Earnings data Q2 2022","quarter":"Q2","hash":"91aac9fa018d2f9258c5e110107a5f182a9db84a8cd52a67ef4e1169bc4625cb"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"94aa3eca432a74384e9b389c6069f5b574ad1454dac389cb40d5982e67bd79a0"},{"date":"2023-02-07","title":"Earnings data Q4 2022","quarter":"Q4","hash":"ed36333721f5623346b2328ad1bff394a437769a579328789ff0f1502d136909"},{"date":"2023-05-02","title":"Earnings data Q1 2023","quarter":"Q1","hash":"a45c17a3eb768ebd7fbcc499a3f73bf94d6be1bdcefda3d0d68e989baa000417"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"aa76f72d03d730103fc67cdad3fb6e4704b5307f9a6e7345518d8e8f26fe7f0a"},{"date":"2023-10-31","title":"Earnings data Q3 2023","quarter":"Q3","hash":"aa53d3950d38c4d53da521f1a2bee65c7db992e1aeb6e24cabfbf3a6a1d1eeab"},{"date":"2024-02-13","title":"Earnings data Q4 2023","quarter":"Q4","hash":"ae78b494d5b58327cc7458923d0f1081c5b6933f544e190d5c05c512582d3910"},{"date":"2024-04-30","title":"Earnings data Q1 2024","quarter":"Q1","hash":"5cb31fc2fde04f3eac535fccada1fc0919dbf00416c6371d9bed6e1c6ba16b14"},{"date":"2024-07-30","title":"Earnings data Q2 2024","quarter":"Q2","hash":"c3ae78f37699b341e961d2b2385f63bb29c80fe64f5159be88ac206202c9346f"},{"date":"2024-10-29","title":"Earnings data Q3 2024","quarter":"Q3","hash":"39d75f04f55408bf41257b0b55e7779b900b47d3a2827224af793018fe7eb670"},{"date":"2025-02-10","title":"Earnings data Q4 2024","quarter":"Q4","hash":"20140e502e8134cdf0e61a783a9d56cb0c8df961b6060d61cb3f553c2426fc6d"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"62865b63ebcf270b30a9339334451adaaeb26d23a36966c8f23b4df8170bb303"},{"date":"2025-07-29","title":"Earnings data Q2 2025","quarter":"Q2","hash":"5efbaed201ca60bf8db9241a9bcde36f367736f1f3766f66863f5167a0f509ef"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Incyte","companyDescription":"Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":1052897999.9999999,"changePercentage":19.53,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":89550000,"changePercentage":15.99,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":963348000,"changePercentage":19.87,"valueToRevenueRatio":0.914949026401418},{"financialKey":"OPERATING_EXPENSES","value":746608000,"changePercentage":4.67,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":746608000,"changePercentage":4.67,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":216740000,"changePercentage":139.71,"valueToRevenueRatio":0.20585089913742835},{"financialKey":"EBITDA","value":239102000,"changePercentage":112.79,"valueToRevenueRatio":0.22708942366686993},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":22362000,"changePercentage":1.89,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":158203000,"changePercentage":-6.69,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.7982,"changePercentage":6.97,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":5749365000,"changePercentage":-19.43,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":3507421000,"changePercentage":-27.67,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":2408658000,"changePercentage":-37.45,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":823134000,"changePercentage":10.41,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":63975000,"changePercentage":0.52,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":211654000,"changePercentage":11.85,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":2241944000,"changePercentage":-1.95,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":795251000,"changePercentage":6.67,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":263204000,"changePercentage":-3.74,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":1183489000,"changePercentage":-6.63,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":2081802000.0000002,"changePercentage":19.55,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":1720290000,"changePercentage":23.19,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":10476000,"changePercentage":23.82,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":1709814000,"changePercentage":23.19,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":361512000.00000024,"changePercentage":4.82,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":32643000,"changePercentage":12.82,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":328869000,"changePercentage":4.09,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":3667563000,"changePercentage":-32.01,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":3667563000,"changePercentage":-32.01,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":5749365000,"changePercentage":-19.43,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":43119000,"changePercentage":15.31,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-2365539000,"changePercentage":37.97,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":18.92609,"changePercentage":-21.22,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":158203000,"changePercentage":-6.69,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":266067000,"changePercentage":21.6,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":253048000,"changePercentage":111.63,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":13019000,"changePercentage":-86.88,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":1097000,"changePercentage":101.5,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":3169000,"changePercentage":-66.81,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":4266000.00000001,"changePercentage":106.71,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-6338000.00000001,"changePercentage":66.81,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-12676000,"changePercentage":-2.12,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":3239000,"changePercentage":579.04,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-1090000,"changePercentage":-25.14,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-14825000,"changePercentage":-23.35,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-552000,"changePercentage":18.34,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":253936000,"changePercentage":91.49,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":262898000.00000003,"changePercentage":25.63,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:20Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T02:16:36Z","bearsSay":["Incyte faces a negative outlook due to several fundamental financial challenges, including reduced pricing power for its lead drug Jakafi, underwhelming performance of its earlier-stage drug pipeline, and potential clinical or regulatory setbacks impacting Jakafi combinations. The concern is exacerbated by a greater-than-expected slowdown in Jakafi's usage against competing treatments and market pressures, which could significantly hinder future sales growth, particularly for Jakafi. Additionally, the management has acknowledged uncertainties regarding upcoming clinical trial readouts and the lack of compelling efficacy signals compared to competitors, contributing to a pessimistic view on Incyte’s ability to sustain or enhance revenue streams."],"bullsSay":["Incyte's performance in the fourth quarter was robust, highlighted by Jakafi's impressive $773 million in sales, which exceeded expectations and demonstrated strong demand without reliance on inventory benefits. The positive clinical outcomes for Opzelura in treating atopic dermatitis and vitiligo indicate strong potential for further market expansion, reinforcing the product's competitiveness against emerging therapies. Furthermore, the firm's strategic focus on its commercial legacy business and promising pipeline assets, including povorcitinib, positions Incyte well for continued revenue growth of approximately 5%-7% leading up to the Jakafi patent cliff in 2028."],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"PFE","name":"Pfizer","displayName":"Pfizer","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"PFE","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":24.9298,"high":25.1068,"low":24.8315,"volume":65192,"volumeDate":"2025-07-25","last":24.92,"open":24.9593,"gainPercentage":-0.039,"gainValue":-0.0098,"ask":24.99,"bid":24.98,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":144124129500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":42531143.2258,"highPriceLast52Weeks":31.54,"lowPriceLast52Weeks":20.915,"companyName":"Pfizer Inc.","longBusinessDescription":"Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.","dividendRate":1.7,"salesOrRevenue":63627000000,"oneYearAnnualRevenueGrowthRate":8.77153993435449,"threeYearAnnualRevenueGrowthRate":-3.4589,"fiveYearAnnualRevenueGrowthRate":17.1903,"earningsGrowth":2770.5769,"totalDebt":66993000000,"totalAssets":213396000000,"floatAsPercentOfSharesOutstanding":99.8331,"dividendYield":6.710000000000001,"betaTwelveMonth":0.4462,"salesOrRevenueTtm":62463000000,"ebitdaTtm":24091000000,"debtToEquityRatioQuarterly":68.751798800062,"totalEnterpriseValue":198031000000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":5.03605255117629,"fiveYearAverageDebtEquityRatio":57.49,"currentRatio":1.25812026774937,"peratio":18.37},"recommendation":{"currentConsensusRating":2.5,"recommendationTargetPrice":36.13,"totalRatings":31,"strongSellRatings":0,"sellRatings":1,"holdRatings":19,"buyRatings":4,"strongBuyRatings":7,"lastUpdated":"2025-04-30T14:06:59Z"},"earningEstimates":[{"actual":1.34,"estimate":1.09,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T10:51:10Z","audioUrl":"https://files.quartr.com/audio-files/deaef-2022-10-19-04-43-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0c188-2021-11-02-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/54030-2023-01-25-10-09-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":1.08,"estimate":0.87,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-08T11:48:10Z","audioUrl":"https://files.quartr.com/audio-files/5fb2e-2022-10-19-10-18-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a05a1-2022-02-08-09-38-39-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5b28a-2023-01-25-12-11-24.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-08T09:39:38Z","earningsSummary":null},{"actual":1.62,"estimate":1.5,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-03T11:00:23Z","audioUrl":"https://files.quartr.com/audio-files/1f06d-2022-10-28-05-32-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a1285-2022-05-03-10-48-52-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/11875-2023-01-25-01-21-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-03T10:52:48Z","earningsSummary":null},{"actual":2.04,"estimate":1.8,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T10:54:11Z","audioUrl":"https://files.quartr.com/audio-files/59906-2022-07-28-06-47-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4d8f4-2022-07-28-11-40-29.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e451c-2022-07-28-11-39-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-28T00:27:00Z","earningsSummary":null},{"actual":1.78,"estimate":1.47,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T10:45:46Z","audioUrl":"https://files.quartr.com/audio-files/cd885-2022-11-01-03-21-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/34a97-2022-11-01-11-50-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e7044-2022-11-01-11-50-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T14:00:00Z","earningsSummary":null},{"actual":1.14,"estimate":1.05,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-01-31T11:47:47Z","audioUrl":"https://files.quartr.com/audio-files/367d6-2023-01-31-05-07-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/99645-2023-01-31-12-10-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/2db00-2023-01-31-12-10-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-01-31T15:00:00Z","earningsSummary":{"summary":"Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.\nStrategic investments in R\u0026D and new product launches drive revenue growth expectations.\nChallenges include transitioning from emergency status and revenue decline from COVID-related products.\nOpportunities lie in increased adoption of combo vaccines and business development goals.","headline":"Pfizer exceeds $100B in revenue, eyes growth amid challenges","lastUpdated":"2024-05-05T00:37:00.633849Z"}},{"actual":1.23,"estimate":0.98,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-02T10:46:09Z","audioUrl":"https://files.quartr.com/audio-files/be8f7-2023-05-02-04-43-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a7ec2-2023-05-02-11-25-03.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/56fc5-2023-05-02-11-25-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-02T14:00:00Z","earningsSummary":{"summary":"Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.\nThe company faces challenges in COVID franchise transition and stock performance.\nStrategic acquisitions, new product launches, and market monitoring offer growth opportunities.\nPfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.","headline":"Pfizer reports solid Q1 results, eyes growth through innovation","lastUpdated":"2024-05-06T18:25:48.453464Z"}},{"actual":0.67,"estimate":0.57,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T10:47:36Z","audioUrl":"https://files.quartr.com/audio-files/77a45-2023-08-01-06-19-19.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5ad78-2023-08-01-11-55-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f125d-2023-08-01-11-55-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T14:00:00Z","earningsSummary":{"summary":"Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.","headline":"Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism","lastUpdated":"2024-05-05T01:27:18.129484Z"}},{"actual":-0.17,"estimate":-0.32,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-31T10:46:09Z","audioUrl":"https://files.quartr.com/audio-files/f3cfc-2023-10-31-06-17-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/58cd3-2023-10-31-11-36-02.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/58c08-2023-10-31-11-25-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-31T14:00:00Z","earningsSummary":{"summary":"Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.","headline":"Pfizer reports strong Q3 performance, eyes growth in non-COVID products","lastUpdated":"2024-05-06T16:29:04.239767Z"}},{"actual":0.1,"estimate":-0.22,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-30T11:47:48Z","audioUrl":"https://files.quartr.com/audio-files/dcec1-2024-01-30-06-45-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6a7a3-2024-01-30-12-29-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9b59a-2024-01-30-12-29-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-01-30T15:00:00Z","earningsSummary":{"summary":"Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R\u0026D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.","headline":"Pfizer reports solid 2023 performance, eyes growth and cost savings","lastUpdated":"2024-05-06T15:52:09.272070Z"}},{"actual":0.82,"estimate":0.52,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-01T10:56:46Z","audioUrl":"https://files.quartr.com/audio-files/fa042-2024-05-01-03-45-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/db5dd-2024-05-01-10-34-47.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4641-2024-05-01-10-23-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-01T14:00:00Z","earningsSummary":{"summary":"Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.\nWhile facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.\nThe company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.","headline":"Pfizer reports robust Q1 earnings, eyes international growth and pipeline","lastUpdated":"2024-05-05T01:22:10.485683Z"}},{"actual":0.6,"estimate":0.46,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-30T10:46:13Z","audioUrl":"https://files.quartr.com/audio-files/0136e-2024-07-30-03-32-44.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8e57f-2024-07-30-11-54-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/77bc2-2024-07-30-11-39-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-30T14:30:00Z","earningsSummary":{"summary":"Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.","headline":"Pfizer reports strong Q2 earnings, raises guidance amid leadership changes","lastUpdated":"2024-07-30T18:05:00.001209Z"}},{"actual":1.06,"estimate":0.62,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-29T10:46:28Z","audioUrl":"https://files.quartr.com/audio-files/750fa-2024-10-29-03-05-45.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4ace6-2024-10-29-11-39-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7bf77-2024-10-29-11-55-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-29T14:00:00Z","earningsSummary":{"summary":"Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.","headline":"Pfizer reports robust Q3 earnings, eyes international market growth","lastUpdated":"2024-10-29T18:10:12.471222Z"}},{"actual":0.63,"estimate":0.46,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-04T11:51:01Z","audioUrl":"https://files.quartr.com/audio-files/c3fcb-2025-02-04-04-13-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/61b0f-2025-02-04-12-35-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/75f9a-2025-02-04-12-28-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-04T15:30:00Z","earningsSummary":null},{"actual":0.92,"estimate":0.67,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-29T10:48:34Z","audioUrl":"https://files.quartr.com/audio-files/aa715-2025-04-29-03-40-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/15d3b-2025-04-29-11-27-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/da0c3-2025-04-29-11-15-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-29T14:00:00Z","earningsSummary":{"summary":"Pfizer's Q1 performance reflects a strong emphasis on strategic priorities and shareholder value. The company is on track to achieve its full-year 2025 guidance, expecting revenues of $61-64 billion. Investors are keen on Pfizer's pipeline progress, revenue growth, and cost-saving initiatives.","headline":"Pfizer reports solid Q1 performance, focuses on R\u0026D and dividends","lastUpdated":"2025-04-29T17:42:37.615633Z"}},{"actual":null,"estimate":0.58,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:31Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-05T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"1c0111bd918ce5c792124b55f58cc22cd1871584655d9e79d16d258269fb2451"},{"date":"2022-02-08","title":"Earnings data Q4 2021","quarter":"Q4","hash":"c2d5986423c76d6bb0335befeee920f9e512a9ef7c067b03ce18240c30f48f44"},{"date":"2022-05-03","title":"Earnings data Q1 2022","quarter":"Q1","hash":"91dab3213be7d2f7c489120bc93662aee668d6d488b972c87ed1aa35d6ad7430"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"50ef629d498d6cebc4f714fd82e93f3c965c3390301fdf0b0d983013b0dec8c9"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"ec91684c88afeb03c504549a265cc419eb8304b0dd83d4342fca23f1a9ca37f7"},{"date":"2023-01-31","title":"Earnings data Q4 2022","quarter":"Q4","hash":"84f1c7b1e87413af2c2bec078b96e466b9d9e6fc7e43d42e0a013e07ec44f18f"},{"date":"2023-05-02","title":"Earnings data Q1 2023","quarter":"Q1","hash":"ab105752c9bc302a17bb580c35d1a10cfa8c788ed2c3463b91f47ad625ae78a4"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"8312665a2b92f91ecc22769b685736dea5c7fbfb069d98a886a4e293259450b0"},{"date":"2023-10-31","title":"Earnings data Q3 2023","quarter":"Q3","hash":"a09e64f5350d99252bb16d3c479bc8f0ec5614ee2fe63e2858e3cc7b7a1a6716"},{"date":"2024-01-30","title":"Earnings data Q4 2023","quarter":"Q4","hash":"514832afbc0aa46f5e3b5239aa116e9d40806174330677154296f5b78d7be90d"},{"date":"2024-05-01","title":"Earnings data Q1 2024","quarter":"Q1","hash":"09fa6b46562c315f1bb4dcf9c073bb64f6a559919eb306f039d5c17f1c8e7a25"},{"date":"2024-07-30","title":"Earnings data Q2 2024","quarter":"Q2","hash":"b9e6a9279abd155085ecb9dc3911a98d5142fd0cfad0eb4621b06fa48220f087"},{"date":"2024-10-29","title":"Earnings data Q3 2024","quarter":"Q3","hash":"58932492d18a724ebd50bd5bb6738c11aaaa77a52cb7d2b484f5b59d9f1e6a46"},{"date":"2025-02-04","title":"Earnings data Q4 2024","quarter":"Q4","hash":"d55abf75ff048295af908f9ae8ad7a12d93ca16ea1ff53154b99d768c5345c5b"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"77e139317023694ad56cbd4bd55b894a01d22a79bd281345e269768b4c371871"},{"date":"2025-08-05","title":"Earnings data Q2 2025","quarter":"Q2","hash":"90cf12d68e96c853c8759ce5df902aaaf0765232d1e51e126ce7b3ad69747214"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Pfizer","companyDescription":"Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.","executives":null,"brands":[{"id":"ffb43038-b3d2-4497-9554-e92419796323","name":"Viagra","description":"Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/rf3apah-STiWyE-CZoyjfw-thumbnail-300x300.png"},{"id":"234b3335-b8fe-473f-b3fb-7c171adbae82","name":"Lipitor","description":"Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/_FLhgMqmS5uobmmLP67-Gw-thumbnail-300x300.png"}]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":13715000000,"changePercentage":-7.82,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3888000000,"changePercentage":-11.25,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":9827000000,"changePercentage":-6.39,"valueToRevenueRatio":0.7165147648559971},{"financialKey":"OPERATING_EXPENSES","value":5203000000,"changePercentage":-12.39,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":5203000000,"changePercentage":-12.39,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":4624000000,"changePercentage":1.43,"valueToRevenueRatio":0.3371491068173533},{"financialKey":"EBITDA","value":6242000000,"changePercentage":-0.84,"valueToRevenueRatio":0.45512212905577837},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1618000000,"changePercentage":-6.8,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":2973000000,"changePercentage":-4.96,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.5196,"changePercentage":-5.13,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":208028000000,"changePercentage":-5.91,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":45861000000,"changePercentage":8.12,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":17317000000,"changePercentage":45.18,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":11845000000,"changePercentage":7.79,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":10852000000,"changePercentage":-0.37,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":5847000000,"changePercentage":-32.05,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":162167000000,"changePercentage":-9.24,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":18347000000,"changePercentage":-2.43,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":122420000000,"changePercentage":-7.35,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":21400000000,"changePercentage":-22.89,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":117391000000,"changePercentage":-8.67,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":36452000000,"changePercentage":-9.99,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":4470000000,"changePercentage":-45.7,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":3105000000,"changePercentage":-2.73,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":28877000000,"changePercentage":-0.67,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":80939000000,"changePercentage":-8.06,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":57639000000,"changePercentage":-5.98,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":23300000000,"changePercentage":-12.84,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":90637000000,"changePercentage":-2.08,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":90338000000,"changePercentage":-2.11,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":299000000,"changePercentage":8.33,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":208028000000,"changePercentage":-5.91,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":62109000000,"changePercentage":-10.68,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":44792000000,"changePercentage":-22.25,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":15.89059,"changePercentage":-2.42,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":2973000000,"changePercentage":-4.8,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":2335000000,"changePercentage":114.02,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":4254000000,"changePercentage":-3.91,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1919000000,"changePercentage":42.48,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":3274000000,"changePercentage":89.03,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":564000000,"changePercentage":-19.89,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":3539000000,"changePercentage":45.34,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-829000000,"changePercentage":41.08,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-5227000000,"changePercentage":-6,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":2437000000,"changePercentage":2.74,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-356000000,"changePercentage":7.77,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-7000000,"changePercentage":75.86,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":375000000,"changePercentage":117.55,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1771000000,"changePercentage":357.62,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:51Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.43,"priorDividend":0.42,"dividendYieldPercentage":7.08,"announcementDate":"2025-06-25","exDividendDate":"2025-07-25","payableDate":"2025-09-02","recordDate":"2025-07-25","updatedAt":"2025-06-25T21:43:27Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T02:18:55Z","bearsSay":["Pfizer's stock faces a negative outlook primarily due to disappointing commercial execution on critical marketed products and the potential for setbacks in clinical data and regulatory approvals for essential pipeline assets. Additionally, concerns surrounding U.S. drug pricing reform could diminish investor confidence in large-cap biopharma companies, negatively impacting Pfizer's market appeal. Furthermore, significant adjustments to revenue estimates for key products, combined with internal forecast reductions, suggest challenges in maintaining growth momentum in the face of increasing competition and market pressures."],"bullsSay":["Pfizer reported a strong performance in the fourth quarter of 2024, exceeding both internal and consensus estimates, primarily due to robust sales of key products such as Comirnaty, Paxlovid, Eliquis, and Ibrance. The company is optimistic about its future, reaffirming its fiscal year 2025 guidance while focusing on stabilizing COVID-19 revenues and leveraging its drug pipeline, which includes developments in obesity and oncology expected to yield updates in 2025. Additionally, the firm is positioned to benefit from expanded patient access through initiatives related to the Low-Income Subsidy program, potentially stabilizing prescription volumes and reinforcing its market presence in both domestic and emerging international markets."],"charts":[{"title":"Revenue by Geography","description":null,"chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"United States","dataPoints":[{"key":"21 Q2","value":7593},{"key":"21 Q3","value":7079},{"key":"21 Q4","value":7680},{"key":"22 Q1","value":8918},{"key":"22 Q2","value":11222},{"key":"22 Q3","value":13851},{"key":"22 Q4","value":8481},{"key":"23 Q1","value":8507},{"key":"23 Q2","value":6185},{"key":"23 Q3","value":7804},{"key":"23 Q4","value":4591},{"key":"24 Q1","value":9514},{"key":"24 Q2","value":7892},{"key":"24 Q3","value":12064},{"key":"24 Q4","value":9221},{"key":"25 Q1","value":8374}]},{"title":"Developed Europe","dataPoints":[{"key":"21 Q2","value":4577},{"key":"21 Q3","value":6221},{"key":"21 Q4","value":4499},{"key":"22 Q1","value":6090},{"key":"22 Q2","value":5480},{"key":"22 Q3","value":3136},{"key":"22 Q4","value":7277},{"key":"23 Q1","value":2822},{"key":"23 Q2","value":2415},{"key":"23 Q3","value":1981},{"key":"23 Q4","value":4433}]},{"title":"Developed Rest of World","dataPoints":[{"key":"21 Q2","value":2997},{"key":"21 Q3","value":4498},{"key":"21 Q4","value":3889},{"key":"22 Q1","value":3286},{"key":"22 Q2","value":5034},{"key":"22 Q3","value":2351},{"key":"22 Q4","value":5107},{"key":"23 Q1","value":2473},{"key":"23 Q2","value":1305},{"key":"23 Q3","value":1073},{"key":"23 Q4","value":2909}]},{"title":"Emerging Markets","dataPoints":[{"key":"21 Q2","value":3810},{"key":"21 Q3","value":6296},{"key":"21 Q4","value":7771},{"key":"22 Q1","value":7367},{"key":"22 Q2","value":6006},{"key":"22 Q3","value":3300},{"key":"22 Q4","value":3424},{"key":"23 Q1","value":4480},{"key":"23 Q2","value":2828},{"key":"23 Q3","value":2373},{"key":"23 Q4","value":2315}]},{"title":"Total Internetional","dataPoints":[{"key":"24 Q1","value":5365},{"key":"24 Q2","value":5391},{"key":"24 Q3","value":5638},{"key":"24 Q4","value":8542},{"key":"25 Q1","value":5341}]}],"overlayChart":null},{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Primary Care","dataPoints":[{"key":"22 Q3","value":15846},{"key":"22 Q4","value":17348},{"key":"23 Q1","value":11505},{"key":"23 Q2","value":5810},{"key":"23 Q3","value":6287},{"key":"23 Q4","value":6986},{"key":"24 Q1","value":7211},{"key":"24 Q2","value":4952},{"key":"24 Q3","value":9060},{"key":"24 Q4","value":8911},{"key":"25 Q1","value":5696}]},{"title":"Specialty Care","dataPoints":[{"key":"22 Q3","value":3404},{"key":"22 Q4","value":3566},{"key":"23 Q1","value":3612},{"key":"23 Q2","value":3653},{"key":"23 Q3","value":3757},{"key":"23 Q4","value":3949},{"key":"24 Q1","value":3843},{"key":"24 Q2","value":4083},{"key":"24 Q3","value":4289},{"key":"24 Q4","value":4438},{"key":"25 Q1","value":3987}]},{"title":"Oncology","dataPoints":[{"key":"21 Q2","value":3145},{"key":"21 Q3","value":3085},{"key":"21 Q4","value":3242},{"key":"22 Q1","value":2967},{"key":"22 Q2","value":3088},{"key":"22 Q3","value":3070},{"key":"22 Q4","value":3007},{"key":"23 Q1","value":2855},{"key":"23 Q2","value":2956},{"key":"23 Q3","value":2885},{"key":"23 Q4","value":2932},{"key":"24 Q1","value":3549},{"key":"24 Q2","value":3956},{"key":"24 Q3","value":4043},{"key":"24 Q4","value":4064},{"key":"25 Q1","value":3758}]},{"title":"Pfizer CentreOne","dataPoints":[{"key":"21 Q4","value":382},{"key":"22 Q1","value":338},{"key":"22 Q2","value":317},{"key":"22 Q3","value":319},{"key":"22 Q4","value":368},{"key":"23 Q1","value":306},{"key":"23 Q2","value":306},{"key":"23 Q3","value":291},{"key":"23 Q4","value":363},{"key":"24 Q1","value":258},{"key":"24 Q2","value":278},{"key":"24 Q3","value":285},{"key":"24 Q4","value":325},{"key":"25 Q1","value":257}]},{"title":"Vaccines","dataPoints":[{"key":"21 Q2","value":9234},{"key":"21 Q3","value":14583},{"key":"21 Q4","value":13914},{"key":"22 Q1","value":14941},{"key":"22 Q2","value":10459}]},{"title":"Hospital","dataPoints":[{"key":"21 Q2","value":2259},{"key":"21 Q3","value":2367},{"key":"21 Q4","value":1884},{"key":"22 Q1","value":3191},{"key":"22 Q2","value":9714}]},{"title":"Internal Medicine","dataPoints":[{"key":"21 Q2","value":2403},{"key":"21 Q3","value":2097},{"key":"21 Q4","value":2235},{"key":"22 Q1","value":2440},{"key":"22 Q2","value":2405}]},{"title":"Rare Disease","dataPoints":[{"key":"21 Q2","value":895},{"key":"21 Q3","value":869},{"key":"21 Q4","value":950},{"key":"22 Q1","value":963},{"key":"22 Q2","value":909}]},{"title":"Inflammation \u0026 Immunology","dataPoints":[{"key":"21 Q2","value":1041},{"key":"21 Q3","value":1094},{"key":"21 Q4","value":1231},{"key":"22 Q1","value":821},{"key":"22 Q2","value":850}]},{"title":"Pfizer Ignite","dataPoints":[{"key":"23 Q1","value":4},{"key":"23 Q2","value":10},{"key":"23 Q3","value":10},{"key":"23 Q4","value":20},{"key":"24 Q1","value":17},{"key":"24 Q2","value":15},{"key":"24 Q3","value":25},{"key":"24 Q4","value":26},{"key":"25 Q1","value":17}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":62.85},{"key":"21 Q3","value":58.6},{"key":"21 Q4","value":59.15},{"key":"22 Q1","value":61.09},{"key":"22 Q2","value":68.82},{"key":"22 Q3","value":73.21},{"key":"22 Q4","value":60.27},{"key":"23 Q1","value":73.27},{"key":"23 Q2","value":74.58},{"key":"23 Q3","value":29.93},{"key":"23 Q4","value":46.93},{"key":"24 Q1","value":77.28},{"key":"24 Q2","value":75.15},{"key":"24 Q3","value":70.26},{"key":"24 Q4","value":66.73},{"key":"25 Q1","value":79.25}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":34.82},{"key":"21 Q3","value":32.53},{"key":"21 Q4","value":16.05},{"key":"22 Q1","value":35.27},{"key":"22 Q2","value":41.26},{"key":"22 Q3","value":39.76},{"key":"22 Q4","value":21.53},{"key":"23 Q1","value":34.29},{"key":"23 Q2","value":17.81},{"key":"23 Q3","value":-25.35},{"key":"23 Q4","value":-28.97},{"key":"24 Q1","value":22.99},{"key":"24 Q2","value":-0.78},{"key":"24 Q3","value":26.64},{"key":"24 Q4","value":-0.06},{"key":"25 Q1","value":20.3}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":29.31},{"key":"21 Q3","value":33.8},{"key":"21 Q4","value":14.23},{"key":"22 Q1","value":30.64},{"key":"22 Q2","value":35.7},{"key":"22 Q3","value":38.02},{"key":"22 Q4","value":20.56},{"key":"23 Q1","value":30.31},{"key":"23 Q2","value":18.27},{"key":"23 Q3","value":-18.01},{"key":"23 Q4","value":-23.65},{"key":"24 Q1","value":20.93},{"key":"24 Q2","value":0.3},{"key":"24 Q3","value":25.22},{"key":"24 Q4","value":2.3},{"key":"25 Q1","value":21.63}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, informational and administrative expenses","dataPoints":[{"key":"21 Q2","value":2928},{"key":"21 Q3","value":2905},{"key":"21 Q4","value":4104},{"key":"22 Q1","value":2593},{"key":"22 Q2","value":3048},{"key":"22 Q3","value":3391},{"key":"22 Q4","value":4644},{"key":"23 Q1","value":3418},{"key":"23 Q2","value":3497},{"key":"23 Q3","value":3281},{"key":"23 Q4","value":4575},{"key":"24 Q1","value":3495},{"key":"24 Q2","value":3717},{"key":"24 Q3","value":3244},{"key":"24 Q4","value":4274},{"key":"25 Q1","value":3031}]},{"title":"Research and development expenses","dataPoints":[{"key":"21 Q2","value":2459},{"key":"21 Q3","value":3447},{"key":"21 Q4","value":5915},{"key":"22 Q1","value":2301},{"key":"22 Q2","value":2815},{"key":"22 Q3","value":2696},{"key":"22 Q4","value":3615},{"key":"23 Q1","value":2505},{"key":"23 Q2","value":2648},{"key":"23 Q3","value":2711},{"key":"23 Q4","value":2815},{"key":"24 Q1","value":2493},{"key":"24 Q2","value":2696},{"key":"24 Q3","value":2598},{"key":"24 Q4","value":3035},{"key":"25 Q1","value":2203}]},{"title":"Amortization of intangible assets","dataPoints":[{"key":"21 Q2","value":931},{"key":"21 Q3","value":981},{"key":"21 Q4","value":957},{"key":"22 Q1","value":835},{"key":"22 Q2","value":822},{"key":"22 Q3","value":822},{"key":"22 Q4","value":1130},{"key":"23 Q1","value":1103},{"key":"23 Q2","value":1184},{"key":"23 Q3","value":1179},{"key":"23 Q4","value":1267},{"key":"24 Q1","value":1308},{"key":"24 Q2","value":1307},{"key":"24 Q3","value":1312},{"key":"24 Q4","value":1359},{"key":"25 Q1","value":1211}]},{"title":"Restructuring charges and certain acquisition-related costs","dataPoints":[{"key":"21 Q2","value":-1},{"key":"21 Q3","value":646},{"key":"21 Q4","value":135},{"key":"22 Q1","value":192},{"key":"22 Q2","value":189},{"key":"22 Q3","value":199},{"key":"22 Q4","value":795},{"key":"23 Q1","value":9},{"key":"23 Q2","value":214},{"key":"23 Q3","value":155},{"key":"23 Q4","value":2566},{"key":"24 Q1","value":102},{"key":"24 Q2","value":1254},{"key":"24 Q3","value":313},{"key":"24 Q4","value":750},{"key":"25 Q1","value":678}]},{"title":"Other (income)/deductions","dataPoints":[{"key":"21 Q2","value":-998},{"key":"21 Q3","value":-1696},{"key":"21 Q4","value":-835},{"key":"22 Q1","value":350},{"key":"22 Q2","value":772},{"key":"22 Q3","value":-59},{"key":"22 Q4","value":-846},{"key":"23 Q1","value":70},{"key":"23 Q2","value":-347},{"key":"23 Q3","value":-79},{"key":"23 Q4","value":-480},{"key":"24 Q1","value":680},{"key":"24 Q2","value":1107},{"key":"24 Q3","value":243},{"key":"24 Q4","value":2358},{"key":"25 Q1","value":953}]},{"title":"Acquired in-process research and development expenses","dataPoints":[{"key":"22 Q1","value":355},{"key":"22 Q2","value":1},{"key":"22 Q3","value":524},{"key":"22 Q4","value":73},{"key":"23 Q1","value":21},{"key":"23 Q2","value":33},{"key":"23 Q3","value":67},{"key":"23 Q4","value":73},{"key":"24 Q2","value":6},{"key":"24 Q3","value":13},{"key":"24 Q4","value":88},{"key":"25 Q1","value":9}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":60.81},{"key":"21 Q3","value":98.62},{"key":"21 Q4","value":104.02},{"key":"22 Q1","value":75.98},{"key":"22 Q2","value":46.19},{"key":"22 Q3","value":-6.04},{"key":"22 Q4","value":1.89},{"key":"23 Q1","value":-28.76},{"key":"23 Q2","value":-54.09},{"key":"23 Q3","value":-41.56},{"key":"23 Q4","value":-41.33},{"key":"24 Q1","value":-18.62},{"key":"24 Q2","value":4.31},{"key":"24 Q3","value":33.8},{"key":"24 Q4","value":24.66},{"key":"25 Q1","value":-7.82}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":-4.45},{"key":"21 Q3","value":-15.39},{"key":"21 Q4","value":19.67},{"key":"22 Q1","value":41.34},{"key":"22 Q2","value":43.77},{"key":"22 Q3","value":20.53},{"key":"22 Q4","value":-8.42},{"key":"23 Q1","value":7.55},{"key":"23 Q2","value":-5.47},{"key":"23 Q3","value":-3.42},{"key":"23 Q4","value":14.93},{"key":"24 Q1","value":13.36},{"key":"24 Q2","value":39.54},{"key":"24 Q3","value":5.59},{"key":"24 Q4","value":9.69},{"key":"25 Q1","value":0.09}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":5598},{"key":"21 Q3","value":5609},{"key":"21 Q4","value":5616},{"key":"22 Q1","value":5617},{"key":"22 Q2","value":5593},{"key":"22 Q3","value":5607},{"key":"22 Q4","value":5615},{"key":"23 Q1","value":5634},{"key":"23 Q2","value":5646},{"key":"23 Q3","value":5646},{"key":"23 Q4","value":5647},{"key":"24 Q1","value":5657},{"key":"24 Q2","value":5666},{"key":"24 Q3","value":5667},{"key":"24 Q4","value":5667},{"key":"25 Q1","value":5675}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":217762.2},{"key":"21 Q3","value":248478.7},{"key":"21 Q4","value":277992},{"key":"22 Q1","value":291522.3},{"key":"22 Q2","value":281887.2},{"key":"22 Q3","value":271939.5},{"key":"22 Q4","value":266151},{"key":"23 Q1","value":242825.4},{"key":"23 Q2","value":216241.8},{"key":"23 Q3","value":199303.8},{"key":"23 Q4","value":170539.4},{"key":"24 Q1","value":156698.9},{"key":"24 Q2","value":155815},{"key":"24 Q3","value":165476.4},{"key":"24 Q4","value":153575.7},{"key":"25 Q1","value":148685}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":2.87},{"key":"21 Q3","value":2.58},{"key":"21 Q4","value":2.92},{"key":"22 Q1","value":2.84},{"key":"22 Q2","value":2.54},{"key":"22 Q3","value":3},{"key":"22 Q4","value":2.74},{"key":"23 Q1","value":3.32},{"key":"23 Q2","value":4.25},{"key":"23 Q3","value":3.77},{"key":"23 Q4","value":2.99},{"key":"24 Q1","value":2.63},{"key":"24 Q2","value":2.93},{"key":"24 Q3","value":2.34},{"key":"24 Q4","value":2.16},{"key":"25 Q1","value":2.71}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-29T15:50:40Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.28,"sell":0.72,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"NKTR","name":"Nektar Therapeutics","displayName":"Nektar Therapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"NKTR","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":25,"high":25.99,"low":24.3,"volume":64,"volumeDate":"2025-07-25","last":24.58,"open":25.23,"gainPercentage":-1.68,"gainValue":-0.42,"ask":25.1,"bid":24.58,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":425261000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1790667.5269,"highPriceLast52Weeks":37.38,"lowPriceLast52Weeks":6.48,"companyName":"Nektar Therapeutics","longBusinessDescription":"Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.","dividendRate":0,"salesOrRevenue":98427000,"oneYearAnnualRevenueGrowthRate":9.21528594571803,"threeYearAnnualRevenueGrowthRate":-0.8507,"fiveYearAnnualRevenueGrowthRate":-0.4991,"earningsGrowth":31.0005,"totalDebt":194340000,"totalAssets":303850000,"floatAsPercentOfSharesOutstanding":97.4464,"dividendYield":0,"betaTwelveMonth":1.883,"salesOrRevenueTtm":87248000,"ebitdaTtm":-136622000,"debtToEquityRatioQuarterly":1358.70577958946,"totalEnterpriseValue":130378729.80869901,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-4.73527319294252,"fiveYearAverageDebtEquityRatio":116.49,"currentRatio":3.24140702100663,"peratio":-2.58},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":25.64,"totalRatings":25,"strongSellRatings":1,"sellRatings":1,"holdRatings":4,"buyRatings":5,"strongBuyRatings":14,"lastUpdated":"2025-07-08T17:58:34Z"},"earningEstimates":[{"actual":-10.5,"estimate":-12,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2025-07-11T11:49:59Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":-11.85,"estimate":-12.15,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2025-07-11T11:49:59Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/cf667-2023-11-25-03-19-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-03-01T12:00:00Z","earningsSummary":null},{"actual":-7.35,"estimate":-10.2,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2025-07-11T11:50:00Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-05-05T00:00:00Z","earningsSummary":null},{"actual":-12.75,"estimate":-14.1,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2025-07-11T11:50:00Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-08-04T00:00:00Z","earningsSummary":null},{"actual":-4.65,"estimate":-6.75,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2025-07-11T11:50:03Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-11-03T00:00:00Z","earningsSummary":null},{"actual":-4.8,"estimate":-6.75,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2025-07-11T11:50:04Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/be998-2023-11-25-03-04-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-28T12:00:00Z","earningsSummary":null},{"actual":-3.75,"estimate":-3.75,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2025-07-11T11:50:04Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_09T21_00_00_00_00_Nektar_Therapeutics_Q1_2023.7KDMTZ8G6F8U_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3453d-2023-05-09-08-55-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-09T21:00:00Z","earningsSummary":null},{"actual":-4.05,"estimate":-4.2,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2025-07-11T11:50:05Z","audioUrl":"https://files.quartr.com/audio-files/replay_f_Nektar_Therapeutics_Q2_2023_Financial_Results.UCN1UBH1005J_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/85f63-2023-08-08-08-26-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T21:00:00Z","earningsSummary":null},{"actual":-2.85,"estimate":-3,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2025-07-11T11:50:06Z","audioUrl":"https://files.quartr.com/audio-files/90fdf-2023-11-07-10-17-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/30475-2023-11-07-09-10-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-07T22:00:00Z","earningsSummary":null},{"actual":-3.3,"estimate":-3.15,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2025-07-11T11:50:06Z","audioUrl":"https://files.quartr.com/audio-files/6488d-2024-03-04-10-43-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e1ca1-2024-03-04-09-01-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-04T22:00:00Z","earningsSummary":null},{"actual":-2.85,"estimate":-2.85,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2025-07-11T11:50:07Z","audioUrl":"https://files.quartr.com/audio-files/31fd2-2024-05-09-09-02-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/062c9-2024-05-09-08-44-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-09T21:00:00Z","earningsSummary":{"summary":"Nektar Therapeutics demonstrated solid financial performance in Q1 2024, with a positive revenue outlook for the full year.\nThe company's pipeline strength lies in REZPEG's promising results, NKTR-255's progress, and the advancement of NKTR-0165.\nChallenges include patient selection complexities and timing uncertainties, while opportunities exist in therapeutic optimization and pipeline expansion.\nOverall, Nektar remains focused on advancing its immunology programs and leveraging its financial stability for future growth.","headline":"Nektar Therapeutics reports strong Q1 results and advances pipeline","lastUpdated":"2024-05-10T06:00:27.743710Z"}},{"actual":-3.75,"estimate":-3,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2025-07-11T11:50:08Z","audioUrl":"https://files.quartr.com/audio-files/f522b-2024-08-08-09-55-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e7e9d-2024-08-08-08-45-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T21:00:00Z","earningsSummary":null},{"actual":-2.7,"estimate":-3.15,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2025-07-11T11:50:08Z","audioUrl":"https://files.quartr.com/audio-files/d94e7-2024-11-07-11-06-02.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/194df-2024-11-07-09-20-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-07T22:00:00Z","earningsSummary":null},{"actual":-2.25,"estimate":-2.85,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-07-11T11:50:09Z","audioUrl":"https://files.quartr.com/audio-files/095f9-2025-03-12-09-19-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/eb069-2025-03-12-08-17-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-03-12T21:00:00Z","earningsSummary":{"summary":"Nektar Therapeutics had a productive year with significant clinical milestones and a strong financial position. While revenue growth and expense management are key challenges, the company's focus on innovation and clear guidance for 2025 indicate a proactive approach. Leveraging upcoming data releases and exploring new applications for REZPEG offer promising opportunities for future success.","headline":"Nektar Therapeutics excels in 2024, eyes growth through innovative pipeline","lastUpdated":"2025-03-13T05:42:31.686891Z"}},{"actual":-3.6,"estimate":-2.7,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-07-11T11:50:10Z","audioUrl":"https://files.quartr.com/audio-files/ddbe6-2025-05-08-10-34-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fa43e-2025-05-08-08-12-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-08T21:00:00Z","earningsSummary":{"summary":"Nektar Therapeutics reported solid financials in Q1 2025 with a focus on advancing REZPEG for immune disorders and expanding its immunology pipeline. While facing challenges with high expenses and a net loss, the company remains optimistic about its cash position and future prospects. The upcoming disclosure of REZOLVE-AD study results presents both opportunities and risks for Nektar's growth trajectory. Overall, Nektar's strategic focus on innovation, financial stability, and upcoming milestones positions it for potential growth and market impact.","headline":"Nektar Therapeutics reports Q1 revenue, eyes REZPEG study results","lastUpdated":"2025-05-09T21:42:54.051118Z"}},{"actual":null,"estimate":-2.93,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:31:25Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"cb56309505d2378c3379a6e63fb2a366041c94dab1f4adecaeb72c8357988608"},{"date":"2022-02-28","title":"Earnings data Q4 2021","quarter":"Q4","hash":"7075ea97ccb4f26787b67b16b665adfa972399f98abbb8c7c82ed17018dca1c9"},{"date":"2022-05-05","title":"Earnings data Q1 2022","quarter":"Q1","hash":"1853a15250270ed275959abc2a9069cb9b88ee7a4f67a09c74c200d183b59fbc"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"4b769dfedb54357c29a10db71c4e618ea27a43b275bcb78e40ec482d36554e54"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"32bb925771f5e0ebe36d97dd43464a4b4574ba48f3bf4c5d0985205f14e4a8a6"},{"date":"2023-02-28","title":"Earnings data Q4 2022","quarter":"Q4","hash":"f1b28161d413636b14b73eefce79310e1942a5c180467b947c4d736291343422"},{"date":"2023-05-09","title":"Earnings data Q1 2023","quarter":"Q1","hash":"f4de355696fb0c50f297b5b5779bffe1dd452b2a67020aafe7405e1a2b114fa7"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"d28970a1172f588cb534927fa9ed3e68a0ef39c41938332b8d1afa33d6cdb9de"},{"date":"2023-11-07","title":"Earnings data Q3 2023","quarter":"Q3","hash":"6eb8133cf60cfb17ac64c0e1b0702c60625aa56056d506fbfde8d42baffff7bf"},{"date":"2024-03-04","title":"Earnings data Q4 2023","quarter":"Q4","hash":"18d8afcd3f74a9b3a9102e62a5a02ecab2510ea44c1348fcdf87381ada0cfdde"},{"date":"2024-05-09","title":"Earnings data Q1 2024","quarter":"Q1","hash":"f9f09147a6643e90cb729f849463ed385f7b084a5da1f85372965832916e0dea"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"eeb09b183431097334fafe908615ec3f063d485cc86dd079430670c1b15b1213"},{"date":"2024-11-07","title":"Earnings data Q3 2024","quarter":"Q3","hash":"fb174eff2debecd6a5718eade616df5c8010fef115a1b0a0abb5e65dd75ba083"},{"date":"2025-03-12","title":"Earnings data Q4 2024","quarter":"Q4","hash":"1427a24221a704f2c51935044bfed653fb61f3a40888f33d4296284dadc68a3f"},{"date":"2025-05-08","title":"Earnings data Q1 2025","quarter":"Q1","hash":"fdb7742f7a02a81f1731dbad856ed1d19e237a2648c2b40372f8ccc11f0371e9"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"bbb87286de0c5b4cafbaae415efc8611569ea6541c7e73929dc572aa763c2c8e"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Nektar Therapeutics","companyDescription":"Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":10460000,"changePercentage":-51.66,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":426000,"changePercentage":-95.01,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":10034000,"changePercentage":-23.43,"valueToRevenueRatio":0.9592734225621415},{"financialKey":"OPERATING_EXPENSES","value":54400000,"changePercentage":14.39,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":54400000,"changePercentage":14.39,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-44366000,"changePercentage":-28.78,"valueToRevenueRatio":-4.241491395793499},{"financialKey":"EBITDA","value":-43940000,"changePercentage":-33.78,"valueToRevenueRatio":-4.2007648183556405},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":426000,"changePercentage":-73.49,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-50882000,"changePercentage":-38.26,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-3.6184,"changePercentage":-27.65,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":256241000,"changePercentage":-35.29,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":229913000,"changePercentage":-28.12,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":218632000,"changePercentage":-24.41,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":1714000,"changePercentage":-68.45,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":9567000,"changePercentage":7.17,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":26328000,"changePercentage":-65.44,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":11161000,"changePercentage":-67.87,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":15167000,"changePercentage":-63.39,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":242503000,"changePercentage":-9.95,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":70930000,"changePercentage":35.35,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":21842000,"changePercentage":12.77,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":49088000,"changePercentage":48.58,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":171573000,"changePercentage":-20.9,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":164817000,"changePercentage":-22.46,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":6756000,"changePercentage":55.88,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":13738000,"changePercentage":-89.16,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":13738000,"changePercentage":-89.16,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":256241000,"changePercentage":-35.29,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":186659000,"changePercentage":-19.52,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-31973000,"changePercentage":44.2,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":1.10729,"changePercentage":-89.3,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-50882000,"changePercentage":-38.26,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-49053000,"changePercentage":-2.43,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-48907000,"changePercentage":-18.51,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-146000,"changePercentage":97.79,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":43689000,"changePercentage":126.86,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":2000,"changePercentage":-98.73,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":44388000,"changePercentage":128.63,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-701000,"changePercentage":-123.25,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":7000,"changePercentage":-99.98,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":7000,"changePercentage":-99.97,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-1000,"changePercentage":87.5,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-5358000,"changePercentage":-140.09,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-49055000,"changePercentage":-2.1,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:38Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T04:04:58Z","bearsSay":["Nektar Therapeutics reported a loss on revaluation of liability related to the sale of future royalties, which amounted to $6.25 million, indicating financial pressures and potential issues in managing their liabilities. In the fourth quarter of 2024, the company generated revenue of $29.2 million, falling short of the consensus estimate of $35.5 million, while also reporting a net loss of $0.14 per share compared to a positive EPS of $0.03. These factors contribute to a negative outlook on the company's financial stability and its ability to meet market expectations."],"bullsSay":["Nektar Therapeutics is projected to see substantial growth in revenue from its lead product, REZPEG (NKTR-358), with risk-adjusted adult revenue expected to rise from $85 million in 2029 to $641 million by 2035, indicating strong demand and market acceptance potential. The modified recombinant human IL-2, REZPEG, offers advantages over conventional IL-2 therapies by selectively stimulating regulatory T cells and extending therapeutic half-life, which may address limitations associated with existing treatments for Type 1 diabetes and atopic dermatitis. Recent clinical milestones, such as the completion of enrollment in the Phase 2b REZOLVE-AD study, position Nektar Therapeutics favorably for potential value inflections by 2025, supporting a optimistic outlook for the company’s financial future."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.4,"sell":0.6,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"EXAS","name":"Exact Sciences","displayName":"Exact Sciences","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"EXAS","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":48.41,"high":49.93,"low":48.26,"volume":6,"volumeDate":"2025-07-25","last":48.77,"open":48.5,"gainPercentage":0.744,"gainValue":0.36,"ask":53,"bid":48.4,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":9199875300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2906964.9194,"highPriceLast52Weeks":72.83,"lowPriceLast52Weeks":39.97,"companyName":"EXACT Sciences Corp.","longBusinessDescription":"EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.","dividendRate":0,"salesOrRevenue":2758867000,"oneYearAnnualRevenueGrowthRate":10.3650101649514,"threeYearAnnualRevenueGrowthRate":16.0831,"fiveYearAnnualRevenueGrowthRate":27.3857,"earningsGrowth":-315.251,"totalDebt":2775758000,"totalAssets":6171975000,"floatAsPercentOfSharesOutstanding":98.7055,"dividendYield":0,"betaTwelveMonth":0.6343,"salesOrRevenueTtm":2828128000,"ebitdaTtm":24137000,"debtToEquityRatioQuarterly":105.931686127163,"totalEnterpriseValue":12087761430,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":-5.8888479489069,"fiveYearAverageDebtEquityRatio":84.56,"currentRatio":2.72723672295583,"peratio":-8.87},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":64.97,"totalRatings":36,"strongSellRatings":1,"sellRatings":0,"holdRatings":5,"buyRatings":14,"strongBuyRatings":16,"lastUpdated":"2025-07-08T12:57:42Z"},"earningEstimates":[{"actual":-0.79,"estimate":-0.85,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T21:18:15Z","audioUrl":"https://files.quartr.com/audio-files/751f5-2022-10-19-04-44-23.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/79d3e-2021-11-02-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ed422-2024-08-28-07-56-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":-1.28,"estimate":-1.04,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-22T21:17:39Z","audioUrl":"https://files.quartr.com/audio-files/94fd0-2022-10-19-11-57-31.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/49876-2022-02-22-11-35-49-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/efa3d-2025-01-21-02-19-50.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-22T12:00:00Z","earningsSummary":null},{"actual":-1.04,"estimate":-1.07,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-26T21:18:13Z","audioUrl":"https://files.quartr.com/audio-files/d28c1-2022-10-28-04-59-32.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/76800-2022-04-26-12-55-29-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b1549-2024-08-28-07-50-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-26T12:29:55Z","earningsSummary":null},{"actual":-0.9,"estimate":-1.07,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-02T22:34:16Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_02_23_00_Q2_2022_Exact_Sciences_Corp_Earnings_Call.KSMM9LDKC2XA_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d5801-2022-08-08-08-48-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1b105-2024-09-03-05-36-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-02T00:08:00Z","earningsSummary":null},{"actual":-0.84,"estimate":-1.08,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T20:53:12Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_03T21_00_00_00_00_Exact_Sciences_Corp_Earnings_Call_Q3_2022.XKE53HH3GVEU_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7e3d2-2022-11-03-11-21-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ba93d-2024-08-28-07-53-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T21:00:00Z","earningsSummary":null},{"actual":-0.72,"estimate":-0.84,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-21T21:23:55Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_21T22_00_00_00_00_Exact_Sciences_Corp_Earnings_Call_Q4_2022.WFS5B15WQ21K_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b0d7c-2023-02-21-10-06-02.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e9c3f-2025-01-21-02-44-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-21T22:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.\nThe company's focus on compliance improvements, international expansion, and new product development positions it for future success.\nChallenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.\nOpportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.","headline":"Exact Sciences excels in Q4, eyes international growth and innovation","lastUpdated":"2024-05-06T21:12:09.907560Z"}},{"actual":-0.42,"estimate":-0.75,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-09T20:08:22Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_09T21_00_00_00_00_Exact_Sciences_Corporation_Q1_2023.VH9CX7YMEB7V_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f0357-2023-05-09-11-51-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/45723-2024-08-28-07-40-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-09T21:00:00Z","earningsSummary":{"summary":"Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.","headline":"Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities","lastUpdated":"2024-05-06T22:40:41.405198Z"}},{"actual":-0.45,"estimate":-0.5,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T20:07:57Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_01T21_00_00_00_00_Exact_Sciences_Corporation_Q2_2023.7QA5YNW5XD96_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a76da-2023-08-01-08-19-28.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/50318-2023-08-01-08-46-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T21:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.\nWhile facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.\nStrategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.\nFocus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.","headline":"Exact Sciences excels in Q2 earnings, eyes international expansion","lastUpdated":"2024-05-07T04:22:22.082386Z"}},{"actual":0,"estimate":-0.48,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-01T20:58:49Z","audioUrl":"https://files.quartr.com/audio-files/6419d-2023-11-01-10-48-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/88c6e-2023-11-01-09-46-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/15397-2023-11-01-08-47-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-01T21:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.\nThe company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.\nChallenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.\nOpportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.","headline":"Exact Sciences excels in Q3, eyes growth through innovation and partnerships","lastUpdated":"2024-05-07T06:00:48.299834Z"}},{"actual":-0.27,"estimate":-0.46,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-21T21:06:31Z","audioUrl":"https://files.quartr.com/audio-files/70bd9-2024-02-21-11-08-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/73cd5-2024-02-22-08-41-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/46cdf-2024-02-21-09-53-44.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-21T22:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.\nChallenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.\nWith a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.","headline":"Exact Sciences reports record-breaking 2023 results and eyes international growth","lastUpdated":"2024-05-06T07:11:31.586887Z"}},{"actual":-0.6,"estimate":-0.46,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-08T20:14:23Z","audioUrl":"https://files.quartr.com/audio-files/19f48-2024-05-08-10-48-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f894d-2024-05-08-09-35-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/002bf-2024-05-08-08-16-42.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-08T21:00:00Z","earningsSummary":{"summary":"Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.\nWhile facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.\nWith a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.","headline":"Exact Sciences reports robust Q1 earnings, eyes growth opportunities","lastUpdated":"2024-05-09T00:32:06.529296Z"}},{"actual":-0.09,"estimate":-0.32,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-31T20:09:50Z","audioUrl":"https://files.quartr.com/audio-files/02cc2-2024-07-31-10-48-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/97821-2024-07-31-11-27-31.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/14b91-2024-07-31-08-37-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-31T21:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.\nTheir focus on innovation and product launches indicates a commitment to advancing cancer screening technology.\nWhile facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.","headline":"Exact Sciences excels in Q2 with record screening and revenue","lastUpdated":"2024-08-01T00:17:05.067904Z"}},{"actual":-0.21,"estimate":-0.21,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-05T21:08:45Z","audioUrl":"https://files.quartr.com/audio-files/7de1e-2024-11-05-11-11-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f69e4-2024-11-06-12-22-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f6045-2024-11-05-09-15-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-05T22:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.\nThe company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.\nWith a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.","headline":"Exact Sciences reports 13% revenue growth in Q3 2024","lastUpdated":"2024-11-06T04:09:17.840060Z"}},{"actual":-0.06,"estimate":-0.31,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-19T21:07:26Z","audioUrl":"https://files.quartr.com/audio-files/7f8a8-2025-02-19-11-55-07.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bfcec-2025-02-19-10-30-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3584d-2025-02-19-09-48-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-19T22:00:00Z","earningsSummary":{"summary":"Exact Sciences delivered a strong performance in Q4 2024 with revenue growth and positive financial results. The company's focus on increasing screening rates and launching new tests positions it for future growth. Challenges include potential hurdles related to pricing, reimbursement, and the Braidwood case. Opportunities for Exact Sciences include leveraging its strengths in product approvals and expanding market presence.","headline":"Exact Sciences excels in Q4 2024, eyes growth opportunities","lastUpdated":"2025-02-20T03:31:25.105140Z"}},{"actual":-0.21,"estimate":-0.37,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T21:47:58Z","audioUrl":"https://files.quartr.com/audio-files/3af35-2025-05-01-10-43-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bf6f2-2025-05-01-10-45-49.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1091a-2025-05-01-08-15-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T21:00:00Z","earningsSummary":{"summary":"Exact Sciences' Q1 2025 performance reflects strong growth, improved financial metrics, and strategic product launches that position the company for continued success. With a focus on driving commercial initiatives, enhancing margins, and expanding market reach, Exact Sciences is poised to capitalize on opportunities for growth and innovation. While facing challenges in sustaining momentum and optimizing capital allocation, Exact Sciences has the potential to leverage its strengths and seize opportunities to drive long-term value creation.","headline":"Exact Sciences excels in Q1 2025, poised for growth","lastUpdated":"2025-05-02T03:41:32.785911Z"}},{"actual":null,"estimate":0.02,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:30:50Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-06T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"e916b9ff9a24c68e845daf97520096db05ac7c9539620325c22d71c87a902b6d"},{"date":"2022-02-22","title":"Earnings data Q4 2021","quarter":"Q4","hash":"d0b152492baa8b42672a706b8b482f51b3234fe20b93809e1c2bb827b836bbdf"},{"date":"2022-04-26","title":"Earnings data Q1 2022","quarter":"Q1","hash":"9051ca1720f50545d58560064c78d2e6e0d213afca887579a5c5b4e8eee58503"},{"date":"2022-08-02","title":"Earnings data Q2 2022","quarter":"Q2","hash":"49e0326d5be5b409b944ec5ee0890ac771317a6e2946180eb4841231ae242057"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"2746bd88e30eda80538534518280414088b564cbc82fa608360b9ea5f366f172"},{"date":"2023-02-21","title":"Earnings data Q4 2022","quarter":"Q4","hash":"d4b0374dc3bde3da4d8ce192698b553fc9398f482ac1ab8e7f36f6c00945ae56"},{"date":"2023-05-09","title":"Earnings data Q1 2023","quarter":"Q1","hash":"293c8746014a7450004f0ee37d1736f1648eebb636b8e23ff629003ede7ac601"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"77f7e9118261a9a26e2ca9360c224da043b5897a18ad18d884586f6873b119ad"},{"date":"2023-11-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"76ccd58843805153231ee445d326a8b69f6522f1cff5faa4d741cde7256b0042"},{"date":"2024-02-21","title":"Earnings data Q4 2023","quarter":"Q4","hash":"c89f9f7512e43d1b837d7c5c7829f5b61f7a658d0a87fca17cdf0d99de5fbff6"},{"date":"2024-05-08","title":"Earnings data Q1 2024","quarter":"Q1","hash":"fb57c988ccbff51edd6fc1b78ae91a0e7b876d841a5705562c65d9aec4bfdf39"},{"date":"2024-07-31","title":"Earnings data Q2 2024","quarter":"Q2","hash":"bcc2364b0371c36369152270aca3902f3885f28ad9707b9bab80f1e846c0a516"},{"date":"2024-11-05","title":"Earnings data Q3 2024","quarter":"Q3","hash":"a4c3b9b49b968e91d954e6bc5474b1c25f1c25e47aa3e7f7e410ead0807740ca"},{"date":"2025-02-19","title":"Earnings data Q4 2024","quarter":"Q4","hash":"dd044d2187f333896a2fd5062898365223fddba3081695302a9278b519e11138"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"7996448dda1f168a20c84bbec1201de8f55581dcfed5d72ca2de82b327256983"},{"date":"2025-08-06","title":"Earnings data Q2 2025","quarter":"Q2","hash":"168dad4726bbb6810a7c344bc55e80ca9fc8a274f52daf9e2110fb60aec4f841"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Exact Sciences","companyDescription":"EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":706785000,"changePercentage":10.86,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":206238000,"changePercentage":6.63,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":500547000,"changePercentage":12.71,"valueToRevenueRatio":0.7082026358793693},{"financialKey":"OPERATING_EXPENSES","value":598593000,"changePercentage":8.5,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":598593000,"changePercentage":8.5,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-98046000,"changePercentage":8.86,"valueToRevenueRatio":-0.13872111038010146},{"financialKey":"EBITDA","value":-43985000,"changePercentage":18,"valueToRevenueRatio":-0.062232503519457825},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":54061000,"changePercentage":0.22,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-101215000,"changePercentage":8.18,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.5418,"changePercentage":10.37,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":5711073000,"changePercentage":-10.43,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":1370341000,"changePercentage":22.32,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":786175000,"changePercentage":20.56,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":279800000,"changePercentage":14.3,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":176574000,"changePercentage":37.38,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":127792000,"changePercentage":34.72,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":4340732000,"changePercentage":-17.41,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":841366000,"changePercentage":-2.47,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":3355984000,"changePercentage":-20.74,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":143382000,"changePercentage":-10.1,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":3314166000,"changePercentage":2.17,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":502465000,"changePercentage":-26.66,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":36608000,"changePercentage":-88.99,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":465857000,"changePercentage":32.09,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":2811701000,"changePercentage":9.89,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":2502476000,"changePercentage":11.6,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":309225000,"changePercentage":-2.23,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":2396907000,"changePercentage":-23.49,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":2396907000,"changePercentage":-23.49,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":5711073000,"changePercentage":-10.43,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":2539084000,"changePercentage":-1.39,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":1752909000,"changePercentage":-8.83,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":12.7093,"changePercentage":-25.41,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-101215000,"changePercentage":8.18,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":30809000,"changePercentage":137.43,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":32649000,"changePercentage":26.07,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1840000,"changePercentage":98.3,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-34437000,"changePercentage":79.91,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":31174000,"changePercentage":-17.2,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-2758000,"changePercentage":97.94,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-62853000,"changePercentage":16.75,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-256171000,"changePercentage":-8433.34,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-249172000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-6999000,"changePercentage":-133.14,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":290000,"changePercentage":125.44,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-259509000,"changePercentage":-0.63,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-365000,"changePercentage":99.7,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:01Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-03T08:09:34Z","bearsSay":["Exact Sciences's financial outlook is hindered by its performance in FY24, which concluded slightly below initial projections despite meeting revised expectations for 4Q24. The company faces potential revenue impacts from regulatory surprises and increasing costs, compounded by a noted downward trend in reimbursement for its services, which introduces volatility to revenue stability. Furthermore, the risk of regulatory non-compliance presents a significant threat to its operations, potentially jeopardizing both revenue and profitability."],"bullsSay":["Exact Sciences is well-positioned for future growth, driven by an under-screened patient population and market expansion into younger demographics, particularly the 45-49 age group, which has contributed to an increase in revenue through higher repeat order rates. The anticipated launch of Cologuard Plus, which offers higher accuracy and improved Medicare pricing, alongside ongoing successful Cologuard rescreen initiatives and care gap programs, enhances the company's competitive edge in the advanced diagnostics sector. Additionally, Exact Sciences is expected to benefit from a robust product pipeline and industry-leading margins, indicating a strong potential for sustained financial performance in the near to medium term."],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"XLV","name":"Health Care Select Sector SPDR Fund","displayName":"Health Care Select Sector SPDR Fund","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"XLV","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":136.27,"high":136.93,"low":135.54,"volume":1283,"volumeDate":"2025-07-25","last":135.76,"open":136.13,"gainPercentage":-0.374,"gainValue":-0.51,"ask":136.27,"bid":135.77,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":null,"instrumentClass":"EXCHANGE_TRADED_FUND","averageDailyVolumeLast3Months":12505674.5968,"highPriceLast52Weeks":159.64,"lowPriceLast52Weeks":127.35,"companyName":null,"longBusinessDescription":"XLV tracks health care stocks from within the S\u0026P 500 Index, weighted by market cap.","dividendRate":2.3938,"salesOrRevenue":null,"oneYearAnnualRevenueGrowthRate":null,"threeYearAnnualRevenueGrowthRate":null,"fiveYearAnnualRevenueGrowthRate":null,"earningsGrowth":null,"totalDebt":null,"totalAssets":null,"floatAsPercentOfSharesOutstanding":null,"dividendYield":1.76,"betaTwelveMonth":0.4989,"salesOrRevenueTtm":null,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":null,"industry":"InvestmentTrustsOrMutualFunds","sector":"Miscellaneous","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":null,"currentRatio":null,"peratio":null},"recommendation":null,"earningEstimates":[],"earningDates":[],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Health Care Select Sector SPDR Fund","companyDescription":"XLV tracks health care stocks from within the S\u0026P 500 Index, weighted by market cap.","executives":null,"brands":[]},"etfFundamental":{"returnInception":0.0813,"etfType":"US Equities","category":"Large Cap","netExpenseRatio":0.09,"inceptionDate":"1998-12-16","assetsUnderManagement":33925873328,"returnYTD":-0.0056,"return1Month":0.0311,"return3Month":0.009,"return1Year":-0.0672,"return3Year":0.0378,"return5Year":0.0704,"return10Year":0.0762,"returnsAsOfDate":"2025-07-23","quarterlyNavBasedReturns":{"returnYTD":-1.14,"return1Month":2.31,"return3Month":-6.34,"return1Year":-6.15,"return3Year":3.66,"return5Year":7.77,"return10Year":7.63,"returnInception":8.29,"returnsAsOfDate":"2025-06-30"},"quarterlyPriceBasedReturns":{"returnYTD":-1.64,"return1Month":1.84,"return3Month":-6.73,"return1Year":-6.62,"return3Year":3.5,"return5Year":7.66,"return10Year":7.57,"returnInception":8.1,"returnsAsOfDate":"2025-06-30"},"monthlyNavBasedReturns":{"returnYTD":-1.14,"return1Month":2.31,"return3Month":-6.34,"return1Year":-6.15,"return3Year":3.66,"return5Year":7.77,"return10Year":7.63,"returnInception":8.29,"returnsAsOfDate":"2025-06-30"},"monthlyPriceBasedReturns":{"returnYTD":-1.64,"return1Month":1.84,"return3Month":-6.73,"return1Year":-6.62,"return3Year":3.5,"return5Year":7.66,"return10Year":7.57,"returnInception":8.1,"returnsAsOfDate":"2025-06-30"},"secYieldPercentage":null,"prospectusLink":"https://www.ssga.com/us/en/institutional/etfs/resources/doc-viewer#xlv\u0026prospectus"},"financials":null,"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":{"totalHoldings":63,"holdings":[{"symbol":"LLY","name":"Eli Lilly","weight":0.127},{"symbol":"JNJ","name":"Johnson \u0026 Johnson","weight":0.08220000000000001},{"symbol":"ABBV","name":"AbbVie","weight":0.068},{"symbol":"UNH","name":"UnitedHealth Group","weight":0.0536},{"symbol":"ABT","name":"Abbott Labs","weight":0.0443},{"symbol":"MRK","name":"Merck","weight":0.0426},{"symbol":"ISRG","name":"Intuitive Surgical","weight":0.0364},{"symbol":"TMO","name":"Thermo Fisher Scientific","weight":0.0356},{"symbol":"AMGN","name":"Amgen","weight":0.0336},{"symbol":"BSX","name":"Boston Scientific","weight":0.0322}]},"etfHoldingsLastUpdated":"2025-07-23T00:00:00Z"},"advancedCryptoData":null,"buySellRatio":{"buy":0.58,"sell":0.42,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"VXRT","name":"Vaxart","displayName":"Vaxart","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"LIQUIDATION_ONLY","optionsTrading":"LIQUIDATION_ONLY","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"VXRT","lastUpdated":"2025-07-24T19:59:41Z","batsLastUpdated":"2025-07-24T19:59:41Z","previousClose":0.42,"high":0.44,"low":0.4021,"volume":745434,"volumeDate":"2025-07-24","last":0.408,"open":0.42,"gainPercentage":-2.857,"gainValue":-0.012,"ask":0,"bid":0,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":93150500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":5135778.6129,"highPriceLast52Weeks":1.07,"lowPriceLast52Weeks":0.2606,"companyName":"Vaxart, Inc.","longBusinessDescription":"Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.","dividendRate":0,"salesOrRevenue":28700000,"oneYearAnnualRevenueGrowthRate":288.941591001491,"threeYearAnnualRevenueGrowthRate":2332.3996,"fiveYearAnnualRevenueGrowthRate":1372.0543,"earningsGrowth":49.0354,"totalDebt":23284000,"totalAssets":166389000,"floatAsPercentOfSharesOutstanding":97.3028,"dividendYield":0,"betaTwelveMonth":1.5044,"salesOrRevenueTtm":47395000,"ebitdaTtm":-52758000,"debtToEquityRatioQuarterly":45.0721206541278,"totalEnterpriseValue":105396259.2751,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":-22.3283933984507,"fiveYearAverageDebtEquityRatio":22.17,"currentRatio":0.635964021765614,"peratio":-1.5},"recommendation":{"currentConsensusRating":1.5,"recommendationTargetPrice":9.67,"totalRatings":6,"strongSellRatings":0,"sellRatings":0,"holdRatings":0,"buyRatings":3,"strongBuyRatings":3,"lastUpdated":"2025-03-27T17:19:04Z"},"earningEstimates":[{"actual":-0.14,"estimate":-0.15,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T23:11:16Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":-0.15,"estimate":-0.17,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-24T22:55:23Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/8248d-2023-11-24-05-12-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-24T12:00:00Z","earningsSummary":null},{"actual":-0.2,"estimate":null,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-09T22:59:21Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-05-09T00:00:00Z","earningsSummary":null},{"actual":-0.23,"estimate":-0.21,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-08T21:11:18Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_08_22_30_Q2_2022_Vaxart_Inc_Earnings_Call.WD97VM1DBJVN_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/5f7a1-2022-08-22-04-14-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-08T20:30:00Z","earningsSummary":null},{"actual":-0.23,"estimate":-0.24,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-08T21:43:32Z","audioUrl":"https://files.quartr.com/audio-files/5e352-2022-11-09-09-45-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/0f654-2022-11-08-09-38-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-08T21:30:00Z","earningsSummary":null},{"actual":-0.18,"estimate":-0.23,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-03-15T20:04:28Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_03_15T20_30_00_00_00_Vaxart_Inc_Q4_2022.Q6R7X30UOX7A_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fe239-2023-03-15-08-13-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-03-15T20:30:00Z","earningsSummary":null},{"actual":-0.19,"estimate":-0.19,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T20:21:28Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_04T20_30_00_00_00_Vaxart_Inc_Q1_2023.2BNVCXV20Y9Y_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4e282-2023-05-04-08-44-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T20:30:00Z","earningsSummary":null},{"actual":-0.16,"estimate":-0.18,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:25:56Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T20_30_00_00_00_Vaxart_Inc_Q2_2023.PVM2GUPTPMLK_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/310cc-2023-08-03-08-02-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T20:30:00Z","earningsSummary":null},{"actual":-0.11,"estimate":-0.18,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T20:23:57Z","audioUrl":"https://files.quartr.com/audio-files/e293d-2023-11-02-09-23-19.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5de90-2023-11-02-08-41-36.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a0115-2023-11-02-08-28-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T20:30:00Z","earningsSummary":null},{"actual":-0.12,"estimate":-0.14,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-03-14T20:09:27Z","audioUrl":"https://files.quartr.com/audio-files/30513-2024-03-14-09-42-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/ced2c-2024-03-14-08-05-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-14T20:30:00Z","earningsSummary":null},{"actual":-0.14,"estimate":-0.14,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-13T20:05:43Z","audioUrl":"https://files.quartr.com/audio-files/fc34a-2024-05-13-09-47-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/03264-2024-05-13-08-00-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-13T20:30:00Z","earningsSummary":{"summary":"Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.\nWhile the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.\nBy addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.","headline":"Vaxart reports solid Q1 earnings, progresses in vaccine development","lastUpdated":"2024-05-14T00:02:15.491474Z"}},{"actual":-0.09,"estimate":-0.03,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T21:13:48Z","audioUrl":"https://files.quartr.com/audio-files/12c41-2024-08-08-09-13-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/d8b73-2024-08-08-08-11-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T20:30:00Z","earningsSummary":null},{"actual":-0.06,"estimate":-0.1,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-13T21:16:18Z","audioUrl":"https://files.quartr.com/audio-files/cb711-2024-11-13-10-30-50.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e3d05-2024-11-13-09-54-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-13T21:30:00Z","earningsSummary":{"summary":"Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.\nThe company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.\nWith a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.\nStrong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.","headline":"Vaxart reports strong Q3 revenue, advances in COVID and norovirus","lastUpdated":"2024-11-14T00:09:28.438209Z"}},{"actual":-0.04,"estimate":-0.11,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-03-20T20:07:09Z","audioUrl":"https://files.quartr.com/audio-files/2c1b3-2025-03-20-09-03-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/8305f-2025-03-20-08-40-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-03-20T20:30:00Z","earningsSummary":{"summary":"Vaxart's Q4 2024 earnings call highlighted revenue of $28.7 million, progress in norovirus program, and a temporary halt in the COVID-19 study. The company's strengths lie in innovative vaccine development, research capabilities, and commitment to safety and efficacy. Challenges include the stop work order impact, funding needs, and navigating market dynamics, while opportunities exist in new vaccine constructs and partnerships. Strategic planning and addressing challenges will be crucial for Vaxart's future growth and success in vaccine development.","headline":"Vaxart reports Q4 revenue, faces COVID-19 study halt challenges","lastUpdated":"2025-03-20T23:31:33.598965Z"}},{"actual":-0.07,"estimate":-0.07,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-07-23T14:50:26Z","audioUrl":"https://files.quartr.com/audio-files/e62a0-2025-05-13-09-50-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/86cee-2025-05-13-08-44-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-13T20:30:00Z","earningsSummary":{"summary":"Vaxart advances COVID-19 and Norovirus vaccine trials, CFO transition noted. Facing communication hurdles but aims for transparency. Addressing shareholder queries and considering strategic moves for growth.","headline":"Vaxart progresses in vaccine trials, addresses shareholder queries and transitions CFO","lastUpdated":"2025-05-14T06:21:31.941141Z"}},{"actual":null,"estimate":-0.1,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-10T23:35:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"1aeae062be6bd597681a28b7b153efa3df40f67281a64c557e5f86a47fcba416"},{"date":"2022-02-24","title":"Earnings data Q4 2021","quarter":"Q4","hash":"cfad3a23d708abcff5a59c9d0fc728f8fe5c92e2dafe81b3794d2e1b1ed81337"},{"date":"2022-05-09","title":"Earnings data Q1 2022","quarter":"Q1","hash":"e2e06ddafa8963390e2386fa452b771692ba8a7a6afdce94c8893b81a77812d5"},{"date":"2022-08-08","title":"Earnings data Q2 2022","quarter":"Q2","hash":"828529cc2235d1ca6038953d76aebbb7751a49f4ddaf019ffd4ac503e63d03e5"},{"date":"2022-11-08","title":"Earnings data Q3 2022","quarter":"Q3","hash":"4224ad5d22df37fde7188ffd775adf0472a27fbac8f3d610c53e333d7a3caa63"},{"date":"2023-03-15","title":"Earnings data Q4 2022","quarter":"Q4","hash":"d35009037b1a6cade8589d6ac053d26bd1d47ddb745c03c7a61d1e4b5e13a163"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"e2c6b5e532d701230b125ceb8540ab4782a388361726b82dfc438ac2ded00dec"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"b0fce07e525f5fe521d387e21d84c09955b3e3dc4bdbe747cb36a793de1a81d3"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"33893509d2d9e535beb5fdb2c29f3949c268b2efd09a1c51e6b45fdc4cecb7bb"},{"date":"2024-03-14","title":"Earnings data Q4 2023","quarter":"Q4","hash":"18e751c6c77175d350cf3df4d8159ec86da27bbaabac52a5fcce1d02c171875f"},{"date":"2024-05-13","title":"Earnings data Q1 2024","quarter":"Q1","hash":"ee242a1044754c0a91d31e2f94c4126618057390e02b19f760301454952fb970"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"7eec10f31e5ea575de5b6d09d808ceae8decd6e74ba2dca6c0a1b614e0d1ef4d"},{"date":"2024-11-13","title":"Earnings data Q3 2024","quarter":"Q3","hash":"02857e580fe6f6342f8243c5f13a411394b94c6b73450166f752c15b7155d328"},{"date":"2025-03-20","title":"Earnings data Q4 2024","quarter":"Q4","hash":"2dcca6289eb6f49184f7ec3d6c7f395be029dfa633cfca4a6105915a92bb38ef"},{"date":"2025-05-13","title":"Earnings data Q1 2025","quarter":"Q1","hash":"13ee76763288d772aa0ebd0db703520eb1ed55c3a8c4e681c2f184b4a6f494be"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"d94da1bb52654d1d04f991e2377d23765524127a731e7b3c2d8a528c333adf81"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Vaxart","companyDescription":"Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":20876000,"changePercentage":857.18,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1100000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":19776000,"changePercentage":1729.42,"valueToRevenueRatio":0.9473079133933704},{"financialKey":"OPERATING_EXPENSES","value":34711000,"changePercentage":38.01,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":34711000,"changePercentage":38.01,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-14935000,"changePercentage":37.95,"valueToRevenueRatio":-0.7154148304272849},{"financialKey":"EBITDA","value":-13835000,"changePercentage":39.77,"valueToRevenueRatio":-0.6627227438206553},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1100000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-15591000,"changePercentage":36.15,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.0684,"changePercentage":52.7,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":158559000,"changePercentage":78.82,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":62645000,"changePercentage":41.46,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":41938000,"changePercentage":14.38,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":16322000,"changePercentage":612.13,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":4385000,"changePercentage":-17.7,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":95914000,"changePercentage":116.09,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":27076000,"changePercentage":-22.32,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":7883000,"changePercentage":-8.49,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":60955000,"changePercentage":6547.22,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":112941000,"changePercentage":242.45,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":98504000,"changePercentage":597.77,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":6579000,"changePercentage":27.52,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":91925000,"changePercentage":926.18,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":14437000,"changePercentage":-23.46,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":13982000,"changePercentage":-24.64,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":455000,"changePercentage":47.25,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":45618000,"changePercentage":-18.09,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":45618000,"changePercentage":-18.09,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":158559000,"changePercentage":78.82,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":20561000,"changePercentage":-13.29,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-21377000,"changePercentage":-65.06,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0.19988,"changePercentage":-36.64,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-15591000,"changePercentage":36.15,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-9599000,"changePercentage":54.7,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-13028000,"changePercentage":36.18,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":3429000,"changePercentage":541.31,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":13232000,"changePercentage":363.38,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":130000,"changePercentage":-0.76,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":13362000,"changePercentage":373.08,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-260000,"changePercentage":0.76,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-164000,"changePercentage":-100.9,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":3000,"changePercentage":-99.98,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-167000,"changePercentage":8.24,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":3469000,"changePercentage":143.25,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-9729000,"changePercentage":54.37,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:44Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":null,"advancedCryptoData":null,"buySellRatio":{"buy":0,"sell":1,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":false,"advancedInfoDummy":false},{"instrument":{"symbol":"HTBX","name":"Heat Biologics","displayName":"Heat Biologics","availableForFractional":false,"availableForTrade":false,"safetyLabel":null,"trading":"DISABLED","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"DISABLED","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":"CORPORATE_ACTION","newSymbol":"NHWK","newSymbolDate":"2022-05-03","nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"HTBX","lastUpdated":"2025-04-21T20:00:00Z","batsLastUpdated":"2025-04-21T20:00:00Z","previousClose":0.132,"high":0.1311,"low":0.0579,"volume":382330,"volumeDate":"2025-04-21","last":0.07,"open":0.1205,"gainPercentage":-46.97,"gainValue":-0.062,"ask":199999,"bid":0.0001,"tradingHalted":true},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":619400,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":90447.6935,"highPriceLast52Weeks":7.2192,"lowPriceLast52Weeks":0.011,"companyName":"Scorpius Holdings, Inc.","longBusinessDescription":"Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in San Antonio, TX.","dividendRate":0,"salesOrRevenue":6243022,"oneYearAnnualRevenueGrowthRate":-10.7481545676969,"threeYearAnnualRevenueGrowthRate":565.4568,"fiveYearAnnualRevenueGrowthRate":332.9447,"earningsGrowth":82.2545,"totalDebt":28548576,"totalAssets":39177719,"floatAsPercentOfSharesOutstanding":97.3522,"dividendYield":0,"betaTwelveMonth":1.7869,"salesOrRevenueTtm":6243022,"ebitdaTtm":-25696870,"debtToEquityRatioQuarterly":453.179334626533,"totalEnterpriseValue":23593488.86,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-34.4648977677714,"fiveYearAverageDebtEquityRatio":46.13,"currentRatio":0.13425592843208,"peratio":0},"recommendation":null,"earningEstimates":[],"earningDates":[],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Heat Biologics","companyDescription":"NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q4 2024","values":[{"financialKey":"REVENUE","value":1046765,"changePercentage":-78.41,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2350981,"changePercentage":-21.69,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":-1304216,"changePercentage":-170.66,"valueToRevenueRatio":-1.2459491863025607},{"financialKey":"OPERATING_EXPENSES","value":6671850,"changePercentage":-19.43,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":6671850,"changePercentage":-19.43,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-7976070,"changePercentage":-23.94,"valueToRevenueRatio":-7.61973317793392},{"financialKey":"EBITDA","value":-6193170,"changePercentage":-33.77,"valueToRevenueRatio":-5.916485553108864},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1782900,"changePercentage":-1.26,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-9840639,"changePercentage":-51.23,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-1.8495,"changePercentage":95.52,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":39177719,"changePercentage":-23.24,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":3260955,"changePercentage":-31.5,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":1163140,"changePercentage":-51.36,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":838510,"changePercentage":69.27,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":198688,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":1060617,"changePercentage":-43.4,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":35916764,"changePercentage":-22.39,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":34342180,"changePercentage":-22.13,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":1574580,"changePercentage":-27.58,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":37500241,"changePercentage":64.88,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":24289095,"changePercentage":140.48,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":17435430,"changePercentage":1120.21,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":6853665,"changePercentage":-20.96,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":13211146,"changePercentage":4.49,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":11113146,"changePercentage":-11.89,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":2098000,"changePercentage":6893.33,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":1677478,"changePercentage":-94.07,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":6299620,"changePercentage":-79.94,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":-4622142,"changePercentage":-49,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":39177719,"changePercentage":-23.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":28548576,"changePercentage":103.31,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":27385436,"changePercentage":135.06,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":1.23929,"changePercentage":-99.48,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-9840639,"changePercentage":-73.73,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-5295181,"changePercentage":-383.79,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-5734486,"changePercentage":-4.29,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":439305,"changePercentage":-90.02,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-1611984,"changePercentage":-176.78,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":179455,"changePercentage":35.04,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":115249,"changePercentage":-94.19,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":-547778,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-1358910,"changePercentage":-7363.67,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":3365617,"changePercentage":154.28,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":3329304,"changePercentage":4973.3,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":40895,"changePercentage":-75.58,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-4582,"changePercentage":99.93,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":3923.0000000000005,"changePercentage":140.23,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-3537625,"changePercentage":31.9,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-5474640,"changePercentage":-346.03,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:33Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":null,"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":false,"advancedInfoDummy":false},{"instrument":{"symbol":"AMGN","name":"Amgen","displayName":"Amgen","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"AMGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":309.22,"high":311.28,"low":307.35,"volume":1,"volumeDate":"2025-07-25","last":308.55,"open":309.23,"gainPercentage":-0.217,"gainValue":-0.67,"ask":310,"bid":301.2,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":165909186300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":2660251.6935,"highPriceLast52Weeks":340.89,"lowPriceLast52Weeks":253.3,"companyName":"Amgen, Inc.","longBusinessDescription":"Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.","dividendRate":9.26,"salesOrRevenue":33232000000,"oneYearAnnualRevenueGrowthRate":18.6433416636915,"threeYearAnnualRevenueGrowthRate":8.7994,"fiveYearAnnualRevenueGrowthRate":7.5734,"earningsGrowth":56.9861,"totalDebt":60879000000,"totalAssets":91839000000,"floatAsPercentOfSharesOutstanding":99.7943,"dividendYield":3,"betaTwelveMonth":0.4816,"salesOrRevenueTtm":33929000000,"ebitdaTtm":14489000000,"debtToEquityRatioQuarterly":924.456259062349,"totalEnterpriseValue":189912240000,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":2.57847394540943,"fiveYearAverageDebtEquityRatio":778,"currentRatio":1.17041898470097,"peratio":28.17},"recommendation":{"currentConsensusRating":2.3,"recommendationTargetPrice":285.74,"totalRatings":35,"strongSellRatings":1,"sellRatings":3,"holdRatings":12,"buyRatings":9,"strongBuyRatings":10,"lastUpdated":"2025-07-23T13:24:45Z"},"earningEstimates":[{"actual":4.67,"estimate":4.27,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T20:20:05Z","audioUrl":"https://files.quartr.com/audio-files/87346-2022-10-19-04-32-23.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d4a7d-2021-11-02-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/92f29-2023-01-25-10-32-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T00:00:00Z","earningsSummary":null},{"actual":4.36,"estimate":4.12,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-03-02T22:54:36Z","audioUrl":"https://files.quartr.com/audio-files/0581c-2022-10-19-11-20-07.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d616a-2022-02-08-07-57-51-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/06088-2023-01-25-12-40-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-08T19:51:57Z","earningsSummary":null},{"actual":4.25,"estimate":4.15,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-27T20:13:40Z","audioUrl":"https://files.quartr.com/audio-files/94463-2022-10-28-04-38-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7e979-2022-04-27-02-28-16-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/63fa2-2023-01-25-01-05-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-27T14:16:28Z","earningsSummary":null},{"actual":4.65,"estimate":4.4,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T20:04:38Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_04_23_00_Q2_2022_Amgen_Inc_Earnings_Call.Z33P63PZYS1Z_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0247c-2022-08-05-12-45-52.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b9932-2022-08-04-08-22-30.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T00:54:00Z","earningsSummary":null},{"actual":4.7,"estimate":4.44,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T20:14:34Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_03T20_30_00_00_00_Amgen_Inc_Earnings_Call_Q3_2022.NDBPWKSFIV7G_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a21c9-2022-11-03-08-28-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/913b5-2022-11-03-08-33-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T15:45:00Z","earningsSummary":null},{"actual":4.09,"estimate":4.09,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-01-31T21:07:12Z","audioUrl":"https://files.quartr.com/audio-files/6d952-2023-02-01-07-34-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/88fa4-2023-01-31-09-08-30.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/1a16e-2023-01-31-09-24-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-01-31T21:30:00Z","earningsSummary":{"summary":"Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.","headline":"Amgen reports robust Q4 results, navigates pricing challenges for growth","lastUpdated":"2024-05-07T02:47:31.210712Z"}},{"actual":3.98,"estimate":3.85,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T20:08:51Z","audioUrl":"https://files.quartr.com/audio-files/4ad8e-2023-04-27-10-00-32.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8a639-2023-04-27-08-02-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d5678-2023-04-27-08-37-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T20:30:00Z","earningsSummary":{"summary":"Amgen's Q1 2023 earnings call highlighted strong performance, innovative R\u0026D focus, and growth in key markets like Asia-Pacific.\nDespite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.\nOpportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.\nOverall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.","headline":"Amgen reports robust Q1 performance, eyes growth in Asia-Pacific","lastUpdated":"2024-05-05T21:48:04.517661Z"}},{"actual":5,"estimate":4.49,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:07:04Z","audioUrl":"https://files.quartr.com/audio-files/b76e8-2023-08-03-09-24-54.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c42a-2023-08-03-08-26-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e6574-2023-08-03-08-26-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T20:30:00Z","earningsSummary":{"summary":"Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.\nWhile facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.\nWith a solid financial outlook, increased R\u0026D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.\nUpdates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.","headline":"Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions","lastUpdated":"2024-05-05T23:14:01.348462Z"}},{"actual":4.96,"estimate":4.66,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-31T11:09:05Z","audioUrl":"https://files.quartr.com/audio-files/4c377-2023-10-31-01-53-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d3b6d-2023-10-31-11-23-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7bebc-2023-10-31-11-25-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-31T12:00:00Z","earningsSummary":{"summary":"Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R\u0026D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.","headline":"Amgen reports revenue and earnings growth, eyes AI for innovation","lastUpdated":"2024-05-05T23:53:50.223512Z"}},{"actual":4.71,"estimate":4.62,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T21:02:51Z","audioUrl":"https://files.quartr.com/audio-files/31703-2024-02-06-10-43-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f8352-2024-02-06-09-50-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/21e6e-2024-02-06-09-34-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T21:30:00Z","earningsSummary":{"summary":"Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.\nDespite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.\nOpportunities lie in expanding the rare disease portfolio, advancing R\u0026D initiatives, and exploring new therapeutic areas.\nOverall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.","headline":"Amgen reports record sales in Q4 2023, eyes rare diseases","lastUpdated":"2024-05-05T21:27:51.954595Z"}},{"actual":3.96,"estimate":3.87,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T20:27:45Z","audioUrl":"https://files.quartr.com/audio-files/ffc8d-2024-05-02-09-46-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/41c9f-2024-05-02-08-07-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/827b9-2024-05-02-08-00-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T20:30:00Z","earningsSummary":{"summary":"Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.\nDespite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.\nThe company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.\nWith a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.","headline":"Amgen reports strong Q1 growth, eyes new markets and innovations","lastUpdated":"2024-05-06T00:15:03.188606Z"}},{"actual":4.97,"estimate":5,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-06T20:03:32Z","audioUrl":"https://files.quartr.com/audio-files/40a37-2024-08-06-09-07-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c1fb6-2024-08-06-08-33-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e5862-2024-08-06-08-20-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-06T20:30:00Z","earningsSummary":{"summary":"Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.\nWhile facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.\nWith a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.","headline":"Amgen reports strong Q2 earnings, eyes growth in diverse markets","lastUpdated":"2024-08-07T00:22:21.536118Z"}},{"actual":5.58,"estimate":5.11,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T20:02:04Z","audioUrl":"https://files.quartr.com/audio-files/b108b-2024-10-30-10-05-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f7643-2024-10-30-08-33-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bfa11-2024-10-30-08-20-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T20:30:00Z","earningsSummary":{"summary":"Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.","headline":"Amgen reports strong Q3 earnings and outlines growth strategies","lastUpdated":"2024-10-31T00:21:45.793807Z"}},{"actual":5.31,"estimate":5.08,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-04T21:08:35Z","audioUrl":"https://files.quartr.com/audio-files/a3808-2025-02-04-10-09-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e134f-2025-02-04-09-22-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/63c9b-2025-02-04-09-35-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-04T21:30:00Z","earningsSummary":null},{"actual":4.9,"estimate":4.3,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T20:01:43Z","audioUrl":"https://files.quartr.com/audio-files/95892-2025-05-01-09-54-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ed5dc-2025-05-01-08-13-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/69248-2025-05-01-08-19-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T20:30:00Z","earningsSummary":{"summary":"Amgen's Q1 2025 performance reflects strong revenue growth and a focus on meeting patient needs across various therapeutic areas. While challenges exist in evaluating new opportunities like rocutilimab, the company's diverse portfolio and innovation-driven approach present promising growth opportunities.","headline":"Amgen reports robust Q1 earnings, eyes growth in diverse portfolio","lastUpdated":"2025-05-01T23:31:33.438248Z"}},{"actual":null,"estimate":5.26,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-05T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"e0e2168d0f65969307354ee490405e33a9972646a470b47ea500a860a4a575da"},{"date":"2022-02-07","title":"Earnings data Q4 2021","quarter":"Q4","hash":"f0929c2255c905ce0d56431da7ac9b95962e9c696a4974ca443a576e148161a0"},{"date":"2022-04-27","title":"Earnings data Q1 2022","quarter":"Q1","hash":"498bde4adbab6bb399119d4200642447f1a253d737b40df4b191cfb57345d9c6"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"66876d41a02dbe6e4d181a8e1f9506ccbbe83436b83ca882177771c59d29e2a9"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"3b0c6bc5b5bee070621b4f86d906a42d89192311e4a5018aff5bfa8aec442a7b"},{"date":"2023-01-31","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8b2fbee7f8c0f1be873b08c7f7ca473ad77a460021c3f665d9fc9a4514d18f66"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"e9c61a9f0de74922ce54f2bc9df3357daf2fa1f3b2a6343c7e7c58f6c8d4d515"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"2722d6841cd28f91c43f0ed22a45d556212980c369b90d73584436315672fe81"},{"date":"2023-10-31","title":"Earnings data Q3 2023","quarter":"Q3","hash":"3073d862da99735bbd92af337b8d6b56779545e5d9d751de1e8e4f76087c778e"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"c9d397882cf9e012ea8115a8f3eb8b7b3298db49b04b84f5086fdd15e053f596"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"9c48306f877c7fe5fce95504c760d99832415b536eb2a12dad68ce9521b60351"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"a2fa6641a680f13b854e2aedbea0cc409fed58c1072f3573ee663e3ef5869a15"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"15464be47d3b93851f1924c4b259f30cb27215486b3a145089a46155b8911b76"},{"date":"2025-02-04","title":"Earnings data Q4 2024","quarter":"Q4","hash":"68f857c6061826bdd934658e9c8c5fcbbbae0d484ec275dfb541ce0848d98c6e"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"9f2ecf7bc46d1e6ee1fcb50f03bc660ea2015703f0eca60364058a8f8eafd55c"},{"date":"2025-08-05","title":"Earnings data Q2 2025","quarter":"Q2","hash":"2c987065d350e79b00d8327195f32d67be856925efe6b2ae97c87188083845df"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Amgen","companyDescription":"Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":8093000000,"changePercentage":9.42,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2968000000,"changePercentage":-7.25,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":5125000000,"changePercentage":22.14,"valueToRevenueRatio":0.6332633139750402},{"financialKey":"OPERATING_EXPENSES","value":4003000000,"changePercentage":22.94,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":3173000000,"changePercentage":0.7,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":830000000,"changePercentage":690.48,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":1122000000,"changePercentage":19.36,"valueToRevenueRatio":0.13863832942048684},{"financialKey":"EBITDA","value":2509000000,"changePercentage":7.27,"valueToRevenueRatio":0.3100210058074879},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1387000000,"changePercentage":-0.86,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1730000000,"changePercentage":1630.97,"valueToRevenueRatio":null},{"financialKey":"EPS","value":3.1978,"changePercentage":1616.98,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":89367000000,"changePercentage":-3.89,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":26929000000,"changePercentage":-3.92,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":8810000000,"changePercentage":-9.25,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":8132000000,"changePercentage":20.01,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":6729000000,"changePercentage":-22.87,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":3258000000,"changePercentage":15.49,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":62438000000,"changePercentage":-3.87,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":6681000000,"changePercentage":11.31,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":44369000000,"changePercentage":-11.16,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":11388000000,"changePercentage":26.43,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":83160000000,"changePercentage":-5.45,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":23008000000,"changePercentage":16.71,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":3368000000,"changePercentage":-14.93,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":19640000000,"changePercentage":24.66,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":60152000000,"changePercentage":-11.86,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":54013000000,"changePercentage":-10.07,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":6139000000,"changePercentage":-24.98,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":6207000000,"changePercentage":23.6,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":6207000000,"changePercentage":23.6,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":89367000000,"changePercentage":-3.89,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":57381000000,"changePercentage":-10.37,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":48571000000,"changePercentage":-10.57,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":11.54361,"changePercentage":23.3,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":1730000000,"changePercentage":1630.97,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1391000000,"changePercentage":101.89,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":2407000000,"changePercentage":74.29,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1016000000,"changePercentage":-46.82,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-447000000,"changePercentage":-105.99,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":411000000,"changePercentage":78.7,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-858000000,"changePercentage":-91.95,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-4107000000,"changePercentage":-140.46,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-2801000000,"changePercentage":-583.17,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1279000000,"changePercentage":5.88,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-27000000,"changePercentage":70,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-3163000000,"changePercentage":-155.91,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":980000000,"changePercentage":113.51,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:45Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-17T06:13:19Z","bearsSay":["Amgen faces significant risks that may negatively impact its financial outlook, primarily due to heightened competition within its core business franchise, which could lead to market share erosion and increased pricing pressure. Additionally, the company is experiencing challenges related to lower-than-expected uptake for its newer products and potential regulatory setbacks for its late-stage pipeline and biosimilars. Looking ahead, management anticipates a potential mid-single-digit decline in pricing for its cholesterol-lowering drug, Repatha, which may further strain revenue growth as the competitive landscape evolves."],"bullsSay":["Amgen's financial outlook appears robust due to substantial sales growth from its flagship product Tavneos, which saw a remarkable 81% increase in the fourth quarter of 2024, contributing to overall U.S. sales of approximately $716 million in 2022, following a label expansion. The acquisition of Horizon Therapeutics has strengthened the company’s portfolio by adding several rare-disease treatments, including Tepezza, further enhancing its growth prospects alongside a strong emerging pipeline that includes promising candidates like Olpasiran and Imdelltra. Moreover, Amgen's strong cash position, coupled with a well-diversified product portfolio across key therapeutic areas, supports sustained long-term growth potential and reinforces the company's status as a high-quality player in the biotechnology sector."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Product sales","dataPoints":[{"key":"21 Q2","value":6114},{"key":"21 Q3","value":6320},{"key":"21 Q4","value":6271},{"key":"22 Q1","value":5731},{"key":"22 Q2","value":6281},{"key":"22 Q3","value":6237},{"key":"22 Q4","value":6552},{"key":"23 Q1","value":5846},{"key":"23 Q2","value":6683},{"key":"23 Q3","value":6548},{"key":"23 Q4","value":7833},{"key":"24 Q1","value":7118},{"key":"24 Q2","value":8041},{"key":"24 Q3","value":8151},{"key":"24 Q4","value":8716},{"key":"25 Q1","value":7873}]},{"title":"Other revenues","dataPoints":[{"key":"21 Q2","value":412},{"key":"21 Q3","value":386},{"key":"21 Q4","value":575},{"key":"22 Q1","value":507},{"key":"22 Q2","value":313},{"key":"22 Q3","value":415},{"key":"22 Q4","value":287},{"key":"23 Q1","value":259},{"key":"23 Q2","value":303},{"key":"23 Q3","value":355},{"key":"23 Q4","value":363},{"key":"24 Q1","value":329},{"key":"24 Q2","value":347},{"key":"24 Q3","value":352},{"key":"24 Q4","value":370},{"key":"25 Q1","value":276}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":74.91},{"key":"21 Q3","value":76},{"key":"21 Q4","value":74.9},{"key":"22 Q1","value":74.97},{"key":"22 Q2","value":77.1},{"key":"22 Q3","value":76.12},{"key":"22 Q4","value":74.45},{"key":"23 Q1","value":71.82},{"key":"23 Q2","value":74.04},{"key":"23 Q3","value":73.83},{"key":"23 Q4","value":62.03},{"key":"24 Q1","value":57.02},{"key":"24 Q2","value":61.42},{"key":"24 Q3","value":61.07},{"key":"24 Q4","value":65.74},{"key":"25 Q1","value":63.57}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":12.68},{"key":"21 Q3","value":35.46},{"key":"21 Q4","value":33.65},{"key":"22 Q1","value":40.07},{"key":"22 Q2","value":32.99},{"key":"22 Q3","value":39.98},{"key":"22 Q4","value":32.6},{"key":"23 Q1","value":31.46},{"key":"23 Q2","value":38.41},{"key":"23 Q3","value":29.27},{"key":"23 Q4","value":15.5},{"key":"24 Q1","value":13.3},{"key":"24 Q2","value":22.75},{"key":"24 Q3","value":24.07},{"key":"24 Q4","value":25.43},{"key":"25 Q1","value":14.45}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":7.11},{"key":"21 Q3","value":28.09},{"key":"21 Q4","value":27.73},{"key":"22 Q1","value":23.66},{"key":"22 Q2","value":19.97},{"key":"22 Q3","value":32.21},{"key":"22 Q4","value":23.62},{"key":"23 Q1","value":46.53},{"key":"23 Q2","value":19.73},{"key":"23 Q3","value":25.06},{"key":"23 Q4","value":9.35},{"key":"24 Q1","value":-1.52},{"key":"24 Q2","value":8.89},{"key":"24 Q3","value":33.28},{"key":"24 Q4","value":6.9},{"key":"25 Q1","value":21.22}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1082},{"key":"21 Q3","value":1422},{"key":"21 Q4","value":1348},{"key":"22 Q1","value":959},{"key":"22 Q2","value":1039},{"key":"22 Q3","value":1112},{"key":"22 Q4","value":1324},{"key":"23 Q1","value":1058},{"key":"23 Q2","value":1113},{"key":"23 Q3","value":1079},{"key":"23 Q4","value":1534},{"key":"24 Q1","value":1343},{"key":"24 Q2","value":1447},{"key":"24 Q3","value":1450},{"key":"24 Q4","value":1724},{"key":"25 Q1","value":1486}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"21 Q2","value":1505}]},{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":1384},{"key":"21 Q3","value":1305},{"key":"21 Q4","value":1425},{"key":"22 Q1","value":1228},{"key":"22 Q2","value":1327},{"key":"22 Q3","value":1287},{"key":"22 Q4","value":1572},{"key":"23 Q1","value":1258},{"key":"23 Q2","value":1294},{"key":"23 Q3","value":1353},{"key":"23 Q4","value":2274},{"key":"24 Q1","value":1808},{"key":"24 Q2","value":1785},{"key":"24 Q3","value":1625},{"key":"24 Q4","value":1878},{"key":"25 Q1","value":1687}]},{"title":"Other","dataPoints":[{"key":"21 Q2","value":90},{"key":"21 Q3","value":-8},{"key":"21 Q4","value":51},{"key":"22 Q1","value":-10},{"key":"22 Q2","value":542},{"key":"22 Q3","value":5},{"key":"22 Q4","value":-34},{"key":"23 Q1","value":148},{"key":"23 Q2","value":82},{"key":"23 Q3","value":644},{"key":"23 Q4","value":5},{"key":"24 Q1","value":105},{"key":"24 Q2","value":11},{"key":"24 Q3","value":71},{"key":"24 Q4","value":61},{"key":"25 Q1","value":830}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":5.16},{"key":"21 Q3","value":4.41},{"key":"21 Q4","value":3.2},{"key":"22 Q1","value":5.71},{"key":"22 Q2","value":1.04},{"key":"22 Q3","value":-0.81},{"key":"22 Q4","value":-0.1},{"key":"23 Q1","value":-2.13},{"key":"23 Q2","value":5.94},{"key":"23 Q3","value":3.77},{"key":"23 Q4","value":19.84},{"key":"24 Q1","value":21.98},{"key":"24 Q2","value":20.07},{"key":"24 Q3","value":23.18},{"key":"24 Q4","value":10.86},{"key":"25 Q1","value":9.43}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":69.56},{"key":"21 Q3","value":12.87},{"key":"21 Q4","value":-6.77},{"key":"22 Q1","value":-4.6},{"key":"22 Q2","value":-28.39},{"key":"22 Q3","value":-11.59},{"key":"22 Q4","value":1.35},{"key":"23 Q1","value":13.18},{"key":"23 Q2","value":-14.41},{"key":"23 Q3","value":27.95},{"key":"23 Q4","value":33.23},{"key":"24 Q1","value":32.14},{"key":"24 Q2","value":30.29},{"key":"24 Q3","value":2.28},{"key":"24 Q4","value":-3.93},{"key":"25 Q1","value":22.94}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":573},{"key":"21 Q3","value":567},{"key":"21 Q4","value":562},{"key":"22 Q1","value":548},{"key":"22 Q2","value":535},{"key":"22 Q3","value":535},{"key":"22 Q4","value":535},{"key":"23 Q1","value":534},{"key":"23 Q2","value":535},{"key":"23 Q3","value":535},{"key":"23 Q4","value":535},{"key":"24 Q1","value":536},{"key":"24 Q2","value":537},{"key":"24 Q3","value":537},{"key":"24 Q4","value":537},{"key":"25 Q1","value":538}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":140958},{"key":"21 Q3","value":130523.4},{"key":"21 Q4","value":118638.2},{"key":"22 Q1","value":125930.4},{"key":"22 Q2","value":130593.5},{"key":"22 Q3","value":129149},{"key":"22 Q4","value":142952},{"key":"23 Q1","value":130509.6},{"key":"23 Q2","value":123531.5},{"key":"23 Q3","value":133001},{"key":"23 Q4","value":145787.5},{"key":"24 Q1","value":156833.6},{"key":"24 Q2","value":157770.6},{"key":"24 Q3","value":175652.7},{"key":"24 Q4","value":159327.9},{"key":"25 Q1","value":158871.4}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":5.4},{"key":"21 Q3","value":4.87},{"key":"21 Q4","value":4.33},{"key":"22 Q1","value":5.05},{"key":"22 Q2","value":4.95},{"key":"22 Q3","value":4.85},{"key":"22 Q4","value":5.23},{"key":"23 Q1","value":5.34},{"key":"23 Q2","value":4.42},{"key":"23 Q3","value":4.82},{"key":"23 Q4","value":4.45},{"key":"24 Q1","value":5.26},{"key":"24 Q2","value":4.7},{"key":"24 Q3","value":5.16},{"key":"24 Q4","value":4.38},{"key":"25 Q1","value":4.87}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T23:50:21Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.52,"sell":0.48,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"XBI","name":"SPDR S\u0026P Biotech ETF","displayName":"SPDR S\u0026P Biotech ETF","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"XBI","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":88.22,"high":88.56,"low":87.255,"volume":372,"volumeDate":"2025-07-25","last":87.49,"open":88.27,"gainPercentage":-0.827,"gainValue":-0.73,"ask":87.92,"bid":87.32,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":null,"instrumentClass":"EXCHANGE_TRADED_FUND","averageDailyVolumeLast3Months":10905999.3065,"highPriceLast52Weeks":105.47,"lowPriceLast52Weeks":66.66,"companyName":null,"longBusinessDescription":"XBI tracks an equal-weighted index of US biotechnology stocks.","dividendRate":0.0305,"salesOrRevenue":null,"oneYearAnnualRevenueGrowthRate":null,"threeYearAnnualRevenueGrowthRate":null,"fiveYearAnnualRevenueGrowthRate":null,"earningsGrowth":null,"totalDebt":null,"totalAssets":null,"floatAsPercentOfSharesOutstanding":null,"dividendYield":0.03,"betaTwelveMonth":0.9881,"salesOrRevenueTtm":null,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":null,"industry":"InvestmentTrustsOrMutualFunds","sector":"Miscellaneous","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":null,"currentRatio":null,"peratio":null},"recommendation":null,"earningEstimates":[],"earningDates":[],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"SPDR S\u0026P Biotech ETF","companyDescription":"XBI tracks an equal-weighted index of US biotechnology stocks.","executives":null,"brands":[]},"etfFundamental":{"returnInception":0.0931,"etfType":"US Equities","category":"Broad Market / Multi-Cap","netExpenseRatio":0.35000000000000003,"inceptionDate":"2006-01-31","assetsUnderManagement":4919073913,"returnYTD":-0.0204,"return1Month":0.0723,"return3Month":0.1363,"return1Year":-0.0951,"return3Year":0.0348,"return5Year":-0.053,"return10Year":0.0014,"returnsAsOfDate":"2025-07-23","quarterlyNavBasedReturns":{"returnYTD":-8.01,"return1Month":3.01,"return3Month":-1.83,"return1Year":-10,"return3Year":2.85,"return5Year":-6.07,"return10Year":-0.28,"returnInception":8.93,"returnsAsOfDate":"2025-06-30"},"quarterlyPriceBasedReturns":{"returnYTD":-7.91,"return1Month":3.07,"return3Month":-1.74,"return1Year":-10.02,"return3Year":2.91,"return5Year":-6.05,"return10Year":-0.28,"returnInception":8.98,"returnsAsOfDate":"2025-06-30"},"monthlyNavBasedReturns":{"returnYTD":-8.01,"return1Month":3.01,"return3Month":-1.83,"return1Year":-10,"return3Year":2.85,"return5Year":-6.07,"return10Year":-0.28,"returnInception":8.93,"returnsAsOfDate":"2025-06-30"},"monthlyPriceBasedReturns":{"returnYTD":-7.91,"return1Month":3.07,"return3Month":-1.74,"return1Year":-10.02,"return3Year":2.91,"return5Year":-6.05,"return10Year":-0.28,"returnInception":8.98,"returnsAsOfDate":"2025-06-30"},"secYieldPercentage":null,"prospectusLink":"https://www.ssga.com/us/en/institutional/etfs/resources/doc-viewer#xbi\u0026prospectus"},"financials":null,"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":{"totalHoldings":125,"holdings":[{"symbol":"MRNA","name":"Moderna","weight":0.029500000000000002},{"symbol":"UTHR","name":"United Therapeutics","weight":0.026099999999999998},{"symbol":"REGN","name":"Regeneron Pharmaceuticals","weight":0.026099999999999998},{"symbol":"EXEL","name":"Exelixis","weight":0.0259},{"symbol":"ALNY","name":"Alnylam Pharmaceuticals","weight":0.0258},{"symbol":"HALO","name":"Halozyme Therapeutics","weight":0.025699999999999997},{"symbol":"NBIX","name":"Neurocrine Biosciences","weight":0.0254},{"symbol":"AMGN","name":"Amgen","weight":0.025},{"symbol":"INSM","name":"Insmed","weight":0.024900000000000002},{"symbol":"VRTX","name":"Vertex Pharmaceuticals","weight":0.024900000000000002}]},"etfHoldingsLastUpdated":"2025-07-23T00:00:00Z"},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"INO","name":"Inovio Pharmaceuticals","displayName":"Inovio Pharmaceuticals","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"INO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":1.56,"high":1.5686,"low":1.48,"volume":270,"volumeDate":"2025-07-25","last":1.51,"open":1.56,"gainPercentage":-3.205,"gainValue":-0.05,"ask":1.53,"bid":1.45,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":76949900,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1535223.8065,"highPriceLast52Weeks":12.33,"lowPriceLast52Weeks":1.3,"companyName":"Inovio Pharmaceuticals, Inc.","longBusinessDescription":"Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.","dividendRate":0,"salesOrRevenue":217756,"oneYearAnnualRevenueGrowthRate":-73.827718416846,"threeYearAnnualRevenueGrowthRate":104.1715,"fiveYearAnnualRevenueGrowthRate":63.3397,"earningsGrowth":42.4149,"totalDebt":11865187,"totalAssets":114901206,"floatAsPercentOfSharesOutstanding":99.2055,"dividendYield":0,"betaTwelveMonth":1.1094,"salesOrRevenueTtm":283099,"ebitdaTtm":-102850720,"debtToEquityRatioQuarterly":21.9918005451006,"totalEnterpriseValue":-32543962.71,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-641.044800458857,"fiveYearAverageDebtEquityRatio":10.36,"currentRatio":2.63090586997125,"peratio":-0.47},"recommendation":{"currentConsensusRating":2.4,"recommendationTargetPrice":13.88,"totalRatings":16,"strongSellRatings":1,"sellRatings":1,"holdRatings":5,"buyRatings":5,"strongBuyRatings":4,"lastUpdated":"2025-07-09T14:01:02Z"},"earningEstimates":[{"actual":-3.48,"estimate":-3.96,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2024-02-06T13:10:04Z","audioUrl":"https://files.quartr.com/audio-files/9c84b-2022-10-19-05-08-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/973a2-2023-01-25-11-45-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-09T00:00:00Z","earningsSummary":null},{"actual":-6,"estimate":-3.84,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2024-02-06T13:10:05Z","audioUrl":"https://files.quartr.com/audio-files/8df7a-2022-10-19-12-50-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4c77c-2023-01-25-12-14-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-03-01T11:27:08Z","earningsSummary":null},{"actual":-4.32,"estimate":-4.08,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2024-02-06T13:10:06Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_05_10_22_30_Q1_2022_Inovio_Pharmaceuticals_Inc_Earnings_Call.62OO653RJMJ9.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/adce7-2023-01-25-02-58-41.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-10T12:43:34Z","earningsSummary":null},{"actual":-5.52,"estimate":-3.72,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2024-02-06T13:10:06Z","audioUrl":"https://files.quartr.com/audio-files/ff80c-2022-08-09-11-49-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/f9658-2022-08-09-08-11-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-09T20:30:00Z","earningsSummary":null},{"actual":-1.8,"estimate":-3.6,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2024-02-06T13:10:07Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_08T21_30_00_00_00_Inovio_Pharmaceuticals_Inc_Earnings_Call_Q3_2022.N3A49DX0WAWI_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b4dcb-2022-11-08-09-06-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-08T13:00:00Z","earningsSummary":null},{"actual":-2.64,"estimate":-2.04,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2024-02-06T13:10:07Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_03_01T21_30_00_00_00_Inovio_Pharmaceuticals_Inc_Earnings_Call_Q4_2022.N0AFW52QCS7J_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fa137-2023-03-01-09-01-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-03-01T21:30:00Z","earningsSummary":null},{"actual":-1.92,"estimate":-1.68,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2024-02-06T13:10:08Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_10T20_30_00_00_00_Inovio_Pharmaceuticals_Inc_Q1_2023.3RYB8M9HMC4R_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/bddf3-2023-05-10-08-58-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-10T20:30:00Z","earningsSummary":null},{"actual":-1.56,"estimate":-1.68,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2024-02-06T13:10:09Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_09T20_30_00_00_00_Inovio_Pharmaceuticals_Inc_Q2_2023.D3QNFAX3C3GN_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/19654-2023-08-09-08-23-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-09T20:30:00Z","earningsSummary":null},{"actual":-1.56,"estimate":-1.56,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2024-02-06T13:10:09Z","audioUrl":"https://files.quartr.com/audio-files/01047-2023-11-09-10-26-27.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/81a9a-2023-11-09-09-15-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-09T21:30:00Z","earningsSummary":null},{"actual":-1.1,"estimate":-1.27,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-03-06T21:45:42Z","audioUrl":"https://files.quartr.com/audio-files/0d86a-2024-03-06-10-27-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/2112b-2024-03-06-09-54-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-06T21:30:00Z","earningsSummary":null},{"actual":-1.31,"estimate":-1,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-13T20:47:54Z","audioUrl":"https://files.quartr.com/audio-files/94a57-2024-05-13-09-59-31.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/7d9c8-2024-05-13-08-15-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-13T20:30:00Z","earningsSummary":{"summary":"Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.\nThe company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.\nOverall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.\nAnalysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.","headline":"Inovio progresses on RRP treatment, faces trial challenges and opportunities","lastUpdated":"2024-05-14T00:02:38.388395Z"}},{"actual":-1.19,"estimate":-1.1,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T20:37:34Z","audioUrl":"https://files.quartr.com/audio-files/ebe01-2024-08-08-09-27-30.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fd25a-2024-08-08-08-00-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T20:30:00Z","earningsSummary":null},{"actual":-0.89,"estimate":-1.13,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-14T21:07:03Z","audioUrl":"https://files.quartr.com/audio-files/4332f-2024-11-14-10-51-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/a8295-2024-11-14-09-22-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-14T21:30:00Z","earningsSummary":{"summary":"INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.\nDespite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.\nAddressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.\nBy leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.","headline":"INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion","lastUpdated":"2024-11-15T04:06:10.426094Z"}},{"actual":-0.65,"estimate":-0.83,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-03-18T20:18:29Z","audioUrl":"https://files.quartr.com/audio-files/9b4d0-2025-03-18-09-07-44.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/58d42-2025-03-18-08-28-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-03-18T20:30:00Z","earningsSummary":{"summary":"INOVIO Pharmaceuticals delivered strong performance in Q4 2024, backed by promising clinical data and financial stability While facing regulatory challenges and industry competition, the company's strategic priorities and technological advancements present growth opportunities","headline":"INOVIO Pharmaceuticals excels in Q4 with promising clinical data","lastUpdated":"2025-03-19T03:31:21.897808Z"}},{"actual":-0.51,"estimate":-0.74,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-13T20:14:43Z","audioUrl":"https://files.quartr.com/audio-files/c395a-2025-05-13-09-04-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/cdd56-2025-05-13-08-48-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-13T20:30:00Z","earningsSummary":null},{"actual":null,"estimate":-0.62,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:08Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-09","title":"Earnings data Q3 2021","quarter":"Q3","hash":"ca936a104a61eb4a230f7894dab69211791104068fb08ba2ef394e2d54cfc4e1"},{"date":"2022-03-01","title":"Earnings data Q4 2021","quarter":"Q4","hash":"469d20cb6ffbb602d030ae182ffebb5b28e000bb461ca910997cc8c500595a30"},{"date":"2022-05-10","title":"Earnings data Q1 2022","quarter":"Q1","hash":"f3697ef06b2308073c4c3941ab44e268a1880b7b6b8e68afb4ab44c276a0ef3d"},{"date":"2022-08-09","title":"Earnings data Q2 2022","quarter":"Q2","hash":"b0f951553127865cb7fa4344d0f205f1720b97630caeef751f870f726a0b2d72"},{"date":"2022-11-08","title":"Earnings data Q3 2022","quarter":"Q3","hash":"fe1c5272e7600b7a98ea3864ff14634b33e8ef451b34c350216fa4e2b15b3aa2"},{"date":"2023-03-01","title":"Earnings data Q4 2022","quarter":"Q4","hash":"e6e08227c715aaa97e23b966533a34df2ccb1c7c3f3ad193855c6efa302f6d0b"},{"date":"2023-05-10","title":"Earnings data Q1 2023","quarter":"Q1","hash":"0a37cb119203e17cd695eed3c88f17c6eb02e30a1e2cef5643f24f79a2233065"},{"date":"2023-08-09","title":"Earnings data Q2 2023","quarter":"Q2","hash":"26a93460e0e085c847d76a177e5116ed5b177f95ae7d387804b7245a5517c853"},{"date":"2023-11-09","title":"Earnings data Q3 2023","quarter":"Q3","hash":"851ba7b7f5e1c3ea047ddccaaead246ed1e48c9b1b07dbb5d8df56f4066a8215"},{"date":"2024-03-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"ad91392f6fd7a87b246822fb2bf9389715e00338b5830c559486207ad907577f"},{"date":"2024-05-13","title":"Earnings data Q1 2024","quarter":"Q1","hash":"bb758491a14ea2eaf00d6567a2f9c492e826e083664c52067d31c861be25ab23"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"82965f5e5f72a1a168e1b24ca48d42679efc44cc4b85a404aa14a87ea884af16"},{"date":"2024-11-14","title":"Earnings data Q3 2024","quarter":"Q3","hash":"c1f79e24591ae77b8d1177ea42b0701f5682b1455df06ea0cc692ed28ab7f151"},{"date":"2025-03-18","title":"Earnings data Q4 2024","quarter":"Q4","hash":"394fc05a463a58996feb864b8ec7de06a0a4e8655d73ef88eb53fcc512029335"},{"date":"2025-05-13","title":"Earnings data Q1 2025","quarter":"Q1","hash":"efd99e0ad6bd73a84377f4de3c3d156244d205f17c461784f6eed559b3225180"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"305e535f40e8a75efa1bfd75c67d99b8ff19c7b4706872453170d19060b21cc8"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Inovio Pharmaceuticals","companyDescription":"Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":65343,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":743450,"changePercentage":-2.14,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":-678107,"changePercentage":10.74,"valueToRevenueRatio":-10.377653306398543},{"financialKey":"OPERATING_EXPENSES","value":24372422,"changePercentage":-20.68,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":24372422,"changePercentage":-20.68,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-25050530,"changePercentage":20.44,"valueToRevenueRatio":-383.3697565156176},{"financialKey":"EBITDA","value":-24307080,"changePercentage":20.89,"valueToRevenueRatio":-371.99210320921907},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":743450,"changePercentage":-2.14,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-19694697,"changePercentage":35.36,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.51,"changePercentage":61.02,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":87272659,"changePercentage":-32.41,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":71894449,"changePercentage":-35.63,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":68362544,"changePercentage":-35.27,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":1310237,"changePercentage":-48.64,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":2221668,"changePercentage":-36.83,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":15378210,"changePercentage":-11.78,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":11089581,"changePercentage":-21.75,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":4288625,"changePercentage":31.57,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":36021935,"changePercentage":3.89,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":27326880,"changePercentage":16.78,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":2575902,"changePercentage":19.5,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":24750978,"changePercentage":16.5,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":8695055,"changePercentage":-22.86,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":8695055,"changePercentage":-22.86,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":51250724,"changePercentage":-45.73,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":51250724,"changePercentage":-45.73,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":87272659,"changePercentage":-32.41,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":11270957,"changePercentage":-16.06,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-57091587,"changePercentage":38.07,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":1.39745,"changePercentage":-65.42,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-19694697,"changePercentage":35.36,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-26874027,"changePercentage":6.56,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-22100039,"changePercentage":20.81,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-4773988,"changePercentage":-460.82,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-51753,"changePercentage":-100.11,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":59373,"changePercentage":66.88,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":7620,"changePercentage":-99.98,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-118746,"changePercentage":-66.88,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":1027930,"changePercentage":109.05,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":1102149,"changePercentage":-78.91,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-74219,"changePercentage":57.41,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-25897850,"changePercentage":-589.47,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-26933400,"changePercentage":6.47,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:58Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-03T02:43:36Z","bearsSay":["Inovio Pharmaceuticals is experiencing a concerning outlook due to multiple risks associated with its clinical development programs, particularly with its candidate INO-3107, which may not meet efficacy or safety endpoints, jeopardizing regulatory approval. The company has a history of losses and lacks a proven track record of profitability, complicating its ability to attract partnerships necessary for successful commercialization. Additionally, external factors, including strong competition and unfavorable market conditions, coupled with potential dilution risks, further threaten Inovio's commercial viability."],"bullsSay":["Inovio Pharmaceuticals is advancing its innovative DNA medicines, with expected milestones in 2025 that include alignment on Phase 3 trial design for a combination therapy targeting HPV-positive oropharyngeal squamous cell carcinoma and the initiation of a Phase 2 trial for glioblastoma. The company's immunotherapy platform demonstrates significant potential, particularly with the promising early clinical data from its DMAb technology, indicating a broad capacity for in vivo protein production through DNA plasmids. Furthermore, Inovio's DNA-based therapies offer advantages in cost of goods, administration, and storage, positioning the company favorably against traditional monoclonal antibodies if validated in future trials."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.02,"sell":0.98,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"DVAX","name":"Dynavax Technologies","displayName":"Dynavax Technologies","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"DVAX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":11.35,"high":11.48,"low":11.14,"volume":770244,"volumeDate":"2025-07-24","last":11.16,"open":11.35,"gainPercentage":-1.674,"gainValue":-0.19,"ask":13.98,"bid":9.3,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":1340104000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1916975.8548,"highPriceLast52Weeks":14.63,"lowPriceLast52Weeks":9.22,"companyName":"Dynavax Technologies Corp.","longBusinessDescription":"Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.","dividendRate":0,"salesOrRevenue":277246000,"oneYearAnnualRevenueGrowthRate":19.3564774155775,"threeYearAnnualRevenueGrowthRate":5.6187,"fiveYearAnnualRevenueGrowthRate":177.5755,"earningsGrowth":-783.3795,"totalDebt":254417000,"totalAssets":986256000,"floatAsPercentOfSharesOutstanding":95.2657,"dividendYield":0,"betaTwelveMonth":0.5574,"salesOrRevenueTtm":294621000,"ebitdaTtm":-980000,"debtToEquityRatioQuarterly":54.640346102486,"totalEnterpriseValue":1243385880,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":-0.606711804533412,"fiveYearAverageDebtEquityRatio":121.3,"currentRatio":11.9330496204975,"peratio":-21.14},"recommendation":{"currentConsensusRating":2.1,"recommendationTargetPrice":20.89,"totalRatings":9,"strongSellRatings":1,"sellRatings":0,"holdRatings":1,"buyRatings":4,"strongBuyRatings":3,"lastUpdated":"2025-05-07T16:40:09Z"},"earningEstimates":[{"actual":-0.24,"estimate":0.05,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T21:37:05Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":0.55,"estimate":0.69,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-28T21:18:03Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4e5e8-2023-11-24-01-55-44.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-28T12:00:00Z","earningsSummary":null},{"actual":0.22,"estimate":0.24,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-05T22:36:03Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-05-05T00:00:00Z","earningsSummary":null},{"actual":0.87,"estimate":0.22,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T21:04:35Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_04_22_30_Q2_2022_Dynavax_Technologies_Corp_Earnings_Call.K1JHD0OAYZ2K_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0cb05-2022-08-05-12-21-21.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ac12c-2022-08-04-08-53-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T20:30:00Z","earningsSummary":null},{"actual":0.43,"estimate":0.33,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T21:15:38Z","audioUrl":"https://files.quartr.com/audio-files/d593f-2022-11-03-10-06-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6af3a-2022-11-03-08-10-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/53769-2022-11-03-08-10-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T17:30:00Z","earningsSummary":null},{"actual":0.45,"estimate":0.43,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-23T22:16:26Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_23T21_30_00_00_00_Dynavax_Technologies_Corp_Earnings_Call_Q4_2022.SEFCAQJJL5L0_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4c377-2023-02-23-09-37-31.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f9266-2023-02-23-09-28-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-23T21:30:00Z","earningsSummary":{"summary":"Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.","headline":"Dynavax Technologies reports strong Q4 earnings, eyes continued growth","lastUpdated":"2024-05-07T08:46:27.297405Z"}},{"actual":-0.19,"estimate":-0.13,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-02T20:44:57Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_02T20_30_00_00_00_Dynavax_Technologies_Corporation_Q1_2023.GVT9JABSL6QD_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7df06-2023-05-02-09-01-24.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/830c0-2023-05-02-08-51-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-02T20:30:00Z","earningsSummary":{"summary":"Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.\nWhile facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.\nManagement's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.\nOverall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.","headline":"Dynavax reports record revenue growth, eyes market expansion opportunities","lastUpdated":"2024-05-07T06:48:43.339190Z"}},{"actual":0.03,"estimate":-0.09,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T21:45:58Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T20_30_00_00_00_Dynavax_Technologies_Corporation_Q2_2023.NBPICU2JN38A_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e3397-2023-08-03-08-23-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ed60c-2023-08-03-08-22-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T20:30:00Z","earningsSummary":{"summary":"Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.\nThe company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.\nWhile facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.\nBy leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.","headline":"Dynavax reports strong Q2 earnings, eyes growth through innovation","lastUpdated":"2024-05-07T07:33:14.163979Z"}},{"actual":0.1,"estimate":-0.01,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T20:18:38Z","audioUrl":"https://files.quartr.com/audio-files/26bfa-2023-11-02-09-25-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f6c09-2023-11-02-08-25-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3628e-2023-11-02-08-01-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T20:30:00Z","earningsSummary":{"summary":"Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.\nWhile facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.\nWith raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.","headline":"Dynavax reports record revenue growth and raises full-year guidance","lastUpdated":"2024-05-06T19:53:59.007429Z"}},{"actual":0,"estimate":-0.01,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-22T21:02:15Z","audioUrl":"https://files.quartr.com/audio-files/0fc83-2024-02-22-10-09-28.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b8631-2024-02-22-09-37-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/db1c4-2024-02-22-09-26-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-22T21:30:00Z","earningsSummary":{"summary":"Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.\nThe company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.\nWith a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.","headline":"Dynavax Technologies reports record revenue growth and strategic investments","lastUpdated":"2024-05-07T06:46:40.700516Z"}},{"actual":-0.07,"estimate":-0.02,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-08T20:03:33Z","audioUrl":"https://files.quartr.com/audio-files/61dad-2024-05-08-09-35-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a387d-2024-05-08-08-37-38.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5d5f1-2024-05-08-08-18-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-08T20:30:00Z","earningsSummary":{"summary":"Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R\u0026D advancement.\nDespite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.\nWith a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.","headline":"Dynavax Technologies reports robust Q1 earnings and growth outlook","lastUpdated":"2024-05-09T00:40:30.685275Z"}},{"actual":0.08,"estimate":0.06,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-06T20:04:13Z","audioUrl":"https://files.quartr.com/audio-files/a92fe-2024-08-06-09-08-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/32053-2024-08-06-08-01-21.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a9af8-2024-08-06-08-22-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-06T20:30:00Z","earningsSummary":{"summary":"Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.\nThe company's pipeline progress and robust cash position position it well for future growth and innovation.\nWhile challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.\nDynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.","headline":"Dynavax reports record sales and market share gains in Q2 2024","lastUpdated":"2024-08-07T05:06:01.961741Z"}},{"actual":0.12,"estimate":0.11,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-07T21:31:16Z","audioUrl":"https://files.quartr.com/audio-files/2ea34-2024-11-07-10-47-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c98d0-2024-11-07-09-25-24.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0530c-2024-11-07-09-12-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-07T21:30:00Z","earningsSummary":null},{"actual":0.05,"estimate":0.04,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-20T21:10:38Z","audioUrl":"https://files.quartr.com/audio-files/b8f00-2025-02-20-10-17-28.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fdda8-2025-02-20-09-54-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/31c67-2025-02-20-09-47-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-20T21:30:00Z","earningsSummary":{"summary":"Dynavax Technologies delivered strong financial performance in 2024, achieving profitability and setting the stage for a promising 2025. The company's pipeline programs show potential for growth and innovation, with a focus on expanding market reach and product development. While facing challenges in upcoming studies and market dynamics, Dynavax has opportunities to capitalize on new markets and drive revenue growth.","headline":"Dynavax Technologies reports record revenue and pipeline advancements for 2025","lastUpdated":"2025-02-21T03:40:20.942947Z"}},{"actual":-0.11,"estimate":0.02,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-06T22:28:57Z","audioUrl":"https://files.quartr.com/audio-files/df0ff-2025-05-06-09-12-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/271d8-2025-05-06-08-47-18.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/72e30-2025-05-06-08-17-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-06T20:30:00Z","earningsSummary":{"summary":"Dynavax Technologies demonstrated robust revenue growth and strategic advancements in its vaccine portfolio, positioning for future success. While facing challenges such as increased R\u0026D expenses and accounting impacts, the company's disciplined approach and market potential are key strengths. Opportunities in new vaccine programs and sustained revenue growth underscore Dynavax's commitment to innovation and market leadership.","headline":"Dynavax Technologies reports record Q1 revenue and strategic vaccine expansions","lastUpdated":"2025-05-07T03:31:43.585740Z"}},{"actual":null,"estimate":0.13,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-10T23:31:52Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-05T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"aea29bbdffaedf2f33c13943f9a0682ce979dbf26e14c18003fed0c25a94726e"},{"date":"2022-02-28","title":"Earnings data Q4 2021","quarter":"Q4","hash":"5252a34810adc3b2c7da5dbc975bdae2a13b4ae52c31ca66f3826d8456c67221"},{"date":"2022-05-05","title":"Earnings data Q1 2022","quarter":"Q1","hash":"f9df36bf7f32e0727fa5a352083722010e1646a93b49a44b79a09ec4f142c34d"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"91be08fa4e6792b09b9c435185a40063be34258be52140f740553d93e70ce77f"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"44f9326be014448e5021d0d799a48c73a1591e0d791d153f7882d4251fc82d29"},{"date":"2023-02-23","title":"Earnings data Q4 2022","quarter":"Q4","hash":"f1f588eb4a60c0bbfe0d9484c98dfbcab45082915977854da638333eb358a09c"},{"date":"2023-05-02","title":"Earnings data Q1 2023","quarter":"Q1","hash":"16bcdb86f932d36f50faa8738a38b2f3d82aa388343209325c03d4736b4e2692"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"f22085cf261dc503e200a969f4a9449300016949f475b68c179c14d71bb5a057"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"cdd7d03ae0cd0903daed810b374d42e4950b6aa3e74978f91ce8982c1b974df4"},{"date":"2024-02-22","title":"Earnings data Q4 2023","quarter":"Q4","hash":"63efda0d7f446e3fb8ae2bcb717069273d81d40de376d83d595d2ce3b4aac6ba"},{"date":"2024-05-08","title":"Earnings data Q1 2024","quarter":"Q1","hash":"b3daf477b08674e7ecf74295c269302464c5bc360f0e4927cf9848764621dfde"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"c8fe180cbbe0d541eb05917b7a947dd9f50f1ca4769bca4aeb6d32475ddca1f3"},{"date":"2024-11-07","title":"Earnings data Q3 2024","quarter":"Q3","hash":"ff0171266d061397ce6fb2eafe70d99eb3f30b7b9d9371f936f38523300d3410"},{"date":"2025-02-20","title":"Earnings data Q4 2024","quarter":"Q4","hash":"5b6815e0301b22c8121bf900f91dad57e54050a0ec1575068344f32c860f8cd9"},{"date":"2025-05-06","title":"Earnings data Q1 2025","quarter":"Q1","hash":"7545adb1ed30ff9c19e8ac307f19e5ba20d9f5424ca46c6faef172d7af384506"},{"date":"2025-08-05","title":"Earnings data Q2 2025","quarter":"Q2","hash":"f6ec63a579b5f62298696d853e3427dd49f90a47a695e4ffa947e3a49a6b3346"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Dynavax Technologies","companyDescription":"Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":68164000,"changePercentage":34.21,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":13769000,"changePercentage":25.56,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":54395000,"changePercentage":36.59,"valueToRevenueRatio":0.7980018778240714},{"financialKey":"OPERATING_EXPENSES","value":78025000,"changePercentage":38.33,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":78025000,"changePercentage":38.33,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-23630000,"changePercentage":-42.52,"valueToRevenueRatio":-0.3466639281732293},{"financialKey":"EBITDA","value":-21594000,"changePercentage":-47.58,"valueToRevenueRatio":-0.31679478903820196},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":2036000,"changePercentage":4.52,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-96099000,"changePercentage":-1001.93,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.7696,"changePercentage":-1048.66,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":945928000,"changePercentage":-4.12,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":815970000,"changePercentage":-4.15,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":661336000,"changePercentage":-8.6,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":56557000,"changePercentage":22.54,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":74403000,"changePercentage":20.38,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":23674000,"changePercentage":19.64,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":129958000,"changePercentage":-3.93,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":64141000.00000001,"changePercentage":7.25,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":2027000.0000000002,"changePercentage":0.25,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":63790000,"changePercentage":-13.15,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":414987000,"changePercentage":12.74,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":68379000,"changePercentage":22.1,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":4080000,"changePercentage":-10.47,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":64299000,"changePercentage":24.99,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":346608000,"changePercentage":11.06,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":286028000,"changePercentage":13.71,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":60580000,"changePercentage":0.07,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":530941000.00000006,"changePercentage":-14.15,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":530941000.00000006,"changePercentage":-14.15,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":945928000,"changePercentage":-4.12,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":290108000,"changePercentage":13.28,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-371228000,"changePercentage":20.58,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":4.29227,"changePercentage":-9.18,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-96099000,"changePercentage":-1001.93,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-19639000,"changePercentage":-17.75,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":16987000,"changePercentage":80,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-36626000,"changePercentage":-40.24,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":6910000,"changePercentage":144.08,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":3928000,"changePercentage":424.43,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":10838000,"changePercentage":202.74,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-7856000,"changePercentage":-424.43,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-31882000,"changePercentage":-658.55,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":24427000,"changePercentage":862.07,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":35770000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-92079000,"changePercentage":-1265.75,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":458000,"changePercentage":327.86,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-44153000,"changePercentage":-141.91,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-23567000,"changePercentage":-35.22,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:43Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T08:38:18Z","bearsSay":["Dynavax Technologies Corp faces significant challenges that contribute to a negative outlook, including the uncertainty surrounding the efficacy and safety of its current and future clinical candidates, which could impair approval and commercialization efforts. The company also faces risks associated with market conditions, competition, and potential difficulties in securing beneficial partnerships for its proprietary candidates, which could hinder its commercial launch prospects. Furthermore, despite reporting a slight revenue increase in the fourth quarter of 2024, Dynavax has a history of losses and lacks a proven track record of sustained profitability, raising further concerns about its financial viability moving forward."],"bullsSay":["Dynavax Technologies Corp demonstrated substantial financial growth, with HEPLISAV-B sales increasing by 39% year-over-year in the fourth quarter of 2024 and achieving total sales of $268.4 million for the fiscal year, reflecting a 26% year-over-year increase. The company’s anticipated sales growth for HEPLISAV-B is projected to continue at double-digit annual rates through 2030, with market share expected to exceed 60% in a hepatitis B vaccination market valued at over $900 million. Additionally, Dynavax's strategic plans to implement a $400 million share repurchase program signal confidence in its financial stability and commitment to returning value to shareholders."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"TAK","name":"Takeda Pharmaceutical","displayName":"Takeda Pharmaceutical","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"TAK","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":14.74,"high":14.78,"low":14.625,"volume":23,"volumeDate":"2025-07-25","last":14.66,"open":14.71,"gainPercentage":-0.543,"gainValue":-0.08,"ask":14.66,"bid":14.44,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":46139711200,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":2383877.7419,"highPriceLast52Weeks":15.53,"lowPriceLast52Weeks":12.8,"companyName":"Takeda Pharmaceutical Co., Ltd.","longBusinessDescription":"Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.","dividendRate":0.6651,"salesOrRevenue":30052738450.605297,"oneYearAnnualRevenueGrowthRate":1.92161856426739,"threeYearAnnualRevenueGrowthRate":-1.7632,"fiveYearAnnualRevenueGrowthRate":-0.0693,"earningsGrowth":-30.8048,"totalDebt":34028286746.0212,"totalAssets":95281155543.6672,"floatAsPercentOfSharesOutstanding":99.9762,"dividendYield":4.54,"betaTwelveMonth":0.1925,"salesOrRevenueTtm":30052640935.2091,"ebitdaTtm":8909480220,"debtToEquityRatioQuarterly":73.3745979140269,"totalEnterpriseValue":79201260145.98639,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":3.35627567483299,"fiveYearAverageDebtEquityRatio":76.13,"currentRatio":1.00585313268869,"peratio":65.33},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":23.5,"totalRatings":4,"strongSellRatings":0,"sellRatings":0,"holdRatings":0,"buyRatings":3,"strongBuyRatings":1,"lastUpdated":"2023-05-16T11:19:09Z"},"earningEstimates":[{"actual":0.45,"estimate":null,"period":"Q2 2021","fiscalQuarter":"Q2","fiscalYear":2021,"lastUpdated":"2021-12-17T08:16:59Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":0.52,"estimate":null,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2022-02-03T22:32:54Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-02-03T00:00:00Z","earningsSummary":null},{"actual":0.4,"estimate":null,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-05-18T13:35:49Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-05-11T00:00:00Z","earningsSummary":null},{"actual":0.56,"estimate":null,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-07-28T12:44:47Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-07-28T00:00:00Z","earningsSummary":null},{"actual":0.52,"estimate":null,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-10-27T07:48:07Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-10-27T00:00:00Z","earningsSummary":null},{"actual":0.59,"estimate":null,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2023-02-02T08:25:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-02-02T00:00:00Z","earningsSummary":null},{"actual":0.39,"estimate":null,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-05-11T07:46:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-05-11T00:00:00Z","earningsSummary":null},{"actual":0.52,"estimate":null,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-07-27T07:32:51Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-07-27T00:00:00Z","earningsSummary":null},{"actual":0.48,"estimate":null,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-10-26T07:18:12Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-10-26T00:00:00Z","earningsSummary":null},{"actual":0.51,"estimate":null,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2024-02-01T07:12:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-02-01T00:00:00Z","earningsSummary":null},{"actual":0.24,"estimate":null,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-05-09T06:46:39Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-05-09T00:00:00Z","earningsSummary":null},{"actual":0.56,"estimate":null,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-07-31T06:34:30Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-07-31T00:00:00Z","earningsSummary":null},{"actual":0.45,"estimate":0.57,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-10-31T11:13:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-10-31T00:00:00Z","earningsSummary":null},{"actual":0.44,"estimate":null,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2025-01-30T09:14:55Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-01-30T00:00:00Z","earningsSummary":null},{"actual":0.16,"estimate":null,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-05-08T07:57:29Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-05-08T00:00:00Z","earningsSummary":null},{"actual":null,"estimate":0.47,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-07-25T06:00:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-08T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q2 2021","quarter":"Q2","hash":"ae341a948cc13de135c178d58dbf3c01c742de6528eeb1b9b44d8d59f9a9546a"},{"date":"2022-02-03","title":"Earnings data Q3 2021","quarter":"Q3","hash":"0773a9a4c67d612d8936d0161d62d67f4878dc948c64ff2ba8165ed947a1eac2"},{"date":"2022-05-11","title":"Earnings data Q4 2021","quarter":"Q4","hash":"8533639056b0e8bc1a0976133b79fb8cdbca470253f8ec606ee5ab45edf0924b"},{"date":"2022-07-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"68b10d54336191fd2464cddc578b9dfe12a96ceff931be89a4b079bac7e4d417"},{"date":"2022-10-27","title":"Earnings data Q2 2022","quarter":"Q2","hash":"25db3117d734d2168c66f259a193a93b294194a740879a1af21edcba46c3d5ed"},{"date":"2023-02-02","title":"Earnings data Q3 2022","quarter":"Q3","hash":"69ada96745838c5212af66bb050626bf24397fa70ed9af93260c2f802f8e0512"},{"date":"2023-05-11","title":"Earnings data Q4 2022","quarter":"Q4","hash":"e0806e8197f7397563db065784d5e24b56544e2ef0f067434e42bd6ea2f5a4a0"},{"date":"2023-07-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"fc98e867fd7a133d30b727c6388d0a744d4ef6ed6e96d297f84d8571a6a05bf3"},{"date":"2023-10-26","title":"Earnings data Q2 2023","quarter":"Q2","hash":"abffcba96342c95b41eba6061d540d5b6c084f011a9ee80da56012f1115a7bd2"},{"date":"2024-02-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"05b436d72a2842fe9810b22b4445b5ba8e09dba447f8ea4ed41041dc312300c9"},{"date":"2024-05-09","title":"Earnings data Q4 2023","quarter":"Q4","hash":"a25d6d3074c36ea519c1128ca433b9b126e15f47dc37e90d93db83034f73777d"},{"date":"2024-07-31","title":"Earnings data Q1 2024","quarter":"Q1","hash":"a1d2c7ddcfec5c200f1bd430b70fadabcf81426f5453caf061485ec2b0a9830e"},{"date":"2024-10-31","title":"Earnings data Q2 2024","quarter":"Q2","hash":"adb33d71fec2a14d60bf10d2601fe0660c886a0aa5796e13b37deebccf5961bb"},{"date":"2025-01-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"92826f74088faeef8e6115cce073a882682b66aa28cdaaaf391943adfe809e94"},{"date":"2025-05-08","title":"Earnings data Q4 2024","quarter":"Q4","hash":"96f10a7b3ad6743462716c282e7664613c68705b812c29b3621e5589d6324bd6"},{"date":"2025-08-08","title":"Earnings data Q1 2025","quarter":"Q1","hash":"5441716f04e4f267508720710d0955966814fcffcb17a98226817f94a5516a8c"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Takeda Pharmaceutical","companyDescription":"Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":6911840162.72432,"changePercentage":-2.34,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3353243003.83846,"changePercentage":-3.57,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":3558597158.88586,"changePercentage":-1.15,"valueToRevenueRatio":0.5148552447837899},{"financialKey":"OPERATING_EXPENSES","value":3358636527.67298,"changePercentage":3.66,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":3358636527.67298,"changePercentage":3.66,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":199960630,"changePercentage":-44.45,"valueToRevenueRatio":0.02893015829248936},{"financialKey":"EBITDA","value":1445123190,"changePercentage":-10.67,"valueToRevenueRatio":0.20907937046831257},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1245162560,"changePercentage":-1,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-676473868.9675541,"changePercentage":-3254.74,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.2144,"changePercentage":-3198.46,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":95281155543.6672,"changePercentage":-4.56,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":16859649592.082401,"changePercentage":-0.27,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":2575317640.76501,"changePercentage":-14.86,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":4849899692.39,"changePercentage":5.22,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":8140624582.05162,"changePercentage":1.83,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":1293807676.87575,"changePercentage":1.3,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":78421505951.58481,"changePercentage":-5.43,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":13161756051.8925,"changePercentage":0.11,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":59890263474.6556,"changePercentage":-6.41,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":5369486421.94998,"changePercentage":-7.2,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":48899057108.465996,"changePercentage":-5.54,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":16761542062.324501,"changePercentage":9.67,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":4101792162.6320705,"changePercentage":43.22,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":892717667.513709,"changePercentage":22.93,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":11767032232.17872,"changePercentage":0.63,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":32137515046.141495,"changePercentage":-11.91,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":29926494583.3891,"changePercentage":-9.95,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":2211020465.1210327,"changePercentage":-31.95,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":46382098435.2012,"changePercentage":-3.5,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":46376113414.471,"changePercentage":-3.5,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":5985020.7302394,"changePercentage":22.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":95281155543.6672,"changePercentage":-4.56,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":34028286746.02117,"changePercentage":-5.74,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":31452969105.25616,"changePercentage":-4.9,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":14.73521,"changePercentage":-3.78,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-685212325.9350779,"changePercentage":-3944.25,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1214295689.54974,"changePercentage":-35.78,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":716759964.86613,"changePercentage":-41.06,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":497535724.683607,"changePercentage":-26.28,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-138853439.43486002,"changePercentage":74.41,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":593525842.015859,"changePercentage":30.51,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":378202409.655755,"changePercentage":1023.04,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":71451713.1346347,"changePercentage":-80.45,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-1182033404.2411087,"changePercentage":15.36,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-1727051693.64288,"changePercentage":-569.92,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-326837497.812288,"changePercentage":-553986.48,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-3218497131.32269,"changePercentage":-887.7,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":48745644.89716,"changePercentage":-30.44,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-332565606.060484,"changePercentage":34.05,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-63360375.7211708,"changePercentage":-186.42,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-714969816.611907,"changePercentage":-161.43,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":902878980,"changePercentage":-42.86,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:24Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":null,"advancedCryptoData":null,"buySellRatio":{"buy":0.43,"sell":0.57,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":false,"advancedInfoDummy":false},{"instrument":{"symbol":"SNY","name":"Sanofi","displayName":"Sanofi","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"SNY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":50.16,"high":50.49,"low":50,"volume":1103,"volumeDate":"2025-07-25","last":50.13,"open":50.27,"gainPercentage":-0.06,"gainValue":-0.03,"ask":50.16,"bid":50.13,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":122139739800,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":2160784.3065,"highPriceLast52Weeks":60.115,"lowPriceLast52Weeks":45.8,"companyName":"Sanofi","longBusinessDescription":"Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.","dividendRate":2.1953,"salesOrRevenue":44436937960.5009,"oneYearAnnualRevenueGrowthRate":-4.56732044182917,"threeYearAnnualRevenueGrowthRate":0.1365,"fiveYearAnnualRevenueGrowthRate":2.1309,"earningsGrowth":2.9647,"totalDebt":18541663000,"totalAssets":137512329000,"floatAsPercentOfSharesOutstanding":99.977,"dividendYield":4.38,"betaTwelveMonth":0.3048,"salesOrRevenueTtm":44435469721.9503,"ebitdaTtm":14209808300,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":132243256000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":14.6924265847987,"fiveYearAverageDebtEquityRatio":24.37,"currentRatio":null,"peratio":20.86},"recommendation":{"currentConsensusRating":2.4,"recommendationTargetPrice":62,"totalRatings":5,"strongSellRatings":0,"sellRatings":0,"holdRatings":3,"buyRatings":1,"strongBuyRatings":1,"lastUpdated":"2025-03-21T09:22:46Z"},"earningEstimates":[{"actual":1.29,"estimate":1.17,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-29T08:27:52Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":0.79,"estimate":0.72,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-04T12:38:45Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-02-04T00:00:00Z","earningsSummary":null},{"actual":1.09,"estimate":0.92,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T22:20:57Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-04-28T00:00:00Z","earningsSummary":null},{"actual":0.93,"estimate":0.87,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T14:06:29Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-07-28T00:00:00Z","earningsSummary":null},{"actual":1.45,"estimate":1.33,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-28T09:06:15Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-10-28T00:00:00Z","earningsSummary":null},{"actual":0.87,"estimate":0.9,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-03T11:13:07Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-02-03T00:00:00Z","earningsSummary":null},{"actual":1.16,"estimate":1.87,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T11:45:44Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-04-27T00:00:00Z","earningsSummary":null},{"actual":0.95,"estimate":1.58,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-28T07:57:08Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-07-28T00:00:00Z","earningsSummary":null},{"actual":1.39,"estimate":2.26,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-27T07:43:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-10-27T00:00:00Z","earningsSummary":null},{"actual":0.89,"estimate":1.5,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-01T07:01:01Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-02-01T00:00:00Z","earningsSummary":null},{"actual":0.97,"estimate":0.94,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T07:12:19Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-04-25T00:00:00Z","earningsSummary":null},{"actual":0.93,"estimate":0.86,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-25T07:21:49Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-07-25T00:00:00Z","earningsSummary":null},{"actual":1.57,"estimate":1.39,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-25T07:00:26Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-10-25T00:00:00Z","earningsSummary":null},{"actual":0.7,"estimate":0.74,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-30T09:09:18Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-01-30T00:00:00Z","earningsSummary":null},{"actual":0.941,"estimate":0.95,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-24T06:32:09Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-04-24T00:00:00Z","earningsSummary":null},{"actual":null,"estimate":0.96,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-19T23:30:26Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q3 2021","quarter":"Q3","hash":"c5d50de978e92251264b6039b052c142a65c0188758315da54012c2be457927e"},{"date":"2022-02-04","title":"Earnings data Q4 2021","quarter":"Q4","hash":"8aaa8cef2514f6902d23bc6580feee7aa21eaf490744b488c450d023cb5ed861"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"34f7ba56db909454abbf112c6d435a04fc56ddae944df4253f10ce4a85ebe7b4"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"6a07db64b59eeaf5d6e614772c307c40ab70e383fcb509e22fc17e445486ee59"},{"date":"2022-10-28","title":"Earnings data Q3 2022","quarter":"Q3","hash":"58a7b3279fd779b7c89ade21e5fd4d518e5261f6c509c86ca544018b640b03c1"},{"date":"2023-02-03","title":"Earnings data Q4 2022","quarter":"Q4","hash":"24d8a6fd88ebb7d34adee15d5d29cfb7f0359bc39e9525363b8034b635d7aa2b"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"71d61e93163259070578bb7a2cf5a156b11f7ad0d70654150a939acd2b124f77"},{"date":"2023-07-28","title":"Earnings data Q2 2023","quarter":"Q2","hash":"a19f918eb0d30b6cfe727ed6ed78996be6aa71633350ee55b533d309f29bce56"},{"date":"2023-10-27","title":"Earnings data Q3 2023","quarter":"Q3","hash":"3f538c82436400a9316d3ecbb7846f15b6503ff3b52722b85a63ebc65fe556e1"},{"date":"2024-02-01","title":"Earnings data Q4 2023","quarter":"Q4","hash":"26d91ff9b95523c065d7ec10e4ee54760256636deaa56ff72661e3e0ed5b3cf9"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"438dfa3a7e9245d41c43d292c856772774e83747a5c75bf412f6d65963fb4905"},{"date":"2024-07-25","title":"Earnings data Q2 2024","quarter":"Q2","hash":"bbb54371827603a28311cfd5d2d27392f38949b51bfa71b665c8cbf21b1704c2"},{"date":"2024-10-25","title":"Earnings data Q3 2024","quarter":"Q3","hash":"22f5999009621897e656addf1d97e872b455e1ed24dbe8945803f8cf48bd856a"},{"date":"2025-01-30","title":"Earnings data Q4 2024","quarter":"Q4","hash":"00e38ce164b8b1a58f48426e865bde1ded50a504959eeb33350b1b8bb835d18b"},{"date":"2025-04-24","title":"Earnings data Q1 2025","quarter":"Q1","hash":"88b187f97dfeb2bbd635f68f189da84754941bf2c5b74ac2669f307c00445304"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"70332d10d08c29f98b37dfece2b65dd86d766e4201522f6f50f3438254d4b07e"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Sanofi","companyDescription":"Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.","executives":null,"brands":[]},"etfFundamental":null,"financials":null,"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":"2024-05-30T00:00:00Z","bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.74,"sell":0.26,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"ABBV","name":"AbbVie","displayName":"AbbVie","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"ABBV","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":190.55,"high":192.24,"low":189.99,"volume":133,"volumeDate":"2025-07-25","last":190.83,"open":190.76,"gainPercentage":0.147,"gainValue":0.28,"ask":192.35,"bid":190.15,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":337082112000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":6555188.7097,"highPriceLast52Weeks":218.66,"lowPriceLast52Weeks":163.81,"companyName":"AbbVie, Inc.","longBusinessDescription":"AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.","dividendRate":6.47,"salesOrRevenue":56334000000,"oneYearAnnualRevenueGrowthRate":3.71147685849994,"threeYearAnnualRevenueGrowthRate":0.1935,"fiveYearAnnualRevenueGrowthRate":12.1922,"earningsGrowth":-30.2106,"totalDebt":67841000000,"totalAssets":135161000000,"floatAsPercentOfSharesOutstanding":99.9094,"dividendYield":3.39,"betaTwelveMonth":0.4395,"salesOrRevenueTtm":57367000000,"ebitdaTtm":25942000000,"debtToEquityRatioQuarterly":4921.76056338028,"totalEnterpriseValue":377387100000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":5.62796208530806,"fiveYearAverageDebtEquityRatio":742.88,"currentRatio":0.760239540697195,"peratio":81.37},"recommendation":{"currentConsensusRating":2.1,"recommendationTargetPrice":177.83,"totalRatings":36,"strongSellRatings":1,"sellRatings":0,"holdRatings":10,"buyRatings":15,"strongBuyRatings":10,"lastUpdated":"2025-06-02T20:38:10Z"},"earningEstimates":[{"actual":3.33,"estimate":3.22,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-29T11:49:29Z","audioUrl":"https://files.quartr.com/audio-files/18278-2022-10-19-04-32-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/cb7ea-2023-01-25-10-40-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-29T00:00:00Z","earningsSummary":null},{"actual":3.31,"estimate":3.28,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-02T13:00:26Z","audioUrl":"https://files.quartr.com/audio-files/01400-2022-10-19-10-46-27.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d3535-2022-02-02-07-40-50-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e2715-2023-01-25-12-48-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-02T19:50:40Z","earningsSummary":null},{"actual":3.16,"estimate":3.14,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-29T12:10:18Z","audioUrl":"https://files.quartr.com/audio-files/298af-2022-10-28-04-01-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/dccc2-2023-01-25-01-55-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-29T16:59:03Z","earningsSummary":null},{"actual":3.37,"estimate":3.33,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-29T11:45:09Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_29_15_00_Q2_2022_Abbvie_Inc_Earnings_Call.N4E75JRNABFE_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/da7c4-2022-07-29-11-29-48.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-29T10:27:00Z","earningsSummary":null},{"actual":3.66,"estimate":3.59,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-28T11:48:30Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_28T13_00_00_00_00_Abbvie_Inc_Earnings_Call_Q3_2022.W9JTJ5RO58UZ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/9ed29-2022-10-28-12-48-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-28T13:00:00Z","earningsSummary":null},{"actual":3.6,"estimate":3.56,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-09T12:50:42Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_09T14_00_00_00_00_Abbvie_Inc_Earnings_Call_Q4_2022.CZ00D49OLAMC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ffd98-2023-02-21-08-32-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/d437c-2023-02-09-12-11-53.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-09T14:00:00Z","earningsSummary":{"summary":"AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R\u0026D and BD aim to navigate market dynamics and drive future success.","headline":"AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges","lastUpdated":"2024-05-06T15:50:51.451716Z"}},{"actual":2.46,"estimate":2.46,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T11:35:47Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T13_00_00_00_00_AbbVie_Inc_Q1_2023.66NXQHLMPVG0_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/5e27b-2023-04-27-11-10-46.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T13:00:00Z","earningsSummary":{"summary":"AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.","headline":"AbbVie surpasses Q1 expectations, eyes international growth amid challenges","lastUpdated":"2024-05-06T19:39:30.628390Z"}},{"actual":2.91,"estimate":2.8,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-27T11:39:59Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_07_27T13_00_00_00_00_AbbVie_Inc_Q2_2023.0PTF03MF14U2_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/44aab-2023-07-27-11-37-46.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-27T13:00:00Z","earningsSummary":{"summary":"AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.","headline":"AbbVie surpasses Q2 expectations, eyes revenue growth opportunities","lastUpdated":"2024-05-06T21:42:08.479285Z"}},{"actual":2.95,"estimate":2.86,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-27T11:46:42Z","audioUrl":"https://files.quartr.com/audio-files/d4ff1-2023-10-27-02-36-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3e226-2023-10-27-11-47-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-27T13:00:00Z","earningsSummary":{"summary":"AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.\nChallenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.\nConfidence in pipeline assets and strategic focus on combination therapies for future growth.\nMaintaining strong market positions and investing in transformative therapies for competitive advantage.","headline":"AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies","lastUpdated":"2024-05-06T21:59:56.126265Z"}},{"actual":2.79,"estimate":2.77,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-02T12:48:02Z","audioUrl":"https://files.quartr.com/audio-files/454c2-2024-02-02-03-11-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1f834-2024-02-09-08-17-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/be5d9-2024-02-02-12-50-52.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-02T14:00:00Z","earningsSummary":{"summary":"AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.","headline":"AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions","lastUpdated":"2024-05-06T17:31:02.665535Z"}},{"actual":2.31,"estimate":2.23,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-26T11:38:49Z","audioUrl":"https://files.quartr.com/audio-files/64b42-2024-04-26-02-31-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/0b7c5-2024-04-26-11-19-45.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-26T13:00:00Z","earningsSummary":{"summary":"AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.","headline":"AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth","lastUpdated":"2024-05-06T19:05:01.341772Z"}},{"actual":2.65,"estimate":2.57,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-25T11:38:27Z","audioUrl":"https://files.quartr.com/audio-files/d38fd-2024-07-25-02-30-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/c136e-2024-07-25-11-03-44.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-25T13:00:00Z","earningsSummary":{"summary":"AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.\nDespite near-term challenges, the company's focus on key growth areas positions it for long-term success.\nInvestments in innovation and market expansion underscore AbbVie's commitment to sustained growth.\nOverall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.","headline":"AbbVie reports robust Q2 results and raises 2024 guidance","lastUpdated":"2024-07-25T16:11:30.045899Z"}},{"actual":3,"estimate":2.92,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T11:39:27Z","audioUrl":"https://files.quartr.com/audio-files/9e9cf-2024-10-30-02-53-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4cf76-2024-10-30-11-04-45.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T13:00:00Z","earningsSummary":{"summary":"AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.\nThe company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.\nWhile facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.","headline":"AbbVie reports strong Q3 performance, raises guidance and dividend","lastUpdated":"2024-10-30T17:03:01.521609Z"}},{"actual":2.16,"estimate":2.26,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-31T12:37:58Z","audioUrl":"https://files.quartr.com/audio-files/a8351-2025-01-31-03-41-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/59a2e-2025-01-31-01-57-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-01-31T14:00:00Z","earningsSummary":{"summary":"AbbVie's Q4 2024 earnings call showcased strong financial performance, resilience in sales growth, and strategic advancements in key therapeutic areas. Despite challenges in aesthetics, the company is well-positioned for growth with a focus on innovation and market expansion.","headline":"AbbVie exceeds Q4 earnings, anticipates strong revenue growth in 2025","lastUpdated":"2025-01-31T18:17:58.859790Z"}},{"actual":2.46,"estimate":2.38,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-25T11:44:26Z","audioUrl":"https://files.quartr.com/audio-files/c8a42-2025-04-25-02-49-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/476ea-2025-04-25-11-27-50.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-25T13:00:00Z","earningsSummary":{"summary":"AbbVie's Q1 earnings call highlighted strong financial performance, strategic investments in key therapeutic areas, and a positive outlook for long-term growth. Despite challenges like share erosion and tariff impacts, the company remains focused on innovation and diversification. Opportunities in emerging oncology, neuroscience, and market expansion present avenues for continued success.","headline":"AbbVie reports robust Q1 earnings, eyes growth in oncology and China","lastUpdated":"2025-04-25T15:42:14.911501Z"}},{"actual":null,"estimate":2.91,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:13Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-29","title":"Earnings data Q3 2021","quarter":"Q3","hash":"437d71bdd6350429d4b4fc8ff37c34903887f84f41701631a4b8d06b93c17615"},{"date":"2022-02-02","title":"Earnings data Q4 2021","quarter":"Q4","hash":"ff0c51163c710cc7dc6dd45364a9ccd63be67cc61a28f59a83c48fc31b2c8eec"},{"date":"2022-04-29","title":"Earnings data Q1 2022","quarter":"Q1","hash":"da97c2d2f01235fbee9e1e8e6af022d795ed5a19bfa0a2a9dbbdced445f89c1e"},{"date":"2022-07-29","title":"Earnings data Q2 2022","quarter":"Q2","hash":"1d26c4138773dc72976cf729b7f2f102a5f9b74f30b7b7b3cc0d71127d81270c"},{"date":"2022-10-28","title":"Earnings data Q3 2022","quarter":"Q3","hash":"8f5663d9bfb255a1c29345797438136463d4068954e128e8d89c426a943e153d"},{"date":"2023-02-09","title":"Earnings data Q4 2022","quarter":"Q4","hash":"37575a8cfcd53f28bae003e7de4eefdb7ac4607dceaf42744aba31822c0655c0"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"6b6bcb5d4120550b22d5ef8990818965dcf7b7ba6fd05e213cf85eb8f6d55152"},{"date":"2023-07-27","title":"Earnings data Q2 2023","quarter":"Q2","hash":"4d6b0ce226e784690ab42fd357404b936a7548a4eecb9de1e66cbc551cfaa4cc"},{"date":"2023-10-27","title":"Earnings data Q3 2023","quarter":"Q3","hash":"045c07afc1156b335b334031d3ea2ef8e8c1cad7a1ef6bf872e305697b0bdeec"},{"date":"2024-02-02","title":"Earnings data Q4 2023","quarter":"Q4","hash":"0dde380a146811d68d3538ae34026ca4fd3ff11e8e0a60a393bdc599389d15e7"},{"date":"2024-04-26","title":"Earnings data Q1 2024","quarter":"Q1","hash":"18a232ecd38238243940b9256333c65bb3a09f66af26a3d7ef2701c9b5c86e8e"},{"date":"2024-07-25","title":"Earnings data Q2 2024","quarter":"Q2","hash":"99a6088c268e861f640f8cbc1991991b06de3d36b732dd261d9fe8d622cfd1b9"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"d92d62102c2a17d4a86fff31851c653103d0b0971a0220c01fc1e2436e47a82c"},{"date":"2025-01-31","title":"Earnings data Q4 2024","quarter":"Q4","hash":"79d2ac46f35c538e7a832badd319346c4dae15514c509bd2f278d4df6470d302"},{"date":"2025-04-25","title":"Earnings data Q1 2025","quarter":"Q1","hash":"e248b6115a9d16cec57a3d5020a04c2f6bd9c4b938f9699dea7051f0b300f032"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"52fa2bd699a7f24587f56545c83bcc898a266e1b94680bbca5fa28cec36b13af"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"AbbVie","companyDescription":"AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":13343000000,"changePercentage":8.39,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":4003000000,"changePercentage":-1.94,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":9340000000,"changePercentage":13.51,"valueToRevenueRatio":0.6999925054335606},{"financialKey":"OPERATING_EXPENSES","value":5343000000,"changePercentage":1.99,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":5343000000,"changePercentage":1.99,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":3997000000,"changePercentage":33.72,"valueToRevenueRatio":0.29955782058007946},{"financialKey":"EBITDA","value":6036000000,"changePercentage":19.22,"valueToRevenueRatio":0.4523720302780484},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":2039000000,"changePercentage":-1.69,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1279000000,"changePercentage":-6.09,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.7201,"changePercentage":-6.05,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":136165000000,"changePercentage":-8.54,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":27675000000,"changePercentage":-28.8,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":5176000000,"changePercentage":-71.35,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":12477000000,"changePercentage":4.42,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":4526000000,"changePercentage":6.62,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":5496000000,"changePercentage":19.27,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":108490000000,"changePercentage":-1.38,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":5237000000,"changePercentage":5.16,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":93774000000,"changePercentage":-1.96,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":9479000000,"changePercentage":1.14,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":134703000000,"changePercentage":-4.35,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":36403000000,"changePercentage":-12.33,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":5362000000,"changePercentage":-47.41,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":31041000000,"changePercentage":-0.91,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":98300000000,"changePercentage":-1.01,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":64527000000,"changePercentage":1.13,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":33773000000,"changePercentage":-4.86,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":1462000000,"changePercentage":-81.83,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":1420000000,"changePercentage":-82.27,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":42000000,"changePercentage":5,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":136165000000,"changePercentage":-8.54,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":69889000000,"changePercentage":-5.56,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":64713000000,"changePercentage":15.7,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0.80395,"changePercentage":-82.27,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":1289000000,"changePercentage":-6.05,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1635000000,"changePercentage":-59.53,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":4215000000,"changePercentage":11.13,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-2580000000,"changePercentage":-1144.53,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-735000000,"changePercentage":92.33,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":235000000,"changePercentage":21.76,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":22000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":204000000,"changePercentage":-97.78,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-1196000000,"changePercentage":93.7,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-1258000000,"changePercentage":-111.63,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-905000000,"changePercentage":24.39,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":948000000,"changePercentage":-93.58,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":2925000000,"changePercentage":5.52,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":31000000,"changePercentage":29.17,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":9000000,"changePercentage":150,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-349000000,"changePercentage":-106.64,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1400000000,"changePercentage":-63.61,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:09Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":1.64,"priorDividend":1.55,"dividendYieldPercentage":3.54,"announcementDate":"2025-06-20","exDividendDate":"2025-07-15","payableDate":"2025-08-15","recordDate":"2025-07-15","updatedAt":"2025-06-20T12:22:24Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-18T02:12:52Z","bearsSay":["AbbVie faces several significant risks that contribute to a negative outlook on its stock. The company is grappling with disappointing sales performance in its key products, such as Humira and its aesthetic offerings, while experiencing competitive pressures in both its immunology and oncology segments. Furthermore, ongoing macroeconomic challenges, potential regulatory setbacks, and heightened risks in the clinical development pipeline may hinder the company's ability to achieve its long-term growth expectations."],"bullsSay":["AbbVie has reaffirmed its guidance for a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, signaling robust growth potential driven primarily by its strong immunology products, Skyrizi and Rinvoq, with anticipated sales exceeding $20 billion and $11 billion, respectively, by 2027. The company's fourth-quarter 2024 results exceeded expectations, with sales reaching $15.1 billion, highlighting the performance of its key immunology offerings. Despite a softened outlook for its Aesthetics franchise, AbbVie's adjusted long-term revenue projections and initial earnings per share guidance for 2025 demonstrate a solid foundation for sustainable growth moving forward."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Immunology","dataPoints":[{"key":"21 Q2","value":6120},{"key":"21 Q3","value":6674},{"key":"21 Q4","value":6746},{"key":"22 Q1","value":6141},{"key":"22 Q2","value":7207},{"key":"22 Q3","value":7651},{"key":"22 Q4","value":7925},{"key":"23 Q1","value":5587},{"key":"23 Q2","value":6813},{"key":"23 Q3","value":6783},{"key":"23 Q4","value":6953},{"key":"24 Q1","value":5371},{"key":"24 Q2","value":6971},{"key":"24 Q3","value":7046},{"key":"24 Q4","value":7294},{"key":"25 Q1","value":6264}]},{"title":"Hematologic Oncology","dataPoints":[{"key":"21 Q2","value":1816},{"key":"21 Q3","value":1866},{"key":"21 Q4","value":1873},{"key":"22 Q1","value":1646},{"key":"22 Q2","value":1650},{"key":"22 Q3","value":1650},{"key":"22 Q4","value":1631},{"key":"23 Q1","value":1416},{"key":"23 Q2","value":1478},{"key":"23 Q3","value":1512},{"key":"23 Q4","value":1509},{"key":"24 Q1","value":1543},{"key":"24 Q2","value":1634},{"key":"24 Q3","value":1687},{"key":"24 Q4","value":1691},{"key":"25 Q1","value":1633}]},{"title":"Aesthetics","dataPoints":[{"key":"21 Q2","value":1434},{"key":"21 Q3","value":1251},{"key":"21 Q4","value":1407},{"key":"22 Q1","value":1374},{"key":"22 Q2","value":1371},{"key":"22 Q3","value":1301},{"key":"22 Q4","value":1287},{"key":"23 Q1","value":1300},{"key":"23 Q2","value":1384},{"key":"23 Q3","value":1239},{"key":"23 Q4","value":1371},{"key":"24 Q1","value":1249},{"key":"24 Q2","value":1390},{"key":"24 Q3","value":1239},{"key":"24 Q4","value":1298},{"key":"25 Q1","value":1102}]},{"title":"Neuroscience","dataPoints":[{"key":"21 Q2","value":1459},{"key":"21 Q3","value":1566},{"key":"21 Q4","value":1654},{"key":"22 Q1","value":1488},{"key":"22 Q2","value":1658},{"key":"22 Q3","value":1672},{"key":"22 Q4","value":1710},{"key":"23 Q1","value":1695},{"key":"23 Q2","value":1885},{"key":"23 Q3","value":2043},{"key":"23 Q4","value":2094},{"key":"24 Q1","value":1965},{"key":"24 Q2","value":2162},{"key":"24 Q3","value":2363},{"key":"24 Q4","value":2509},{"key":"25 Q1","value":2282}]},{"title":"Eye Care","dataPoints":[{"key":"21 Q2","value":919},{"key":"21 Q3","value":871},{"key":"21 Q4","value":960},{"key":"22 Q1","value":771},{"key":"22 Q2","value":717},{"key":"22 Q3","value":623},{"key":"22 Q4","value":590},{"key":"23 Q1","value":608},{"key":"23 Q2","value":617},{"key":"23 Q3","value":605},{"key":"23 Q4","value":585},{"key":"24 Q1","value":538},{"key":"24 Q2","value":533},{"key":"24 Q3","value":525},{"key":"24 Q4","value":646},{"key":"25 Q1","value":506}]},{"title":"Women's Health","dataPoints":[{"key":"21 Q2","value":191},{"key":"21 Q3","value":202},{"key":"21 Q4","value":223}]},{"title":"Other Key Products","dataPoints":[{"key":"21 Q2","value":1380},{"key":"21 Q3","value":1365},{"key":"21 Q4","value":1429},{"key":"22 Q1","value":907},{"key":"22 Q2","value":971},{"key":"22 Q3","value":990},{"key":"22 Q4","value":986},{"key":"23 Q1","value":928},{"key":"23 Q2","value":947},{"key":"23 Q3","value":963},{"key":"23 Q4","value":968},{"key":"24 Q1","value":900},{"key":"24 Q2","value":962},{"key":"24 Q3","value":874},{"key":"24 Q4","value":912},{"key":"25 Q1","value":809}]},{"title":"All other","dataPoints":[{"key":"21 Q2","value":640},{"key":"21 Q3","value":547},{"key":"21 Q4","value":594},{"key":"22 Q1","value":1211},{"key":"22 Q2","value":1009},{"key":"22 Q3","value":925},{"key":"22 Q4","value":992},{"key":"23 Q1","value":691},{"key":"23 Q2","value":741},{"key":"23 Q3","value":782},{"key":"23 Q4","value":821},{"key":"24 Q1","value":744},{"key":"24 Q2","value":810},{"key":"24 Q3","value":726},{"key":"24 Q4","value":752},{"key":"25 Q1","value":747}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":67.59},{"key":"21 Q3","value":69.39},{"key":"21 Q4","value":70.97},{"key":"22 Q1","value":70.06},{"key":"22 Q2","value":71.4},{"key":"22 Q3","value":66.09},{"key":"22 Q4","value":72.42},{"key":"23 Q1","value":67.39},{"key":"23 Q2","value":69.41},{"key":"23 Q3","value":53.43},{"key":"23 Q4","value":60.11},{"key":"24 Q1","value":66.74},{"key":"24 Q2","value":70.94},{"key":"24 Q3","value":70.87},{"key":"24 Q4","value":70.89},{"key":"25 Q1","value":70}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":31.81},{"key":"21 Q3","value":30.02},{"key":"21 Q4","value":34.08},{"key":"22 Q1","value":34.84},{"key":"22 Q2","value":22.59},{"key":"22 Q3","value":31.07},{"key":"22 Q4","value":36.38},{"key":"23 Q1","value":22.64},{"key":"23 Q2","value":32.54},{"key":"23 Q3","value":16.37},{"key":"23 Q4","value":22.34},{"key":"24 Q1","value":22.72},{"key":"24 Q2","value":27.64},{"key":"24 Q3","value":26.49},{"key":"24 Q4","value":-9.87},{"key":"25 Q1","value":27.97}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":5.48},{"key":"21 Q3","value":22.16},{"key":"21 Q4","value":27.16},{"key":"22 Q1","value":33.16},{"key":"22 Q2","value":6.33},{"key":"22 Q3","value":26.66},{"key":"22 Q4","value":16.35},{"key":"23 Q1","value":1.95},{"key":"23 Q2","value":14.59},{"key":"23 Q3","value":12.76},{"key":"23 Q4","value":5.74},{"key":"24 Q1","value":11.12},{"key":"24 Q2","value":9.47},{"key":"24 Q3","value":10.79},{"key":"24 Q4","value":-0.15},{"key":"25 Q1","value":9.63}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":3164},{"key":"21 Q3","value":3083},{"key":"21 Q4","value":3260},{"key":"22 Q1","value":3127},{"key":"22 Q2","value":5412},{"key":"22 Q3","value":3304},{"key":"22 Q4","value":3417},{"key":"23 Q1","value":3039},{"key":"23 Q2","value":3268},{"key":"23 Q3","value":3372},{"key":"23 Q4","value":3193},{"key":"24 Q1","value":3315},{"key":"24 Q2","value":3377},{"key":"24 Q3","value":4205},{"key":"24 Q4","value":3855},{"key":"25 Q1","value":3293}]},{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1802},{"key":"21 Q3","value":1673},{"key":"21 Q4","value":1827},{"key":"22 Q1","value":1497},{"key":"22 Q2","value":1609},{"key":"22 Q3","value":1614},{"key":"22 Q4","value":1790},{"key":"23 Q1","value":2292},{"key":"23 Q2","value":1733},{"key":"23 Q3","value":1723},{"key":"23 Q4","value":1927},{"key":"24 Q1","value":1939},{"key":"24 Q2","value":1948},{"key":"24 Q3","value":2130},{"key":"24 Q4","value":6774},{"key":"25 Q1","value":2067}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"21 Q2","value":97},{"key":"21 Q3","value":390},{"key":"21 Q4","value":405},{"key":"22 Q1","value":145},{"key":"22 Q2","value":269},{"key":"22 Q3","value":40},{"key":"22 Q4","value":243},{"key":"23 Q1","value":150},{"key":"23 Q2","value":280},{"key":"23 Q3","value":66},{"key":"23 Q4","value":282},{"key":"24 Q1","value":164},{"key":"24 Q2","value":937},{"key":"24 Q3","value":82},{"key":"24 Q4","value":1574},{"key":"25 Q1","value":248}]},{"title":"Other operating expense","dataPoints":[{"key":"21 Q2","value":-68},{"key":"21 Q3","value":500},{"key":"22 Q2","value":-172},{"key":"22 Q3","value":229},{"key":"22 Q4","value":-1},{"key":"23 Q1","value":-10},{"key":"23 Q2","value":-169},{"key":"24 Q4","value":-7}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":33.9},{"key":"21 Q3","value":11.16},{"key":"21 Q4","value":7.42},{"key":"22 Q1","value":4.06},{"key":"22 Q2","value":4.47},{"key":"22 Q3","value":3.28},{"key":"22 Q4","value":1.58},{"key":"23 Q1","value":-9.7},{"key":"23 Q2","value":-4.92},{"key":"23 Q3","value":-5.97},{"key":"23 Q4","value":-5.42},{"key":"24 Q1","value":0.7},{"key":"24 Q2","value":4.31},{"key":"24 Q3","value":3.83},{"key":"24 Q4","value":5.6},{"key":"25 Q1","value":8.39}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":-16.22},{"key":"21 Q3","value":22.82},{"key":"21 Q4","value":1.31},{"key":"22 Q1","value":1.6},{"key":"22 Q2","value":42.5},{"key":"22 Q3","value":-8.13},{"key":"22 Q4","value":-0.78},{"key":"23 Q1","value":14.72},{"key":"23 Q2","value":-28.18},{"key":"23 Q3","value":-0.5},{"key":"23 Q4","value":-0.86},{"key":"24 Q1","value":-0.97},{"key":"24 Q2","value":22.5},{"key":"24 Q3","value":24.34},{"key":"24 Q4","value":125.77},{"key":"25 Q1","value":3.51}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":1776},{"key":"21 Q3","value":1777},{"key":"21 Q4","value":1778},{"key":"22 Q1","value":1778},{"key":"22 Q2","value":1776},{"key":"22 Q3","value":1776},{"key":"22 Q4","value":1778},{"key":"23 Q1","value":1776},{"key":"23 Q2","value":1771},{"key":"23 Q3","value":1771},{"key":"23 Q4","value":1772},{"key":"24 Q1","value":1773},{"key":"24 Q2","value":1771},{"key":"24 Q3","value":1772},{"key":"24 Q4","value":1769},{"key":"25 Q1","value":1772}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":199977.6},{"key":"21 Q3","value":203111.1},{"key":"21 Q4","value":209981.8},{"key":"22 Q1","value":258343.4},{"key":"22 Q2","value":268531.2},{"key":"22 Q3","value":252014.4},{"key":"22 Q4","value":269722.6},{"key":"23 Q1","value":268708.8},{"key":"23 Q2","value":256617.9},{"key":"23 Q3","value":257149.2},{"key":"23 Q4","value":258357.6},{"key":"24 Q1","value":305487.9},{"key":"24 Q2","value":293277.6},{"key":"24 Q3","value":330655.2},{"key":"24 Q4","value":325319.1},{"key":"25 Q1","value":344476.8}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":3.58},{"key":"21 Q3","value":3.54},{"key":"21 Q4","value":3.53},{"key":"22 Q1","value":4.77},{"key":"22 Q2","value":4.6},{"key":"22 Q3","value":4.25},{"key":"22 Q4","value":4.46},{"key":"23 Q1","value":5.5},{"key":"23 Q2","value":4.63},{"key":"23 Q3","value":4.62},{"key":"23 Q4","value":4.52},{"key":"24 Q1","value":6.2},{"key":"24 Q2","value":5.07},{"key":"24 Q3","value":5.72},{"key":"24 Q4","value":5.39},{"key":"25 Q1","value":6.45}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-25T12:57:08Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.58,"sell":0.42,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"NVS","name":"Novartis","displayName":"Novartis","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"NVS","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":117.97,"high":118.105,"low":117.21,"volume":980,"volumeDate":"2025-07-25","last":117.46,"open":117.5,"gainPercentage":-0.432,"gainValue":-0.51,"ask":117.4,"bid":117.34,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":222889746800,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":1677682.7419,"highPriceLast52Weeks":124.8299,"lowPriceLast52Weeks":96.062,"companyName":"Novartis AG","longBusinessDescription":"Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.","dividendRate":3.994,"salesOrRevenue":50288540489.9328,"oneYearAnnualRevenueGrowthRate":10.670203542986,"threeYearAnnualRevenueGrowthRate":0.0287,"fiveYearAnnualRevenueGrowthRate":1.7256,"earningsGrowth":-11.9153,"totalDebt":31258048840.625,"totalAssets":106763166817.188,"floatAsPercentOfSharesOutstanding":99.9989,"dividendYield":3.4000000000000004,"betaTwelveMonth":0.2119,"salesOrRevenueTtm":53546130992.2034,"ebitdaTtm":23137880390,"debtToEquityRatioQuarterly":77.7349053233298,"totalEnterpriseValue":215906877939.06198,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":14.8051823388443,"fiveYearAverageDebtEquityRatio":43.48,"currentRatio":0.817903764898783,"peratio":16.9},"recommendation":{"currentConsensusRating":2.5,"recommendationTargetPrice":113.44,"totalRatings":8,"strongSellRatings":0,"sellRatings":0,"holdRatings":6,"buyRatings":0,"strongBuyRatings":2,"lastUpdated":"2024-10-30T14:05:56Z"},"earningEstimates":[{"actual":1.4,"estimate":1.42,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-02T11:41:58Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-02-02T00:00:00Z","earningsSummary":null},{"actual":1.46,"estimate":1.44,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-26T13:30:58Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-04-26T00:00:00Z","earningsSummary":null},{"actual":1.56,"estimate":1.52,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-19T10:42:28Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-07-19T00:00:00Z","earningsSummary":null},{"actual":1.58,"estimate":1.57,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-25T07:27:07Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-10-25T00:00:00Z","earningsSummary":null},{"actual":1.52,"estimate":1.44,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-01T07:24:24Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-02-01T00:00:00Z","earningsSummary":null},{"actual":1.71,"estimate":1.55,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-25T07:24:30Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-04-25T00:00:00Z","earningsSummary":null},{"actual":1.83,"estimate":1.66,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-18T06:02:26Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-07-18T00:00:00Z","earningsSummary":null},{"actual":1.74,"estimate":1.7,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-24T08:14:04Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-10-24T00:00:00Z","earningsSummary":null},{"actual":1.53,"estimate":1.68,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-31T07:30:20Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-01-31T00:00:00Z","earningsSummary":null},{"actual":1.8,"estimate":1.69,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-23T12:24:11Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-04-23T00:00:00Z","earningsSummary":null},{"actual":1.97,"estimate":1.86,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-18T05:20:06Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-07-18T00:00:00Z","earningsSummary":null},{"actual":2.06,"estimate":1.96,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-29T06:27:50Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-10-29T00:00:00Z","earningsSummary":null},{"actual":1.98,"estimate":1.79,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-31T07:22:03Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-01-31T00:00:00Z","earningsSummary":null},{"actual":2.28,"estimate":2.08,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-29T05:11:05Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-04-29T00:00:00Z","earningsSummary":null},{"actual":2.42,"estimate":2.38,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-17T05:05:02Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-17T00:00:00Z","earningsSummary":null},{"actual":null,"estimate":2.29,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-23T23:31:26Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-28T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-02-02","title":"Earnings data Q4 2021","quarter":"Q4","hash":"c4faf3d6e32b75c80ececf123896b535f64f2b7d6e57b76b49c510a1f844ac07"},{"date":"2022-04-26","title":"Earnings data Q1 2022","quarter":"Q1","hash":"94e04fe3a26bf2265117553072b3caeaa657872fa370dd8d27caf2914fa00bb6"},{"date":"2022-07-19","title":"Earnings data Q2 2022","quarter":"Q2","hash":"4a4fa96fa0fe5c796cbdeafafc8878ec4178542c9cfd1c4bce54dc39a516e78c"},{"date":"2022-10-25","title":"Earnings data Q3 2022","quarter":"Q3","hash":"e7f7641a64dc52ffa24ffb0b524a2051755812fe057906617ea39cee9e2c7003"},{"date":"2023-02-01","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8388ddf74be8734f8fe5d9ae17c6a5d4f55cabf1d7d1b84c73230738896f805a"},{"date":"2023-04-25","title":"Earnings data Q1 2023","quarter":"Q1","hash":"3800ab42ec93d207377e7b2bad7585edd009a0b7f05546e4778a495210c63138"},{"date":"2023-07-18","title":"Earnings data Q2 2023","quarter":"Q2","hash":"30ee30b09e8ef6a88b23f6d1cf5c47db779bc02e83dc39563792c76ca277abe8"},{"date":"2023-10-24","title":"Earnings data Q3 2023","quarter":"Q3","hash":"1254e25f589676ac6e70afb16c5a0964a4c339242c8d3b6dc08088d68a8d5a58"},{"date":"2024-01-31","title":"Earnings data Q4 2023","quarter":"Q4","hash":"d9813fd1d748b5d1edee8beb495a3c8a448b6fad0c249fce4e42be5cf6cc6e90"},{"date":"2024-04-23","title":"Earnings data Q1 2024","quarter":"Q1","hash":"2fc472fa0f4231d131ad4629409e0563deb3ca826d9db620c9b4b8ce310654cd"},{"date":"2024-07-18","title":"Earnings data Q2 2024","quarter":"Q2","hash":"5e5625c63dd1e8831aff59d4bdcdc623e629fa6ebbf984f18f12558dbd1047d6"},{"date":"2024-10-29","title":"Earnings data Q3 2024","quarter":"Q3","hash":"0c5bcf539f928b8a101ff82d1db0fedc42437a0c18e0dbad175b6193f394ccc4"},{"date":"2025-01-31","title":"Earnings data Q4 2024","quarter":"Q4","hash":"73b209270c82510ca60db76ec4073cd9d9592a1be7b8f7c753060ef6340b0356"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"e2e874b7a15bdbf4575172585e7247c176d63b2f1007bebe0c27d70e9139645d"},{"date":"2025-07-17","title":"Earnings data Q2 2025","quarter":"Q2","hash":"dd400fbca408ae32b360baa6c20921fa5d998aba9073f6cedfe3ac6303cfbead"},{"date":"2025-10-28","title":"Earnings data Q3 2025","quarter":"Q3","hash":"d23d459d049e8df05c4b8c40e911693524d066e36fb901a3ad8d68e3d1930eb6"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Novartis","companyDescription":"Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":14279667862.4488,"changePercentage":14.31,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3372293840.57688,"changePercentage":6.45,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":10907374021.871899,"changePercentage":16.98,"valueToRevenueRatio":0.7638394763056772},{"financialKey":"OPERATING_EXPENSES","value":6154258449.04313,"changePercentage":13.91,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":6154258449.04313,"changePercentage":13.91,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":4753115570,"changePercentage":21.19,"valueToRevenueRatio":0.33285897233641226},{"financialKey":"EBITDA","value":5931741920,"changePercentage":16.72,"valueToRevenueRatio":0.415397751343971},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1178626350,"changePercentage":1.59,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":4088614165.25501,"changePercentage":26.15,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.1077,"changePercentage":32.21,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":104394883077.59999,"changePercentage":7.07,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":25938970948.32,"changePercentage":0.96,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":6999992160,"changePercentage":-17.01,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":9175989722.88,"changePercentage":8.21,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":6306992936.16,"changePercentage":9.74,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":3455996129.2799997,"changePercentage":14.02,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":78455912129.28,"changePercentage":9.25,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":11825986754.88,"changePercentage":11.34,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":54792938631.84,"changePercentage":3.37,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":11836986743.44,"changePercentage":44.69,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":62340930178.08,"changePercentage":12.12,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":31713964480.32,"changePercentage":14.86,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":8572990398.239999,"changePercentage":10.42,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":2825996834.8799996,"changePercentage":47.26,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":20314977247.2,"changePercentage":13.31,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":30626965697.760002,"changePercentage":9.42,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":24063973048.32,"changePercentage":13.39,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":6562992650.48,"changePercentage":-3.03,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":42053952899.520004,"changePercentage":0.36,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":41984952976.8,"changePercentage":0.6,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":68999922.72,"changePercentage":-59.17,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":104394883077.59999,"changePercentage":7.07,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":32636963446.559998,"changePercentage":12.59,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":25636971286.559998,"changePercentage":24.74,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":21.68809,"changePercentage":5.21,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":4102077859.81449,"changePercentage":26.37,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":6769450629.7429,"changePercentage":38.86,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":6862292424.29004,"changePercentage":39.34,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-92841794.5471362,"changePercentage":-85.68,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-2262568052.6431403,"changePercentage":29.45,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":578989881.873357,"changePercentage":-20.47,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":7483779.99276502,"changePercentage":-99.04,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":1693286988.4824452,"changePercentage":-49.54,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-4542328702.991708,"changePercentage":43.74,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-5353761093.79106,"changePercentage":-67.31,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-2749328592.1310797,"changePercentage":-72.81,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":2564970222.45902,"changePercentage":6.12,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-216963965.555402,"changePercentage":-767.86,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":387748690.844458,"changePercentage":1240.44,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-459129825.846848,"changePercentage":70.68,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":6432466670,"changePercentage":39.38,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-22T19:10:50Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":"2024-11-29T02:20:35Z","bearsSay":["The negative outlook on Novartis's stock is influenced by concerns regarding the clinical viability of its late-stage assets, which, if proven unviable, could exert downward pressure on share prices. Furthermore, any shortfalls in sales relative to projections or consensus estimates may lead to additional negative impacts on stock value. Additionally, potential delays or rejections in the approval process for new pipeline assets and label-expanding initiatives could adversely affect future cash flow and overall valuation, compounded by external factors such as unfavorable policy developments or economic downturns."],"bullsSay":["Novartis demonstrates a robust outlook supported by the strong performance of its key drug Cosentyx, which achieved 25% year-over-year growth due to successful label expansions and market uptake. The firm has raised its 2024 financial outlook, indicating positive sales trends across multiple therapeutic areas, with potential for further growth stemming from unmodeled pipeline assets that may prove clinically effective. Additionally, the long lifecycle and targeted approach of Scemblix, alongside the promising revenue potential from other therapies, position Novartis favorably for continued financial success."],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.56,"sell":0.44,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"KPTI","name":"Karyopharm Therapeutics","displayName":"Karyopharm Therapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"KPTI","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":4.86,"high":4.91,"low":4.37,"volume":210125,"volumeDate":"2025-07-24","last":4.43,"open":4.7,"gainPercentage":-8.848,"gainValue":-0.43,"ask":5.27,"bid":4.22,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":38274800,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":123399.5,"highPriceLast52Weeks":16.95,"lowPriceLast52Weeks":3.51,"companyName":"Karyopharm Therapeutics, Inc.","longBusinessDescription":"Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.","dividendRate":0,"salesOrRevenue":145237000,"oneYearAnnualRevenueGrowthRate":-0.54508227592393,"threeYearAnnualRevenueGrowthRate":-10.9042,"fiveYearAnnualRevenueGrowthRate":45.1446,"earningsGrowth":61.6472,"totalDebt":194524000,"totalAssets":164418000,"floatAsPercentOfSharesOutstanding":92.155,"dividendYield":0,"betaTwelveMonth":0.7992,"salesOrRevenueTtm":142126000,"ebitdaTtm":-118607000,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":168197946.9,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-3.19178558067447,"fiveYearAverageDebtEquityRatio":-248.95,"currentRatio":1.33050791191767,"peratio":-0.33},"recommendation":{"currentConsensusRating":2.1,"recommendationTargetPrice":23.76,"totalRatings":17,"strongSellRatings":0,"sellRatings":1,"holdRatings":4,"buyRatings":7,"strongBuyRatings":5,"lastUpdated":"2025-07-11T10:15:07Z"},"earningEstimates":[{"actual":-10.35,"estimate":-10.05,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2025-02-26T10:10:27Z","audioUrl":"https://files.quartr.com/audio-files/3d288-2022-10-19-04-56-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b0a95-2024-08-29-08-05-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-03T00:00:00Z","earningsSummary":null},{"actual":6.9,"estimate":-7.35,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2025-02-26T10:10:24Z","audioUrl":"https://files.quartr.com/audio-files/79809-2022-10-19-11-27-02.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/584ba-2022-02-08-08-26-47-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a387e-2023-01-25-12-56-25.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-08T08:47:26Z","earningsSummary":null},{"actual":-7.95,"estimate":-9.45,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2025-02-26T10:10:22Z","audioUrl":"https://files.quartr.com/audio-files/1820a-2023-01-13-10-01-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4d0bc-2022-05-05-10-44-57-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8e6ac-2023-01-25-02-40-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-05T10:57:44Z","earningsSummary":null},{"actual":-9.3,"estimate":-9.45,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2025-02-26T10:10:21Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_04_14_00_Q2_2022_Karyopharm_Therapeutics_Inc_Earnings_Call.SSJ1IC0634CC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b4873-2022-08-04-01-48-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/857eb-2022-08-04-12-58-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T09:51:00Z","earningsSummary":null},{"actual":-6.75,"estimate":-8.55,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2025-02-26T10:10:21Z","audioUrl":"https://files.quartr.com/audio-files/e00e4-2022-11-04-08-36-01.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cea35-2022-11-03-08-43-59.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8cccf-2024-08-29-08-04-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T12:00:00Z","earningsSummary":null},{"actual":-6.45,"estimate":-5.25,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2025-02-26T10:10:23Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_15T13_00_00_00_00_Karyopharm_Therapeutics_Inc_Earnings_Call_Q4_2022.P7F9U521LTOM_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/524b5-2023-02-18-03-20-19.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b5584-2023-03-30-08-29-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-15T13:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics demonstrated strong performance in revenue growth and clinical pipeline advancements, positioning them for continued success in 2023.\nStrategic strengths in product portfolio, leadership, and innovation align well with opportunities in accelerating growth and exploring novel treatment approaches.\nChallenges in differentiation, data updates, and dose optimization require focused strategies to overcome obstacles and drive sustainable growth.\nOverall, Karyopharm's focus on patient outcomes, strategic expansion, and upcoming milestones indicate a positive trajectory for the company.","headline":"Karyopharm reports robust revenue growth and strategic clinical advancements","lastUpdated":"2024-05-05T20:16:51.760198Z"}},{"actual":-4.5,"estimate":-5.55,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2025-02-26T10:10:20Z","audioUrl":"https://files.quartr.com/audio-files/0e628-2023-05-04-03-29-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/2738d-2023-05-05-06-36-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics faced revenue challenges due to PAP usage and discounts but showcased strong demand for XPOVIO and promising pipeline progress.\nThe company's financial stability was supported by expense reductions and total revenue of $38.7 million for Q1 2023.\nOpportunities lie in commercial expansions, Phase III data advancements, and strategic product development efforts, positioning Karyopharm for future growth and innovation.","headline":"Karyopharm Therapeutics navigates revenue challenges while advancing pipeline innovations","lastUpdated":"2024-05-07T01:37:22.163052Z"}},{"actual":-4.35,"estimate":-5.1,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2025-02-26T10:10:19Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_02T12_00_00_00_00_Karyopharm_Therapeutics_Inc_Q2_2023.7MHM7LCP0FAJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/a4f1d-2023-08-02-11-03-31.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-02T12:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics showcased strong financial performance, strategic workforce reductions, and progress in pivotal Phase III trials during the Q2 earnings call. The company's focus on advancing novel SINE compounds and maintaining financial strength positions them well for future growth and value creation.","headline":"Karyopharm Therapeutics excels in Q2, eyes $2B peak revenues","lastUpdated":"2024-05-07T09:10:58.461325Z"}},{"actual":-4.5,"estimate":-4.2,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2025-02-26T10:10:19Z","audioUrl":"https://files.quartr.com/audio-files/37c53-2023-11-02-12-17-50.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/20ba5-2023-11-02-12-28-26.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/42d7c-2023-11-02-11-02-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T12:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics showcased strong financial performance with revenue of $36 million and emphasized growth potential.\nPromising Phase III trial data for myelofibrosis and endometrial cancer positions selinexor as a treatment paradigm changer.\nChallenges include PAP impact from foundation closures, but opportunities lie in novel drug combinations and growth strategies.","headline":"Karyopharm Therapeutics reports robust Q3 earnings and highlights growth prospects","lastUpdated":"2024-05-07T05:27:47.449293Z"}},{"actual":-5.4,"estimate":-4.65,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2025-02-26T10:10:17Z","audioUrl":"https://files.quartr.com/audio-files/a5a1d-2024-02-29-01-57-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c5026-2024-02-29-01-26-58.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/dde00-2024-02-29-12-26-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-29T13:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics delivered on revenue targets, showcasing strong performance and promising trial results in key indications.\nWhile facing challenges in academic settings and financial obligations, the company's strategic strengths and growth opportunities position it well for the future.\nWith a focus on advancing Phase III trials, leveraging IP advantages, and exploring new treatment avenues, Karyopharm aims for continued innovation and market expansion.\nOverall, Karyopharm's Q4 2023 Earnings Call reflects a balanced outlook with a solid foundation for growth and value creation in the biopharmaceutical sector.","headline":"Karyopharm meets revenue targets, eyes transformative outcomes in trials","lastUpdated":"2024-05-06T23:04:11.615842Z"}},{"actual":-4.8,"estimate":-4.95,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2025-02-26T10:10:16Z","audioUrl":"https://files.quartr.com/audio-files/0c773-2024-05-08-01-42-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a541e-2024-05-08-02-25-59.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c8093-2024-05-08-11-36-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-08T12:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics' Q1 2024 earnings call highlighted robust performance, strategic refinancing, and promising late-stage pipeline developments. While facing challenges in financial clarity and trial progress, the company is well-positioned to capitalize on growth opportunities through biomarker-driven patient selection and combination therapies.","headline":"Karyopharm Therapeutics reports strong Q1 performance and strategic refinancing","lastUpdated":"2024-05-08T19:25:37.977719Z"}},{"actual":-3,"estimate":-4.5,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2025-02-26T10:10:18Z","audioUrl":"https://files.quartr.com/audio-files/9f4f3-2024-08-06-01-30-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d6f04-2024-08-06-12-47-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/56717-2024-08-06-11-14-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-06T12:00:00Z","earningsSummary":null},{"actual":-3.9,"estimate":-3.9,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2025-02-26T10:10:15Z","audioUrl":"https://files.quartr.com/audio-files/e1dae-2024-11-05-01-24-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/67b9d-2024-11-05-12-54-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b79fe-2024-11-05-12-09-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-05T13:00:00Z","earningsSummary":null},{"actual":-3.6,"estimate":-4.05,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-26T10:10:14Z","audioUrl":"https://files.quartr.com/audio-files/c03f1-2025-02-19-02-08-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e47b4-2025-02-19-12-12-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4a867-2025-02-19-12-01-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-19T13:00:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics demonstrated strong financial performance and strategic advancements in myelofibrosis and endometrial cancer programs during Q4 2024. While facing challenges in meeting myelofibrosis milestones and securing adequate financing, the company's focus on extending the cash runway and commercial growth presents opportunities for future success. Overall, Karyopharm's performance, strengths, challenges, and opportunities position the company well for continued growth and innovation in the biopharmaceutical sector.","headline":"Karyopharm excels in Q4 with strong financials and myelofibrosis progress","lastUpdated":"2025-02-19T22:00:59.980509Z"}},{"actual":-2.77,"estimate":-3.09,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-12T20:07:04Z","audioUrl":"https://files.quartr.com/audio-files/862e9-2025-05-12-09-36-32.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/af196-2025-05-12-08-39-21.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d1327-2025-05-12-08-32-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-12T20:30:00Z","earningsSummary":{"summary":"Karyopharm Therapeutics reported a 5% demand growth in Q1 but faced revenue challenges due to atypical returns of expired high-dose XPOVIO units, impacting net product revenue. The company showcased promising data on selinexor's mechanism in myelofibrosis, highlighting its potential in key disease parameters and discussing strategies to extend the cash runway for growth. Analyst questions focused on various aspects of the company's operations, indicating areas for improvement and further clarity, while Karyopharm remains confident in its growth trajectory.","headline":"Karyopharm Therapeutics navigates revenue challenges, highlights selinexor's potential in Q1","lastUpdated":"2025-05-13T08:41:29.414323Z"}},{"actual":null,"estimate":-3.92,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-16T23:30:30Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-05T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-03","title":"Earnings data Q3 2021","quarter":"Q3","hash":"d404340454b9c67bc25999f49763e1bf15b654ab434e39ab4ba7a35f33eeeb2d"},{"date":"2022-02-08","title":"Earnings data Q4 2021","quarter":"Q4","hash":"03bb82241d923266648445d72db721722d9e67f2287934594bc9c1f5336a996f"},{"date":"2022-05-05","title":"Earnings data Q1 2022","quarter":"Q1","hash":"e3785e5d2a151fd21c571abb14f7f4fc08ce3c22248afc9713804440152fff9b"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"56dbc3370a708205d9142bd68c2c3aa68cfff3bf031fc3ef1093839827d602b1"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"532dd07ad171317e05a6923d0f7c32b92826f2c0ba604f7c6108e945618d901d"},{"date":"2023-02-15","title":"Earnings data Q4 2022","quarter":"Q4","hash":"1c32c76f018ff0ed4d42f480df48d4f8354979f5699378b84d3b880eb6bb910f"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"678044b27bc4508e71a73efdfbb746be1331373e2bb3fc4606dfbc28bc2b30ed"},{"date":"2023-08-02","title":"Earnings data Q2 2023","quarter":"Q2","hash":"f1e29bff297c360da8374ee142d769a55f66675cd3af5bfa7c923f9184e0ff12"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"1e0210800a8be01cb3f82131cc38ffdd8598d1d0b0b891fbe1ee19932b0e6dc1"},{"date":"2024-02-29","title":"Earnings data Q4 2023","quarter":"Q4","hash":"96181ee84643c38e4fa28c85c5f25ea31e97e759b621dce9492080813c090f4b"},{"date":"2024-05-08","title":"Earnings data Q1 2024","quarter":"Q1","hash":"be47b056d312068c0d82489c9c59050f681775ef4a4d5d3f575f4f8d5db4675f"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"e7c96e27cbc9ab1456dbba9debf22aea17f0ef2677f06d3b1c989c45e6d312c2"},{"date":"2024-11-05","title":"Earnings data Q3 2024","quarter":"Q3","hash":"da7202ffb1704e0c00292f12fa5dd02d4d8c4c36f33393b0b70dc9aaf046277b"},{"date":"2025-02-19","title":"Earnings data Q4 2024","quarter":"Q4","hash":"ae0a881c16d063e2cf3aad25cc6bac204c1181b1bf443cb63a9149d1ed1163fe"},{"date":"2025-05-12","title":"Earnings data Q1 2025","quarter":"Q1","hash":"41555a99441075c2e92ccf815935ab8e558f42e4e6eb0a96d3c4cd346bf64765"},{"date":"2025-08-05","title":"Earnings data Q2 2025","quarter":"Q2","hash":"359cc5f825c19e1ad87dab3b5d95002c0890eba7a39fe4fd897a446c6a81cb7f"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Karyopharm Therapeutics","companyDescription":"Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":30015000,"changePercentage":-9.39,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1379000,"changePercentage":-30.91,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":28636000,"changePercentage":-8.01,"valueToRevenueRatio":0.9540563051807429},{"financialKey":"OPERATING_EXPENSES","value":61892000,"changePercentage":-4.62,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":61892000,"changePercentage":-4.62,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-33256000,"changePercentage":1.49,"valueToRevenueRatio":-1.1079793436615026},{"financialKey":"EBITDA","value":-33177999.999999996,"changePercentage":1.47,"valueToRevenueRatio":-1.1053806430118274},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":78000.00000000373,"changePercentage":-8.24,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-23462000,"changePercentage":37.2,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-2.77,"changePercentage":42.94,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":127711000,"changePercentage":-37.54,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":120238000,"changePercentage":-39.39,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":69941000,"changePercentage":-53.07,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":35243000,"changePercentage":13.39,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":4769000,"changePercentage":72.23,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":10285000,"changePercentage":-33.55,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":7473000,"changePercentage":22.67,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":5799000,"changePercentage":30.2,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":1674000,"changePercentage":2.2,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":333595000,"changePercentage":-10.66,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":90370000,"changePercentage":38.31,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":25386000,"changePercentage":641.2,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":64984000,"changePercentage":4.96,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":243225000,"changePercentage":-21.05,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":161317000,"changePercentage":-6.76,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":81908000,"changePercentage":-39.35,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":-205884000,"changePercentage":-21.86,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":-205884000,"changePercentage":-21.86,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":127711000,"changePercentage":-37.54,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":186703000,"changePercentage":5.82,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":116762000,"changePercentage":326.15,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":-24.02941,"changePercentage":-10.42,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-23462000,"changePercentage":37.2,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-38984000,"changePercentage":10.84,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-37459000,"changePercentage":-13.48,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1525000,"changePercentage":85.77,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":15288000,"changePercentage":-30.32,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":15288000,"changePercentage":-30.93,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":5000,"changePercentage":131.25,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-23691000,"changePercentage":-8.67,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-38984000,"changePercentage":11.24,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:36Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T07:49:48Z","bearsSay":["Karyopharm Therapeutics faces significant commercial risks due to an increasingly crowded competitive landscape for cancer therapies and the narrow therapeutic window of its primary product, Xpovio, which hampers its market uptake potential. Recent financial results for Q4 2024 showed revenues of $30.5 million and a loss per share of $0.24, which, while better than some estimates, indicate ongoing financial struggles. Additionally, pipeline challenges, particularly concerning selinexor's FDA approval prospects for specific indications, further contribute to a negative outlook for the company's future stock performance."],"bullsSay":["Karyopharm Therapeutics Inc. is positioned favorably in the commercial-stage pharmaceutical sector, particularly with its lead product, XPOVIO (selinexor), which has demonstrated efficacy in treating multiple myeloma and is expanding its indications, potentially increasing out-year sales to approximately $500 million. The company's revenue prospects appear robust, with anticipated steady revenue generation of around $120 million per year over the next decade, driven by adoption in earlier-line treatment and the community clinic setting. Additionally, the positive outlook is reinforced by the expectations of market uptake and potential growth in revenue, with estimates of $115-$130 million projected for 2025, reflecting an 11% year-over-year increase."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"LLY","name":"Eli Lilly","displayName":"Eli Lilly","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"LLY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":798.89,"high":810.14,"low":797.65,"volume":845,"volumeDate":"2025-07-25","last":805.43,"open":801.36,"gainPercentage":0.819,"gainValue":6.54,"ask":808,"bid":803.57,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":763335006500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":3779783.3387,"highPriceLast52Weeks":972.53,"lowPriceLast52Weeks":677.0912,"companyName":"Eli Lilly \u0026 Co.","longBusinessDescription":"Eli Lilly \u0026 Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.","dividendRate":5.6,"salesOrRevenue":45042700000,"oneYearAnnualRevenueGrowthRate":31.9967413059978,"threeYearAnnualRevenueGrowthRate":17.4481,"fiveYearAnnualRevenueGrowthRate":15.538,"earningsGrowth":80.7268,"totalDebt":33644199999.999996,"totalAssets":78714900000,"floatAsPercentOfSharesOutstanding":89.6518,"dividendYield":0.7000000000000001,"betaTwelveMonth":0.7942,"salesOrRevenueTtm":49003200000,"ebitdaTtm":21551100000,"debtToEquityRatioQuarterly":244.315817517507,"totalEnterpriseValue":728234048000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":21.8293620292083,"fiveYearAverageDebtEquityRatio":194.88,"currentRatio":1.3722583069765,"peratio":66.72},"recommendation":{"currentConsensusRating":1.9,"recommendationTargetPrice":691.5,"totalRatings":36,"strongSellRatings":2,"sellRatings":1,"holdRatings":3,"buyRatings":17,"strongBuyRatings":13,"lastUpdated":"2025-07-11T12:32:59Z"},"earningEstimates":[{"actual":1.94,"estimate":1.68,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-26T10:35:10Z","audioUrl":"https://files.quartr.com/audio-files/04d0e-2022-10-19-04-32-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/906e4-2021-10-26-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4ea3-2023-01-25-10-38-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-26T00:00:00Z","earningsSummary":null},{"actual":2.49,"estimate":2.19,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-03T14:22:12Z","audioUrl":"https://files.quartr.com/audio-files/97c8d-2022-10-19-10-16-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/9d451-2023-01-25-12-51-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-03T02:34:14Z","earningsSummary":null},{"actual":2.62,"estimate":2.13,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T10:50:43Z","audioUrl":"https://files.quartr.com/audio-files/71960-2022-10-28-04-27-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a66bc-2022-04-28-03-05-19-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/29f29-2023-01-25-01-38-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T15:19:05Z","earningsSummary":null},{"actual":1.25,"estimate":1.69,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T10:42:38Z","audioUrl":"https://files.quartr.com/audio-files/d07ea-2022-08-04-06-31-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d6a24-2022-08-04-11-33-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/204f9-2022-08-04-11-22-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T01:10:00Z","earningsSummary":null},{"actual":1.98,"estimate":1.92,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T10:28:26Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_01T13_00_00_00_00_Eli_Lilly_and_Co_Earnings_Call_Q3_2022.4RMDVWN3A7M4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/48eeb-2022-11-01-11-41-47.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/607f3-2022-11-01-11-38-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T13:00:00Z","earningsSummary":null},{"actual":2.09,"estimate":1.78,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T11:47:26Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T15_00_00_00_00_Eli_Lilly_and_Co_Earnings_Call_Q4_2022.F190RBWVOKPT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/36d28-2023-02-02-12-39-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/277cd-2023-02-02-12-18-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T15:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.\nThe company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.\nChallenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.\nOpportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.","headline":"Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies","lastUpdated":"2024-05-05T20:12:24.168598Z"}},{"actual":1.62,"estimate":1.73,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T10:47:10Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T14_00_00_00_00_Eli_Lilly_and_Company_Q1_2023.4Q46R9ANHXV0_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/34006-2023-04-27-10-29-51.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/063e9-2023-04-27-10-23-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.\nWhile facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.\nOpportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.\nOverall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.","headline":"Eli Lilly reports robust Q1 growth amidst capacity challenges","lastUpdated":"2024-05-05T20:49:38.351360Z"}},{"actual":2.11,"estimate":1.99,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-08T10:48:25Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_08T13_00_00_00_00_Eli_Lilly_and_Company_Q2_2023.M3DRMXC9JBO9_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f3d4f-2023-08-08-11-02-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f665e-2023-08-08-11-48-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T13:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.\nThe company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.\nOpportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.\nOverall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.","headline":"Eli Lilly reports robust Q2 earnings, eyes growth through innovation","lastUpdated":"2024-05-06T21:52:30.799537Z"}},{"actual":0.1,"estimate":-0.15,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T10:47:24Z","audioUrl":"https://files.quartr.com/audio-files/0d3ec-2023-11-02-05-23-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dcd25-2023-11-02-12-56-13.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/95606-2023-11-02-11-32-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T13:00:00Z","earningsSummary":{"summary":"Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.\nChallenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.\nInvestors advised to focus on guidance range for insights into 2024 expectations.","headline":"Eli Lilly posts robust Q3 results, eyes expansion and commercial growth","lastUpdated":"2024-05-06T20:39:28.344626Z"}},{"actual":2.49,"estimate":2.19,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T11:46:04Z","audioUrl":"https://files.quartr.com/audio-files/ad4dd-2024-02-06-04-32-30.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ae7e1-2024-02-06-12-06-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b5882-2024-02-06-12-11-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T15:00:00Z","earningsSummary":{"summary":"Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.\nThe company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.\nChallenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.\nOverall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.","headline":"Eli Lilly posts robust Q4 results, eyes global expansion opportunities","lastUpdated":"2024-05-05T19:45:11.746779Z"}},{"actual":2.58,"estimate":2.46,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-30T10:49:22Z","audioUrl":"https://files.quartr.com/audio-files/47147-2024-04-30-03-45-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/415d6-2024-04-30-10-33-55.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ceb03-2024-04-30-10-12-55.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-30T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.\nWhile facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.\nOpportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.\nOverall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.","headline":"Eli Lilly reports robust Q1 growth, eyes pipeline opportunities","lastUpdated":"2024-05-07T03:46:51.597393Z"}},{"actual":3.92,"estimate":2.7,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T10:51:15Z","audioUrl":"https://files.quartr.com/audio-files/97d59-2024-08-08-03-43-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/eef1a-2024-08-08-11-12-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5e779-2024-08-08-11-51-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T14:00:00Z","earningsSummary":null},{"actual":1.18,"estimate":1.45,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-30T10:48:00Z","audioUrl":"https://files.quartr.com/audio-files/a2426-2024-10-30-03-30-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/51a29-2024-10-30-11-59-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4156d-2024-10-30-11-47-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-30T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.\nKey pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.\nChallenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.","headline":"Eli Lilly reports stellar Q3 results, eyes global expansion opportunities","lastUpdated":"2024-10-30T19:13:26.111190Z"}},{"actual":5.32,"estimate":5.08,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-06T11:47:17Z","audioUrl":"https://files.quartr.com/audio-files/e2714-2025-02-06-04-54-18.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c0e8c-2025-02-06-12-14-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b7ff0-2025-02-06-12-55-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-06T15:00:00Z","earningsSummary":{"summary":"Eli Lilly's strong performance in Q4 2024 sets a positive tone for 2025.\nBalancing challenges like pricing pressures with growth opportunities is key.\nInvestors can expect continued focus on R\u0026D and shareholder returns.\nStrategic acquisitions and product launches drive future revenue growth.","headline":"Eli Lilly reports robust Q4 results, eyes growth amidst challenges","lastUpdated":"2025-02-06T17:42:20.124312Z"}},{"actual":3.34,"estimate":3.02,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T10:46:06Z","audioUrl":"https://files.quartr.com/audio-files/e22c5-2025-05-01-03-37-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a1c5f-2025-05-01-11-58-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4a9c-2025-05-01-11-55-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T14:00:00Z","earningsSummary":{"summary":"Eli Lilly's Q1 2025 showcased strong financial performance, promising pipeline developments, and strategic initiatives to drive growth. Despite challenges in trade dynamics and pricing reforms, the company remains focused on innovation and market expansion to sustain its growth trajectory.","headline":"Eli Lilly (LLY) reports stellar Q1 results, eyes global expansion","lastUpdated":"2025-05-01T17:43:57.264355Z"}},{"actual":null,"estimate":5.58,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:15Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-26","title":"Earnings data Q3 2021","quarter":"Q3","hash":"7f8ef586d04d5bb74cc79c76625d5d4926e26405ad682409092c4d02ca32f7d5"},{"date":"2022-02-03","title":"Earnings data Q4 2021","quarter":"Q4","hash":"b59e0c6777ab8aa2c1fbcf612d33086098d38defb4401f317e0e11169d3f19ac"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"d25c4f773b9b09aa21cea6126331b6e9fa115f344b2455928aec5ae908d1d0f8"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"d14a4bdce2da877f80c4a16e4839c6fed82e2a19a725eb0bf0b1dde3b382c560"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"a5540fa9addca16dfab76cebb2cb1994bbbd7bae872214eabe71d04eefc55c14"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"c740e6acb1f333b51d1decc40ebef2150cd3290e689a4e0598047f5d1efa7fb7"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"363ebfb8573a1ed7174fdbed57199060b1cf801251e53f8e1418c98f0e131be2"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"65a38ab51d1d4adfd5cabc80acff84f3930659a62b07eb0fd750e49adf24415b"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"10a1aba78b28d893ce6212fac9f3800655a20304bea6b8e99973dcddc2e48f52"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"1ec4886040d2ea965fc2f84166ebeaedfedb467faa0653393f600be8e529d685"},{"date":"2024-04-30","title":"Earnings data Q1 2024","quarter":"Q1","hash":"375ff4db6181aae2a928745e020a0e3f9b2137d9a287edd6f2e5df1452703e39"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"1271123d5ef93a6a6d4a72633a115c525ed2a48e13768d47adf4b8bf6fa379c7"},{"date":"2024-10-30","title":"Earnings data Q3 2024","quarter":"Q3","hash":"c06499151c959d3d165480d843ccbd40215c65362c9e2462a839f296e017b206"},{"date":"2025-02-06","title":"Earnings data Q4 2024","quarter":"Q4","hash":"1ab968f5eab722e7c1c06a313655c674e949cc766857222e81fb568d3be95605"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"e9958cb317ed372159cf0e7d4b098edb8adc1c467d9e43503963e7a8f315ffc9"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"bf9c7cec88224825e57552974f6f0c133f22f882540fd3da585758584c3af6b0"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Eli Lilly","companyDescription":"Eli Lilly \u0026 Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.","executives":null,"brands":[{"id":"ec3556ba-e79c-48e8-9ed1-e77000e792af","name":"Cialis","description":"Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/NE3e8MaGRpWGaIVfh2dyOA-thumbnail-300x300.png"},{"id":"f0b9c23d-1faf-48ed-b14b-278aaf2be224","name":"Cymbalta","description":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/W4Hje2KxTJSKQx2cWRmXCw-thumbnail-300x300.png"},{"id":"8bfcfab4-31f4-48ce-9850-ae6cf2e67793","name":"Gemzar","description":"Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/sdJ66TnJSuSW_ZR8LtCOPA-thumbnail-300x300.png"},{"id":"ef47a1fc-917d-485e-92c7-29179d2d2b2a","name":"Methadone","description":"Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/hNwNMQUTReeWrrzWD4Gw6Q-thumbnail-300x300.png"},{"id":"e7579738-4aea-491d-8933-ab78dd6af1d4","name":"Prozac","description":"Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/xMWfDQuxRLqCugqvTgLeGQ-thumbnail-300x300.png"}]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":12728500000,"changePercentage":45.17,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2224200000,"changePercentage":32.91,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":10504300000,"changePercentage":48.06,"valueToRevenueRatio":0.8252582786659858},{"financialKey":"OPERATING_EXPENSES","value":5202500000,"changePercentage":16.26,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":5202500000,"changePercentage":16.26,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":5301800000,"changePercentage":102.4,"valueToRevenueRatio":0.4165298346230899},{"financialKey":"EBITDA","value":5764600000,"changePercentage":90.87,"valueToRevenueRatio":0.45288918568566605},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":462800000,"changePercentage":15.53,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":2759300000,"changePercentage":23.02,"valueToRevenueRatio":null},{"financialKey":"EPS","value":3.0638,"changePercentage":23.46,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":89388800000,"changePercentage":39.79,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":41261200000,"changePercentage":63.81,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":3220700000,"changePercentage":24.53,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":14003200000,"changePercentage":39.84,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":9311000000,"changePercentage":52.59,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":14726300000,"changePercentage":127.01,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":48127600000,"changePercentage":24.19,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":18474100000,"changePercentage":35.6,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":11782700000,"changePercentage":0.69,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":17870800000,"changePercentage":33.08,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":73542000000,"changePercentage":44.07,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":30068100000,"changePercentage":61.67,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":4016400000,"changePercentage":143.2,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":6175700000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":19876000000,"changePercentage":17.29,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":43473900000,"changePercentage":33.98,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":34499500000,"changePercentage":40.47,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":8974400000,"changePercentage":13.77,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":15846800000,"changePercentage":22.87,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":15764800000,"changePercentage":23.05,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":82000000,"changePercentage":-3.76,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":89388800000,"changePercentage":39.79,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":38515900000,"changePercentage":46.94,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":35295200000,"changePercentage":49.4,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":16.62787,"changePercentage":23.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":2759300000,"changePercentage":23.02,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1665600000,"changePercentage":42.85,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":5029800000,"changePercentage":72.42,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-3364200000,"changePercentage":-92.11,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-3352300000,"changePercentage":-184.67,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":3266500000,"changePercentage":201.67,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-125100000,"changePercentage":-322.64,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-6493700000,"changePercentage":-191.09,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":1379700000,"changePercentage":543.21,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-1200000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":6461000000,"changePercentage":0.13,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1346300000,"changePercentage":15.15,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-686300000,"changePercentage":-76.06,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":131900000,"changePercentage":471.55,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-175100000,"changePercentage":51.14,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":156100000,"changePercentage":-13.13,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:27Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":1.5,"priorDividend":1.3,"dividendYieldPercentage":0.79,"announcementDate":"2025-06-23","exDividendDate":"2025-08-15","payableDate":"2025-09-10","recordDate":"2025-08-15","updatedAt":"2025-06-23T16:01:36Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2024-12-14T06:31:40Z","bearsSay":["Eli Lilly faces significant revenue risks due to the impending loss of exclusivity for several of its key products, which may lead to increased generic competition and a rapid decline in sales, particularly in the U.S. The company is also vulnerable to heightened pricing pressures and potential setbacks in its drug pipeline, which could further impede growth prospects and negatively impact future revenues and net income. Additionally, unforeseen quality and manufacturing issues could exacerbate these challenges, creating a compounded threat to the firm's financial stability."],"bullsSay":["Eli Lilly has demonstrated substantial growth in its top-line revenue and operational efficiencies, supported by a capable leadership team navigating the company’s strategic initiatives. The company’s robust pipeline, featuring promising developments such as orforglipron, retatrutide, and donanemab, showcases significant potential for further revenue expansion and market penetration, particularly in light of favorable trial results and regulatory support. Revenue projections for 2024, 2025, and 2026 have been positively adjusted to $42.6 billion, $51.0 billion, and $59.7 billion, respectively, indicating sustained growth momentum for the firm."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Diabetes","dataPoints":[{"key":"21 Q2","value":3175.5},{"key":"21 Q3","value":3274.1},{"key":"21 Q4","value":3627.5},{"key":"22 Q1","value":3388.2},{"key":"22 Q2","value":3438.2},{"key":"22 Q3","value":3662.6},{"key":"22 Q4","value":3975.9},{"key":"23 Q1","value":4190.4},{"key":"23 Q2","value":5010.9},{"key":"23 Q3","value":4720.4},{"key":"23 Q4","value":5745.9},{"key":"24 Q1","value":5493},{"key":"24 Q2","value":7514.6},{"key":"24 Q3","value":7407},{"key":"24 Q4","value":9106.3},{"key":"25 Q1","value":9208.1}]},{"title":"Oncology","dataPoints":[{"key":"21 Q2","value":1554},{"key":"21 Q3","value":1406.1},{"key":"21 Q4","value":1408.9},{"key":"22 Q1","value":1353},{"key":"22 Q2","value":1368.7},{"key":"22 Q3","value":1293.3},{"key":"22 Q4","value":1651.1},{"key":"23 Q1","value":1356},{"key":"23 Q2","value":1671},{"key":"23 Q3","value":1747.1},{"key":"23 Q4","value":1884.2},{"key":"24 Q1","value":1810},{"key":"24 Q2","value":2158.7},{"key":"24 Q3","value":2231.8},{"key":"24 Q4","value":2551.9},{"key":"25 Q1","value":1947.5}]},{"title":"Immunology","dataPoints":[{"key":"21 Q2","value":785.4},{"key":"21 Q3","value":1004.9},{"key":"21 Q4","value":956.5},{"key":"22 Q1","value":748.1},{"key":"22 Q2","value":796.5},{"key":"22 Q3","value":866.4},{"key":"22 Q4","value":933.6},{"key":"23 Q1","value":777.8},{"key":"23 Q2","value":928.5},{"key":"23 Q3","value":986.9},{"key":"23 Q4","value":1104.4},{"key":"24 Q1","value":834},{"key":"24 Q2","value":1082.4},{"key":"24 Q3","value":1185.7},{"key":"24 Q4","value":1290.9},{"key":"25 Q1","value":1088}]},{"title":"Neuroscience","dataPoints":[{"key":"21 Q2","value":512.2},{"key":"21 Q3","value":450.2},{"key":"21 Q4","value":470.6},{"key":"22 Q1","value":397.7},{"key":"22 Q2","value":389.9},{"key":"22 Q3","value":373.2},{"key":"22 Q4","value":385.3},{"key":"23 Q1","value":360.5},{"key":"23 Q2","value":387.2},{"key":"23 Q3","value":1768.1},{"key":"23 Q4","value":362.8},{"key":"24 Q1","value":389.1},{"key":"24 Q2","value":339.5},{"key":"24 Q3","value":351.8},{"key":"24 Q4","value":393.1},{"key":"25 Q1","value":272.1}]},{"title":"Other","dataPoints":[{"key":"21 Q2","value":712.9},{"key":"21 Q3","value":637.7},{"key":"21 Q4","value":1536.3},{"key":"22 Q1","value":1923},{"key":"22 Q2","value":494.7},{"key":"22 Q3","value":746},{"key":"22 Q4","value":355.9},{"key":"23 Q1","value":275.3},{"key":"23 Q2","value":314.6},{"key":"23 Q3","value":276.1},{"key":"23 Q4","value":256.2},{"key":"24 Q1","value":241.9},{"key":"24 Q2","value":207.6},{"key":"24 Q3","value":262.8},{"key":"24 Q4","value":190.6},{"key":"25 Q1","value":212.9}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":71.02},{"key":"21 Q3","value":78.87},{"key":"21 Q4","value":74.37},{"key":"22 Q1","value":73.46},{"key":"22 Q2","value":77.95},{"key":"22 Q3","value":77.25},{"key":"22 Q4","value":78.79},{"key":"23 Q1","value":76.62},{"key":"23 Q2","value":78.25},{"key":"23 Q3","value":80.41},{"key":"23 Q4","value":80.88},{"key":"24 Q1","value":80.91},{"key":"24 Q2","value":80.79},{"key":"24 Q3","value":81.02},{"key":"24 Q4","value":82.23},{"key":"25 Q1","value":82.52}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":20.82},{"key":"21 Q3","value":27.77},{"key":"21 Q4","value":23.96},{"key":"22 Q1","value":30.78},{"key":"22 Q2","value":18.65},{"key":"22 Q3","value":24.15},{"key":"22 Q4","value":25.14},{"key":"23 Q1","value":21.46},{"key":"23 Q2","value":25.57},{"key":"23 Q3","value":4.74},{"key":"23 Q4","value":25.52},{"key":"24 Q1","value":28.61},{"key":"24 Q2","value":32.86},{"key":"24 Q3","value":13.34},{"key":"24 Q4","value":38.04},{"key":"25 Q1","value":29.03}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":20.62},{"key":"21 Q3","value":16.39},{"key":"21 Q4","value":21.57},{"key":"22 Q1","value":24.36},{"key":"22 Q2","value":14.68},{"key":"22 Q3","value":20.91},{"key":"22 Q4","value":26.53},{"key":"23 Q1","value":19.32},{"key":"23 Q2","value":21.21},{"key":"23 Q3","value":-0.61},{"key":"23 Q4","value":23.4},{"key":"24 Q1","value":25.58},{"key":"24 Q2","value":26.25},{"key":"24 Q3","value":8.48},{"key":"24 Q4","value":32.58},{"key":"25 Q1","value":21.67}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1672.8},{"key":"21 Q3","value":1708.9},{"key":"21 Q4","value":1959.4},{"key":"22 Q1","value":1610.1},{"key":"22 Q2","value":1781.9},{"key":"22 Q3","value":1802.9},{"key":"22 Q4","value":1995.9},{"key":"23 Q1","value":1985.1},{"key":"23 Q2","value":2356.5},{"key":"23 Q3","value":2409.1},{"key":"23 Q4","value":2562.7},{"key":"24 Q1","value":2522.8},{"key":"24 Q2","value":2711.2},{"key":"24 Q3","value":2734.1},{"key":"24 Q4","value":3022.5},{"key":"25 Q1","value":2733.7}]},{"title":"Marketing, selling and administrative","dataPoints":[{"key":"21 Q2","value":1685.7},{"key":"21 Q3","value":1577.9},{"key":"21 Q4","value":1592},{"key":"22 Q1","value":1557.9},{"key":"22 Q2","value":1625.1},{"key":"22 Q3","value":1614.2},{"key":"22 Q4","value":1643.2},{"key":"23 Q1","value":1749.2},{"key":"23 Q2","value":1925.4},{"key":"23 Q3","value":1803.9},{"key":"23 Q4","value":1924.6},{"key":"24 Q1","value":1952.2},{"key":"24 Q2","value":2117.3},{"key":"24 Q3","value":2099.8},{"key":"24 Q4","value":2424.5},{"key":"25 Q1","value":2468.8}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"21 Q2","value":25},{"key":"21 Q3","value":174},{"key":"21 Q4","value":376.6},{"key":"22 Q1","value":165.6},{"key":"22 Q2","value":440.4},{"key":"22 Q3","value":62.4},{"key":"22 Q4","value":240.1},{"key":"23 Q1","value":105},{"key":"23 Q2","value":97.1},{"key":"23 Q3","value":2975.1},{"key":"23 Q4","value":622.6},{"key":"24 Q1","value":110.5},{"key":"24 Q2","value":154.3},{"key":"24 Q3","value":2826.4},{"key":"24 Q4","value":189.2},{"key":"25 Q1","value":1571.7}]},{"title":"Asset impairment, restructuring and other special charges","dataPoints":[{"key":"21 Q4","value":104.5},{"key":"22 Q3","value":206.5},{"key":"22 Q4","value":38.1},{"key":"23 Q4","value":67.7},{"key":"24 Q2","value":435},{"key":"24 Q3","value":81.6},{"key":"24 Q4","value":344},{"key":"25 Q1","value":35}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":22.56},{"key":"21 Q3","value":17.98},{"key":"21 Q4","value":7.53},{"key":"22 Q1","value":14.76},{"key":"22 Q2","value":-3.74},{"key":"22 Q3","value":2.49},{"key":"22 Q4","value":-8.73},{"key":"23 Q1","value":-10.88},{"key":"23 Q2","value":28.12},{"key":"23 Q3","value":36.84},{"key":"23 Q4","value":28.1},{"key":"24 Q1","value":25.98},{"key":"24 Q2","value":35.98},{"key":"24 Q3","value":20.43},{"key":"24 Q4","value":44.68},{"key":"25 Q1","value":45.17}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":9.83},{"key":"21 Q3","value":10.36},{"key":"21 Q4","value":8.17},{"key":"22 Q1","value":-11.62},{"key":"22 Q2","value":13.71},{"key":"22 Q3","value":6.51},{"key":"22 Q4","value":-2.86},{"key":"23 Q1","value":15.17},{"key":"23 Q2","value":13.82},{"key":"23 Q3","value":95.01},{"key":"23 Q4","value":32.17},{"key":"24 Q1","value":19.44},{"key":"24 Q2","value":23.72},{"key":"24 Q3","value":7.7},{"key":"24 Q4","value":15.5},{"key":"25 Q1","value":48.49}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":907.3},{"key":"21 Q3","value":906.7},{"key":"21 Q4","value":909.555},{"key":"22 Q1","value":906.35},{"key":"22 Q2","value":902.94},{"key":"22 Q3","value":903.782},{"key":"22 Q4","value":904.732},{"key":"23 Q1","value":903.283},{"key":"23 Q2","value":902.699},{"key":"23 Q3","value":899.838},{"key":"23 Q4","value":903.98},{"key":"24 Q1","value":903.802},{"key":"24 Q2","value":904.248},{"key":"24 Q3","value":905.027},{"key":"24 Q4","value":903.158},{"key":"25 Q1","value":900.604}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":182251.166},{"key":"21 Q3","value":223783.534},{"key":"21 Q4","value":230574.012},{"key":"22 Q1","value":233256.423},{"key":"22 Q2","value":270617.439},{"key":"22 Q3","value":285920.474},{"key":"22 Q4","value":320366.506},{"key":"23 Q1","value":304164.291},{"key":"23 Q2","value":378152.346},{"key":"23 Q3","value":463270.796},{"key":"23 Q4","value":527654.03},{"key":"24 Q1","value":643207.866},{"key":"24 Q2","value":723325.156},{"key":"24 Q3","value":813663.619},{"key":"24 Q4","value":747820.243},{"key":"25 Q1","value":749384.483}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":6.76},{"key":"21 Q3","value":8.26},{"key":"21 Q4","value":7.21},{"key":"22 Q1","value":7.47},{"key":"22 Q2","value":10.43},{"key":"22 Q3","value":10.3},{"key":"22 Q4","value":10.97},{"key":"23 Q1","value":10.93},{"key":"23 Q2","value":11.37},{"key":"23 Q3","value":12.19},{"key":"23 Q4","value":14.1},{"key":"24 Q1","value":18.34},{"key":"24 Q2","value":16},{"key":"24 Q3","value":17.78},{"key":"24 Q4","value":13.81},{"key":"25 Q1","value":14.72}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T13:19:13Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.49,"sell":0.51,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"GILD","name":"Gilead Sciences","displayName":"Gilead Sciences","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"GILD","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":113.56,"high":113.7,"low":112.51,"volume":310,"volumeDate":"2025-07-25","last":113.2,"open":113.58,"gainPercentage":-0.317,"gainValue":-0.36,"ask":113.64,"bid":113.08,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":140812876000,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":8035005.5,"highPriceLast52Weeks":119.96,"lowPriceLast52Weeks":72.43,"companyName":"Gilead Sciences, Inc.","longBusinessDescription":"Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.","dividendRate":3.12,"salesOrRevenue":28727000000,"oneYearAnnualRevenueGrowthRate":6.16823120703674,"threeYearAnnualRevenueGrowthRate":1.6733,"fiveYearAnnualRevenueGrowthRate":5.2984,"earningsGrowth":1144.0052,"totalDebt":27322000000,"totalAssets":58995000000,"floatAsPercentOfSharesOutstanding":99.8384,"dividendYield":2.76,"betaTwelveMonth":0.3662,"salesOrRevenueTtm":28687000000,"ebitdaTtm":13677000000,"debtToEquityRatioQuarterly":130.216052604112,"totalEnterpriseValue":131594350000,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":10.9109518935517,"fiveYearAverageDebtEquityRatio":125.19,"currentRatio":1.36916720674012,"peratio":23.8},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":102.34,"totalRatings":38,"strongSellRatings":1,"sellRatings":0,"holdRatings":14,"buyRatings":14,"strongBuyRatings":9,"lastUpdated":"2025-05-21T12:00:57Z"},"earningEstimates":[{"actual":2.65,"estimate":1.74,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-28T20:10:48Z","audioUrl":"https://files.quartr.com/audio-files/f8c97-2022-10-19-04-27-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c632-2021-10-28-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9fb51-2023-01-25-10-08-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":0.69,"estimate":1.58,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-01T21:15:20Z","audioUrl":"https://files.quartr.com/audio-files/fc905-2022-10-19-10-35-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/04784-2022-02-01-07-28-44-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/38498-2023-01-25-12-41-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-01T19:44:28Z","earningsSummary":null},{"actual":2.12,"estimate":1.8,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T20:14:46Z","audioUrl":"https://files.quartr.com/audio-files/4b5ad-2022-10-28-04-17-45.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/38f08-2022-04-28-04-09-40-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/89fb1-2023-01-25-01-23-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T16:40:09Z","earningsSummary":null},{"actual":1.58,"estimate":1.53,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-02T20:20:43Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_02_22_30_Q2_2022_Gilead_Sciences_Inc_Earnings_Call.IRK8Y6FE94DL_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/46bfe-2022-08-02-08-18-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2b4ba-2022-08-02-08-18-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-02T01:00:00Z","earningsSummary":null},{"actual":1.9,"estimate":1.48,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T20:12:31Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_27T20_30_00_00_00_Gilead_Sciences_Inc_Earnings_Call_Q3_2022.YC8QPJSQOKZJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dbec7-2022-10-27-08-42-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f0b7c-2022-10-27-08-42-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T20:30:00Z","earningsSummary":null},{"actual":1.67,"estimate":1.49,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T21:59:21Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T21_30_00_00_00_Gilead_Sciences_Inc_Earnings_Call_Q4_2022.V5VFGT84GJLT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/b9d3d-2023-02-02-09-43-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/39e82-2023-02-02-09-43-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.","headline":"Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth","lastUpdated":"2024-05-06T20:04:40.207569Z"}},{"actual":1.37,"estimate":1.54,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T20:06:44Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T20_30_00_00_00_Gilead_Sciences_Inc_Q1_2023.0FAPHEOFAACJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4cfdc-2023-04-27-08-05-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1e4a4-2023-04-27-08-05-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T20:30:00Z","earningsSummary":{"summary":"Gilead Sciences delivered strong sales driven by key products in Q1 2023.\nWhile facing challenges like lower Veklury sales, Gilead maintains revenue guidance.\nThe company's strengths lie in its pipeline, successful products, and manufacturing capabilities.\nOpportunities in new indications and therapies position Gilead for future growth.","headline":"Gilead reports strong Q1 sales, focuses on pipeline growth","lastUpdated":"2024-05-06T18:41:44.086286Z"}},{"actual":1.34,"estimate":1.61,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T20:15:28Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T21_00_00_00_00_Gilead_Sciences_Inc_Q2_2023.73QI67M9O4UX_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f6c30-2023-08-03-08-23-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b1cd9-2023-08-03-08-23-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T21:00:00Z","earningsSummary":{"summary":"Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.\nTrodelvy's performance in different markets and potential Medicare coverage are key highlights.\nChallenges include unsuccessful trials and addressing revenue aspirations.\nOpportunities lie in expanding BD activities and exploring cell therapy beyond oncology.","headline":"Gilead Sciences reports robust Q2 performance and eyes future growth","lastUpdated":"2024-05-07T03:26:46.816619Z"}},{"actual":2.29,"estimate":1.92,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-07T21:06:05Z","audioUrl":"https://files.quartr.com/audio-files/15d27-2023-11-07-10-28-39.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0db43-2023-11-07-09-07-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b754e-2023-11-07-09-09-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-07T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.\nWhile facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.\nThe company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.\nOverall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.","headline":"Gilead Sciences reports robust Q3 performance amidst market challenges","lastUpdated":"2024-05-06T21:05:20.385019Z"}},{"actual":1.72,"estimate":1.78,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T21:04:58Z","audioUrl":"https://files.quartr.com/audio-files/e686d-2024-02-07-10-59-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c20ea-2024-02-06-09-14-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cdab3-2024-02-06-09-04-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T22:00:00Z","earningsSummary":{"summary":"Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.","headline":"Gilead Sciences reports strong 2023 performance, eyes transformative therapies","lastUpdated":"2024-05-06T17:26:57.049520Z"}},{"actual":-1.32,"estimate":-1.49,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T20:04:34Z","audioUrl":"https://files.quartr.com/audio-files/d69c4-2024-04-25-09-15-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5db00-2024-04-25-08-38-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/62635-2024-04-25-08-18-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-25T20:30:00Z","earningsSummary":{"summary":"Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.\nChallenges include IP R\u0026D charge from Sema Bay acquisition and competitive market dynamics.\nOpportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.\nOverall, Gilead remains focused on growth through innovation and strategic portfolio advancements.","headline":"Gilead Sciences reports robust Q1 performance and eyes future growth","lastUpdated":"2024-05-06T16:16:55.027380Z"}},{"actual":2.01,"estimate":1.6,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T20:03:28Z","audioUrl":"https://files.quartr.com/audio-files/bcb06-2024-08-08-09-18-38.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2691f-2024-08-08-08-50-40.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6288a-2024-08-08-08-44-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T20:30:00Z","earningsSummary":null},{"actual":2.02,"estimate":1.55,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-06T21:02:52Z","audioUrl":"https://files.quartr.com/audio-files/cc814-2024-11-06-10-24-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f99b3-2024-11-06-09-22-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e4eda-2024-11-06-09-22-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-06T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.\nThe company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.\nWhile challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.","headline":"Gilead Sciences reports robust Q3 performance and eyes market expansion","lastUpdated":"2024-11-07T03:38:23.538594Z"}},{"actual":1.9,"estimate":1.7,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-11T21:04:27Z","audioUrl":"https://files.quartr.com/audio-files/3b06c-2025-02-11-10-41-52.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8f8f2-2025-02-11-09-56-44.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/dbd39-2025-02-11-09-05-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-11T21:30:00Z","earningsSummary":{"summary":"Gilead Sciences' robust financial performance in 2024, driven by HIV sales and new product launches, reflects resilience and strategic growth. The company's focus on pipeline expansion, expense management, and regulatory milestones positions them for sustained success. While challenges like market competition and regulatory uncertainties persist, Gilead's diverse portfolio and growth opportunities offer a promising outlook. Investors can look forward to Gilead's continued innovation in HIV, inflammation, and oncology, supported by a strong financial foundation.","headline":"Gilead Sciences excels in Q4 2024, poised for growth","lastUpdated":"2025-02-11T23:42:42.641293Z"}},{"actual":1.81,"estimate":1.76,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-24T20:03:21Z","audioUrl":"https://files.quartr.com/audio-files/d07d2-2025-04-24-09-58-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1fcb9-2025-04-24-08-46-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4b3b-2025-04-24-08-09-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-24T20:30:00Z","earningsSummary":{"summary":"Gilead Sciences posted strong Q1 2025 results driven by growth in HIV and liver disease sales, despite challenges in certain product segments. The company's focus on expense management, pipeline advancement, and policy engagement underscores its commitment to innovation and patient-centric healthcare. While facing headwinds in specific areas, Gilead's upcoming launches and tax advantages position it favorably for future growth and adaptation to policy changes. Overall, Gilead's performance reflects resilience and strategic foresight in navigating market dynamics and advancing its position in the healthcare industry.","headline":"Gilead Sciences reports robust Q1 results amidst evolving healthcare landscape","lastUpdated":"2025-04-24T23:42:08.927706Z"}},{"actual":null,"estimate":1.96,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-25T06:30:43Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q3 2021","quarter":"Q3","hash":"ccf12ef6be28fd468ba01855c94d025a567aca8a31f0276506b790a1fe9899db"},{"date":"2022-02-01","title":"Earnings data Q4 2021","quarter":"Q4","hash":"b248df9e6e385b113a036ed95649e85bc985517ee18d3aa069d5fa30e91ce74d"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"6ba985ce145f12dddc7c61811c144f8b32d4f577d26223679c660926c61b6ad4"},{"date":"2022-08-02","title":"Earnings data Q2 2022","quarter":"Q2","hash":"ca0e5f307adfa7acf5522cd2217febfcf7cd81b6a22c553f035d67365de7e078"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"98913d0dd4f041399810707f612ee7e76ff58fcb15563da5c389653180bae266"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"a3636c6885fbd3ba09a8fa7760c0063f56bfccf0dc9c166302465c84f85a2786"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"9fcf504a1fc0ac5d54212d6dc39c42f6271f76a9d29ad3782b777607f23b83bb"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"3e4b41cd04eb3dd8cfb8a3fe40b30ff980c748ca2a74a560a426ba7477663024"},{"date":"2023-11-07","title":"Earnings data Q3 2023","quarter":"Q3","hash":"39fee44c8e56644745ef3e27720ff22f5e126ab50779c62d6d1a96c44da6c824"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"f4c388c9c03925d0adb7734af9e77778626fa8f116265be1c7d26e1f577f15aa"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"fe2fa9856a139bb0f10b40b6362589e2b9c0e221fbf9d6c770a0293508080363"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"5eab0b50bcb4562f682d7d2ecd239a996aa6fb912c16f61b57556eb9b3265792"},{"date":"2024-11-06","title":"Earnings data Q3 2024","quarter":"Q3","hash":"69fa7c834c88ca6a02c49090d92e06167b80b2cd238bbfb1f909987f093aed69"},{"date":"2025-02-11","title":"Earnings data Q4 2024","quarter":"Q4","hash":"9b9964903ea6c1466da299bcfe489b1e7cf2769841dfc78a59eb3364a7eb5b7f"},{"date":"2025-04-24","title":"Earnings data Q1 2025","quarter":"Q1","hash":"a195a35814b1741876db789d76bc89762ef623dcb417cd6ebf329a545c7e6b79"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"db7d568cb71d246b8b1254dbfe8bd633f88a75b5a006a586500efb1948f5dbfb"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Gilead Sciences","companyDescription":"Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":6646000000,"changePercentage":-0.6,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":1540000000,"changePercentage":-0.77,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":5106000000,"changePercentage":-0.55,"valueToRevenueRatio":0.7682816731868793},{"financialKey":"OPERATING_EXPENSES","value":2561000000,"changePercentage":-9.57,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":2561000000,"changePercentage":-9.57,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":2545000000,"changePercentage":10.56,"valueToRevenueRatio":0.3829371050255793},{"financialKey":"EBITDA","value":3241000000,"changePercentage":8.32,"valueToRevenueRatio":0.48766175142943124},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":696000000,"changePercentage":0.87,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1315000000,"changePercentage":131.53,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.0445,"changePercentage":131.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":56434000000,"changePercentage":0.25,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":16901000000,"changePercentage":20.37,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":9130000000,"changePercentage":50.68,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":4388000000,"changePercentage":-6.02,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":1759000000,"changePercentage":-5.07,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":1624000000,"changePercentage":11.31,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":39533000000,"changePercentage":-6.43,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":5421000000,"changePercentage":1.88,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":27669000000,"changePercentage":-12.83,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":6443000000,"changePercentage":24.19,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":37355000000,"changePercentage":-3.82,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":12344000000,"changePercentage":-5.16,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":2806000000,"changePercentage":-23.48,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":9538000000,"changePercentage":17.03,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":25011000000,"changePercentage":-3.14,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":22146000000,"changePercentage":2.88,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":2865000000,"changePercentage":-33.29,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":19078000000,"changePercentage":9.3,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":19162000000,"changePercentage":9.25,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":-84000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":56433000000,"changePercentage":0.25,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":24952000000,"changePercentage":-0.96,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":15822000000,"changePercentage":-17.31,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":15.39116,"changePercentage":9.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":1315000000,"changePercentage":131.53,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1757000000,"changePercentage":-20.82,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":2790000000,"changePercentage":4.18,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1033000000,"changePercentage":-125.05,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-415000000,"changePercentage":81.2,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":104000000,"changePercentage":-0.95,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-16000000,"changePercentage":-100.83,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":273000000,"changePercentage":-93.25,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-776000000,"changePercentage":90.64,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-3426000000,"changePercentage":-151.73,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-478000000,"changePercentage":-88.19,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-1762000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1010000000,"changePercentage":2.02,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-176000000,"changePercentage":-51.72,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":19000000,"changePercentage":205.56,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-2065000000,"changePercentage":-51.06,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1653000000,"changePercentage":-21.81,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:58Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T05:12:12Z","bearsSay":["Gilead Sciences is facing a negative outlook primarily due to anticipated declines in revenue across key segments, including a projected decrease in Veklury sales as COVID hospitalizations decline and a mid-teen percentage drop in HIV revenue for the first quarter of fiscal year 2025. Despite a forecast for operating margin expansion, driven by flat R\u0026D expenses and a significant reduction in SG\u0026A costs, the company's revenue growth prospects appear limited, especially with the modest outlook for the primary biliary cholangitis market and competitive pressures from emerging therapies. Additionally, concerns around the execution of the next-generation HIV treatment pipeline and the potential underperformance of CAR-T therapies further contribute to the bearish sentiment towards Gilead's stock performance."],"bullsSay":["Gilead Sciences demonstrates strong financial performance with its liver disease franchise achieving $3 billion in FY24 sales, marking a 9% year-over-year increase, bolstered by the successful launch of Livdelzi. The company's total HIV sales rose significantly, reaching $19.6 billion in FY24—a 16% increase year-over-year—driven by robust demand and favorable inventory dynamics, alongside Descovy's impressive 21% year-over-year growth, which outperformed consensus estimates. Additionally, Gilead's oncology portfolio shows promise with Yescarta and Tecartus maintaining steady sales, and Biktarvy has secured over 50% of the treatment market, reflecting solid growth across all business lines with the overall commercial portfolio increasing by 8% in HIV, 12% in oncology, and 9% in liver diseases year-over-year."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Product sales","dataPoints":[{"key":"21 Q2","value":6152},{"key":"21 Q3","value":7356},{"key":"21 Q4","value":7160},{"key":"22 Q1","value":6534},{"key":"22 Q2","value":6138},{"key":"22 Q3","value":6978},{"key":"22 Q4","value":7333},{"key":"23 Q1","value":6306},{"key":"23 Q2","value":6564},{"key":"23 Q3","value":6994},{"key":"23 Q4","value":7070},{"key":"24 Q1","value":6647},{"key":"24 Q2","value":6912},{"key":"24 Q3","value":7515},{"key":"24 Q4","value":7536},{"key":"25 Q1","value":6613}]},{"title":"Royalty, contract and other revenues","dataPoints":[{"key":"21 Q2","value":65},{"key":"21 Q3","value":65},{"key":"21 Q4","value":84},{"key":"22 Q1","value":56},{"key":"22 Q2","value":122},{"key":"22 Q3","value":64},{"key":"22 Q4","value":56},{"key":"23 Q1","value":46},{"key":"23 Q2","value":35},{"key":"23 Q3","value":56},{"key":"23 Q4","value":45},{"key":"24 Q1","value":39},{"key":"24 Q2","value":41},{"key":"24 Q3","value":30},{"key":"24 Q4","value":33},{"key":"25 Q1","value":54}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":77.64},{"key":"21 Q3","value":83.51},{"key":"21 Q4","value":63.73},{"key":"22 Q1","value":78.39},{"key":"22 Q2","value":76.96},{"key":"22 Q3","value":80.19},{"key":"22 Q4","value":81.1},{"key":"23 Q1","value":77.94},{"key":"23 Q2","value":78.14},{"key":"23 Q3","value":77.8},{"key":"23 Q4","value":70.62},{"key":"24 Q1","value":76.78},{"key":"24 Q2","value":77.79},{"key":"24 Q3","value":79.13},{"key":"24 Q4","value":79.11},{"key":"25 Q1","value":76.9}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":36.12},{"key":"21 Q3","value":51.77},{"key":"21 Q4","value":12.97},{"key":"22 Q1","value":2.98},{"key":"22 Q2","value":32.41},{"key":"22 Q3","value":40.28},{"key":"22 Q4","value":30.68},{"key":"23 Q1","value":26.82},{"key":"23 Q2","value":25.23},{"key":"23 Q3","value":37.19},{"key":"23 Q4","value":22.65},{"key":"24 Q1","value":-64.65},{"key":"24 Q2","value":38.01},{"key":"24 Q3","value":11.76},{"key":"24 Q4","value":32.39},{"key":"25 Q1","value":33.55}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":24.48},{"key":"21 Q3","value":34.92},{"key":"21 Q4","value":5.27},{"key":"22 Q1","value":0.28},{"key":"22 Q2","value":18.27},{"key":"22 Q3","value":25.4},{"key":"22 Q4","value":22.19},{"key":"23 Q1","value":15.9},{"key":"23 Q2","value":15.83},{"key":"23 Q3","value":30.92},{"key":"23 Q4","value":20.08},{"key":"24 Q1","value":-62.37},{"key":"24 Q2","value":23.21},{"key":"24 Q3","value":16.6},{"key":"24 Q4","value":23.55},{"key":"25 Q1","value":19.72}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":1134},{"key":"21 Q3","value":1147},{"key":"21 Q4","value":2027},{"key":"22 Q1","value":1186},{"key":"22 Q2","value":1102},{"key":"22 Q3","value":1149},{"key":"22 Q4","value":1548},{"key":"23 Q1","value":1447},{"key":"23 Q2","value":1407},{"key":"23 Q3","value":1457},{"key":"23 Q4","value":1408},{"key":"24 Q1","value":1520},{"key":"24 Q2","value":1351},{"key":"24 Q3","value":1395},{"key":"24 Q4","value":1641},{"key":"25 Q1","value":1379}]},{"title":"Acquired in-process research and development expenses","dataPoints":[{"key":"21 Q2","value":96},{"key":"21 Q3","value":19},{"key":"22 Q2","value":330},{"key":"22 Q3","value":448},{"key":"22 Q4","value":158},{"key":"23 Q1","value":481},{"key":"23 Q2","value":236},{"key":"23 Q3","value":91},{"key":"23 Q4","value":347},{"key":"24 Q1","value":4131},{"key":"24 Q2","value":38},{"key":"24 Q3","value":505},{"key":"24 Q4","value":-11},{"key":"25 Q1","value":253}]},{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":1351},{"key":"21 Q3","value":1190},{"key":"21 Q4","value":1650},{"key":"22 Q1","value":1083},{"key":"22 Q2","value":1357},{"key":"22 Q3","value":1213},{"key":"22 Q4","value":2020},{"key":"23 Q1","value":1319},{"key":"23 Q2","value":1849},{"key":"23 Q3","value":1315},{"key":"23 Q4","value":1608},{"key":"24 Q1","value":1375},{"key":"24 Q2","value":1377},{"key":"24 Q3","value":1433},{"key":"24 Q4","value":1906},{"key":"25 Q1","value":1258}]},{"title":"In-process research and development impairment","dataPoints":[{"key":"22 Q1","value":2700},{"key":"23 Q4","value":50},{"key":"24 Q1","value":2430},{"key":"24 Q3","value":1750}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":20.88},{"key":"21 Q3","value":12.83},{"key":"21 Q4","value":-2.39},{"key":"22 Q1","value":2.6},{"key":"22 Q2","value":0.69},{"key":"22 Q3","value":-5.11},{"key":"22 Q4","value":2},{"key":"23 Q1","value":-3.61},{"key":"23 Q2","value":5.42},{"key":"23 Q3","value":0.11},{"key":"23 Q4","value":-3.71},{"key":"24 Q1","value":5.26},{"key":"24 Q2","value":5.36},{"key":"24 Q3","value":7.02},{"key":"24 Q4","value":6.38},{"key":"25 Q1","value":-0.28}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":-63.45},{"key":"21 Q3","value":-31.41},{"key":"21 Q4","value":9.05},{"key":"22 Q1","value":128.78},{"key":"22 Q2","value":8.06},{"key":"22 Q3","value":19.27},{"key":"22 Q4","value":1.33},{"key":"23 Q1","value":-34.65},{"key":"23 Q2","value":25.21},{"key":"23 Q3","value":1.89},{"key":"23 Q4","value":-8.4},{"key":"24 Q1","value":191.22},{"key":"24 Q2","value":-20.79},{"key":"24 Q3","value":77.54},{"key":"24 Q4","value":3.6},{"key":"25 Q1","value":-69.44}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":1255},{"key":"21 Q3","value":1256},{"key":"21 Q4","value":1256},{"key":"22 Q1","value":1255},{"key":"22 Q2","value":1256},{"key":"22 Q3","value":1255},{"key":"22 Q4","value":1252},{"key":"23 Q1","value":1248},{"key":"23 Q2","value":1249},{"key":"23 Q3","value":1248},{"key":"23 Q4","value":1248},{"key":"24 Q1","value":1247},{"key":"24 Q2","value":1247},{"key":"24 Q3","value":1247},{"key":"24 Q4","value":1248},{"key":"25 Q1","value":1246}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":83834},{"key":"21 Q3","value":88296.8},{"key":"21 Q4","value":86538.4},{"key":"22 Q1","value":80194.5},{"key":"22 Q2","value":76992.8},{"key":"22 Q3","value":78437.5},{"key":"22 Q4","value":98532.4},{"key":"23 Q1","value":102585.6},{"key":"23 Q2","value":98795.9},{"key":"23 Q3","value":95222.4},{"key":"23 Q4","value":97094.4},{"key":"24 Q1","value":95894.3},{"key":"24 Q2","value":83174.9},{"key":"24 Q3","value":95146.1},{"key":"24 Q4","value":112320},{"key":"25 Q1","value":128587.2}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":3.37},{"key":"21 Q3","value":2.97},{"key":"21 Q4","value":2.99},{"key":"22 Q1","value":3.04},{"key":"22 Q2","value":3.07},{"key":"22 Q3","value":2.78},{"key":"22 Q4","value":3.33},{"key":"23 Q1","value":4.04},{"key":"23 Q2","value":3.74},{"key":"23 Q3","value":3.38},{"key":"23 Q4","value":3.41},{"key":"24 Q1","value":3.59},{"key":"24 Q2","value":2.99},{"key":"24 Q3","value":3.15},{"key":"24 Q4","value":3.71},{"key":"25 Q1","value":4.82}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-24T21:16:12Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.56,"sell":0.44,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"AZN","name":"AstraZeneca","displayName":"AstraZeneca","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"AZN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":73,"high":74.38,"low":73.545,"volume":29476,"volumeDate":"2025-07-25","last":73.68,"open":74.13,"gainPercentage":0.932,"gainValue":0.68,"ask":73.32,"bid":73.28,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":228506731200,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":4488304.129,"highPriceLast52Weeks":87.675,"lowPriceLast52Weeks":61.24,"companyName":"AstraZeneca PLC","longBusinessDescription":"AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.","dividendRate":1.55,"salesOrRevenue":54073000000,"oneYearAnnualRevenueGrowthRate":18.0349697670865,"threeYearAnnualRevenueGrowthRate":12.8517,"fiveYearAnnualRevenueGrowthRate":17.7651,"earningsGrowth":22.7046,"totalDebt":30295000000,"totalAssets":104035000000,"floatAsPercentOfSharesOutstanding":99.9868,"dividendYield":2.1,"betaTwelveMonth":0.3914,"salesOrRevenueTtm":54982000000,"ebitdaTtm":18061000000,"debtToEquityRatioQuarterly":77.1120153999854,"totalEnterpriseValue":229541520000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":9.1941049604601,"fiveYearAverageDebtEquityRatio":75.95,"currentRatio":0.897353153215009,"peratio":29.39},"recommendation":{"currentConsensusRating":1.9,"recommendationTargetPrice":68.48,"totalRatings":13,"strongSellRatings":0,"sellRatings":0,"holdRatings":4,"buyRatings":4,"strongBuyRatings":5,"lastUpdated":"2024-08-12T14:58:11Z"},"earningEstimates":[{"actual":0.54,"estimate":0.62,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-12T14:30:57Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-12T00:00:00Z","earningsSummary":null},{"actual":0.84,"estimate":0.73,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-10T11:20:52Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-02-10T00:00:00Z","earningsSummary":null},{"actual":0.95,"estimate":0.83,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-02T09:15:01Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-04-29T00:00:00Z","earningsSummary":null},{"actual":0.86,"estimate":0.77,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-29T13:38:58Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-07-29T00:00:00Z","earningsSummary":null},{"actual":0.84,"estimate":0.72,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-10T09:27:49Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-11-10T00:00:00Z","earningsSummary":null},{"actual":0.69,"estimate":0.67,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-09T08:17:36Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-02-09T00:00:00Z","earningsSummary":null},{"actual":0.96,"estimate":1.07,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T06:37:24Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-04-27T00:00:00Z","earningsSummary":null},{"actual":1.075,"estimate":0.95,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-28T07:52:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-07-28T00:00:00Z","earningsSummary":null},{"actual":0.865,"estimate":0.84,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-09T07:30:37Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2023-11-09T00:00:00Z","earningsSummary":null},{"actual":0.725,"estimate":0.79,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-08T07:24:46Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-02-08T00:00:00Z","earningsSummary":null},{"actual":1.03,"estimate":1.22,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T07:18:29Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-04-25T00:00:00Z","earningsSummary":null},{"actual":0.99,"estimate":1.2,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-25T07:16:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-07-25T00:00:00Z","earningsSummary":null},{"actual":1.04,"estimate":1.03,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-12T08:07:52Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2024-11-12T00:00:00Z","earningsSummary":null},{"actual":1.045,"estimate":1.07,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-06T08:38:54Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-02-06T00:00:00Z","earningsSummary":null},{"actual":1.245,"estimate":1.11,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-06-18T10:56:54Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-04-29T00:00:00Z","earningsSummary":null},{"actual":null,"estimate":1.1,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:24Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-29T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-12","title":"Earnings data Q3 2021","quarter":"Q3","hash":"babca7bd8b4d1e1b91662b511242d8f97aa0720d0ed6c1c2c931a40707d1332f"},{"date":"2022-02-10","title":"Earnings data Q4 2021","quarter":"Q4","hash":"ee9b1b44131fa30386586c4abeb6f35c034077eeb6199eb3e056d8eb969ab225"},{"date":"2022-04-29","title":"Earnings data Q1 2022","quarter":"Q1","hash":"74337e2036fd5b2ed5fa3f122055be7510aeb7bb2d6f6422235ed3d8b7c67537"},{"date":"2022-07-29","title":"Earnings data Q2 2022","quarter":"Q2","hash":"f846185f6a6e05b3873193503c5db01db24b41e19a5d84dea55cfac7ee5ed498"},{"date":"2022-11-10","title":"Earnings data Q3 2022","quarter":"Q3","hash":"81fbc399a4f1a786cb2631c9d2e2cfa64c6a62cc85388b4ca584513163af6cc2"},{"date":"2023-02-09","title":"Earnings data Q4 2022","quarter":"Q4","hash":"80e2286291665d5a8e28f4955f43f4455443a29fb14d41079e7ababfa655f3ca"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"14ffbc688e49977d9013852b645beea1411082e28e416739d6c042cd45eea52b"},{"date":"2023-07-28","title":"Earnings data Q2 2023","quarter":"Q2","hash":"215749b3b9b877db0a1c4a5a6d5082b0d1512e97e16b7efe99f3bd393e231697"},{"date":"2023-11-09","title":"Earnings data Q3 2023","quarter":"Q3","hash":"6981e0131a99a90dc61ce9cf795f7e166ef115007685085b6abd3aff187063a8"},{"date":"2024-02-08","title":"Earnings data Q4 2023","quarter":"Q4","hash":"a902e47f4fc1bf772d8661739664b5c09716f425c1e487e8a8f5b3630a810cb0"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"81faa30b4533aa0b07b53fbf703b9ea61642923e405e73bfdf994747aaf25364"},{"date":"2024-07-25","title":"Earnings data Q2 2024","quarter":"Q2","hash":"5e5c8950f26957b42176af3a36b1b93bba7bf51b3986cc9278a9a739d59dae14"},{"date":"2024-11-12","title":"Earnings data Q3 2024","quarter":"Q3","hash":"57d09d51a9774271389d32bf56b350a3e4aec4af9497a8c58db4ebaca36a2d73"},{"date":"2025-02-06","title":"Earnings data Q4 2024","quarter":"Q4","hash":"4ba481414c2caf4eb69acad0b1bd632caaf7d38f5c2bdb8f97c51d1093e1f27c"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"f487340e0493e6ee5a2b9ef7b7617dc41619c371e78abe7668c281d9eccf51e7"},{"date":"2025-07-29","title":"Earnings data Q2 2025","quarter":"Q2","hash":"2243843ffb63d1f7b34d25e6b6dc078da821a749c865a69b5149264069573c6c"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"AstraZeneca","companyDescription":"AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.","executives":null,"brands":[{"id":"175fe1d9-21d7-4dd7-8e54-c3fca29aada9","name":"MedImmune","description":"MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.","imageUrl":null}]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":13588000000,"changePercentage":7.17,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3200000000,"changePercentage":1.81,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":10388000000,"changePercentage":8.93,"valueToRevenueRatio":0.7644980865469532},{"financialKey":"OPERATING_EXPENSES","value":6706000000,"changePercentage":6.6,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":6706000000,"changePercentage":6.6,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":3682000000,"changePercentage":13.47,"valueToRevenueRatio":0.27097438916691197},{"financialKey":"EBITDA","value":4966000000,"changePercentage":10.36,"valueToRevenueRatio":0.365469531939947},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1284000000,"changePercentage":2.31,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":2921000000,"changePercentage":33.99,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.9406,"changePercentage":33.72,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":106253000000,"changePercentage":3.87,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":26139000000,"changePercentage":2.13,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":5395000000,"changePercentage":-32.74,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":14815000000,"changePercentage":21.19,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":5884000000,"changePercentage":10.25,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":45000000,"changePercentage":309.09,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":80114000000,"changePercentage":4.45,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":12303000000,"changePercentage":15.89,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":58680000000,"changePercentage":-0.22,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":9131000000,"changePercentage":25.58,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":65122000000,"changePercentage":0.51,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":29129000000,"changePercentage":0.79,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":3758000000,"changePercentage":-40.64,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":1656000000,"changePercentage":1.53,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":23715000000,"changePercentage":13.26,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":35993000000,"changePercentage":0.28,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":27888000000,"changePercentage":-1.18,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":8105000000,"changePercentage":5.66,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":41131000000,"changePercentage":9.68,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":41039000000,"changePercentage":9.6,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":92000000,"changePercentage":64.29,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":106253000000,"changePercentage":3.87,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":31646000000,"changePercentage":-8.41,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":26251000000,"changePercentage":-1.05,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":13.23372,"changePercentage":9.57,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":3402000000,"changePercentage":21.5,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":3780000000,"changePercentage":46.57,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":4206000000,"changePercentage":38.63,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-426000000,"changePercentage":6.37,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-1320000000,"changePercentage":47.33,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":969000000,"changePercentage":-39.63,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":1000000,"changePercentage":101.23,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":363000000,"changePercentage":-63.74,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-2653000000,"changePercentage":47.27,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-2707000000,"changePercentage":-233.48,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-478000000,"changePercentage":-8066.67,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":3347000000,"changePercentage":10.35,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":104000000,"changePercentage":112.37,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":24999999.999999598,"changePercentage":154.35,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-222000000,"changePercentage":-110.8,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":3351000000,"changePercentage":55,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:01Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":"2024-05-30T00:00:00Z","bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.52,"sell":0.48,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"NVAX","name":"Novavax","displayName":"Novavax","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"NVAX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":7.84,"high":8.455,"low":7.555,"volume":3481,"volumeDate":"2025-07-25","last":7.64,"open":8.1,"gainPercentage":-2.551,"gainValue":-0.2,"ask":7.76,"bid":7.7,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":1237450800,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":8337051.3387,"highPriceLast52Weeks":17.81,"lowPriceLast52Weeks":5.01,"companyName":"Novavax, Inc.","longBusinessDescription":"Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.","dividendRate":0,"salesOrRevenue":682162000,"oneYearAnnualRevenueGrowthRate":-30.6538037318098,"threeYearAnnualRevenueGrowthRate":-2.7081,"fiveYearAnnualRevenueGrowthRate":516.276,"earningsGrowth":198.04,"totalDebt":263471000,"totalAssets":1602666000,"floatAsPercentOfSharesOutstanding":91.1002,"dividendYield":0,"betaTwelveMonth":1.2941,"salesOrRevenueTtm":1254962000,"ebitdaTtm":467498000,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":553334600,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":-11.5551681195517,"fiveYearAverageDebtEquityRatio":-31.51,"currentRatio":2.05611009782789,"peratio":2.88},"recommendation":{"currentConsensusRating":2.5,"recommendationTargetPrice":34.56,"totalRatings":16,"strongSellRatings":2,"sellRatings":1,"holdRatings":5,"buyRatings":3,"strongBuyRatings":5,"lastUpdated":"2025-07-22T16:16:20Z"},"earningEstimates":[{"actual":-4.31,"estimate":-3.91,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T20:36:33Z","audioUrl":"https://files.quartr.com/audio-files/6c3b2-2022-10-19-04-24-32.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6eb89-2021-11-04-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3d227-2024-08-29-01-22-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":-11.18,"estimate":-1.8,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-28T21:07:34Z","audioUrl":"https://files.quartr.com/audio-files/25601-2022-10-19-12-06-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c824-2022-02-28-09-28-38-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/39d62-2023-01-25-12-29-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-28T09:38:28Z","earningsSummary":null},{"actual":2.56,"estimate":2.69,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-09T20:31:24Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_05_09_22_30_Q1_2022_Novavax_Inc_Earnings_Call.2C5PAO2AN0AU.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4f7d0-2024-08-29-01-23-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-09T09:28:38Z","earningsSummary":null},{"actual":-6.53,"estimate":6.36,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-18T10:06:42Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_08_22_30_Q2_2022_Novavax_Inc_Earnings_Call.5XYSP87LQ4GO_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/350eb-2022-08-08-09-42-56.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b276a-2022-08-08-08-37-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-08T10:27:00Z","earningsSummary":null},{"actual":-2.15,"estimate":1.57,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-08T21:31:58Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_08T21_30_00_00_00_Novavax_Inc_Earnings_Call_Q3_2022.CLXQX2BRO15E_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2dce8-2023-03-07-12-44-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a903d-2022-11-08-09-48-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-08T08:30:00Z","earningsSummary":null},{"actual":-2.28,"estimate":-0.92,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-28T21:10:38Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_28T21_30_00_00_00_Novavax_Inc_Earnings_Call_Q4_2022.SJY0Y1YOPOJJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9e2f3-2023-03-14-04-18-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/66c38-2023-02-28-09-15-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-28T21:30:00Z","earningsSummary":{"summary":"Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.","headline":"Novavax reports strong revenue growth, focuses on fall vaccine launch","lastUpdated":"2024-05-06T16:38:21.368646Z"}},{"actual":-3.41,"estimate":-3.46,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-09T10:31:39Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_09T12_30_00_00_00_Novavax_Inc_Q1_2023.0LMICFO8HARM_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dadd7-2023-05-09-01-04-48.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6fa10-2023-05-09-09-47-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-09T12:30:00Z","earningsSummary":{"summary":"Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.\nThe company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.\nChallenges include ongoing arbitration with Gavi and managing global restructuring impacts on R\u0026D efforts.\nOpportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.","headline":"Novavax reports positive Phase 2 results and revenue guidance","lastUpdated":"2024-05-06T20:31:22.464241Z"}},{"actual":0.58,"estimate":-1.24,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-08T10:51:06Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_08T12_30_00_00_00_Novavax_Inc_Q2_2023.U0YDH8P8NTTE_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0334d-2023-08-08-02-12-05.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/dd4ef-2023-08-08-12-45-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T12:30:00Z","earningsSummary":{"summary":"Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.","headline":"Novavax reports robust Q2 earnings, anticipates strong revenue growth","lastUpdated":"2024-05-06T22:42:28.760485Z"}},{"actual":-1.26,"estimate":-1.83,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-09T12:35:25Z","audioUrl":"https://files.quartr.com/audio-files/9462f-2023-11-09-02-32-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f6a3e-2023-11-09-01-40-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/95979-2023-11-10-12-26-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-09T13:30:00Z","earningsSummary":{"summary":"Novavax is strategically positioned to drive long-term profitability with efficient cost structures.\nThe company's focus on innovation, cost reduction, and market expansion bodes well for future growth.\nDespite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.","headline":"Novavax reports strong Q3 results, eyes market share growth","lastUpdated":"2024-05-06T20:54:33.575976Z"}},{"actual":-1.47,"estimate":-0.45,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-28T13:00:46Z","audioUrl":"https://files.quartr.com/audio-files/c8669-2024-02-28-02-16-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/4a57f-2024-02-28-03-26-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6bacd-2024-02-28-01-36-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-28T13:30:00Z","earningsSummary":{"summary":"Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.\nThe company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.\nChallenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.\nEfforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.","headline":"Novavax reduces expenses, targets growth with new vaccines in 2024","lastUpdated":"2024-05-06T16:34:00.355960Z"}},{"actual":-1.05,"estimate":-1.06,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-10T10:06:54Z","audioUrl":"https://files.quartr.com/audio-files/a5325-2024-05-10-01-39-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f0034-2024-05-10-05-12-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e4898-2024-05-10-11-49-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-10T12:30:00Z","earningsSummary":{"summary":"Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.\nWhile facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.\nThe company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.","headline":"Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal","lastUpdated":"2024-05-10T18:30:54.214308Z"}},{"actual":0.99,"estimate":1.36,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-08T11:41:09Z","audioUrl":"https://files.quartr.com/audio-files/848b3-2024-08-08-01-35-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/891ad-2024-08-08-12-57-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/39779-2024-08-08-12-49-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-08T12:30:00Z","earningsSummary":null},{"actual":-0.76,"estimate":-0.83,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-12T13:07:56Z","audioUrl":"https://files.quartr.com/audio-files/8785c-2024-11-12-02-18-44.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/864ad-2024-11-12-03-48-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9cf7e-2024-11-12-01-58-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-12T13:30:00Z","earningsSummary":{"summary":"Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.\nKey strengths include a strong partnership with Sanofi and a focus on pipeline development.\nChallenges ahead involve cost alignment, trial design complexities, and maintaining margins.\nOpportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.","headline":"Novavax reports $85M revenue, focuses on cost reduction and partnerships","lastUpdated":"2024-11-13T04:07:57.382486Z"}},{"actual":-0.51,"estimate":-0.51,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-27T13:04:25Z","audioUrl":"https://files.quartr.com/audio-files/694a1-2025-02-27-02-00-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7a488-2025-02-27-01-26-49.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2fe97-2025-02-27-01-35-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-27T13:30:00Z","earningsSummary":{"summary":"Novavax showcased strong financial performance, strategic partnerships, and a robust pipeline of vaccine programs. While facing regulatory and market challenges, the company's focus on innovation and cost efficiency bodes well for future growth. Opportunities lie in the Sanofi partnership, diversified vaccine portfolio, and addressing public health needs.","headline":"Novavax reports robust earnings, Sanofi partnership drives growth prospects","lastUpdated":"2025-02-28T01:31:49.023178Z"}},{"actual":2.93,"estimate":0.19,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-08T12:01:08Z","audioUrl":"https://files.quartr.com/audio-files/2edfd-2025-05-08-01-45-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/27cd1-2025-05-08-12-55-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b9b25-2025-05-08-12-58-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-08T12:30:00Z","earningsSummary":null},{"actual":null,"estimate":-0.14,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-22T23:30:42Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-07T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"de24d5cfcb4a752392dfcb535601f4e97ced2dbe1a490fff792d67d2aef2b993"},{"date":"2022-02-28","title":"Earnings data Q4 2021","quarter":"Q4","hash":"0533527bb35cccdf4146e521d6dddcbb9f35b15f8a079ba9d5cc09c9f471d819"},{"date":"2022-05-09","title":"Earnings data Q1 2022","quarter":"Q1","hash":"bd35eace9d14afee8d606e0abc44618718e514d7da2b90d132e85cffd8b7b491"},{"date":"2022-08-08","title":"Earnings data Q2 2022","quarter":"Q2","hash":"2d7a4a130944373ae824f39dc1a02c37088fe37d86ec41e120b197d90ae81799"},{"date":"2022-11-08","title":"Earnings data Q3 2022","quarter":"Q3","hash":"320b1fd97f719f2ac4540512f5c90d8aa17edd7d7e87908617e3f2753efe6d60"},{"date":"2023-02-28","title":"Earnings data Q4 2022","quarter":"Q4","hash":"ee6d38e4ef55d067341d27765acf7817c227e77ff8f1fca87de9820296952adf"},{"date":"2023-05-09","title":"Earnings data Q1 2023","quarter":"Q1","hash":"39b0d52935124a1088498c873ec880176a825294897b9be2fd5e135f9005efdf"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"20fbebafe64a9b3a021dacaacaff1c3eb4b902e1e8e284af212fdad8b9ed1397"},{"date":"2023-11-09","title":"Earnings data Q3 2023","quarter":"Q3","hash":"e7091c46cdf1258a77f54d95ef8e5e8b6a7743492f29411f637c16c4e116c9af"},{"date":"2024-02-28","title":"Earnings data Q4 2023","quarter":"Q4","hash":"130152b2db4120e3d913afa3ebec5c16feefda0415d1a83f69e33740067ea305"},{"date":"2024-05-10","title":"Earnings data Q1 2024","quarter":"Q1","hash":"b83def42b8e7443d98a17be2e003f2c77d355ef248b82351b95e2e1b69bc3f35"},{"date":"2024-08-08","title":"Earnings data Q2 2024","quarter":"Q2","hash":"fe88df7b020344697697694af8b95f6a46fe86ffee2fad416e579c1adc7554d3"},{"date":"2024-11-12","title":"Earnings data Q3 2024","quarter":"Q3","hash":"eed32d26ad15a358c2c146927781d7df7923a24bb8302e937d64ecec5ed6c013"},{"date":"2025-02-27","title":"Earnings data Q4 2024","quarter":"Q4","hash":"31af5447af9ad7fb8ba8973f8fa09311019a1f71fa4f92f2bf21c3c6d60f89d8"},{"date":"2025-05-08","title":"Earnings data Q1 2025","quarter":"Q1","hash":"1fecd5165fd288b1e91bff87536d30dfa8c22436b62691db3ffa59e6fb9ef2bb"},{"date":"2025-08-07","title":"Earnings data Q2 2025","quarter":"Q2","hash":"c78bbe5d37bc39e49992af126f67bb8a4d90204d534e9c432b35bac5302b5445"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Novavax","companyDescription":"Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":666655000,"changePercentage":610.3,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":13815000,"changePercentage":-71.7,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":652840000,"changePercentage":1349.27,"valueToRevenueRatio":0.9792771373499036},{"financialKey":"OPERATING_EXPENSES","value":136822000,"changePercentage":-25.55,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":136522000,"changePercentage":-21.98,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":300000,"changePercentage":-96.59,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":516018000,"changePercentage":471.96,"valueToRevenueRatio":0.7740405457095499},{"financialKey":"EBITDA","value":524357999.99999994,"changePercentage":514.24,"valueToRevenueRatio":0.786550764638381},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":8339999.99999994,"changePercentage":-31.34,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":518645999.99999994,"changePercentage":451.51,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.9199,"changePercentage":376.87,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":1292992000,"changePercentage":-4.47,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":868028000,"changePercentage":19.38,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":742160000,"changePercentage":51.14,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":44510000,"changePercentage":108.19,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":10263000,"changePercentage":-34.95,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":71095000,"changePercentage":-64.26,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":424964000,"changePercentage":-32.16,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":291033000,"changePercentage":-38.38,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":112027000,"changePercentage":-9.05,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":21904000,"changePercentage":-29.27,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":1368635000,"changePercentage":-38.37,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":422170000,"changePercentage":-47.52,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":5478000,"changePercentage":-12.92,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":416692000,"changePercentage":-47.79,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":946465000,"changePercentage":-33.17,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":223181000,"changePercentage":0.06,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":723284000,"changePercentage":-39.38,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":-75643000,"changePercentage":91.28,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":-75643000,"changePercentage":91.28,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":1292992000,"changePercentage":-4.47,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":228659000,"changePercentage":-0.29,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-513501000,"changePercentage":-96.21,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":-0.46705,"changePercentage":92.44,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":518645999.99999994,"changePercentage":451.51,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-185502000,"changePercentage":-122.01,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":554097000,"changePercentage":570.29,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-739599000,"changePercentage":-2258.47,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-73319000,"changePercentage":-911.3,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":1595000,"changePercentage":-78,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-71724000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-3190000,"changePercentage":78,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-7061000,"changePercentage":-219.96,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-4860000,"changePercentage":-177.81,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-2201000,"changePercentage":-511.39,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":-930000,"changePercentage":68.53,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-266812000,"changePercentage":-203.63,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-186722000,"changePercentage":-106.48,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:47Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-05-01T08:53:34Z","bearsSay":["Novavax Inc reported a significant net loss of $121.3 million for the third quarter of 2024, equating to a loss of $0.76 per share, which was below market expectations. Additionally, the company's revenue forecast for the fourth quarter of 2024 has been notably revised downward from $152.5 million to $88.8 million, reflecting growing uncertainties in product sales. Various risks, including potential failures in clinical trials, regulatory hurdles, and challenges in commercialization and intellectual property, contribute to an overall negative outlook for the company's financial performance."],"bullsSay":["Novavax Inc. is experiencing growth potential in the post-COVID-19 vaccine market, evidenced by a lucrative licensing deal with Sanofi that could generate up to $1.2 billion and the company capturing 3% market share this season, despite aiming for 5%. The announcement of their 3Q24 financial results indicates effective cost management and a refinement in R\u0026D strategy, positioning the firm to extend its offerings beyond COVID-19 vaccines. Furthermore, Novavax is implementing additional cost reduction measures aimed at lowering operating expenses to below $500 million by 2025, enhancing its long-term operational viability."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.51,"sell":0.49,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"AGIO","name":"Agios Pharmaceuticals","displayName":"Agios Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"AGIO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":40.56,"high":40.98,"low":39.22,"volume":3,"volumeDate":"2025-07-25","last":39.65,"open":40.53,"gainPercentage":-2.244,"gainValue":-0.91,"ask":50,"bid":15.86,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":2296337700,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":602844.7097,"highPriceLast52Weeks":62.58,"lowPriceLast52Weeks":23.415,"companyName":"Agios Pharmaceuticals, Inc.","longBusinessDescription":"Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.","dividendRate":0,"salesOrRevenue":36498000,"oneYearAnnualRevenueGrowthRate":36.0697908511352,"threeYearAnnualRevenueGrowthRate":41.4779,"fiveYearAnnualRevenueGrowthRate":4.8867,"earningsGrowth":285.7304,"totalDebt":56988000,"totalAssets":1663199000,"floatAsPercentOfSharesOutstanding":95.6252,"dividendYield":0,"betaTwelveMonth":1.2132,"salesOrRevenueTtm":37035000,"ebitdaTtm":-434711000,"debtToEquityRatioQuarterly":3.60988675292937,"totalEnterpriseValue":1065518919.3000001,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":9.46,"currentRatio":18.4970400641638,"peratio":3.51},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":64.9,"totalRatings":21,"strongSellRatings":0,"sellRatings":0,"holdRatings":3,"buyRatings":11,"strongBuyRatings":7,"lastUpdated":"2025-07-22T16:15:36Z"},"earningEstimates":[{"actual":-1.56,"estimate":-1.59,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-03T11:42:10Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-03T00:00:00Z","earningsSummary":null},{"actual":-1.74,"estimate":-1.69,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-24T12:24:45Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/413ef-2023-11-24-11-39-27.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-24T12:00:00Z","earningsSummary":null},{"actual":-1.74,"estimate":-1.81,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-05T11:11:27Z","audioUrl":"https://files.quartr.com/audio-files/e5299-2023-03-21-09-38-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/05a6e-2023-03-21-09-37-55.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f2cf6-2023-03-21-09-37-55.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-05T18:00:00Z","earningsSummary":null},{"actual":-1.68,"estimate":-1.75,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-04T11:30:51Z","audioUrl":"https://files.quartr.com/audio-files/b4306-2022-08-04-05-45-21.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/584f6-2022-11-04-02-10-34.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f1b00-2022-08-04-11-29-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T12:30:00Z","earningsSummary":null},{"actual":-1.49,"estimate":-1.76,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T11:30:18Z","audioUrl":"https://files.quartr.com/audio-files/ef93a-2022-11-03-02-52-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f8d02-2022-11-04-02-59-33.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/83fc0-2022-11-03-11-28-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T12:00:00Z","earningsSummary":null},{"actual":-1.66,"estimate":-1.62,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-23T13:20:27Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_23T13_00_00_00_00_Agios_Pharmaceuticals_Inc_Earnings_Call_Q4_2022.IECU6IVY8KDR_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/44d0a-2023-02-23-02-29-42.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/dfbb0-2023-02-23-12-13-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-23T13:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals showcased strong performance and progress in its Q4 2022 earnings call, emphasizing advancements in its pipeline and commercial capabilities. While facing challenges in estimating sales and patient enrollment progression, the company is well-positioned to capitalize on opportunities for growth and expansion.","headline":"Agios Pharmaceuticals excels in Q4, eyes hematology franchise expansion","lastUpdated":"2024-05-09T14:20:55.989196Z"}},{"actual":-1.47,"estimate":-1.7,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T11:14:46Z","audioUrl":"https://files.quartr.com/audio-files/afd3c-2023-05-04-04-11-54.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/68e4d-2023-05-04-05-16-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ce5c7-2023-05-04-11-26-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals demonstrated strong financial performance, progress in PK activation therapies, and strategic decision-making in Q1 2023.\nWhile facing challenges in distribution and inventory management, the company's focus on persistency, clear milestones, and launch dynamics present growth opportunities.\nOverall, Agios Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges, and leverage opportunities for future success.","headline":"Agios Pharmaceuticals reports robust Q1 earnings and strategic growth outlook","lastUpdated":"2024-05-09T16:32:02.428048Z"}},{"actual":-1.51,"estimate":-1.6,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T10:38:56Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T12_00_00_00_00_Agios_Pharmaceuticals_Inc_Q2_2023.KRYPHTV9F34X_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fb320-2023-08-03-02-06-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f4d45-2023-08-03-11-14-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T12:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals shows strong financial performance and pipeline progress.\nChallenges include slow uptake for PYRUKYND and clinical development queries.\nExciting opportunities lie in potential acquisitions, peak sales targets, and upcoming data readouts.","headline":"Agios Pharmaceuticals reports strong Q2 performance and eyes growth opportunities","lastUpdated":"2024-05-09T15:19:43.617505Z"}},{"actual":-1.64,"estimate":-1.7,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T11:10:25Z","audioUrl":"https://files.quartr.com/audio-files/0e3ad-2023-11-02-12-55-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c88c2-2023-11-02-02-35-43.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/196a5-2023-11-02-11-53-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T12:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals delivered a strong performance in Q3 2023, achieving key milestones and reporting solid financial results, positioning the company for future growth.\nWith a focus on pipeline advancements, commercial success, and financial stability, Agios demonstrates resilience and potential in the competitive pharmaceutical landscape.\nWhile facing challenges in competitive markets and the need for further clarity on certain aspects, Agios has opportunities to capitalize on its strengths and drive innovation and growth.","headline":"Agios Pharmaceuticals excels in Q3, poised for growth and innovation","lastUpdated":"2024-05-09T14:52:40.101782Z"}},{"actual":-1.72,"estimate":-1.65,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-15T12:09:20Z","audioUrl":"https://files.quartr.com/audio-files/195a1-2024-02-15-02-00-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/cec2e-2024-02-15-03-36-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/de2dc-2024-02-15-12-10-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-15T13:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals showcased strong performance in PK activator development, with positive data readouts and financial stability driving growth prospects.\nWhile facing challenges in market differentiation and regulatory approval, the company's strategic strengths in rare disease treatments and operational efficiency position it for long-term success.\nWith upcoming launches for thalassemia and sickle cell disease, Agios has opportunities to expand its market presence, drive revenue growth, and establish itself as a key player in rare disease therapeutics.","headline":"Agios Pharmaceuticals reports robust earnings and eyes market expansion","lastUpdated":"2024-05-09T14:36:18.236810Z"}},{"actual":-1.45,"estimate":-1.65,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T11:14:45Z","audioUrl":"https://files.quartr.com/audio-files/55185-2024-05-02-01-52-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ce88a-2024-05-02-12-26-18.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b30d4-2024-05-02-11-36-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T12:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals showcased strong performance with positive clinical data and solid financials.\nWhile facing challenges in market dynamics and cost management, the company is optimistic about future opportunities.\nWith a focus on partnerships and revenue growth, Agios aims to deliver value to shareholders.\nThe company's robust pipeline and cash position position it well for future success.","headline":"Agios Pharmaceuticals excels in Q1, eyes strong growth opportunities","lastUpdated":"2024-05-09T14:16:24.528715Z"}},{"actual":-1.69,"estimate":-1.59,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T10:36:55Z","audioUrl":"https://files.quartr.com/audio-files/105e4-2024-08-01-01-50-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/639ea-2024-08-01-12-53-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/bfb3e-2024-08-01-11-26-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:00:00Z","earningsSummary":null},{"actual":-1.43,"estimate":1.11,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-21T11:36:14Z","audioUrl":"https://files.quartr.com/audio-files/dbd9b-2024-10-31-01-42-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/13180-2024-10-31-11-00-58.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/52147-2024-10-31-10-04-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals showcased strong financial performance and progress in key therapeutic areas during their Q3 2024 earnings call. While facing challenges in addressing analyst inquiries and market comparisons, the company remains optimistic about their future prospects. Leveraging their strengths in market engagement and scientific innovation, Agios is well-positioned for growth.","headline":"Agios Pharmaceuticals reports robust Q3 performance and eyes future launches","lastUpdated":"2024-10-31T18:34:50.683894Z"}},{"actual":-1.94,"estimate":-1.63,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-13T11:36:41Z","audioUrl":"https://files.quartr.com/audio-files/90bcd-2025-02-13-02-12-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/5999b-2025-02-13-01-48-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/5a9c6-2025-02-13-11-25-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-13T13:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals delivered strong financial performance in Q4 2024, driven by the success of PYRUKYND and positive trial data. The company's focus on rare red blood cell disorders presents a unique strength, but they must address challenges related to safety, market dynamics, and global expansion. Opportunities lie in potential product approvals, treatment advancements, and international market penetration.","headline":"Agios Pharmaceuticals reports robust Q4 revenue growth and expansion plans","lastUpdated":"2025-02-13T21:46:42.406680Z"}},{"actual":-1.55,"estimate":-1.76,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T10:34:35Z","audioUrl":"https://files.quartr.com/audio-files/8afaa-2025-05-01-01-59-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ebfee-2025-05-01-12-42-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7755a-2025-05-01-11-56-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T12:00:00Z","earningsSummary":{"summary":"Agios Pharmaceuticals showcased strong financial performance, promising pipeline advancements, and strategic commercialization plans during the Q1 2025 earnings call. While facing regulatory and operational challenges, the company's focus on rare diseases and commitment to delivering value position them for future success.","headline":"Agios Pharmaceuticals reports solid Q1 results and outlines growth strategies","lastUpdated":"2025-05-01T17:42:40.665418Z"}},{"actual":null,"estimate":-1.77,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-23T23:30:09Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-03","title":"Earnings data Q3 2021","quarter":"Q3","hash":"51d4cb4a2210807d7d1f69a0f3ae9311e13d04096a72d18f7b70c8f8767939f7"},{"date":"2022-02-24","title":"Earnings data Q4 2021","quarter":"Q4","hash":"9cf3ea2ccf63c666498a058b65fcdd31609d9a82843ef0ab7d762476d4f21a7c"},{"date":"2022-05-05","title":"Earnings data Q1 2022","quarter":"Q1","hash":"ae8b8b122f5ff27c90e89eed3b12f21130f96d03ec04cc11b0badf09df45b8a9"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"56f826dcc51b97eff7ff67b47c1b30b676236ae80e41b634dcf5b82e9bba3730"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"1ce55d2b35a41bfe8dec441b3ad291ba0d34cdc73caa28bf6ffbf3d5a78b12d4"},{"date":"2023-02-23","title":"Earnings data Q4 2022","quarter":"Q4","hash":"b4b1a8261823f1389df029b2a0832fff12f7ebd4a01daddad9d163bc473bf7de"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"15c08ed623179248f1c8d45645ac16eba8f6683677fc66ae2018535362ac4357"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"6c48f17e7523ef77dda406420887fde0db875c5f8a341dfeaaf3aa8bf1ce5203"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"3f5f0c32ae0a6f267e2e281a01ff0fc80945d298b768a4088fec58b959f47420"},{"date":"2024-02-15","title":"Earnings data Q4 2023","quarter":"Q4","hash":"6ccc9f97df68683ef4bda330dd03a5b3b09bd017cf7390354234dd19f0017f53"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"143e27ad95e7f52a3c0bafd2e028abf4a58b57a8e82ebb744ad18d0a5d835a76"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"070a576ff76e73caa480339fff6293c9613ad85bca2b1bd7ee81385ea9f5ed60"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"0bc870dd8341f1a203a8ac44c25935b8a63c4e4c7bdd8ffd34f67919138ee0d4"},{"date":"2025-02-13","title":"Earnings data Q4 2024","quarter":"Q4","hash":"18d1561abc0527fbcf45cdb4bfae64a3c206b147925fe1d3d86f0313cf660859"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"fe686fa586657ebe7a674ab3ab6398d9e6e376d3cd894a19e9164e199e068546"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"4cdff678f387b791d7b071a8a33e0a0a90b6cb170f785af79ed7befa3fd9a144"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Agios Pharmaceuticals","companyDescription":"Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":8726000,"changePercentage":6.56,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":2363000,"changePercentage":19.65,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":6363000,"changePercentage":2.4,"valueToRevenueRatio":0.7292000916800366},{"financialKey":"OPERATING_EXPENSES","value":112992000,"changePercentage":14.96,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":112992000,"changePercentage":14.96,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-106629000,"changePercentage":-15.81,"valueToRevenueRatio":-12.219688287875314},{"financialKey":"EBITDA","value":-105351000,"changePercentage":-16.12,"valueToRevenueRatio":-12.073229429291771},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1278000,"changePercentage":-5.19,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-89289000,"changePercentage":-9.49,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-1.554,"changePercentage":-7.45,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":1555518000,"changePercentage":83.06,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":968616000,"changePercentage":45.96,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":893375000,"changePercentage":49.4,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":3344000,"changePercentage":-3.16,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":29605000,"changePercentage":28.33,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":42292000,"changePercentage":8.13,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":586902000,"changePercentage":215.4,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":50928000,"changePercentage":-22.51,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":535974000.00000006,"changePercentage":345.32,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":88990000,"changePercentage":-15.88,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":52366000,"changePercentage":1.31,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":17196000,"changePercentage":11.61,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":683000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":34487000,"changePercentage":-4.95,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":36624000,"changePercentage":-32.3,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":35744000,"changePercentage":-32.48,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":880000,"changePercentage":-23.88,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":1466528000,"changePercentage":97.13,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":1466528000,"changePercentage":97.13,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":1555518000,"changePercentage":83.06,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":52940000,"changePercentage":-22.54,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-840435000,"changePercentage":-58.68,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":25.33442,"changePercentage":93.27,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-89289000,"changePercentage":-9.49,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-111489000,"changePercentage":-11.64,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-74984000,"changePercentage":-5.79,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-36505000,"changePercentage":-25.94,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":112587000,"changePercentage":-9.61,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":766000,"changePercentage":443.26,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":113353000,"changePercentage":-9.07,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-1532000,"changePercentage":-443.26,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":1619000,"changePercentage":-72.39,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":1619000,"changePercentage":-72.39,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":2717000,"changePercentage":-91.11,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-112255000,"changePercentage":-12.25,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:46Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-06-05T10:32:20Z","bearsSay":["Agios Pharmaceuticals Inc. is experiencing significant financial challenges, evidenced by expectations of flat PKD revenues in 2025, which indicate stagnation amid ongoing patient education initiatives and collaborations with advocacy groups. The company has also reported a steep decline in stock value of approximately 45% since December 2024, primarily due to emerging safety concerns related to hepatocellular injury in trial patients, coupled with an expectation of needing an additional $950 million in capital by 2038 to sustain operations. Furthermore, Agios is facing competitive pressures and potential regulatory hurdles that could adversely affect the efficacy and commercial viability of its pipeline products, creating a precarious financial outlook."],"bullsSay":["Agios Pharmaceuticals Inc's strong outlook is supported by the efficacy and safety profile of its lead product candidate, Pyrukynd, which has demonstrated consistent results in clinical trials and is positioned as the only approved treatment for patients with pyruvate kinase deficiency (PKD). The company is actively pursuing market expansion opportunities, including seeking approvals in pediatric populations and new regions such as the UAE and Saudi Arabia, which are anticipated to contribute positively to revenue growth by 2026. Additionally, encouraging results from the RISE UP study and sustained improvements in hemoglobin levels for its other candidates, such as Tebapivat, further enhance the company's potential for future financial performance."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"JNJ","name":"Johnson \u0026 Johnson","displayName":"Johnson \u0026 Johnson","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"JNJ","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":169.1,"high":169.99,"low":168.88,"volume":764,"volumeDate":"2025-07-25","last":169.56,"open":169.5,"gainPercentage":0.272,"gainValue":0.46,"ask":169.3,"bid":169.12,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":407973229200,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":8242389.5484,"highPriceLast52Weeks":169.99,"lowPriceLast52Weeks":140.68,"companyName":"Johnson \u0026 Johnson","longBusinessDescription":"Johnson \u0026 Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.","dividendRate":5.02,"salesOrRevenue":88819000000,"oneYearAnnualRevenueGrowthRate":4.30641676061631,"threeYearAnnualRevenueGrowthRate":-1.3146,"fiveYearAnnualRevenueGrowthRate":2.0324,"earningsGrowth":29.2056,"totalDebt":37834000000,"totalAssets":180104000000,"floatAsPercentOfSharesOutstanding":99.8687,"dividendYield":2.96,"betaTwelveMonth":0.02,"salesOrRevenueTtm":90626000000,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":364651828000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":16.9430431244915,"fiveYearAverageDebtEquityRatio":43.08,"currentRatio":null,"peratio":18.13},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":160.9,"totalRatings":29,"strongSellRatings":0,"sellRatings":0,"holdRatings":14,"buyRatings":6,"strongBuyRatings":9,"lastUpdated":"2025-07-17T14:59:54Z"},"earningEstimates":[{"actual":2.13,"estimate":2.12,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-01-25T11:33:20Z","audioUrl":"https://files.quartr.com/audio-files/1caf4-2022-10-19-09-55-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b8495-2022-01-25-05-59-40-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/04e46-2023-01-25-12-44-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-01-25T17:40:59Z","earningsSummary":null},{"actual":2.67,"estimate":2.61,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-19T10:28:31Z","audioUrl":"https://files.quartr.com/audio-files/1b0c5-2022-10-28-04-31-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/612f5-2022-04-19-10-46-24-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b6f8c-2023-01-25-12-12-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-19T10:24:46Z","earningsSummary":null},{"actual":2.59,"estimate":2.57,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-19T10:29:18Z","audioUrl":"https://files.quartr.com/audio-files/59e36-2022-07-19-01-03-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b22ce-2022-07-19-11-51-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/83b28-2022-07-19-11-50-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-19T00:46:00Z","earningsSummary":null},{"actual":2.55,"estimate":2.52,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-18T10:27:31Z","audioUrl":"https://files.quartr.com/audio-files/fecf2-2022-10-18-01-41-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bf1ff-2022-10-18-11-21-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/aacec-2022-10-18-11-23-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-18T12:00:00Z","earningsSummary":null},{"actual":2.35,"estimate":2.23,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-01-24T11:26:22Z","audioUrl":"https://files.quartr.com/audio-files/0712d-2023-01-24-02-52-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/82d25-2023-01-24-12-48-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/44066-2023-01-24-12-47-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-01-24T13:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.","headline":"Johnson \u0026 Johnson reports solid Q4 earnings, eyes $60B Pharma revenue","lastUpdated":"2024-05-05T05:29:44.134997Z"}},{"actual":2.68,"estimate":2.51,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-18T10:22:21Z","audioUrl":"https://files.quartr.com/audio-files/4c2b4-2023-04-18-01-46-30.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2187b-2023-04-18-10-52-48.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/75805-2023-04-18-10-52-48.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-18T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.\nThe company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.\nWhile facing legal and financial headwinds, Johnson \u0026 Johnson remains optimistic about its outlook for 2023 and beyond.\nIncreased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.","headline":"Johnson \u0026 Johnson reports resilient Q1 performance amidst challenges","lastUpdated":"2024-05-06T20:14:24.682423Z"}},{"actual":2.8,"estimate":2.62,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-20T10:22:11Z","audioUrl":"https://files.quartr.com/audio-files/6f6d9-2023-07-20-02-33-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ecfba-2023-07-20-11-12-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2b41d-2023-07-20-11-12-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-20T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson \u0026 Johnson is poised for continued success in the healthcare sector.","headline":"Johnson \u0026 Johnson reports strong Q2 earnings and strategic growth plans","lastUpdated":"2024-05-06T18:05:30.976915Z"}},{"actual":2.66,"estimate":2.51,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-17T10:24:06Z","audioUrl":"https://files.quartr.com/audio-files/e90d4-2023-10-17-02-04-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/13936-2023-10-17-11-39-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ae77e-2023-10-17-11-34-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-17T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.\nWhile facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.\nWith a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.","headline":"Johnson \u0026 Johnson posts strong Q3 results amidst growth strategies","lastUpdated":"2024-05-06T18:11:50.880755Z"}},{"actual":2.29,"estimate":2.28,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-23T11:22:04Z","audioUrl":"https://files.quartr.com/audio-files/334ab-2024-01-23-02-09-53.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/29197-2024-01-23-12-57-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a8a4c-2024-01-23-12-56-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-01-23T13:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M\u0026A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.","headline":"Johnson \u0026 Johnson reports robust 2023 performance and strategic growth outlook","lastUpdated":"2024-05-06T23:10:18.377434Z"}},{"actual":2.71,"estimate":2.64,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-16T10:26:19Z","audioUrl":"https://files.quartr.com/audio-files/35155-2024-04-16-01-23-45.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e47c8-2024-04-16-10-06-35.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f124f-2024-04-16-10-06-35.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-16T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.\nDespite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.\nOpportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.\nOverall, Johnson \u0026 Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.","headline":"Johnson \u0026 Johnson posts strong Q1 earnings, eyes growth opportunities","lastUpdated":"2024-05-06T19:18:51.733846Z"}},{"actual":2.82,"estimate":2.7,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-17T10:31:24Z","audioUrl":"https://files.quartr.com/audio-files/3b313-2024-07-17-01-20-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ffa7e-2024-07-17-10-33-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/e6ae4-2024-07-17-10-33-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-17T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.\nWhile facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.\nBy capitalizing on opportunities in key products and markets, Johnson \u0026 Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.","headline":"Johnson \u0026 Johnson posts strong Q2 results, eyes growth opportunities","lastUpdated":"2024-07-17T17:17:11.151542Z"}},{"actual":2.42,"estimate":2.21,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-15T10:20:59Z","audioUrl":"https://files.quartr.com/audio-files/2fccd-2024-10-15-01-48-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e6af4-2024-10-15-10-11-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/58337-2024-10-15-10-23-27.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-15T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.","headline":"Johnson \u0026 Johnson reports robust Q3 earnings amidst legal challenges","lastUpdated":"2024-10-15T16:08:17.223478Z"}},{"actual":2.04,"estimate":2.02,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-22T11:20:55Z","audioUrl":"https://files.quartr.com/audio-files/7327e-2025-01-22-02-28-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/dc5fe-2025-01-22-12-31-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3cb2e-2025-01-22-11-27-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-01-22T13:00:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's Q4 2024 earnings call highlighted strong financial performance, strategic decisions, and confidence in future growth.\nThe company's focus on innovative medicine and med tech, along with a purpose-driven approach, positions it well for sustained success.\nWhile challenges like market dynamics and competition exist, opportunities in myeloma treatments, acquisitions, and med tech growth offer avenues for future expansion.","headline":"Johnson \u0026 Johnson posts robust earnings, eyes growth in med tech","lastUpdated":"2025-01-22T16:04:05.466457Z"}},{"actual":2.77,"estimate":2.6,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-15T10:20:49Z","audioUrl":"https://files.quartr.com/audio-files/72d2a-2025-04-15-01-40-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/be5cb-2025-04-15-10-47-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/20a07-2025-04-15-10-48-45.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-15T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson (JNJ) showcased strong financial performance in Q1 2025, with significant operational sales growth and strategic investments. Despite challenges from STELARA, the company's advancements in oncology and MedTech segments position it well for future growth. JNJ's focus on innovation, acquisitions, and financial stability bode well for its long-term prospects.","headline":"Johnson \u0026 Johnson (JNJ) reports robust Q1 earnings and strategic investments","lastUpdated":"2025-04-15T15:31:27.914283Z"}},{"actual":2.77,"estimate":2.67,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-16T10:21:15Z","audioUrl":"https://files.quartr.com/audio-files/90a70-2025-07-16-01-11-49.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/03bf3-2025-07-16-10-45-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f0a59-2025-07-16-10-44-46.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-16T12:30:00Z","earningsSummary":{"summary":"Johnson \u0026 Johnson's Q2 results showcase strong operational sales growth, strategic focus on key therapeutic areas, and a positive outlook for future earnings. The company's progress in oncology and medtech segments underscores its commitment to innovation and growth.","headline":"Johnson \u0026 Johnson reports robust Q2 earnings, raises guidance outlook","lastUpdated":"2025-07-16T15:31:44.948636Z"}},{"actual":null,"estimate":2.76,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:11Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-14T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-01-25","title":"Earnings data Q4 2021","quarter":"Q4","hash":"8560af2ee364edf868e2bbb2a8371f5c849295a56d5c01189310aa921966be3b"},{"date":"2022-04-19","title":"Earnings data Q1 2022","quarter":"Q1","hash":"7f92c9cb67f59d579ca554c81977c95ebd219633e21cb4f5cb1d7e2f994d1500"},{"date":"2022-07-19","title":"Earnings data Q2 2022","quarter":"Q2","hash":"383a7b2db9513702d96d17207d72d19a6295a53d64a28e92f7d2fbf92c1e3c04"},{"date":"2022-10-18","title":"Earnings data Q3 2022","quarter":"Q3","hash":"0db883792ef2b7cff24091a0bea9460832a1cf77e23f29de281c3172fa3e6cd8"},{"date":"2023-01-24","title":"Earnings data Q4 2022","quarter":"Q4","hash":"cd0a90d8fcd910ffdec6657c31454945acb9159e4a01995a3b5e7c854ed54937"},{"date":"2023-04-18","title":"Earnings data Q1 2023","quarter":"Q1","hash":"c737bebd8bbc9ab8f2969eae6ffa80b953c9a093f4d23646d0c0042b6b2a5b3d"},{"date":"2023-07-20","title":"Earnings data Q2 2023","quarter":"Q2","hash":"ec6066c630aa8e7fd28cd834534cf23935df43e14370d84eb482cbdc99292e56"},{"date":"2023-10-17","title":"Earnings data Q3 2023","quarter":"Q3","hash":"e96fa954b1c7ea6ced569887b051daed1dbd976ea41671f40916395cd3813634"},{"date":"2024-01-23","title":"Earnings data Q4 2023","quarter":"Q4","hash":"7f9f0e9ff669e3318eb606fd8c5ded5c38cf0b10f1301f9d48a3996ce7b4ffe1"},{"date":"2024-04-16","title":"Earnings data Q1 2024","quarter":"Q1","hash":"beff3c9df4c25d7ac0bf2481a1efc8c0aa8c057fa30608049e014faded0eb353"},{"date":"2024-07-17","title":"Earnings data Q2 2024","quarter":"Q2","hash":"08168259f590d9b0928665cb88174822a1ed3e115d3d9ada06a983ffa804b4fe"},{"date":"2024-10-15","title":"Earnings data Q3 2024","quarter":"Q3","hash":"b3881b3abc4ff746aa112ed4364216c021d6df7f474eb2f3d2930075b7c48e62"},{"date":"2025-01-22","title":"Earnings data Q4 2024","quarter":"Q4","hash":"1018d24c47ec6f9f276a628a8bb80f315ce00a224c7e54da334908c09c163a47"},{"date":"2025-04-15","title":"Earnings data Q1 2025","quarter":"Q1","hash":"1b00005fe39391fdf13b9e02cee05c2e6b481b74ad425aab91f65684adc355e4"},{"date":"2025-07-16","title":"Earnings data Q2 2025","quarter":"Q2","hash":"db09f32256ab54e7dfe1b72bb134f47f4a14be96481ca9430aa681eedd796b4a"},{"date":"2025-10-14","title":"Earnings data Q3 2025","quarter":"Q3","hash":"8d3e9ddefd1fcf3ef8bd2b826ba13ee44774c85058eecaf8d8e682c8876964e6"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Johnson \u0026 Johnson","companyDescription":"Johnson \u0026 Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.","executives":null,"brands":[{"id":"991ac2c0-10e3-49d8-b22a-4242809b1e0a","name":"Band-Aid","description":"Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson \u0026 Johnson's line of adhesive bandages.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/CwQJW5U6T8qn3gTGSJ8NAQ-thumbnail-300x300.png"},{"id":"c0f1df33-fd89-4694-a64c-bbc8e08150c6","name":"Johnson's Baby","description":"Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson \u0026 Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are \"exceptionally pure and safe\" since at least the 1980s.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/GF2PYlfLR7erH4K6Y06wfw-thumbnail-300x300.png"},{"id":"2ebdeee4-cf0d-4e2f-9c79-b046219f40c8","name":"Aveeno","description":"Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson \u0026 Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as \"active naturals\". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/o-Da42b-RnGPugGo9fqsQg-thumbnail-300x300.png"},{"id":"fc95f1ae-7e45-405e-abe8-8c7e693ba6d3","name":"Neutrogena","description":"Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson \u0026 Johnson conglomerate, which bought the independent company in 1994.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/cNboxYyWSH2QkyiD_hwQIg-thumbnail-300x300.png"},{"id":"d1a06e37-95db-44c7-af85-6abb70098f3b","name":"Clean \u0026 Clear","description":"Clean \u0026 Clear is a line of dermatology products owned by Johnson \u0026 Johnson.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/EfFq5FJeSkSy2FxvfZM7uw-thumbnail-300x300.png"},{"id":"2b4670e8-2026-4eb0-8cf9-eeb8d9fe9594","name":"Listerine","description":"Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan \"Kills germs that cause bad breath\". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/b91I8WMrR6eS597Ijmfnfg-thumbnail-300x300.png"},{"id":"6bb90554-3714-40d1-9389-9b0ba059ce30","name":"Acuvue","description":"Acuvue (from \"Accurate view\") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson \u0026 Johnson (J\u0026J).","imageUrl":"https://s3.amazonaws.com/matador-prod/__sized__/market/brand/HRg_EuzuQLikpv8s1hoaMw-thumbnail-300x300.png"}]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":23743000000,"changePercentage":5.77,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":6361000000,"changePercentage":-8.62,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":17382000000,"changePercentage":12.24,"valueToRevenueRatio":0.7320894579454997},{"financialKey":"OPERATING_EXPENSES","value":10672000000,"changePercentage":16.9,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":9405000000,"changePercentage":3.02,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":1267000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":6710000000,"changePercentage":5.54,"valueToRevenueRatio":0.28260961125384326},{"financialKey":"EBITDA","value":0,"changePercentage":-100,"valueToRevenueRatio":0},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":-6710000000,"changePercentage":-476.54,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":5537000000,"changePercentage":18.16,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.2889,"changePercentage":18.3,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":0,"changePercentage":-100,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:01Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":1.3,"priorDividend":1.24,"dividendYieldPercentage":3.35,"announcementDate":"2025-07-16","exDividendDate":"2025-08-26","payableDate":"2025-09-09","recordDate":"2025-08-26","updatedAt":"2025-07-16T11:42:54Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T04:56:16Z","bearsSay":["Johnson \u0026 Johnson's stock outlook is negatively influenced by anticipated lower organic revenue growth, primarily stemming from the pharmaceutical division's diminishing contributions due to upcoming loss of exclusivity for key drugs and challenges in the drug pipeline. The MedTech division faces competitive pressures, and there are concerns regarding its ability to achieve substantial growth, especially in surgical robotics. Additionally, ongoing litigation, notably related to talc products, coupled with potential price cuts from new legislation like the Inflation Reduction Act, further complicates the company's revenue outlook and operational stability."],"bullsSay":["Johnson \u0026 Johnson has demonstrated a robust growth trajectory, accelerating from a 3-4% growth rate in 2016-2019 to 6.1% in 2022 and an impressive 7.8% in 2023, primarily driven by innovations across its pharmaceutical and medical device segments. The company's expanding product pipeline, including promising therapies like Carvykti, Tecvayli, and Spravato, reinforces its revenue growth and margin enhancement potential, as demonstrated by substantial clinical remission rates in its treatment trials. Furthermore, JNJ's strategic focus following the divestment of its consumer business has not only improved its financial profile but also positioned it for mid-single-digit revenue growth, with attractive valuations relative to its historical multiples."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Consumer Health","dataPoints":[{"key":"21 Q3","value":3700},{"key":"21 Q4","value":3657},{"key":"22 Q1","value":3586},{"key":"22 Q2","value":3805},{"key":"22 Q3","value":3795},{"key":"22 Q4","value":3767},{"key":"23 Q1","value":3852},{"key":"23 Q2","value":4011}]},{"title":"Pharmaceutical","dataPoints":[{"key":"21 Q3","value":12994},{"key":"21 Q4","value":14288},{"key":"22 Q1","value":12869},{"key":"22 Q2","value":13317},{"key":"22 Q3","value":13214},{"key":"22 Q4","value":13163},{"key":"23 Q1","value":13413},{"key":"23 Q2","value":13731}]},{"title":"Medical Devices","dataPoints":[{"key":"21 Q3","value":6644},{"key":"21 Q4","value":6859},{"key":"22 Q1","value":6971},{"key":"22 Q2","value":6898},{"key":"22 Q3","value":6782},{"key":"22 Q4","value":6776},{"key":"23 Q1","value":7481},{"key":"23 Q2","value":7788}]},{"title":"Innovative Medicine","dataPoints":[{"key":"23 Q3","value":13893},{"key":"23 Q4","value":13722},{"key":"24 Q1","value":13562},{"key":"24 Q2","value":14490},{"key":"24 Q3","value":14580},{"key":"24 Q4","value":14332},{"key":"25 Q1","value":13873},{"key":"25 Q2","value":15202}]},{"title":"MedTech","dataPoints":[{"key":"23 Q3","value":7458},{"key":"23 Q4","value":7673},{"key":"24 Q1","value":7821},{"key":"24 Q2","value":7957},{"key":"24 Q3","value":7891},{"key":"24 Q4","value":8188},{"key":"25 Q1","value":8020},{"key":"25 Q2","value":8541}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":68.93},{"key":"21 Q4","value":67.92},{"key":"22 Q1","value":67.56},{"key":"22 Q2","value":67.03},{"key":"22 Q3","value":67.18},{"key":"22 Q4","value":67.24},{"key":"23 Q1","value":66.07},{"key":"23 Q2","value":67.83},{"key":"23 Q3","value":69.05},{"key":"23 Q4","value":68.22},{"key":"24 Q1","value":69.55},{"key":"24 Q2","value":69.39},{"key":"24 Q3","value":69.01},{"key":"24 Q4","value":68.34},{"key":"25 Q1","value":66.39},{"key":"25 Q2","value":67.87}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":16.49},{"key":"21 Q4","value":19.49},{"key":"22 Q1","value":25.02},{"key":"22 Q2","value":24.31},{"key":"22 Q3","value":24.47},{"key":"22 Q4","value":17.72},{"key":"23 Q1","value":-2.98},{"key":"23 Q2","value":26.48},{"key":"23 Q3","value":24.43},{"key":"23 Q4","value":22.55},{"key":"24 Q1","value":30.11},{"key":"24 Q2","value":25.6},{"key":"24 Q3","value":14.85},{"key":"24 Q4","value":17.26},{"key":"25 Q1","value":62.26},{"key":"25 Q2","value":27.33}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":15.71},{"key":"21 Q4","value":19.09},{"key":"22 Q1","value":21.97},{"key":"22 Q2","value":20.04},{"key":"22 Q3","value":18.73},{"key":"22 Q4","value":14.84},{"key":"23 Q1","value":-0.28},{"key":"23 Q2","value":20.14},{"key":"23 Q3","value":121.9},{"key":"23 Q4","value":18.92},{"key":"24 Q1","value":25.03},{"key":"24 Q2","value":20.87},{"key":"24 Q3","value":11.98},{"key":"24 Q4","value":15.23},{"key":"25 Q1","value":50.23},{"key":"25 Q2","value":23.32}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, marketing and administrative expenses","dataPoints":[{"key":"21 Q3","value":6000},{"key":"21 Q4","value":7154},{"key":"22 Q1","value":5938},{"key":"22 Q2","value":6226},{"key":"22 Q3","value":6089},{"key":"22 Q4","value":6512},{"key":"23 Q1","value":6138},{"key":"23 Q2","value":6665},{"key":"23 Q3","value":5400},{"key":"23 Q4","value":5810},{"key":"24 Q1","value":5257},{"key":"24 Q2","value":5681},{"key":"24 Q3","value":5478},{"key":"24 Q4","value":6453},{"key":"25 Q1","value":5112},{"key":"25 Q2","value":5889}]},{"title":"Research and development expense","dataPoints":[{"key":"21 Q3","value":3422},{"key":"21 Q4","value":4720},{"key":"22 Q1","value":3462},{"key":"22 Q2","value":3703},{"key":"22 Q3","value":3597},{"key":"22 Q4","value":3841},{"key":"23 Q1","value":3563},{"key":"23 Q2","value":3829},{"key":"23 Q3","value":3447},{"key":"23 Q4","value":4480},{"key":"24 Q1","value":3542},{"key":"24 Q2","value":3440},{"key":"24 Q3","value":4952},{"key":"24 Q4","value":5298},{"key":"25 Q1","value":3225},{"key":"25 Q2","value":3516}]},{"title":"In-process research and development","dataPoints":[{"key":"21 Q3","value":900},{"key":"22 Q1","value":610},{"key":"22 Q4","value":173},{"key":"23 Q1","value":49},{"key":"23 Q3","value":206},{"key":"23 Q4","value":58},{"key":"24 Q2","value":194},{"key":"24 Q4","value":17}]},{"title":"Interest expense","dataPoints":[{"key":"21 Q3","value":7},{"key":"21 Q4","value":47},{"key":"22 Q1","value":-12},{"key":"22 Q2","value":-26},{"key":"22 Q3","value":-99},{"key":"22 Q4","value":-77},{"key":"23 Q1","value":-20},{"key":"23 Q2","value":-23},{"key":"23 Q3","value":-182},{"key":"23 Q4","value":-212},{"key":"24 Q1","value":-209},{"key":"24 Q2","value":-125},{"key":"24 Q3","value":-99},{"key":"24 Q4","value":-144},{"key":"25 Q1","value":-128},{"key":"25 Q2","value":48}]},{"title":"Other expense","dataPoints":[{"key":"21 Q3","value":1850},{"key":"21 Q4","value":9},{"key":"22 Q1","value":-102},{"key":"22 Q2","value":273},{"key":"22 Q3","value":493},{"key":"22 Q4","value":1207},{"key":"23 Q1","value":7228},{"key":"23 Q2","value":-60},{"key":"23 Q3","value":499},{"key":"23 Q4","value":-421},{"key":"24 Q1","value":-322},{"key":"24 Q2","value":653},{"key":"24 Q3","value":1798},{"key":"24 Q4","value":-161},{"key":"25 Q1","value":-7321},{"key":"25 Q2","value":107}]},{"title":"Restructuring","dataPoints":[{"key":"21 Q3","value":60},{"key":"21 Q4","value":83},{"key":"22 Q1","value":70},{"key":"22 Q2","value":85},{"key":"22 Q3","value":82},{"key":"22 Q4","value":84},{"key":"23 Q1","value":130},{"key":"23 Q2","value":145},{"key":"23 Q3","value":158},{"key":"23 Q4","value":56},{"key":"24 Q1","value":164},{"key":"24 Q2","value":-13},{"key":"24 Q3","value":41},{"key":"24 Q4","value":42},{"key":"25 Q1","value":17},{"key":"25 Q2","value":64}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":10.7},{"key":"21 Q4","value":10.36},{"key":"22 Q1","value":4.95},{"key":"22 Q2","value":3.04},{"key":"22 Q3","value":1.94},{"key":"22 Q4","value":-4.43},{"key":"23 Q1","value":5.63},{"key":"23 Q2","value":6.29},{"key":"23 Q3","value":-10.26},{"key":"23 Q4","value":-9.75},{"key":"24 Q1","value":-13.59},{"key":"24 Q2","value":-12.08},{"key":"24 Q3","value":5.25},{"key":"24 Q4","value":5.26},{"key":"25 Q1","value":2.39},{"key":"25 Q2","value":5.77}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":26.06},{"key":"21 Q4","value":-7.69},{"key":"22 Q1","value":27.3},{"key":"22 Q2","value":13.22},{"key":"22 Q3","value":-16.97},{"key":"22 Q4","value":-2.27},{"key":"23 Q1","value":71.46},{"key":"23 Q2","value":2.87},{"key":"23 Q3","value":-6.24},{"key":"23 Q4","value":-16.77},{"key":"24 Q1","value":-50.66},{"key":"24 Q2","value":-6.88},{"key":"24 Q3","value":27.73},{"key":"24 Q4","value":17.75},{"key":"25 Q1","value":-89.27},{"key":"25 Q2","value":-2.1}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":2674.9},{"key":"21 Q4","value":2670.2},{"key":"22 Q1","value":2666.5},{"key":"22 Q2","value":2667.9},{"key":"22 Q3","value":2661.3},{"key":"22 Q4","value":2650.1},{"key":"23 Q1","value":2605.5},{"key":"23 Q2","value":2625.7},{"key":"23 Q3","value":2549.7},{"key":"23 Q4","value":2430.7},{"key":"24 Q1","value":2430.1},{"key":"24 Q2","value":2422},{"key":"24 Q3","value":2427.9},{"key":"24 Q4","value":2427.1},{"key":"25 Q1","value":2423.8},{"key":"25 Q2","value":2419.1}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":456337.94},{"key":"21 Q4","value":437111.74},{"key":"22 Q1","value":453838.3},{"key":"22 Q2","value":473552.25},{"key":"22 Q3","value":448695.18},{"key":"22 Q4","value":456082.21},{"key":"23 Q1","value":419224.95},{"key":"23 Q2","value":421949.99},{"key":"23 Q3","value":418915.71},{"key":"23 Q4","value":372626.31},{"key":"24 Q1","value":386871.92},{"key":"24 Q2","value":360151.4},{"key":"24 Q3","value":386764.47},{"key":"24 Q4","value":376200.5},{"key":"25 Q1","value":379324.7},{"key":"25 Q2","value":371815.67}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":4.89},{"key":"21 Q4","value":4.41},{"key":"22 Q1","value":4.84},{"key":"22 Q2","value":4.93},{"key":"22 Q3","value":4.71},{"key":"22 Q4","value":4.81},{"key":"23 Q1","value":4.24},{"key":"23 Q2","value":4.13},{"key":"23 Q3","value":4.91},{"key":"23 Q4","value":4.35},{"key":"24 Q1","value":4.52},{"key":"24 Q2","value":4.01},{"key":"24 Q3","value":4.3},{"key":"24 Q4","value":4.18},{"key":"25 Q1","value":4.33},{"key":"25 Q2","value":3.92}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-16T13:29:26Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.51,"sell":0.49,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"MRK","name":"Merck","displayName":"Merck","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"MRK","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":83.98,"high":84.51,"low":83.52,"volume":855,"volumeDate":"2025-07-25","last":84.11,"open":84.2,"gainPercentage":0.155,"gainValue":0.13,"ask":84.18,"bid":84,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":211202733300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":15306711.871,"highPriceLast52Weeks":128.73,"lowPriceLast52Weeks":73.31,"companyName":"Merck \u0026 Co., Inc.","longBusinessDescription":"Merck \u0026 Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.","dividendRate":3.2,"salesOrRevenue":63973000000,"oneYearAnnualRevenueGrowthRate":6.85139717058342,"threeYearAnnualRevenueGrowthRate":9.6006,"fiveYearAnnualRevenueGrowthRate":7.1414,"earningsGrowth":654.9288,"totalDebt":38270000000,"totalAssets":117106000000,"floatAsPercentOfSharesOutstanding":99.9391,"dividendYield":3.8,"betaTwelveMonth":0.3371,"salesOrRevenueTtm":63783000000,"ebitdaTtm":26684000000,"debtToEquityRatioQuarterly":72.0885486707355,"totalEnterpriseValue":277342680000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":16.2423288749017,"fiveYearAverageDebtEquityRatio":84.43,"currentRatio":1.41030428219592,"peratio":12.25},"recommendation":{"currentConsensusRating":2.2,"recommendationTargetPrice":110.09,"totalRatings":32,"strongSellRatings":1,"sellRatings":0,"holdRatings":12,"buyRatings":9,"strongBuyRatings":10,"lastUpdated":"2025-07-10T16:16:07Z"},"earningEstimates":[{"actual":1.75,"estimate":1.55,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-28T10:43:14Z","audioUrl":"https://files.quartr.com/audio-files/6e470-2022-10-19-04-34-57.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/447ef-2024-08-30-11-44-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-28T00:00:00Z","earningsSummary":null},{"actual":1.8,"estimate":1.53,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-03T11:40:47Z","audioUrl":"https://files.quartr.com/audio-files/24769-2022-10-19-10-09-29.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/f97a8-2023-01-25-12-57-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-03T19:57:28Z","earningsSummary":null},{"actual":2.14,"estimate":1.83,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-28T10:50:01Z","audioUrl":"https://files.quartr.com/audio-files/ca3ae-2022-10-28-04-35-38.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/89fd9-2023-01-25-01-16-18.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-28T14:26:25Z","earningsSummary":null},{"actual":1.87,"estimate":1.69,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-28T10:35:55Z","audioUrl":"https://files.quartr.com/recordings/live_q_2022_07_28_14_00_Q2_2022_Merck___Co_Inc_Earnings_Call.AVIM5EDLGBG6.stream_starts_at_1659009182.12591_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/c8432-2022-07-28-11-18-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-27T23:56:00Z","earningsSummary":null},{"actual":1.85,"estimate":1.75,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-27T10:34:56Z","audioUrl":"https://files.quartr.com/audio-files/8a799-2022-10-27-03-44-02.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d10f2-2022-10-27-11-38-14.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/082fa-2022-10-27-11-38-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-27T12:00:00Z","earningsSummary":null},{"actual":1.62,"estimate":1.54,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T11:34:47Z","audioUrl":"https://files.quartr.com/audio-files/09758-2023-02-02-07-04-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/f639a-2023-02-02-12-02-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/29b8e-2023-02-02-12-01-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T13:00:00Z","earningsSummary":{"summary":"Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.\nWhile facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.\nAnalyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.","headline":"Merck reports robust Q4 earnings, eyes growth through innovation","lastUpdated":"2024-05-07T01:13:13.883932Z"}},{"actual":1.4,"estimate":1.32,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T10:34:31Z","audioUrl":"https://files.quartr.com/audio-files/65e23-2023-04-27-06-33-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a8c43-2023-04-27-11-49-41.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/27194-2023-04-27-10-15-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T13:00:00Z","earningsSummary":{"summary":"Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.\nThe company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.\nChallenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.\nOpportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.","headline":"Merck reports robust Q1 earnings, eyes growth in oncology and vaccines","lastUpdated":"2024-05-07T04:21:01.553753Z"}},{"actual":-2.06,"estimate":-2.17,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T10:31:06Z","audioUrl":"https://files.quartr.com/audio-files/36a1a-2023-08-01-04-56-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fada1-2023-08-01-11-08-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/00725-2023-08-01-10-33-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T12:00:00Z","earningsSummary":{"summary":"Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth\nDespite challenges like regulatory concerns and price pressures, the company remains focused on innovation\nOpportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology\nOverall, Merck's strategic acquisitions and commitment to growth position it well for the future","headline":"Merck reports robust Q2 earnings, focuses on growth opportunities","lastUpdated":"2024-05-07T00:25:27.356469Z"}},{"actual":2.13,"estimate":1.95,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-26T10:31:09Z","audioUrl":"https://files.quartr.com/audio-files/aa051-2023-10-26-04-48-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bdf84-2023-10-26-11-44-28.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/fb22a-2023-10-26-10-52-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-26T13:00:00Z","earningsSummary":{"summary":"Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.","headline":"Merck reports robust Q3 earnings, eyes growth in precision medicine","lastUpdated":"2024-05-05T04:47:43.526189Z"}},{"actual":0.03,"estimate":-0.11,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-01T11:32:46Z","audioUrl":"https://files.quartr.com/audio-files/628b9-2024-02-01-03-40-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b0b28-2024-02-01-12-30-10.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8c247-2024-02-01-11-42-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-01T14:00:00Z","earningsSummary":{"summary":"Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R\u0026D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.","headline":"Merck reports robust Q4 earnings, eyes growth through strategic investments","lastUpdated":"2024-05-05T06:27:43.042298Z"}},{"actual":2.07,"estimate":1.87,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T10:31:12Z","audioUrl":"https://files.quartr.com/audio-files/f8e79-2024-04-25-02-46-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ad9cf-2024-05-03-01-01-57.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/a023c-2024-04-25-10-09-43.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-25T13:00:00Z","earningsSummary":{"summary":"Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.\nThe company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.\nChallenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.\nOpportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.","headline":"Merck reports robust Q1 earnings, eyes growth in innovative treatments","lastUpdated":"2024-05-06T18:46:48.338401Z"}},{"actual":2.28,"estimate":2.15,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-30T10:37:32Z","audioUrl":"https://files.quartr.com/audio-files/4aae5-2024-07-30-02-24-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2fcdc-2024-07-30-11-31-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/88cd4-2024-07-30-10-41-43.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-30T13:00:00Z","earningsSummary":{"summary":"Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.","headline":"Merck reports robust Q2 earnings, eyes future drug launches","lastUpdated":"2024-07-30T16:15:48.587645Z"}},{"actual":1.57,"estimate":1.51,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T10:31:28Z","audioUrl":"https://files.quartr.com/audio-files/1d77b-2024-10-31-02-12-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/65e99-2024-10-31-11-09-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c8342-2024-10-31-10-53-45.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T13:00:00Z","earningsSummary":{"summary":"Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.\nThe company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.\nWhile facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.","headline":"Merck reports solid Q3 earnings, eyes growth through diversification","lastUpdated":"2024-10-31T16:37:30.513790Z"}},{"actual":1.72,"estimate":1.68,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-04T11:30:54Z","audioUrl":"https://files.quartr.com/audio-files/3d01a-2025-02-04-03-15-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/75bae-2025-02-04-12-57-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d14be-2025-02-04-12-42-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-04T14:00:00Z","earningsSummary":null},{"actual":2.22,"estimate":2.14,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-24T10:30:39Z","audioUrl":"https://files.quartr.com/audio-files/12e92-2025-04-24-02-17-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/edc6e-2025-04-24-12-24-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c6131-2025-04-24-10-01-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-24T13:00:00Z","earningsSummary":{"summary":"Merck's Q1 performance reflects strong revenue growth and strategic investments in manufacturing and R\u0026D. While facing challenges related to tariffs and regulatory changes, the company remains focused on innovation and long-term value creation, leveraging opportunities in its pipeline for future growth.","headline":"Merck posts robust Q1 earnings, eyes growth through innovation","lastUpdated":"2025-04-24T15:43:10.375321Z"}},{"actual":null,"estimate":2.01,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:21Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-29T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-28","title":"Earnings data Q3 2021","quarter":"Q3","hash":"c8e6e05188c6baf26b878be1bc2eb61de737dc35b1f6d300e94257784b84796d"},{"date":"2022-02-03","title":"Earnings data Q4 2021","quarter":"Q4","hash":"a2ac3b54ee17cfce0fa398d76613a4a9e6d7facb3c853ba2dc04acd7382a5661"},{"date":"2022-04-28","title":"Earnings data Q1 2022","quarter":"Q1","hash":"aca95377ac5a63f7096ffacd5bf5e9574c31d90f253610d4b531e32abead492d"},{"date":"2022-07-28","title":"Earnings data Q2 2022","quarter":"Q2","hash":"eccaf2a13f0c3257bfbe94978ca934bcd676b211282b536d6a94635cb9679904"},{"date":"2022-10-27","title":"Earnings data Q3 2022","quarter":"Q3","hash":"73a73a56ef9f99de9e31db7c72189296eafee03a4e8c80f9c7965307527d8ad2"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8751c9084d8b7bae3ab536f732489cd1234338851eae60e775b0400f8f306a0e"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"fb73ad03f0be75f3d9c6def6f942eea0ac8fb954a0d449c1ca453ff59f9e312a"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"05a8ac92579ea609971e26e96563177242af1db617df35356e7297020e396d41"},{"date":"2023-10-26","title":"Earnings data Q3 2023","quarter":"Q3","hash":"ec3586ce622dacdaf32fa0b29df704b4b0b89aba0c2de00030994f946fd1704f"},{"date":"2024-02-01","title":"Earnings data Q4 2023","quarter":"Q4","hash":"1400ce05ffac57d36e7349fe418019613090517527376f4aaadc98ba645b2c70"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"2394770226a096fc8c0ede7f80884657a29879ef0e635f9bbee5451598ce9163"},{"date":"2024-07-30","title":"Earnings data Q2 2024","quarter":"Q2","hash":"139d0270b2b941a643fa5dcd9e9cd1ea4d129d6903b245923133b47b15a12c28"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"3ab377eaf4331af0e63ed5572f421896dedeb5fee2a4182a12077d40572ad55e"},{"date":"2025-02-04","title":"Earnings data Q4 2024","quarter":"Q4","hash":"e8974a6f849415a67d13fd224f0175f791d7b782613774be688cbce688c1bee3"},{"date":"2025-04-24","title":"Earnings data Q1 2025","quarter":"Q1","hash":"c0ec2986a9b3de1eda0395b2ed12d511a19551ab46b0cb0cfaa5f21cd2a17bee"},{"date":"2025-07-29","title":"Earnings data Q2 2025","quarter":"Q2","hash":"18a9b74fbe10937925fb32189d20ee0a4d1b4be16fcc2de97956ebd90dfc262f"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Merck","companyDescription":"Merck \u0026 Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":15619000000,"changePercentage":-1.2,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3885000000,"changePercentage":-1.27,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":11734000000,"changePercentage":-1.18,"valueToRevenueRatio":0.751264485562456},{"financialKey":"OPERATING_EXPENSES","value":5024000000,"changePercentage":-15.66,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":5024000000,"changePercentage":-15.66,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":6710000000,"changePercentage":13.4,"valueToRevenueRatio":0.4296049683078302},{"financialKey":"EBITDA","value":7809000000,"changePercentage":13.16,"valueToRevenueRatio":0.49996798770727957},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1099000000,"changePercentage":11.69,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":5085000000,"changePercentage":6.67,"valueToRevenueRatio":null},{"financialKey":"EPS","value":2.0067,"changePercentage":7.2,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":115122000000,"changePercentage":8.76,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":35503000000,"changePercentage":12.91,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":9331000000,"changePercentage":63.39,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":11584000000,"changePercentage":-7.86,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":6196000000,"changePercentage":-4.82,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":8392000000,"changePercentage":26.16,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":79619000000,"changePercentage":7.01,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":24793000000,"changePercentage":7.59,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":37442000000,"changePercentage":-3.38,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":17384000000,"changePercentage":37.9,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":66722000000,"changePercentage":1.98,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":25174000000,"changePercentage":0.3,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":1360000000,"changePercentage":-55.8,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":5181000000,"changePercentage":116.06,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":18633000000,"changePercentage":-5.05,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":41548000000,"changePercentage":3.03,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":33484000000,"changePercentage":7.52,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":8064000000,"changePercentage":-12.2,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":48400000000,"changePercentage":19.73,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":48335000000,"changePercentage":19.75,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":65000000,"changePercentage":8.33,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":115122000000,"changePercentage":8.76,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":34844000000,"changePercentage":1.83,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":25513000000,"changePercentage":-10.51,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":19.21043,"changePercentage":20.54,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":5085000000,"changePercentage":6.67,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":2500000000,"changePercentage":-19.09,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":6212000000,"changePercentage":-4.02,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-3712000000,"changePercentage":-9.76,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-1487000000,"changePercentage":-8.07,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":1328000000,"changePercentage":54.24,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-139000000,"changePercentage":-156.73,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-2676000000,"changePercentage":17.1,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-5755000000,"changePercentage":-104.51,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-1145000000,"changePercentage":-3171.43,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-2500000000,"changePercentage":-232.89,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":2050000000,"changePercentage":5.13,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-60000000,"changePercentage":23.08,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":156000000,"changePercentage":213.04,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-4586000000,"changePercentage":-270.44,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1172000000,"changePercentage":-47.42,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:43Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.81,"priorDividend":0.77,"dividendYieldPercentage":4.09,"announcementDate":"2025-07-22","exDividendDate":"2025-09-15","payableDate":"2025-10-07","recordDate":"2025-09-15","updatedAt":"2025-07-22T20:34:03Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-03T09:40:17Z","bearsSay":["Merck \u0026 Co faces significant challenges impacting its stock outlook, primarily due to anticipated revenue declines from its Keytruda immunotherapy treatment following the loss of exclusivity and increased competition from biosimilars, with projections estimating a revenue reduction of up to 58%. Additionally, performance issues with other products, such as Winrevair, which underperformed relative to both management expectations and consensus estimates, raise concerns about the company's ability to maintain growth across its portfolio. Overall, these factors contribute to a lowered valuation and heightened uncertainty regarding Merck's future revenue streams, particularly in light of regulatory pressures from initiatives like the Medicare IRA price negotiations."],"bullsSay":["Merck \u0026 Co. is anticipated to experience robust growth beginning in the second half of 2025 and extending into 2026 and 2027, driven by a diverse portfolio that includes successful vaccines and innovative treatments in oncology and infectious diseases. The company is strategically positioned to capture significant market share with its Capvaxive pneumococcal vaccine and RSV antibody products, while its transition to Keytruda’s subcutaneous formulation may further bolster revenues post-loss of exclusivity. Additionally, anticipated launches of clesrovimab and advancements in ongoing trials, such as MK-8527 for HIV prevention, underscore Merck's ongoing commitment to expanding its market presence and product offerings."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Pharmaceutical","dataPoints":[{"key":"21 Q2","value":9980},{"key":"21 Q3","value":11496},{"key":"21 Q4","value":12039},{"key":"22 Q1","value":14107},{"key":"22 Q2","value":12756},{"key":"22 Q3","value":12963},{"key":"22 Q4","value":12180},{"key":"23 Q1","value":12721},{"key":"23 Q2","value":13457},{"key":"23 Q3","value":14263},{"key":"23 Q4","value":13141},{"key":"24 Q1","value":14006},{"key":"24 Q2","value":14408},{"key":"24 Q3","value":14943},{"key":"24 Q4","value":14042},{"key":"25 Q1","value":13638}]},{"title":"Animal Health","dataPoints":[{"key":"21 Q2","value":1472},{"key":"21 Q3","value":1417},{"key":"21 Q4","value":1261},{"key":"22 Q1","value":1482},{"key":"22 Q2","value":1467},{"key":"22 Q3","value":1371},{"key":"22 Q4","value":1230},{"key":"23 Q1","value":1491},{"key":"23 Q2","value":1456},{"key":"23 Q3","value":1400},{"key":"23 Q4","value":1278},{"key":"24 Q1","value":1511},{"key":"24 Q2","value":1482},{"key":"24 Q3","value":1487},{"key":"24 Q4","value":1397},{"key":"25 Q1","value":1588}]},{"title":"Other Revenues","dataPoints":[{"key":"21 Q2","value":-50},{"key":"21 Q3","value":241},{"key":"21 Q4","value":221},{"key":"22 Q1","value":312},{"key":"22 Q2","value":370},{"key":"22 Q3","value":625},{"key":"22 Q4","value":420},{"key":"23 Q1","value":275},{"key":"23 Q2","value":122},{"key":"23 Q3","value":299},{"key":"23 Q4","value":211},{"key":"24 Q1","value":258},{"key":"24 Q2","value":222},{"key":"24 Q3","value":227},{"key":"24 Q4","value":185},{"key":"25 Q1","value":303}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":72.77},{"key":"21 Q3","value":73.77},{"key":"21 Q4","value":71.35},{"key":"22 Q1","value":66.16},{"key":"22 Q2","value":71.1},{"key":"22 Q3","value":73.7},{"key":"22 Q4","value":71.93},{"key":"23 Q1","value":72.89},{"key":"23 Q2","value":73.23},{"key":"23 Q3","value":73.28},{"key":"23 Q4","value":73.26},{"key":"24 Q1","value":77.55},{"key":"24 Q2","value":76.75},{"key":"24 Q3","value":75.5},{"key":"24 Q4","value":75.49},{"key":"25 Q1","value":77.98}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":15.05},{"key":"21 Q3","value":40.03},{"key":"21 Q4","value":28.91},{"key":"22 Q1","value":30.57},{"key":"22 Q2","value":30.74},{"key":"22 Q3","value":23.95},{"key":"22 Q4","value":25.4},{"key":"23 Q1","value":25.19},{"key":"23 Q2","value":-35.49},{"key":"23 Q3","value":35.2},{"key":"23 Q4","value":-13.99},{"key":"24 Q1","value":35.94},{"key":"24 Q2","value":37.27},{"key":"24 Q3","value":24.55},{"key":"24 Q4","value":26.68},{"key":"25 Q1","value":38.01}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":13.55},{"key":"21 Q3","value":34.71},{"key":"21 Q4","value":27.79},{"key":"22 Q1","value":27.1},{"key":"22 Q2","value":27.02},{"key":"22 Q3","value":21.71},{"key":"22 Q4","value":21.81},{"key":"23 Q1","value":19.47},{"key":"23 Q2","value":-39.75},{"key":"23 Q3","value":29.72},{"key":"23 Q4","value":-8.39},{"key":"24 Q1","value":30.18},{"key":"24 Q2","value":33.85},{"key":"24 Q3","value":18.95},{"key":"24 Q4","value":23.95},{"key":"25 Q1","value":32.7}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Selling, general and administrative","dataPoints":[{"key":"21 Q2","value":2281},{"key":"21 Q3","value":2336},{"key":"21 Q4","value":2830},{"key":"22 Q1","value":2323},{"key":"22 Q2","value":2512},{"key":"22 Q3","value":2520},{"key":"22 Q4","value":2687},{"key":"23 Q1","value":2479},{"key":"23 Q2","value":2702},{"key":"23 Q3","value":2519},{"key":"23 Q4","value":2804},{"key":"24 Q1","value":2483},{"key":"24 Q2","value":2739},{"key":"24 Q3","value":2731},{"key":"24 Q4","value":2864},{"key":"25 Q1","value":2552}]},{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":4321},{"key":"21 Q3","value":2445},{"key":"21 Q4","value":3068},{"key":"22 Q1","value":2576},{"key":"22 Q2","value":2798},{"key":"22 Q3","value":4399},{"key":"22 Q4","value":3775},{"key":"23 Q1","value":4276},{"key":"23 Q2","value":13321},{"key":"23 Q3","value":3307},{"key":"23 Q4","value":9628},{"key":"24 Q1","value":3992},{"key":"24 Q2","value":3500},{"key":"24 Q3","value":5862},{"key":"24 Q4","value":4585},{"key":"25 Q1","value":3621}]},{"title":"Restructuring costs","dataPoints":[{"key":"21 Q2","value":82},{"key":"21 Q3","value":107},{"key":"21 Q4","value":174},{"key":"22 Q1","value":53},{"key":"22 Q2","value":142},{"key":"22 Q3","value":94},{"key":"22 Q4","value":49},{"key":"23 Q1","value":67},{"key":"23 Q2","value":151},{"key":"23 Q3","value":126},{"key":"23 Q4","value":255},{"key":"24 Q1","value":123},{"key":"24 Q2","value":80},{"key":"24 Q3","value":56},{"key":"24 Q4","value":51},{"key":"25 Q1","value":69}]},{"title":"Other (income) expense, net","dataPoints":[{"key":"21 Q2","value":-103},{"key":"21 Q3","value":-450},{"key":"21 Q4","value":-333},{"key":"22 Q1","value":708},{"key":"22 Q2","value":438},{"key":"22 Q3","value":429},{"key":"22 Q4","value":-75},{"key":"23 Q1","value":89},{"key":"23 Q2","value":172},{"key":"23 Q3","value":126},{"key":"23 Q4","value":78},{"key":"24 Q1","value":-33},{"key":"24 Q2","value":42},{"key":"24 Q3","value":-162},{"key":"24 Q4","value":126},{"key":"25 Q1","value":-35}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":21.91},{"key":"21 Q3","value":20.36},{"key":"21 Q4","value":23.5},{"key":"22 Q1","value":49.63},{"key":"22 Q2","value":27.99},{"key":"22 Q3","value":13.72},{"key":"22 Q4","value":2.29},{"key":"23 Q1","value":-8.89},{"key":"23 Q2","value":3.03},{"key":"23 Q3","value":6.7},{"key":"23 Q4","value":5.78},{"key":"24 Q1","value":8.89},{"key":"24 Q2","value":7.16},{"key":"24 Q3","value":4.35},{"key":"24 Q4","value":6.79},{"key":"25 Q1","value":-1.56}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":70.27},{"key":"21 Q3","value":-14.82},{"key":"21 Q4","value":-32.2},{"key":"22 Q1","value":27.45},{"key":"22 Q2","value":-10.5},{"key":"22 Q3","value":67.69},{"key":"22 Q4","value":12.14},{"key":"23 Q1","value":22.1},{"key":"23 Q2","value":177.52},{"key":"23 Q3","value":-18.33},{"key":"23 Q4","value":98.34},{"key":"24 Q1","value":-5.01},{"key":"24 Q2","value":-61.09},{"key":"24 Q3","value":39.63},{"key":"24 Q4","value":-40.26},{"key":"25 Q1","value":-5.45}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":2533},{"key":"21 Q3","value":2530},{"key":"21 Q4","value":2527},{"key":"22 Q1","value":2528},{"key":"22 Q2","value":2531},{"key":"22 Q3","value":2533},{"key":"22 Q4","value":2536},{"key":"23 Q1","value":2551},{"key":"23 Q2","value":2539},{"key":"23 Q3","value":2546},{"key":"23 Q4","value":2533},{"key":"24 Q1","value":2544},{"key":"24 Q2","value":2544},{"key":"24 Q3","value":2541},{"key":"24 Q4","value":2537},{"key":"25 Q1","value":2531}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":194534.4},{"key":"21 Q3","value":192533},{"key":"21 Q4","value":201149.2},{"key":"22 Q1","value":199206.4},{"key":"22 Q2","value":222981.1},{"key":"22 Q3","value":224677.1},{"key":"22 Q4","value":257911.2},{"key":"23 Q1","value":273977.4},{"key":"23 Q2","value":286653.1},{"key":"23 Q3","value":272931.2},{"key":"23 Q4","value":262925.4},{"key":"24 Q1","value":313675.2},{"key":"24 Q2","value":327667.2},{"key":"24 Q3","value":301870.8},{"key":"24 Q4","value":261564.7},{"key":"25 Q1","value":236395.4}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":4.27},{"key":"21 Q3","value":3.66},{"key":"21 Q4","value":3.72},{"key":"22 Q1","value":3.13},{"key":"22 Q2","value":3.82},{"key":"22 Q3","value":3.75},{"key":"22 Q4","value":4.66},{"key":"23 Q1","value":4.73},{"key":"23 Q2","value":4.77},{"key":"23 Q3","value":4.27},{"key":"23 Q4","value":4.49},{"key":"24 Q1","value":4.97},{"key":"24 Q2","value":5.08},{"key":"24 Q3","value":4.53},{"key":"24 Q4","value":4.19},{"key":"25 Q1","value":3.81}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-24T15:00:34Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.53,"sell":0.47,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"IDNA","name":"iShares Genomics Immunology and Healthcare ETF","displayName":"iShares Genomics Immunology and Healthcare ETF","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"IDNA","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":22.53,"high":22.5981,"low":22.2508,"volume":20612,"volumeDate":"2025-07-24","last":22.2661,"open":22.53,"gainPercentage":-1.171,"gainValue":-0.2639,"ask":22.9,"bid":21.24,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":null,"instrumentClass":"EXCHANGE_TRADED_FUND","averageDailyVolumeLast3Months":28108.4677,"highPriceLast52Weeks":25.8,"lowPriceLast52Weeks":17.26,"companyName":null,"longBusinessDescription":"IDNA tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering.","dividendRate":0.264,"salesOrRevenue":null,"oneYearAnnualRevenueGrowthRate":null,"threeYearAnnualRevenueGrowthRate":null,"fiveYearAnnualRevenueGrowthRate":null,"earningsGrowth":null,"totalDebt":null,"totalAssets":null,"floatAsPercentOfSharesOutstanding":null,"dividendYield":1.1900000000000002,"betaTwelveMonth":0.8443,"salesOrRevenueTtm":null,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":null,"industry":"InvestmentTrustsOrMutualFunds","sector":"Miscellaneous","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":null,"currentRatio":null,"peratio":null},"recommendation":null,"earningEstimates":[],"earningDates":[],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"iShares Genomics Immunology and Healthcare ETF","companyDescription":"IDNA tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering.","executives":null,"brands":[]},"etfFundamental":{"returnInception":-0.0095,"etfType":"Global Equities","category":"Broad Market / Multi-Cap","netExpenseRatio":0.47000000000000003,"inceptionDate":"2019-06-11","assetsUnderManagement":115842117,"returnYTD":-0.0044,"return1Month":0.105,"return3Month":0.1265,"return1Year":-0.0698,"return3Year":-0.0964,"return5Year":-0.1017,"return10Year":null,"returnsAsOfDate":"2025-07-23","quarterlyNavBasedReturns":{"returnYTD":-8.43,"return1Month":1.45,"return3Month":-1.43,"return1Year":-10.79,"return3Year":-10.43,"return5Year":-11.33,"return10Year":null,"returnInception":-2.04,"returnsAsOfDate":"2025-06-30"},"quarterlyPriceBasedReturns":{"returnYTD":-9.37,"return1Month":0.39,"return3Month":-2.33,"return1Year":-11.44,"return3Year":-10.75,"return5Year":-11.51,"return10Year":null,"returnInception":-2.48,"returnsAsOfDate":"2025-06-30"},"monthlyNavBasedReturns":{"returnYTD":-8.43,"return1Month":1.45,"return3Month":-1.43,"return1Year":-10.79,"return3Year":-10.43,"return5Year":-11.33,"return10Year":null,"returnInception":-2.04,"returnsAsOfDate":"2025-06-30"},"monthlyPriceBasedReturns":{"returnYTD":-9.37,"return1Month":0.39,"return3Month":-2.33,"return1Year":-11.44,"return3Year":-10.75,"return5Year":-11.51,"return10Year":null,"returnInception":-2.48,"returnsAsOfDate":"2025-06-30"},"secYieldPercentage":null,"prospectusLink":"https://www.ishares.com/us/library/stream-document?stream=reg\u0026product=IUS-IDNA\u0026shareClass=NA\u0026documentId=1709203%7E1709202%7E926300%7E1595236%7E1686316\u0026iframeUrlOverride=%2Fus%2Fliterature%2Fprospectus%2Fp-ishares-genomics-immunology-and-healthcare-etf-7-31.pdf"},"financials":null,"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":{"totalHoldings":39,"holdings":[{"symbol":"MRNA","name":"Moderna","weight":0.048799999999999996},{"symbol":"REGN","name":"Regeneron Pharmaceuticals","weight":0.0449},{"symbol":"TWST","name":"Twist Bioscience Corp","weight":0.0441},{"symbol":"MRK","name":"Merck","weight":0.041100000000000005},{"symbol":"EXEL","name":"Exelixis","weight":0.0408},{"symbol":"GMAB","name":"Genmab - ADR","weight":0.039900000000000005},{"symbol":"INCY","name":"Incyte","weight":0.0397},{"symbol":"ACLX","name":"Arcellx","weight":0.0397},{"symbol":"ROG","name":"Rogers","weight":0.0391},{"symbol":"AZN","name":"AstraZeneca","weight":0.0384}]},"etfHoldingsLastUpdated":"2025-07-23T00:00:00Z"},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"ATRA","name":"Atara Biotherapeutics","displayName":"Atara Biotherapeutics","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"LIQUIDATION_ONLY","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"ATRA","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":12.26,"high":13.4599,"low":12.1827,"volume":90316,"volumeDate":"2025-07-24","last":12.23,"open":13.26,"gainPercentage":-0.245,"gainValue":-0.03,"ask":12.2,"bid":11.39,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":83110600,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":61185.1129,"highPriceLast52Weeks":18.705,"lowPriceLast52Weeks":5.005,"companyName":"Atara Biotherapeutics, Inc.","longBusinessDescription":"Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.","dividendRate":0,"salesOrRevenue":128940000,"oneYearAnnualRevenueGrowthRate":1404.02426221859,"threeYearAnnualRevenueGrowthRate":510.0204,"fiveYearAnnualRevenueGrowthRate":306.0122,"earningsGrowth":89.9406,"totalDebt":84056000,"totalAssets":109098000,"floatAsPercentOfSharesOutstanding":56.2227,"dividendYield":0,"betaTwelveMonth":1.4946,"salesOrRevenueTtm":199732000,"ebitdaTtm":1635000,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":141079280,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":-16.9731310942579,"fiveYearAverageDebtEquityRatio":-12.06,"currentRatio":0.567568696233191,"peratio":-3.29},"recommendation":{"currentConsensusRating":2.5,"recommendationTargetPrice":17.43,"totalRatings":11,"strongSellRatings":2,"sellRatings":0,"holdRatings":3,"buyRatings":2,"strongBuyRatings":4,"lastUpdated":"2025-03-11T13:07:52Z"},"earningEstimates":[{"actual":-22.5,"estimate":-23.5,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2024-06-20T07:00:49Z","audioUrl":"https://files.quartr.com/audio-files/30d73-2024-03-18-10-44-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/03f74-2024-03-18-08-49-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-04T12:30:00Z","earningsSummary":null},{"actual":-24,"estimate":-17.25,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2024-06-20T07:00:45Z","audioUrl":"https://files.quartr.com/audio-files/f425d-2024-03-18-09-11-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/70cef-2024-03-18-07-20-59.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-28T21:30:00Z","earningsSummary":null},{"actual":-21.75,"estimate":-24.5,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2024-06-20T07:00:50Z","audioUrl":"https://files.quartr.com/audio-files/55ff0-2024-03-18-09-48-55.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/eb550-2024-03-18-07-24-47.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/71187-2024-03-18-07-22-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-05T20:30:00Z","earningsSummary":null},{"actual":-7.75,"estimate":-23.25,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2024-06-20T07:00:51Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_08_22_30_Q2_2022_Atara_Biotherapeutics_Inc_Earnings_Call.GGG2ZACOVF7L_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2af8f-2022-08-08-09-28-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d271c-2022-08-08-08-12-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-08T20:30:00Z","earningsSummary":null},{"actual":-20.5,"estimate":-19.5,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2024-06-20T07:00:55Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_08T21_30_00_00_00_Atara_Biotherapeutics_Inc_Earnings_Call_Q3_2022.PG1XW73JNCMX_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ec955-2022-11-08-09-27-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/88d17-2022-11-08-09-20-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-08T15:15:00Z","earningsSummary":null},{"actual":-18,"estimate":-12.75,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2024-06-20T07:00:59Z","audioUrl":null,"pdfUrl":"https://files.quartr.com/reports/c5822-2023-02-08-09-20-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/e63f7-2023-02-08-09-20-07.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-08T21:15:00Z","earningsSummary":null},{"actual":-18,"estimate":-9.75,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2024-06-20T07:00:52Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/181eb-2023-06-22-04-50-53.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-08T11:00:00Z","earningsSummary":null},{"actual":-17,"estimate":-16.75,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2024-06-20T07:00:52Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/a2e71-2023-08-14-01-08-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T11:00:00Z","earningsSummary":null},{"actual":-16.5,"estimate":-16.5,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2024-06-20T07:00:53Z","audioUrl":"https://files.quartr.com/audio-files/5cde8-2023-12-11-03-47-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/f34b0-2023-12-11-03-47-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-01T13:00:00Z","earningsSummary":{"summary":"Atara Biotherapeutics is strategically positioned to drive growth through financial stability, pipeline advancements, and operational efficiency.\nDespite workforce reductions, the company's focus on key clinical milestones and regulatory milestones bodes well for future revenue potential.\nNavigating challenges in workforce restructuring and regulatory hurdles, Atara remains focused on leveraging opportunities in CAR-T therapies and autoimmune diseases.","headline":"Atara Biotherapeutics strengthens financial position and advances clinical milestones","lastUpdated":"2024-05-06T21:45:48.926221Z"}},{"actual":-14,"estimate":-12,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-06-20T07:00:53Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/fdb5f-2024-03-28-12-25-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-28T11:00:00Z","earningsSummary":null},{"actual":-5.75,"estimate":-6.5,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-06-20T07:00:54Z","audioUrl":null,"pdfUrl":"https://files.quartr.com/conference-calls/46594-2024-05-09-08-22-23.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f9c93-2024-05-09-08-59-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-09T20:15:00Z","earningsSummary":null},{"actual":-3.1,"estimate":-1.56,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-12T21:55:33Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4e5e2-2024-08-12-09-21-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-12T20:00:00Z","earningsSummary":null},{"actual":-2.93,"estimate":-1.93,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-12T21:10:05Z","audioUrl":null,"pdfUrl":"https://files.quartr.com/conference-calls/467f3-2024-11-12-10-56-28.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/822a4-2024-11-12-09-43-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-12T21:00:00Z","earningsSummary":null},{"actual":-1.19,"estimate":-2.48,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-03-07T21:06:57Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/30c8c-2025-03-07-09-15-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-03-07T14:30:00Z","earningsSummary":null},{"actual":3.5,"estimate":-1.92,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-15T13:16:34Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/d5038-2025-05-15-12-11-43.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-15T12:30:00Z","earningsSummary":null},{"actual":null,"estimate":-0.32,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-22T23:30:10Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-11T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"3b1fde84e7db919fb23eae82275d01c3cb8c70e99233b44c89a0d1b8e829093c"},{"date":"2022-02-28","title":"Earnings data Q4 2021","quarter":"Q4","hash":"32ada4380ad5787dcfe3e4936ff9ed5442908220df1cdf5bcd595dfbc933b395"},{"date":"2022-05-05","title":"Earnings data Q1 2022","quarter":"Q1","hash":"00ebe711ff026338f37d0f99ae92989d01d9a2191230da580288f6f7856ed264"},{"date":"2022-08-08","title":"Earnings data Q2 2022","quarter":"Q2","hash":"92a66f461a725c66db024da30b782dbb22acb09e712c9fd71ff4c5957ec1ba00"},{"date":"2022-11-08","title":"Earnings data Q3 2022","quarter":"Q3","hash":"b0627e5406ebd1ee0de34cca767cf4e4adc110b75a8d6bcb857cf55bc1e22ab9"},{"date":"2023-02-08","title":"Earnings data Q4 2022","quarter":"Q4","hash":"cd50dda0d843149d3bec94e5cf241955723b156812b2f0f19a6be695d206f3e5"},{"date":"2023-05-08","title":"Earnings data Q1 2023","quarter":"Q1","hash":"81e97fd195a588006bfa27bf5695e7934b6452edc58425848f0a1bb3a85ad400"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"80e878dfe7d1e3c66b687684d83af2d479949a8c60525cc24b2c00abeebda3cc"},{"date":"2023-11-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"cbfdd5830d9e82c12b98d6b84141ffbff44697dfb6150165bf2453d9534af8b5"},{"date":"2024-03-28","title":"Earnings data Q4 2023","quarter":"Q4","hash":"60c4fa9f570dbab581178e0d826df7b76e282e742c219519d6b3f841bfc85e48"},{"date":"2024-05-09","title":"Earnings data Q1 2024","quarter":"Q1","hash":"8c12b21ade0d539caa7b2d535e9ca024e241d5171354887dfbe6efa88adf12dc"},{"date":"2024-08-12","title":"Earnings data Q2 2024","quarter":"Q2","hash":"c08caeddce397f50fba0a9436dbd9d97d19f9d2a5df675bc62f2d64a6e2d8052"},{"date":"2024-11-12","title":"Earnings data Q3 2024","quarter":"Q3","hash":"6febfb2f6071f0695111559ca0bace85380375ac917c46d9d9f64c361594666e"},{"date":"2025-03-07","title":"Earnings data Q4 2024","quarter":"Q4","hash":"81f02f095bf3d105537327ab17388551c156452943ceb3afbcea77eed64a98e5"},{"date":"2025-05-15","title":"Earnings data Q1 2025","quarter":"Q1","hash":"128f38490b66f576480f2364e991fdcbd0ee5152159257e30d28aef24a9e4804"},{"date":"2025-08-11","title":"Earnings data Q2 2025","quarter":"Q2","hash":"3fc5c592f62a1919e63498971f0adb305a9af609f0ed185dab6a4dc82ab2e687"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Atara Biotherapeutics","companyDescription":"Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":98149000,"changePercentage":258.77,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":20439000,"changePercentage":929.67,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":77710000,"changePercentage":206.28,"valueToRevenueRatio":0.7917553923116893},{"financialKey":"OPERATING_EXPENSES","value":29095000,"changePercentage":-43.91,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":29095000,"changePercentage":-43.91,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":48615000,"changePercentage":283.48,"valueToRevenueRatio":0.49531834252004603},{"financialKey":"EBITDA","value":50410000,"changePercentage":300.8,"valueToRevenueRatio":0.5136068630347737},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1795000,"changePercentage":29.04,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":38010000,"changePercentage":219.71,"valueToRevenueRatio":null},{"financialKey":"EPS","value":3.5029,"changePercentage":162.04,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":62038000,"changePercentage":-62.46,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":27182000,"changePercentage":-74.46,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":13987000,"changePercentage":-69.85,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":8875000,"changePercentage":-75.37,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":4320000,"changePercentage":-45.53,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":34856000,"changePercentage":-40.76,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":32012000,"changePercentage":-41.76,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":2844000,"changePercentage":-26.47,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":117110000,"changePercentage":-55.57,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":47892000,"changePercentage":-73.49,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":14405000,"changePercentage":-1.15,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":33487000,"changePercentage":-79.84,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":69218000,"changePercentage":-16.49,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":66090999.99999999,"changePercentage":-15.02,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":3127000,"changePercentage":-38.93,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":-55072000,"changePercentage":43.98,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":-55072000,"changePercentage":43.98,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":62038000,"changePercentage":-62.46,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":80496000,"changePercentage":-12.83,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":66509000,"changePercentage":44.72,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":-9.29642,"changePercentage":54.49,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":38010000,"changePercentage":219.71,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-28138000,"changePercentage":4.98,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":53975000,"changePercentage":401.89,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-82113000,"changePercentage":-599.85,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":17199000,"changePercentage":16.86,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":17199000,"changePercentage":15.86,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-250000,"changePercentage":-101.04,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-250000,"changePercentage":-10.13,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-11189000,"changePercentage":-221.01,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-28138000,"changePercentage":5.38,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:38Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-17T03:26:15Z","bearsSay":["Atara Biotherapeutics operates in a competitive biotechnology sector, facing potential challenges from emerging competitors that could significantly lower expected revenues. The company currently has no revenue and may remain without revenue for several years, necessitating substantial capital raises that could dilute shareholder value. Additionally, the recently announced workforce reduction, impacting approximately 50% of employees, underscores the financial strain and operational risks the company is confronting."],"bullsSay":["Atara Biotherapeutics is poised for a positive outlook primarily due to its strategic restructuring, which is expected to optimize operations and support the pathway to FDA approval for its lead product, tab-cel. The company has assigned a high probability of approval for tab-cel in EBV+ PTLD, which, if achieved, could unlock a significant $60 million milestone payment and substantial tiered royalties from net sales and commercial milestones. Additionally, the anticipated resubmission of the Biologics License Application for EBVALLO underscores Atara's commitment to overcoming regulatory challenges and advancing its portfolio of transformative therapies."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"REGN","name":"Regeneron Pharmaceuticals","displayName":"Regeneron Pharmaceuticals","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"REGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":572.39,"high":577.7299,"low":563.67,"volume":42,"volumeDate":"2025-07-25","last":564.64,"open":572.54,"gainPercentage":-1.354,"gainValue":-7.75,"ask":591.33,"bid":546,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":60961357600,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":1304015.871,"highPriceLast52Weeks":1211.1999,"lowPriceLast52Weeks":476.4869,"companyName":"Regeneron Pharmaceuticals, Inc.","longBusinessDescription":"Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.","dividendRate":0.88,"salesOrRevenue":14202000000,"oneYearAnnualRevenueGrowthRate":8.27005763425121,"threeYearAnnualRevenueGrowthRate":-2.7438,"fiveYearAnnualRevenueGrowthRate":22.0977,"earningsGrowth":15.6547,"totalDebt":2938800000,"totalAssets":37852400000,"floatAsPercentOfSharesOutstanding":96.3933,"dividendYield":0.16,"betaTwelveMonth":0.7139,"salesOrRevenueTtm":14085700000,"ebitdaTtm":4455500000,"debtToEquityRatioQuarterly":9.20388190937675,"totalEnterpriseValue":75915483000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":75.6123188405797,"fiveYearAverageDebtEquityRatio":13.45,"currentRatio":4.92673694835418,"peratio":14.37},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":783.15,"totalRatings":40,"strongSellRatings":0,"sellRatings":1,"holdRatings":6,"buyRatings":17,"strongBuyRatings":16,"lastUpdated":"2025-07-23T13:09:28Z"},"earningEstimates":[{"actual":15.37,"estimate":9.49,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T10:37:51Z","audioUrl":"https://files.quartr.com/audio-files/2161d-2022-10-19-04-55-35.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/93592-2023-01-25-10-20-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-04T00:00:00Z","earningsSummary":null},{"actual":23.72,"estimate":18.11,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-04T11:43:01Z","audioUrl":"https://files.quartr.com/audio-files/8985b-2022-10-19-10-28-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/58817-2023-01-25-12-19-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-04T02:54:15Z","earningsSummary":null},{"actual":11.49,"estimate":10.04,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-04T10:39:45Z","audioUrl":"https://files.quartr.com/audio-files/c8e56-2022-10-28-05-10-04.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/53164-2022-05-04-09-16-12-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ca18c-2023-01-25-01-02-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-04T09:12:16Z","earningsSummary":null},{"actual":9.77,"estimate":9.54,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-03T10:36:28Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_03_14_30_Q2_2022_Regeneron_Pharmaceuticals_Inc_Earnings_Call.8QKH4B59NJAO_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9c0d1-2022-08-03-05-40-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/eff6c-2022-08-03-11-07-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-03T01:06:00Z","earningsSummary":null},{"actual":11.14,"estimate":9.52,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T10:32:55Z","audioUrl":"https://files.quartr.com/audio-files/a8b82-2022-11-03-03-53-50.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/057ac-2022-11-03-02-54-30.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f942c-2022-11-03-11-55-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T12:30:00Z","earningsSummary":null},{"actual":12.56,"estimate":10.03,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-03T11:39:13Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_03T13_30_00_00_00_Regeneron_Pharmaceuticals_Inc_Earnings_Call_Q4_2022.CN8O9BB2MDF1_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/f9ba5-2023-02-03-01-09-31.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/1657e-2023-02-03-12-49-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-03T13:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.\nThe company's focus on safety, efficacy, and strategic imperatives positions it for future growth.\nChallenges include competitive positioning, trial data anticipation, and managing uncertainties.\nOpportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.","headline":"Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations","lastUpdated":"2024-05-04T03:19:35.084482Z"}},{"actual":10.09,"estimate":9.6,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T10:32:19Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_04T12_30_00_00_00_Regeneron_Pharmaceuticals_Inc_Q1_2023.T6BO2WGPKQWI_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9725b-2023-05-04-01-26-48.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2d369-2023-05-04-11-40-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.\nDespite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.\nWith a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.\nNavigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.","headline":"Regeneron excels in Q1 with strong revenue growth and pipeline advancements","lastUpdated":"2024-05-04T01:28:49.860354Z"}},{"actual":10.24,"estimate":9.92,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T10:31:04Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T12_30_00_00_00_Regeneron_Pharmaceuticals_Inc_Q2_2023.S1JTF5F8M0FM_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ff1f3-2023-08-03-02-56-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cfb47-2023-08-03-10-27-49.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.\nWhile facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.\nBalancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.\nRobust cash position and focus on patient well-being position Regeneron for continued success and market expansion.","headline":"Regeneron reports strong Q2 earnings, eyes aflibercept launch","lastUpdated":"2024-05-04T01:24:39.684032Z"}},{"actual":11.59,"estimate":10.77,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T10:35:42Z","audioUrl":"https://files.quartr.com/audio-files/4522f-2023-11-02-01-08-54.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b5ca5-2023-11-02-12-32-29.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9a1b1-2023-11-02-11-53-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T12:30:00Z","earningsSummary":{"summary":"Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.\nWhile facing legal challenges and competitive pressures, the company's strategic focus on innovation, R\u0026D, and shareholder value management positions it for long-term success.\nWith a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.","headline":"Regeneron posts robust Q3 results, eyes innovation and market growth","lastUpdated":"2024-05-04T02:51:08.005413Z"}},{"actual":11.86,"estimate":10.77,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-02T11:31:21Z","audioUrl":"https://files.quartr.com/audio-files/cb154-2024-02-02-02-14-52.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/3d54d-2024-02-02-01-24-34.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ba766-2024-02-02-12-16-02.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-02T13:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.\nThe company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.\nWhile facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.\nOverall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.","headline":"Regeneron posts strong Q4 results, eyes growth through innovation","lastUpdated":"2024-05-03T15:52:43.207068Z"}},{"actual":9.55,"estimate":10.1,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T10:31:43Z","audioUrl":"https://files.quartr.com/audio-files/31cf1-2024-05-02-01-14-41.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/90684-2024-05-02-12-39-33.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4f4fa-2024-05-02-10-15-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.\nThe company's robust pipeline and focus on innovation position it well for future growth.\nChallenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.\nOpportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.","headline":"Regeneron posts solid Q1 results, faces FDA request challenges","lastUpdated":"2024-05-03T16:36:27.013190Z"}},{"actual":11.56,"estimate":10.53,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T10:30:46Z","audioUrl":"https://files.quartr.com/audio-files/63cf9-2024-08-01-01-30-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9adbc-2024-08-01-12-49-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/be877-2024-08-01-11-15-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.\nWhile facing regulatory challenges, the company's pipeline and market position remain robust.\nOpportunities for expansion and innovation present avenues for future growth.\nOverall, Regeneron's Q2 results reflect resilience and strategic focus.","headline":"Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities","lastUpdated":"2024-08-01T16:08:26.153917Z"}},{"actual":12.46,"estimate":11.69,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T10:30:36Z","audioUrl":"https://files.quartr.com/audio-files/576d8-2024-10-31-02-37-26.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6c8f2-2024-10-31-12-16-37.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/75254-2024-10-31-11-17-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:30:00Z","earningsSummary":{"summary":"Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.","headline":"Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth","lastUpdated":"2024-10-31T16:33:08.315795Z"}},{"actual":12.07,"estimate":11.19,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-04T11:32:08Z","audioUrl":"https://files.quartr.com/audio-files/a8f68-2025-02-04-02-29-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2b884-2025-02-04-01-55-25.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c0966-2025-02-04-12-17-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-04T13:30:00Z","earningsSummary":null},{"actual":8.22,"estimate":8.82,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-29T10:30:33Z","audioUrl":"https://files.quartr.com/audio-files/255a7-2025-04-29-01-47-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/adfed-2025-04-29-12-43-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c65c3-2025-04-29-10-38-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-29T12:30:00Z","earningsSummary":{"summary":"Regeneron Pharmaceuticals navigated mixed performance in Q1 2025, with strong sales growth for DUPIXENT and Libtayo but challenges with EYLEA sales and FDA interactions. The company's financials remain robust, with total revenues of $3 billion and an updated gross margin guidance. Strategic investments in manufacturing facilities and pipeline advancements present growth potential amidst regulatory challenges.","headline":"Regeneron reports mixed Q1 performance, plans U.S. manufacturing investments","lastUpdated":"2025-04-29T15:31:28.799001Z"}},{"actual":null,"estimate":7.55,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:36Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-01T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"6514eb0c74aac5656bf2d6c329b32c557a3810d76793d52969d6c3ee7fcc5b6e"},{"date":"2022-02-04","title":"Earnings data Q4 2021","quarter":"Q4","hash":"86e60734e6ef4bfe0c752e8145584a0aa9e2530c22a0aaccf652098ae8dfa7de"},{"date":"2022-05-04","title":"Earnings data Q1 2022","quarter":"Q1","hash":"10f8132875b0e6f057e152d5e0803a6e89e8d0d301819ec10277955b952e8b36"},{"date":"2022-08-03","title":"Earnings data Q2 2022","quarter":"Q2","hash":"068bbb9ac1c2db3b6bc7d2a99c056832b83d9a131f5bc22c3f1049cf1e3a46f9"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"cf91839225fb4ac0f624e046a58e696f6ce362c81342b708e5bd26bdfe18be6e"},{"date":"2023-02-03","title":"Earnings data Q4 2022","quarter":"Q4","hash":"bb9f727a0597d7a3548447c05aed6c625803c6a2a448764b6fbfc2cfd7cbe29c"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"e0ac74ee6473c0186ab671482622034d780facf6ae986ad4bea203c01975cf34"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"d55cc49bc2f39837a9e699326a41c85b327acaf7515fad266b5f5cadc75eafdc"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"095ff751f339599e12ed885eb8a0d0beeebd4f0708823c3dd824ee512b832587"},{"date":"2024-02-02","title":"Earnings data Q4 2023","quarter":"Q4","hash":"bf03b589bd788a694b1b90ae52cf4cb47dd87bcbb30588dac9c2ed8fb83b9185"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"8fb65ab5c16812e3efc9edfe094ff10188854ec058f3d7bc3bd1d49c66ddfb5a"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"fdef64c360f17c42f1dcb70c09c63d614f732322a1cf36a0932e38e572e5f97e"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"bd0d04334aad00ef2d368267c753d1dcc32b34e382cee4fbbfc32d885c3c7ead"},{"date":"2025-02-04","title":"Earnings data Q4 2024","quarter":"Q4","hash":"519bd5e00572dd7d40ef6c33cd736b9a4b946d6430519d853239149f016c9979"},{"date":"2025-04-29","title":"Earnings data Q1 2025","quarter":"Q1","hash":"515f26c440a221ea7368d4ef29483c6500b837c01c954f0eb34d485162ae61dc"},{"date":"2025-08-01","title":"Earnings data Q2 2025","quarter":"Q2","hash":"aa8f1c616f54487d65667e29de27888dc7a6e72b308f65d5b716854605c15d16"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Regeneron Pharmaceuticals","companyDescription":"Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":3028700000,"changePercentage":-3.7,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":591200000,"changePercentage":7.9,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":2437500000,"changePercentage":-6.15,"valueToRevenueRatio":0.8048007395912438},{"financialKey":"OPERATING_EXPENSES","value":1833500000,"changePercentage":-0.28,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":1833500000,"changePercentage":0.56,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":604000000,"changePercentage":-20.37,"valueToRevenueRatio":0.19942549608743024},{"financialKey":"EBITDA","value":730900000,"changePercentage":-16.24,"valueToRevenueRatio":0.24132466074553438},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":126900000,"changePercentage":11.22,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":808700000,"changePercentage":12.01,"valueToRevenueRatio":null},{"financialKey":"EPS","value":7.2725,"changePercentage":15.94,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":37545200000,"changePercentage":9.24,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":17571700000,"changePercentage":-6.89,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":8349400000,"changePercentage":-20.63,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":5561000000,"changePercentage":6.49,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":3192400000,"changePercentage":17.59,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":468900000,"changePercentage":13.02,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":19973500000,"changePercentage":28.88,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":4694200000,"changePercentage":11.09,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":1167000000,"changePercentage":10.23,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":14112300000,"changePercentage":38.17,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":8157600000,"changePercentage":10.56,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":3566600000,"changePercentage":-0.4,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":3566600000,"changePercentage":-0.4,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":4591000000,"changePercentage":20.89,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":2704800000,"changePercentage":0.06,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":1886200000,"changePercentage":72.37,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":29387600000,"changePercentage":8.88,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":29387600000,"changePercentage":8.88,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":37545200000,"changePercentage":9.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":2704800000,"changePercentage":0.06,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-5644600000,"changePercentage":27.78,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":271.60444,"changePercentage":10.89,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":808700000,"changePercentage":12.01,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1045099999.9999999,"changePercentage":-30.9,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":915500000,"changePercentage":-14.6,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":129600000,"changePercentage":-70.58,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":647500000,"changePercentage":138.38,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":271500000,"changePercentage":67.8,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":919000000,"changePercentage":160.25,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-543000000,"changePercentage":-67.8,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-1089200000,"changePercentage":-2412.53,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-980800000,"changePercentage":-350.97,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":93800000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-14600000,"changePercentage":95.75,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":600000,"changePercentage":220,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":604000000,"changePercentage":571.88,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":815800000,"changePercentage":-40.82,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:32Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-04-24T13:11:30Z","bearsSay":["The negative outlook on Regeneron Pharmaceuticals's stock is primarily driven by potential significant erosion in Eylea sales, projected at a decline of 30%, which would also adversely affect revenue from collaborations with Bayer and Sanofi. This anticipated decline is attributed to competitive pressures from biosimilars and new market entrants, as well as slower uptake and growth rates for both Eylea and Dupixent. Additionally, risks are compounded by potential clinical setbacks in the oncology pipeline, contributing to downward adjustments in total revenue projections for the Eylea franchise over the upcoming fiscal years."],"bullsSay":["Regeneron Pharmaceuticals demonstrates a positive outlook driven by growing demand for its existing therapies, particularly Dupixent, which is expected to maintain its momentum due to its established long-term efficacy in treating type 2 inflammatory diseases. The company is poised for continued revenue growth linked to strategic collaborations with Bayer and Sanofi, as well as new drug developments that could enhance its market position and expand its product pipeline. Furthermore, manufacturing efficiencies are projected to bolster profit margins, solidifying Regeneron's financial outlook as it navigates patent protection and potential market share increases from high-dose Eylea and other emerging therapies."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Net product sales","dataPoints":[{"key":"21 Q2","value":4137.8},{"key":"21 Q3","value":2279.9},{"key":"21 Q4","value":3975.2},{"key":"22 Q1","value":1638.6},{"key":"22 Q2","value":1754.4},{"key":"22 Q3","value":1801.4},{"key":"22 Q4","value":1699.3},{"key":"23 Q1","value":1668},{"key":"23 Q2","value":1772.1},{"key":"23 Q3","value":1786.1},{"key":"23 Q4","value":1851.8},{"key":"24 Q1","value":1761.3},{"key":"24 Q2","value":1918.6},{"key":"24 Q3","value":1946.4},{"key":"24 Q4","value":2002.9},{"key":"25 Q1","value":1415.6}]},{"title":"Collaboration revenue","dataPoints":[{"key":"21 Q2","value":954.7},{"key":"21 Q3","value":1073.9},{"key":"21 Q4","value":890.3},{"key":"22 Q1","value":1232.5},{"key":"22 Q2","value":1043.6},{"key":"22 Q3","value":1050.6},{"key":"22 Q4","value":1587.4},{"key":"23 Q1","value":1378.1},{"key":"23 Q2","value":1316.7},{"key":"23 Q3","value":1438.3},{"key":"23 Q4","value":1370},{"key":"24 Q1","value":1266.8},{"key":"24 Q2","value":1524},{"key":"24 Q3","value":1660.1},{"key":"24 Q4","value":1606.9},{"key":"25 Q1","value":1531.2}]},{"title":"Other revenue","dataPoints":[{"key":"21 Q2","value":46},{"key":"21 Q3","value":99},{"key":"21 Q4","value":86.2},{"key":"22 Q1","value":94},{"key":"22 Q2","value":59.2},{"key":"22 Q3","value":84.2},{"key":"22 Q4","value":127.7},{"key":"23 Q1","value":116},{"key":"23 Q2","value":69.3},{"key":"23 Q3","value":138.3},{"key":"23 Q4","value":212.5},{"key":"24 Q1","value":116.9},{"key":"24 Q2","value":104.5},{"key":"24 Q3","value":114.2},{"key":"24 Q4","value":179.4},{"key":"25 Q1","value":81.9}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":86.49},{"key":"21 Q3","value":86.87},{"key":"21 Q4","value":80.15},{"key":"22 Q1","value":86.34},{"key":"22 Q2","value":89.6},{"key":"22 Q3","value":89.17},{"key":"22 Q4","value":84.16},{"key":"23 Q1","value":85.53},{"key":"23 Q2","value":87.17},{"key":"23 Q3","value":87.02},{"key":"23 Q4","value":84.94},{"key":"24 Q1","value":86.2},{"key":"24 Q2","value":86.46},{"key":"24 Q3","value":86.8},{"key":"24 Q4","value":85.07},{"key":"25 Q1","value":84.66}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":65.13},{"key":"21 Q3","value":53.49},{"key":"21 Q4","value":53.3},{"key":"22 Q1","value":42.44},{"key":"22 Q2","value":38.84},{"key":"22 Q3","value":41.67},{"key":"22 Q4","value":33.58},{"key":"23 Q1","value":29.93},{"key":"23 Q2","value":32.18},{"key":"23 Q3","value":33.03},{"key":"23 Q4","value":28.32},{"key":"24 Q1","value":23.89},{"key":"24 Q2","value":30.15},{"key":"24 Q3","value":31.7},{"key":"24 Q4","value":26.13},{"key":"25 Q1","value":19.53}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":60.3},{"key":"21 Q3","value":47.27},{"key":"21 Q4","value":45.01},{"key":"22 Q1","value":32.83},{"key":"22 Q2","value":29.82},{"key":"22 Q3","value":44.8},{"key":"22 Q4","value":35.06},{"key":"23 Q1","value":25.86},{"key":"23 Q2","value":30.66},{"key":"23 Q3","value":29.96},{"key":"23 Q4","value":33.76},{"key":"24 Q1","value":22.95},{"key":"24 Q2","value":40.37},{"key":"24 Q3","value":36.03},{"key":"24 Q4","value":24.21},{"key":"25 Q1","value":26.7}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":714.2},{"key":"21 Q3","value":665.4},{"key":"21 Q4","value":785.6},{"key":"22 Q1","value":843.8},{"key":"22 Q2","value":794.3},{"key":"22 Q3","value":911.3},{"key":"22 Q4","value":1043.1},{"key":"23 Q1","value":1101.2},{"key":"23 Q2","value":1085.3},{"key":"23 Q3","value":1075.3},{"key":"23 Q4","value":1177.2},{"key":"24 Q1","value":1248.4},{"key":"24 Q2","value":1200},{"key":"24 Q3","value":1271.5},{"key":"24 Q4","value":1412.1},{"key":"25 Q1","value":1327.4}]},{"title":"Selling, general, and administrative","dataPoints":[{"key":"21 Q2","value":414.7},{"key":"21 Q3","value":445},{"key":"21 Q4","value":559.6},{"key":"22 Q1","value":450},{"key":"22 Q2","value":476.3},{"key":"22 Q3","value":529.1},{"key":"22 Q4","value":660.5},{"key":"23 Q1","value":601.1},{"key":"23 Q2","value":652},{"key":"23 Q3","value":640.5},{"key":"23 Q4","value":737.7},{"key":"24 Q1","value":689},{"key":"24 Q2","value":758.8},{"key":"24 Q3","value":714.4},{"key":"24 Q4","value":792.2},{"key":"25 Q1","value":633}]},{"title":"Other operating (income) expense, net","dataPoints":[{"key":"21 Q2","value":-31.3},{"key":"21 Q3","value":42},{"key":"21 Q4","value":-15.8},{"key":"22 Q1","value":-20.2},{"key":"22 Q2","value":-17.4},{"key":"22 Q3","value":-45.7},{"key":"22 Q4","value":-6.6},{"key":"23 Q1","value":-0.5},{"key":"23 Q2","value":-0.6},{"key":"23 Q3","value":-0.5},{"key":"23 Q4","value":-0.5},{"key":"24 Q1","value":15.3},{"key":"24 Q2","value":14.6},{"key":"24 Q3","value":8},{"key":"24 Q4","value":15.5}]},{"title":"Acquired in-process research and development","dataPoints":[{"key":"22 Q1","value":28.1},{"key":"22 Q2","value":197},{"key":"22 Q4","value":30},{"key":"23 Q1","value":56.1},{"key":"23 Q3","value":100},{"key":"23 Q4","value":30},{"key":"24 Q1","value":7.1},{"key":"24 Q2","value":23.9},{"key":"24 Q3","value":56.2},{"key":"24 Q4","value":13.8},{"key":"25 Q1","value":12.3}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":163.24},{"key":"21 Q3","value":50.51},{"key":"21 Q4","value":104.37},{"key":"22 Q1","value":17.26},{"key":"22 Q2","value":-44.4},{"key":"22 Q3","value":-14.96},{"key":"22 Q4","value":-31.05},{"key":"23 Q1","value":6.64},{"key":"23 Q2","value":10.53},{"key":"23 Q3","value":14.53},{"key":"23 Q4","value":0.58},{"key":"24 Q1","value":-0.54},{"key":"24 Q2","value":12.32},{"key":"24 Q3","value":10.65},{"key":"24 Q4","value":10.33},{"key":"25 Q1","value":-3.7}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":7.6},{"key":"21 Q3","value":19.19},{"key":"21 Q4","value":47.25},{"key":"22 Q1","value":17.48},{"key":"22 Q2","value":32.12},{"key":"22 Q3","value":21.03},{"key":"22 Q4","value":29.91},{"key":"23 Q1","value":35.05},{"key":"23 Q2","value":19.76},{"key":"23 Q3","value":30.16},{"key":"23 Q4","value":12.59},{"key":"24 Q1","value":11.49},{"key":"24 Q2","value":15.01},{"key":"24 Q3","value":12.93},{"key":"24 Q4","value":14.87},{"key":"25 Q1","value":0.66}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":105},{"key":"21 Q3","value":106.2},{"key":"21 Q4","value":106.2},{"key":"22 Q1","value":106.8},{"key":"22 Q2","value":107.9},{"key":"22 Q3","value":106.9},{"key":"22 Q4","value":107},{"key":"23 Q1","value":107.1},{"key":"23 Q2","value":107},{"key":"23 Q3","value":106.3},{"key":"23 Q4","value":106.6},{"key":"24 Q1","value":107.8},{"key":"24 Q2","value":108.1},{"key":"24 Q3","value":108.1},{"key":"24 Q4","value":107.6},{"key":"25 Q1","value":106.7}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":53193},{"key":"21 Q3","value":65928.96},{"key":"21 Q4","value":65291.76},{"key":"22 Q1","value":67572.36},{"key":"22 Q2","value":70135},{"key":"22 Q3","value":67282.86},{"key":"22 Q4","value":78955.3},{"key":"23 Q1","value":80774.82},{"key":"23 Q2","value":82497},{"key":"23 Q3","value":83541.17},{"key":"23 Q4","value":87785.1},{"key":"24 Q1","value":102507.02},{"key":"24 Q2","value":104792.14},{"key":"24 Q3","value":120304.49},{"key":"24 Q4","value":90297.92},{"key":"25 Q1","value":73388.26}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":2.59},{"key":"21 Q3","value":4.77},{"key":"21 Q4","value":3.3},{"key":"22 Q1","value":5.7},{"key":"22 Q2","value":6.14},{"key":"22 Q3","value":5.73},{"key":"22 Q4","value":5.78},{"key":"23 Q1","value":6.39},{"key":"23 Q2","value":6.53},{"key":"23 Q3","value":6.21},{"key":"23 Q4","value":6.39},{"key":"24 Q1","value":8.15},{"key":"24 Q2","value":7.39},{"key":"24 Q3","value":8.08},{"key":"24 Q4","value":5.96},{"key":"25 Q1","value":6.06}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-29T14:44:59Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.48,"sell":0.52,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"SYRS","name":"Syros Pharmaceuticals","displayName":"Syros Pharmaceuticals","availableForFractional":false,"availableForTrade":true,"safetyLabel":"LOW_MARKET_CAP","trading":"LIQUIDATION_ONLY","optionsTrading":"LIQUIDATION_ONLY","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"SYRS","lastUpdated":"2025-07-24T19:59:59Z","batsLastUpdated":"2025-07-24T19:59:59Z","previousClose":0.0195,"high":0.02,"low":0.0002,"volume":4651,"volumeDate":"2025-07-24","last":0.02,"open":0.0002,"gainPercentage":2.564,"gainValue":0.0005,"ask":0,"bid":0,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":536600,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":133720.7581,"highPriceLast52Weeks":6.9275,"lowPriceLast52Weeks":0.0002,"companyName":"Syros Pharmaceuticals, Inc.","longBusinessDescription":"Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.","dividendRate":0,"salesOrRevenue":null,"oneYearAnnualRevenueGrowthRate":null,"threeYearAnnualRevenueGrowthRate":null,"fiveYearAnnualRevenueGrowthRate":null,"earningsGrowth":19.3723,"totalDebt":null,"totalAssets":null,"floatAsPercentOfSharesOutstanding":99.3989,"dividendYield":0,"betaTwelveMonth":0.7413,"salesOrRevenueTtm":386000,"ebitdaTtm":-110255000,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":null,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":null,"currentRatio":2.2517258382643,"peratio":-0.01},"recommendation":{"currentConsensusRating":2,"recommendationTargetPrice":9.29,"totalRatings":7,"strongSellRatings":0,"sellRatings":0,"holdRatings":2,"buyRatings":3,"strongBuyRatings":2,"lastUpdated":"2024-11-13T11:53:29Z"},"earningEstimates":[{"actual":-2.3,"estimate":-4.6,"period":"Q1 2021","fiscalQuarter":"Q1","fiscalYear":2021,"lastUpdated":"2022-09-19T06:44:27Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-05-06T00:00:00Z","earningsSummary":null},{"actual":-3.6,"estimate":-3.7,"period":"Q2 2021","fiscalQuarter":"Q2","fiscalYear":2021,"lastUpdated":"2022-09-19T06:44:29Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-08-05T00:00:00Z","earningsSummary":null},{"actual":-4.1,"estimate":-4.4,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2022-09-19T06:44:29Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-11-05T00:00:00Z","earningsSummary":null},{"actual":-3.8,"estimate":-4.7,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-09-19T06:44:30Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2022-03-15T00:00:00Z","earningsSummary":null},{"actual":-4,"estimate":-4.7,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-09-19T06:44:30Z","audioUrl":"https://files.quartr.com/audio-files/e0a3c-2023-02-13-12-42-51.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/5d842-2024-08-30-05-18-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-16T12:44:31Z","earningsSummary":null},{"actual":-5.4,"estimate":-3.5,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-09-19T06:44:31Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_09_14_30_Q2_2022_Syros_Pharmaceuticals_Inc_Earnings_Call.2SC7T4HMOQ5G_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/1448e-2022-08-09-11-32-41.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-09T06:19:00Z","earningsSummary":null},{"actual":-3.21,"estimate":-4.01,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-14T12:53:07Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_14T13_30_00_00_00_Syros_Pharmaceuticals_Inc_Earnings_Call_Q3_2022.O1JUZ9M4HSFC_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/dc9a3-2022-11-14-12-08-31.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-14T13:30:00Z","earningsSummary":null},{"actual":-0.17,"estimate":-1.35,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-03-06T07:33:14Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_03_02T13_30_00_00_00_Syros_Pharmaceuticals_Inc_Earnings_Call_Q4_2022.JN8F2TMTGN2T_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/67ba0-2023-03-02-12-38-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-03-02T13:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals demonstrated strong performance in heme programs, financial resilience, and strategic collaborations, despite challenges in expenses and net losses.\nThe company's focus on upcoming catalysts and clinical program advancements presents opportunities for growth and innovation in the competitive biopharmaceutical landscape.\nNavigating challenges in trial protocols and financial management, Syros Pharmaceuticals aims to leverage strengths in regulatory designations and partnerships for sustainable growth.","headline":"Syros Pharmaceuticals excels in heme programs and strategic collaborations","lastUpdated":"2024-05-12T13:27:45.328228Z"}},{"actual":-0.85,"estimate":-1.09,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-10T11:36:16Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_10T12_30_00_00_00_Syros_Pharmaceuticals_Inc_Q1_2023.476RZD5VU9DX_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/82a6b-2023-05-10-11-59-31.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-10T12:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals' Q1 2023 performance reflects ongoing investments in late-stage clinical programs amid revenue generation.\nThe company's focus on key therapeutic areas and proactive approach to trial protocols position it for potential clinical and regulatory milestones.\nWhile facing challenges in financial performance and the need for clarity on trial-related matters, Syros Pharmaceuticals maintains a solid cash position and promising opportunities ahead.","headline":"Syros Pharmaceuticals reports Q1 progress in key programs and trials","lastUpdated":"2024-05-12T12:27:40.397016Z"}},{"actual":-1.3,"estimate":-1.13,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-16T13:05:28Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_08T12_30_00_00_00_Syros_Pharmaceuticals_Inc_Q2_2023.RP7IT5F8H2ZR_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e29b1-2023-08-08-11-50-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T12:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals' Q2 performance reflects a focus on advancing innovative therapies for MDS and AML amid significant R\u0026D investments.\nThe company faces challenges in managing financials, decision-making timelines, and balancing investments with revenue generation.\nOpportunities lie in the potential of tamibarotene, strategic partnerships, and upcoming data readouts to drive future growth and value creation.","headline":"Syros Pharmaceuticals reports Q2 progress in clinical trials and challenges","lastUpdated":"2024-05-12T13:28:43.726849Z"}},{"actual":-1.43,"estimate":-1.14,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-14T12:07:28Z","audioUrl":"https://files.quartr.com/audio-files/23770-2023-11-14-02-32-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/1f0f3-2023-11-14-12-12-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-14T13:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals is strategically advancing tamibarotene for hematologic malignancies under new leadership, with a strong financial performance in the third quarter. While facing challenges in meeting efficacy data expectations, the company has opportunities to address unmet needs in AML and MDS, positioning itself for growth.","headline":"Syros Pharmaceuticals advances tamibarotene for hematologic malignancies under new CEO","lastUpdated":"2024-05-12T12:05:56.676297Z"}},{"actual":-2.18,"estimate":-1.14,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-03-28T06:48:29Z","audioUrl":"https://files.quartr.com/audio-files/58eb4-2024-03-27-01-39-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/6697d-2024-03-27-11-38-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-27T12:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals showcased strong performance in clinical trials and financial management in Q4 2023.\nWhile facing challenges in regulatory aspects and profitability, the company is well-positioned for growth.\nOpportunities lie in upcoming trial data, product launches, and strategic initiatives for revenue expansion.\nOverall, Syros Pharmaceuticals remains optimistic about its future prospects and market positioning.","headline":"Syros Pharmaceuticals reports positive trial results and secures $45M financing","lastUpdated":"2024-05-12T13:46:09.841582Z"}},{"actual":-0.1,"estimate":-0.87,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-14T10:52:41Z","audioUrl":"https://files.quartr.com/audio-files/a0190-2024-05-14-12-36-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3de22-2024-05-14-11-22-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-14T12:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals showcased progress in clinical development programs, particularly with tamibarotene, and secured FDA Fast Track Designation for AML treatment. Despite no revenue in Q1 2024, the company's financial position remains stable with $108.3 million in cash and extended financial flexibility. Challenges include revenue impact from terminated agreements and the need to navigate market competition.","headline":"Syros Pharmaceuticals advances tamibarotene with FDA Fast Track Designation","lastUpdated":"2024-05-14T17:12:06.422592Z"}},{"actual":-0.59,"estimate":-0.77,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-31T11:33:12Z","audioUrl":"https://files.quartr.com/audio-files/fd1a6-2024-07-31-01-48-06.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/e2479-2024-07-31-11-28-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-31T12:30:00Z","earningsSummary":{"summary":"Syros Pharmaceuticals showcased progress on tamibarotene trials with positive results in MDS and AML.\nFinancial performance in Q2 2024 reflected a net loss but maintained solid cash reserves for operations.\nAnalyst inquiries and executive insights highlighted strategic focus on pivotal studies and commercialization plans.","headline":"Syros Pharmaceuticals reports Q2 loss, eyes market expansion opportunities","lastUpdated":"2024-07-31T16:38:39.038792Z"}},{"actual":-0.16,"estimate":-0.72,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2025-04-21T10:45:26Z","audioUrl":"https://files.quartr.com/audio-files/ffdde-2024-10-31-01-18-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/2b8de-2024-10-31-10-41-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:30:00Z","earningsSummary":null},{"actual":null,"estimate":null,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-25T06:00:22Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-08T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-05-06","title":"Earnings data Q1 2021","quarter":"Q1","hash":"9e0fb263c54867a103064e86704b3a3b1fba53fc385ea70c5e800785cb255aa3"},{"date":"2021-08-05","title":"Earnings data Q2 2021","quarter":"Q2","hash":"228c7d54fc4115fb7fb4073c637b01e25ec34915c6e408885cea48e708bb278c"},{"date":"2021-11-05","title":"Earnings data Q3 2021","quarter":"Q3","hash":"a2093ab211e5df202c43eb366242d983f720f30a5754c54324a292a693661865"},{"date":"2022-03-15","title":"Earnings data Q4 2021","quarter":"Q4","hash":"efd8a7134470b0a23e2ca0adda4c10499dcbc94ba9fd27feeee1ec6a55d94476"},{"date":"2022-05-16","title":"Earnings data Q1 2022","quarter":"Q1","hash":"562e30a40ae0f841e37cc40259ed7a06ed863478aebd84e3d6caed5d7e23c1c9"},{"date":"2022-08-09","title":"Earnings data Q2 2022","quarter":"Q2","hash":"a850b9a51b0497fc5a636e1a14821546b29dd1195dc2924772ca3435bddf3bc2"},{"date":"2022-11-14","title":"Earnings data Q3 2022","quarter":"Q3","hash":"950e1a2c92f1ce2b99c103bb8816729d005a74cc985f3a7c1c46ed18f51b87db"},{"date":"2023-03-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"a90de77165fd62c569d8058afc25da63f61c313d03163b6ca36be8b859cc4a7e"},{"date":"2023-05-10","title":"Earnings data Q1 2023","quarter":"Q1","hash":"80cad6ecb96c238f52807c1a0ca09e0c18d4b7a1dfc595528bffb1b1667866de"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"04f6f7949d49ba316a3c410be28c97f80b0dc9953087b3a6386ae5290b06d6fc"},{"date":"2023-11-14","title":"Earnings data Q3 2023","quarter":"Q3","hash":"7622aeeeb2039d9ad5303d52aac6771ac97ef5fb7fd311656273b130b11508ec"},{"date":"2024-03-27","title":"Earnings data Q4 2023","quarter":"Q4","hash":"28028047e6d650b414e17ff5437a3758426a2cf2fb3926b8870ce8f95c9c53f5"},{"date":"2024-05-14","title":"Earnings data Q1 2024","quarter":"Q1","hash":"41123dfe84502c86f18e0732eac473d9fc48df23b7681ed83e4e3bf64fb666a6"},{"date":"2024-07-31","title":"Earnings data Q2 2024","quarter":"Q2","hash":"462d3166883d3ae9b0d207d489e86e98fb98eda46f4d3f5aa780692208d40210"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"6109cc7601a7ac96c189ab819787c2e52d0c389425e89663910f739d8c082b96"},{"date":"2025-08-08","title":"Earnings data Q2 2025","quarter":"Q2","hash":"ce7ac4fb23b0d9c2a2605df972d3a641a351183986acd42154b6369592a58228"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Syros Pharmaceuticals","companyDescription":"Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q3 2024","values":[{"financialKey":"REVENUE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":325000,"changePercentage":-47.24,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":-325000,"changePercentage":-110.33,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES","value":25857000,"changePercentage":-27.02,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":25857000,"changePercentage":-27.02,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-26182000,"changePercentage":18.9,"valueToRevenueRatio":null},{"financialKey":"EBITDA","value":-25857000,"changePercentage":18.34,"valueToRevenueRatio":null},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":325000,"changePercentage":-47.24,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-6396000,"changePercentage":84.07,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.1626,"changePercentage":88.66,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":84995000,"changePercentage":-42.49,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":63931000,"changePercentage":-47.82,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":58275000,"changePercentage":-48.07,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":5656000,"changePercentage":-34.47,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":21064000,"changePercentage":-16.68,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":17579000,"changePercentage":-12.46,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":3485000,"changePercentage":-32.97,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":96118000,"changePercentage":-13.79,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":28392000,"changePercentage":-0.01,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":2584000,"changePercentage":-33.93,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":25808000,"changePercentage":5.41,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":67726000,"changePercentage":-18.5,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":57642000,"changePercentage":-1.55,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":10084000,"changePercentage":-58.92,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":-11123000,"changePercentage":-130.64,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":-11123000,"changePercentage":-130.64,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":84995000,"changePercentage":-42.49,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":60226000,"changePercentage":-3.58,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":1951000,"changePercentage":103.92,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":-0.41454,"changePercentage":-123.66,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-6396000,"changePercentage":84.07,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-20689000,"changePercentage":35.18,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-24602000,"changePercentage":18.35,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":3913000,"changePercentage":318.6,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-20689000,"changePercentage":-541.92,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-20689000,"changePercentage":35.18,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:52Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-04-24T13:08:02Z","bearsSay":["Syros Pharmaceuticals Inc.'s negative outlook stems from several fundamental challenges, including the termination of its collaboration agreement with Pfizer, which led to the removal of tamibarotene from its valuation. Additionally, the recent failure of the Phase 3 SELECT-MDS-1 trial to meet its primary endpoint significantly undermines the potential for tamibarotene in treating higher-risk myelodysplastic syndrome, further complicating the company's revenue prospects. The financial health of Syros is also called into question, as evidenced by a net loss of $6.4 million in the latest quarter, raising concerns about its ability to sustain operations amid escalating risks and competition in a constrained market."],"bullsSay":["Syros Pharmaceuticals's strategic approach to streamlining the trial processes may lead to reduced operational expenses and expedite therapy delivery for hematologic malignancies, potentially enhancing market competitiveness. The promising early clinical data indicating a higher complete response (CR) rate for tamibarotene combined with azacitidine compared to control treatments underscores the therapeutic potential that could positively influence investor sentiment. Additionally, Syros maintains a solid financial position, with sufficient cash reserves to cover anticipated operational expenses through at least the third quarter of 2025, supporting continued investment in its clinical trials and development programs."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"BLUE","name":"bluebird bio","displayName":"bluebird bio","availableForFractional":false,"availableForTrade":false,"safetyLabel":null,"trading":"DISABLED","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"DISABLED","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":"CORPORATE_ACTION","newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":null,"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":48668500,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":534270.4062,"highPriceLast52Weeks":28.6,"lowPriceLast52Weeks":3.2,"companyName":"bluebird bio, Inc.","longBusinessDescription":"bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.","dividendRate":0,"salesOrRevenue":83807000,"oneYearAnnualRevenueGrowthRate":184.120419025664,"threeYearAnnualRevenueGrowthRate":300.7966,"fiveYearAnnualRevenueGrowthRate":160.478,"earningsGrowth":56.9446,"totalDebt":354868000,"totalAssets":460232000,"floatAsPercentOfSharesOutstanding":98.9245,"dividendYield":0,"betaTwelveMonth":1.3607,"salesOrRevenueTtm":103946000,"ebitdaTtm":-149196000,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":373336260,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":-11.8561052305239,"fiveYearAverageDebtEquityRatio":-38.46,"currentRatio":0.553907286449705,"peratio":-0.24},"recommendation":{"currentConsensusRating":2.3,"recommendationTargetPrice":61.66,"totalRatings":32,"strongSellRatings":1,"sellRatings":1,"holdRatings":13,"buyRatings":9,"strongBuyRatings":8,"lastUpdated":"2025-03-31T14:42:43Z"},"earningEstimates":[{"actual":-7.2,"estimate":-52,"period":"Q2 2020","fiscalQuarter":"Q2","fiscalYear":2020,"lastUpdated":"2025-01-02T09:38:57Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2020-08-05T00:00:00Z","earningsSummary":null},{"actual":-58.8,"estimate":-60.2,"period":"Q3 2020","fiscalQuarter":"Q3","fiscalYear":2020,"lastUpdated":"2025-01-02T09:38:56Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2020-11-04T00:00:00Z","earningsSummary":null},{"actual":-60.2,"estimate":-58.4,"period":"Q4 2020","fiscalQuarter":"Q4","fiscalYear":2020,"lastUpdated":"2025-01-02T09:38:56Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/00480-2023-09-06-01-36-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-02-23T12:00:00Z","earningsSummary":null},{"actual":-61.4,"estimate":-60.2,"period":"Q1 2021","fiscalQuarter":"Q1","fiscalYear":2021,"lastUpdated":"2025-01-02T09:39:03Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2021-05-05T00:00:00Z","earningsSummary":null},{"actual":-68.6,"estimate":-63.8,"period":"Q2 2021","fiscalQuarter":"Q2","fiscalYear":2021,"lastUpdated":"2025-01-02T09:38:54Z","audioUrl":"https://files.quartr.com/audio-files/27e85-2022-10-19-01-37-40.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/bcbd0-2021-08-09-10-00-14-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/06e86-2023-07-12-01-24-20.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-08-09T10:14:00Z","earningsSummary":null},{"actual":-63.2,"estimate":-51.6,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2025-01-02T09:38:53Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/828f4-2024-08-30-05-45-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-05T00:00:00Z","earningsSummary":null},{"actual":-42.8,"estimate":-37.6,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2025-01-02T09:38:50Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/af39d-2025-03-11-10-54-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-03-04T21:36:00Z","earningsSummary":null},{"actual":-33.2,"estimate":-27.8,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2025-01-02T09:38:48Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/a6e6a-2024-08-30-05-33-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-09T20:35:00Z","earningsSummary":null},{"actual":-25.4,"estimate":-24.8,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2025-01-02T09:38:48Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/bbb64-2024-08-30-05-31-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T10:52:00Z","earningsSummary":null},{"actual":-18.8,"estimate":-22.4,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2025-01-02T09:38:49Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b753e-2024-08-30-05-36-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-07T12:00:00Z","earningsSummary":null},{"actual":-16.4,"estimate":-8.8,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2025-01-02T09:38:46Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_03_29T12_00_00_00_00_bluebird_bio_Inc_Q4_2022.B0D75PJW07KB_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/54a45-2025-03-11-10-10-40.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-03-29T12:00:00Z","earningsSummary":{"summary":"Bluebird bio demonstrated financial strength and successful gene therapy launches.\nChallenges include potential submission delay and operational complexities.\nOpportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.\nOverall, Bluebird bio remains confident in its products and market positioning.","headline":"Bluebird bio reports strong financials and plans for expansion","lastUpdated":"2024-05-07T07:01:43.285250Z"}},{"actual":4.2,"estimate":-7.4,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2025-01-02T09:38:46Z","audioUrl":null,"pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/c0df2-2023-06-15-05-23-23.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-09T11:00:00Z","earningsSummary":null},{"actual":-13.4,"estimate":-14.4,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2025-01-02T09:38:45Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_08T12_00_00_00_00_bluebird_bio_Inc_Q2_2023.ICOY7MMF9A1V_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/80652-2023-08-08-12-54-43.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/89bf2-2023-08-08-11-00-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-08T12:00:00Z","earningsSummary":{"summary":"Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.\nChallenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.\nOpportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.","headline":"Bluebird bio excels in gene therapy market, faces manufacturing challenges","lastUpdated":"2024-05-05T13:00:05.419692Z"}},{"actual":-13.2,"estimate":-13.4,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2025-01-02T09:38:44Z","audioUrl":"https://files.quartr.com/audio-files/20a2f-2023-11-07-01-32-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/c203b-2023-11-07-12-07-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-07T13:00:00Z","earningsSummary":{"summary":"Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.\nThe company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.\nStrengths lie in a well-established commercial infrastructure and strategic pricing approach.\nOpportunities include financing plans, potential voucher sale, and expansion of treatment centers.","headline":"Bluebird bio reports revenue growth and milestones in Q3","lastUpdated":"2024-05-05T12:35:32.992131Z"}},{"actual":-7.2,"estimate":-8.8,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2025-01-02T09:38:43Z","audioUrl":"https://files.quartr.com/audio-files/b444d-2024-05-09-01-30-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/bf649-2024-05-09-11-11-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-09T12:00:00Z","earningsSummary":null},{"actual":null,"estimate":-13.2,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2025-01-02T09:38:43Z","audioUrl":"https://files.quartr.com/audio-files/9608e-2024-03-26-12-11-48.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0ea21-2024-03-27-03-38-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8725c-2024-03-26-11-22-03.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-26T12:00:00Z","earningsSummary":{"summary":"bluebird bio's Q4 performance showed revenue growth and extended cash runway\nStrengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement\nChallenges include financial restatement, reimbursement dynamics, and Medicaid coverage\nOpportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies","headline":"bluebird bio reports revenue growth and eyes U.S. expansion opportunities","lastUpdated":"2024-05-06T19:50:05.761789Z"}}],"earningDates":[{"date":"2020-08-05","title":"Earnings data Q2 2020","quarter":"Q2","hash":"fb113b4c496bce76ee9542fb0b5fa32fdb93e4e7f4dc56a4b96fcaa256369158"},{"date":"2020-11-04","title":"Earnings data Q3 2020","quarter":"Q3","hash":"5ca347758ee963a38fd87f1a15194f4bc83459bc428337a1e0a5df8fda5b4a14"},{"date":"2021-02-23","title":"Earnings data Q4 2020","quarter":"Q4","hash":"f6bf6e5d482936acf73f75aa958409d5afa26a5f14f3909e8fbfaa1a00da4f21"},{"date":"2021-05-05","title":"Earnings data Q1 2021","quarter":"Q1","hash":"d45358212e46c2e0cca8f6c68c5dfb0e9a079da15a7da3ead346fd9709fca41f"},{"date":"2021-08-09","title":"Earnings data Q2 2021","quarter":"Q2","hash":"738ab516ea2eac5228ee9e709b062fa50030b1ad734d7bc94bc747e540667722"},{"date":"2021-11-05","title":"Earnings data Q3 2021","quarter":"Q3","hash":"3848efd105d7d76035a17a4fa08739ddcf26a6677dee786a0c4a7e1cc2258ffc"},{"date":"2022-03-04","title":"Earnings data Q4 2021","quarter":"Q4","hash":"5874be680c5ca1ee781542fb489af2aa6192b99cec6d2bb5202a5dec698c7afa"},{"date":"2022-05-09","title":"Earnings data Q1 2022","quarter":"Q1","hash":"93811f6b45db48df45ce0593c7e88ad481c22d8302ceea6cf50d0943ef294207"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"fff2781cb55d6903445d4106d95727882cd0b3bd04dd0c0e612dcac97e35ccf2"},{"date":"2022-11-07","title":"Earnings data Q3 2022","quarter":"Q3","hash":"3a894b7feff522b62be9b3535e78c844bac2b43675895241bd99cb257f3e3658"},{"date":"2023-03-29","title":"Earnings data Q4 2022","quarter":"Q4","hash":"e1706b4baab2f14677adb34ff403cb081f9a2103311d8acd7284d45313b615f0"},{"date":"2023-05-09","title":"Earnings data Q1 2023","quarter":"Q1","hash":"de9216e6a4abbcf36d0d82ef2b338fff2371b0eeb91ab6c77455ed7108e375f7"},{"date":"2023-08-08","title":"Earnings data Q2 2023","quarter":"Q2","hash":"8864acf3d0eb477e08cd0180e6219f0e3ac88136a488d7984bb3108282a2e5c6"},{"date":"2023-11-07","title":"Earnings data Q3 2023","quarter":"Q3","hash":"050078ea6d28f9b963eb361ad1db3e1fb1a3291cd08594dd16c5b44132cebd91"},{"date":"2024-09-13","title":"Earnings data Q1 2024","quarter":"Q1","hash":"0b0a2b86fc8931ee4be3763dd61bf08df6bce7269128227daa32ad8ea56b0a32"},{"date":"2024-09-13","title":"Earnings data Q4 2023","quarter":"Q4","hash":"41934b91fed49930617600d70ef4d981273815a4baad5fba3dcafc0a01dce4f7"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"bluebird bio","companyDescription":"bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":38712000,"changePercentage":108.43,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":20008500,"changePercentage":-22.64,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":18703500,"changePercentage":356.53,"valueToRevenueRatio":0.48314476131432116},{"financialKey":"OPERATING_EXPENSES","value":40210500,"changePercentage":-43.68,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":40210500,"changePercentage":-43.68,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-21507000,"changePercentage":72.67,"valueToRevenueRatio":-0.555564166150031},{"financialKey":"EBITDA","value":-5964000,"changePercentage":90.57,"valueToRevenueRatio":-0.15406075635461872},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":15543000,"changePercentage":0.48,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-29069000,"changePercentage":58.36,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-2.9811,"changePercentage":58.76,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":295957000,"changePercentage":-53.13,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":174524000,"changePercentage":-35.74,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":78779000,"changePercentage":-62.85,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":2873000,"changePercentage":196.19,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":83283000,"changePercentage":174.82,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":9589000,"changePercentage":-66.09,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":121433000,"changePercentage":-66.26,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":87478000,"changePercentage":-69.37,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":14961000,"changePercentage":-5.85,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":18994000,"changePercentage":-67.49,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":353823000,"changePercentage":-29.3,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":315078000,"changePercentage":7.33,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":149275000,"changePercentage":-28.08,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":165803000,"changePercentage":92.79,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":38745000,"changePercentage":-81.27,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":38653000,"changePercentage":-81.31,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":92000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":-57866000,"changePercentage":-144.16,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":-57866000,"changePercentage":-144.16,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":295957000,"changePercentage":-53.13,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":187928000,"changePercentage":-54.64,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":109149000,"changePercentage":-46.04,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":-5.91073,"changePercentage":-143.66,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-29069000,"changePercentage":58.36,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-43442000,"changePercentage":41.83,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":742000,"changePercentage":101.64,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-44184000,"changePercentage":-49.95,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":3102000,"changePercentage":573.59,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":859000,"changePercentage":-51.61,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":2243000,"changePercentage":192.3,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":26709000,"changePercentage":-58.68,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-28019000,"changePercentage":-156.58,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":54728000,"changePercentage":261.96,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-13631000,"changePercentage":-27.56,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-44301000,"changePercentage":42.05,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:58Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-03-06T01:56:47Z","bearsSay":["bluebird bio Inc. has experienced a significant revenue decline, reporting total product revenue of $16.1 million in Q2 2024, which raises concerns about the sustainability of Zynteglo's adoption nearly two years post-launch. The company faces negative gross margins and lacks clarity on how manufacturing costs might improve with future sales, indicating potential financial distress. Additionally, the persistent net losses, amounting to $61 million in the latest quarter, alongside a missed revenue consensus, suggest challenges in achieving profitable operations in the near term."],"bullsSay":["bluebird bio Inc. is emphasizing its commitment to developing potentially curative gene therapies for severe genetic diseases, including sickle cell disease and beta-thalassemia, which may lead to significant value creation and cost reduction in healthcare. The company's alignment with ESG principles suggests a strategic focus on sustainable finance, positioning bluebird bio favorably for long-term growth in the biotechnology sector. Despite currently negative gross margins, there is potential for improvement as sales increase, particularly for treatments like SCD, which have lower cost of goods sold, indicating potential future profitability."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"VHT","name":"Vanguard Health Care ETF","displayName":"Vanguard Health Care ETF","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"VHT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":251.4,"high":252.38,"low":249.9201,"volume":3,"volumeDate":"2025-07-25","last":250.14,"open":250.86,"gainPercentage":-0.501,"gainValue":-1.26,"ask":255,"bid":246.15,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":null,"instrumentClass":"EXCHANGE_TRADED_FUND","averageDailyVolumeLast3Months":308481.8871,"highPriceLast52Weeks":289.1385,"lowPriceLast52Weeks":234.11,"companyName":null,"longBusinessDescription":"The fund tracks a market-cap-weighted index of US healthcare stocks.","dividendRate":3.9869,"salesOrRevenue":null,"oneYearAnnualRevenueGrowthRate":null,"threeYearAnnualRevenueGrowthRate":null,"fiveYearAnnualRevenueGrowthRate":null,"earningsGrowth":null,"totalDebt":null,"totalAssets":null,"floatAsPercentOfSharesOutstanding":null,"dividendYield":1.59,"betaTwelveMonth":0.5564,"salesOrRevenueTtm":null,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":null,"industry":"InvestmentTrustsOrMutualFunds","sector":"Miscellaneous","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":null,"currentRatio":null,"peratio":null},"recommendation":null,"earningEstimates":[],"earningDates":[],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Vanguard Health Care ETF","companyDescription":"VHT tracks a market-cap-weighted index of US health care stocks.","executives":null,"brands":[]},"etfFundamental":{"returnInception":0.0929,"etfType":"US Equities","category":"Broad Market / Multi-Cap","netExpenseRatio":0.09,"inceptionDate":"2004-01-26","assetsUnderManagement":15419077778,"returnYTD":-0.0056,"return1Month":0.0281,"return3Month":0.0247,"return1Year":-0.0615,"return3Year":0.036,"return5Year":0.0591,"return10Year":0.0727,"returnsAsOfDate":"2025-07-23","quarterlyNavBasedReturns":{"returnYTD":-1.33,"return1Month":2.51,"return3Month":-5.19,"return1Year":-5.45,"return3Year":3.49,"return5Year":6.59,"return10Year":7.35,"returnInception":9.22,"returnsAsOfDate":"2025-06-30"},"quarterlyPriceBasedReturns":{"returnYTD":-1.77,"return1Month":2.06,"return3Month":-5.54,"return1Year":-5.84,"return3Year":3.33,"return5Year":6.49,"return10Year":7.21,"returnInception":9.26,"returnsAsOfDate":"2025-06-30"},"monthlyNavBasedReturns":{"returnYTD":-1.33,"return1Month":2.51,"return3Month":-5.19,"return1Year":-5.45,"return3Year":3.49,"return5Year":6.59,"return10Year":7.35,"returnInception":9.22,"returnsAsOfDate":"2025-06-30"},"monthlyPriceBasedReturns":{"returnYTD":-1.77,"return1Month":2.06,"return3Month":-5.54,"return1Year":-5.84,"return3Year":3.33,"return5Year":6.49,"return10Year":7.21,"returnInception":9.26,"returnsAsOfDate":"2025-06-30"},"secYieldPercentage":null,"prospectusLink":"https://personal.vanguard.com/pub/Pdf/p954.pdf?2210143046"},"financials":null,"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":{"totalHoldings":408,"holdings":[{"symbol":"LLY","name":"Eli Lilly","weight":0.1105},{"symbol":"UNH","name":"UnitedHealth Group","weight":0.050199999999999995},{"symbol":"ABBV","name":"AbbVie","weight":0.0489},{"symbol":"JNJ","name":"Johnson \u0026 Johnson","weight":0.0453},{"symbol":"ABT","name":"Abbott Labs","weight":0.0415},{"symbol":"MRK","name":"Merck","weight":0.035},{"symbol":"ISRG","name":"Intuitive Surgical","weight":0.0342},{"symbol":"BSX","name":"Boston Scientific","weight":0.0279},{"symbol":"TMO","name":"Thermo Fisher Scientific","weight":0.0269},{"symbol":"AMGN","name":"Amgen","weight":0.0264}]},"etfHoldingsLastUpdated":"2025-06-30T00:00:00Z"},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"ADAP","name":"Adaptimmune Therapeutics","displayName":"Adaptimmune Therapeutics","availableForFractional":false,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"SELL_ALL_ONLY","instrumentClass":"DEPOSITORY_RECEIPT","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"ADAP","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":0.29,"high":0.3578,"low":0.2979,"volume":1059,"volumeDate":"2025-07-25","last":0.3323,"open":0.2999,"gainPercentage":14.586,"gainValue":0.0423,"ask":0.38,"bid":0.3399,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":85683200,"instrumentClass":"DEPOSITORY_RECEIPT","averageDailyVolumeLast3Months":986713.4194,"highPriceLast52Weeks":1.48,"lowPriceLast52Weeks":0.1951,"companyName":"Adaptimmune Therapeutics Plc","longBusinessDescription":"Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.","dividendRate":0,"salesOrRevenue":178106913.861284,"oneYearAnnualRevenueGrowthRate":194.320306982241,"threeYearAnnualRevenueGrowthRate":219.5491,"fiveYearAnnualRevenueGrowthRate":193.3655,"earningsGrowth":62.93,"totalDebt":74208999.999999,"totalAssets":245962999.999999,"floatAsPercentOfSharesOutstanding":89.0622,"dividendYield":0,"betaTwelveMonth":1.4102,"salesOrRevenueTtm":180200332.313662,"ebitdaTtm":-45225930,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":58518984.3287325,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":-19.0633224545487,"fiveYearAverageDebtEquityRatio":135.8,"currentRatio":2.01672149122807,"peratio":-1.21},"recommendation":{"currentConsensusRating":1.9,"recommendationTargetPrice":6.85,"totalRatings":13,"strongSellRatings":0,"sellRatings":1,"holdRatings":3,"buyRatings":3,"strongBuyRatings":6,"lastUpdated":"2025-06-26T14:56:10Z"},"earningEstimates":[{"actual":-0.3,"estimate":-0.26,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T11:51:54Z","audioUrl":"https://files.quartr.com/audio-files/f5721-2024-03-21-09-48-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/613ad-2024-03-21-09-42-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-04T13:00:00Z","earningsSummary":null},{"actual":-0.25,"estimate":0.14,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-10-17T20:45:27Z","audioUrl":"https://files.quartr.com/audio-files/51179-2024-03-21-09-54-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/874ca-2024-03-21-09-09-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-03-14T13:00:00Z","earningsSummary":null},{"actual":-0.32,"estimate":-0.22,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-10-17T20:44:33Z","audioUrl":"https://files.quartr.com/audio-files/d0906-2024-03-21-10-31-00.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/1c412-2024-03-21-09-22-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-09T12:00:00Z","earningsSummary":null},{"actual":-0.28,"estimate":-0.25,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-10-17T20:43:11Z","audioUrl":"https://files.quartr.com/audio-files/ba6ad-2024-03-21-09-26-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b8001-2024-03-21-09-45-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-04T12:00:00Z","earningsSummary":null},{"actual":-0.24,"estimate":-0.24,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-08T12:38:11Z","audioUrl":"https://files.quartr.com/audio-files/3a2a8-2024-03-21-09-34-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/55bca-2024-03-21-09-14-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-08T13:00:00Z","earningsSummary":null},{"actual":-0.18,"estimate":-0.25,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-03-06T11:36:32Z","audioUrl":"https://files.quartr.com/audio-files/56c8e-2024-03-21-09-20-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/cbf09-2024-03-21-09-59-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-03-06T13:00:00Z","earningsSummary":null},{"actual":0,"estimate":-0.14,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-12T11:33:22Z","audioUrl":"https://files.quartr.com/audio-files/e6a45-2024-03-21-09-02-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/8cf12-2024-03-21-09-09-13.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-12T12:00:00Z","earningsSummary":null},{"actual":-0.12,"estimate":-0.13,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-17T17:50:36Z","audioUrl":"https://files.quartr.com/audio-files/1e29b-2024-03-21-09-43-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/52be7-2024-03-21-09-35-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-09T12:00:00Z","earningsSummary":null},{"actual":-0.18,"estimate":-0.15,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-08T12:39:43Z","audioUrl":"https://files.quartr.com/audio-files/d2997-2024-03-21-09-56-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/b0d56-2024-03-21-09-48-11.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-08T13:00:00Z","earningsSummary":null},{"actual":-0.24,"estimate":-0.1,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-03-06T12:19:03Z","audioUrl":"https://files.quartr.com/audio-files/2e616-2024-03-21-09-17-58.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/3ef17-2024-03-21-09-39-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-03-06T13:00:00Z","earningsSummary":null},{"actual":-0.18,"estimate":-0.1,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-15T12:01:36Z","audioUrl":"https://files.quartr.com/audio-files/4dce9-2024-05-15-12-03-37.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/22be0-2024-05-15-11-30-35.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-15T12:00:00Z","earningsSummary":{"summary":"Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.\nStrengths lie in innovative therapies, financial stability, and clear development plans.\nChallenges include managing debt impact, FDA processes, and successful product launches.\nOpportunities exist in market leadership, upcoming presentations, and growth strategies.","headline":"Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel","lastUpdated":"2024-05-15T17:11:52.152208Z"}},{"actual":0.24,"estimate":-0.08,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-12T13:28:52Z","audioUrl":"https://files.quartr.com/audio-files/9c051-2024-08-12-12-27-44.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/edc73-2024-08-12-11-54-00.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-12T12:00:00Z","earningsSummary":{"summary":"Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.\nWhile facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.\nBy capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.","headline":"Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth","lastUpdated":"2024-08-13T03:08:54.627545Z"}},{"actual":-0.07,"estimate":-0.13,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-13T21:33:12Z","audioUrl":"https://files.quartr.com/audio-files/a423c-2024-11-13-10-07-56.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/d691e-2024-11-13-09-03-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-13T21:30:00Z","earningsSummary":{"summary":"Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.\nThe company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.\nWhile facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.\nOverall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.","headline":"Adaptimmune targets breakeven by 2027 with strong sarcoma franchise","lastUpdated":"2024-11-14T03:06:11.919828Z"}},{"actual":-0.3,"estimate":-0.15,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-03-25T13:54:50Z","audioUrl":"https://files.quartr.com/audio-files/5045f-2025-03-20-01-55-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/4e043-2025-03-20-11-53-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-03-20T12:00:00Z","earningsSummary":{"summary":"Adaptimmune Therapeutics (ADAP) is on a positive growth trajectory with strong TECELRA sales and efficient manufacturing processes. While facing short-term financial reporting delays and cost management challenges, the company's strategic restructuring aims for profitability by 2027. Opportunities lie in expanding market reach, exploring strategic partnerships, and optimizing TECELRA launch progress for sustained growth.","headline":"Adaptimmune (ADAP) excels in Q4 2024, eyes profitability by 2027","lastUpdated":"2025-03-21T02:21:30.933766Z"}},{"actual":-0.03,"estimate":-0.17,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-13T11:32:53Z","audioUrl":"https://files.quartr.com/audio-files/a30eb-2025-05-13-12-30-42.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":null,"reportUrl":"https://files.quartr.com/reports/2230f-2025-05-13-11-01-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-13T12:00:00Z","earningsSummary":{"summary":"Adaptimmune's Q1 2025 performance reflects strong sales and operational efficiency. The company's strengths lie in successful manufacturing, patient access, and strategic planning. Challenges include awaiting franchise approval and scaling operations for growth. Opportunities exist in market expansion, strategic partnerships, and revenue growth.","headline":"Adaptimmune reports robust Q1 sales, eyes market expansion opportunities","lastUpdated":"2025-05-13T17:31:26.306033Z"}},{"actual":null,"estimate":-0.13,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:15Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-11T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"535bc9565d50111a11d9962e8bdf7bc83410736f2e682213883d1b7e4a6d760c"},{"date":"2022-03-14","title":"Earnings data Q4 2021","quarter":"Q4","hash":"83dae19542854188c02147ee1d8f53a5e4c5be8df8456f004faae3efec9d0a1f"},{"date":"2022-05-09","title":"Earnings data Q1 2022","quarter":"Q1","hash":"584f6f3f5047e6ed80f31699b90c670db661a3ed902c9a9fc36e933d3041b04f"},{"date":"2022-08-04","title":"Earnings data Q2 2022","quarter":"Q2","hash":"5809233e04246685c812cf11dc4639041b7f8912e75437a50408a85eecfeb498"},{"date":"2022-11-08","title":"Earnings data Q3 2022","quarter":"Q3","hash":"6d18e45f3aa1f1f2afd1f3fb7a1673bf2904cf9e3593ae818c2077856551bfdf"},{"date":"2023-03-06","title":"Earnings data Q4 2022","quarter":"Q4","hash":"e803fe93ecf14ea86fe5d5e57341cd0890d5dcf5f99939b33f8ef87a3de57de1"},{"date":"2023-05-12","title":"Earnings data Q1 2023","quarter":"Q1","hash":"13bd09c99fcb98eacadef6b14278a85213df7128891a1aae79f9c5cdd3d431d0"},{"date":"2023-08-09","title":"Earnings data Q2 2023","quarter":"Q2","hash":"aadbf9f21ac4b566550a702c25e985b76e53ccb32317e141b963b903b055b3cf"},{"date":"2023-11-08","title":"Earnings data Q3 2023","quarter":"Q3","hash":"5d3923e1ea0d3e2e9603027a3804b2abe8e77eadfa88bbbeb85ebfa6e9d687d2"},{"date":"2024-03-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"0d805e57d644e016021bbe149f8caa349e9ba1ac32b655dcfb98c2c4d9fd53ff"},{"date":"2024-05-15","title":"Earnings data Q1 2024","quarter":"Q1","hash":"6b1f5bda245c7f5aec79984a094bce7bdda3339f845ea7c5463d669809214877"},{"date":"2024-08-12","title":"Earnings data Q2 2024","quarter":"Q2","hash":"8ef5f69b95fa26a666398b4d7fd12427acdffb723eeb0d4f7e433bbbd505b74e"},{"date":"2024-11-13","title":"Earnings data Q3 2024","quarter":"Q3","hash":"b70eac4daf9fdae629b4ead773d9070ba842b8104893ba91257729ca470bb20c"},{"date":"2025-03-20","title":"Earnings data Q4 2024","quarter":"Q4","hash":"6c8219cc95990159e1426982fc63d09c28ef8e443e2f057fc08901cd43bc7bd9"},{"date":"2025-05-13","title":"Earnings data Q1 2025","quarter":"Q1","hash":"ef3d72b3278924eab283aeff6be0acb14c0c3961544c391fc2dcdb0d81bcdce1"},{"date":"2025-08-11","title":"Earnings data Q2 2025","quarter":"Q2","hash":"ad45e4b7e0c754a7a396ee1417fd79e58885b1886a3b7697d87ad4eec710e94f"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Adaptimmune Therapeutics","companyDescription":"Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":7312970.441253,"changePercentage":28.87,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3357842.982291,"changePercentage":18.72,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":3955127.458962,"changePercentage":38.95,"valueToRevenueRatio":0.5408373369938483},{"financialKey":"OPERATING_EXPENSES","value":49438089.397569,"changePercentage":-11.03,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":49438089.397569,"changePercentage":-11.03,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-45482960,"changePercentage":13.73,"valueToRevenueRatio":-6.219491841978098},{"financialKey":"EBITDA","value":-43007490,"changePercentage":13.8,"valueToRevenueRatio":-5.880987807278915},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":2475470,"changePercentage":-12.48,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-47766696.702346005,"changePercentage":1.46,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-0.1859,"changePercentage":7.24,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":158072000,"changePercentage":-38.73,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":102998000,"changePercentage":-44.89,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":59563000,"changePercentage":-58.54,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":20852000,"changePercentage":-27.83,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":11758999.999999,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":10823999.999999,"changePercentage":-24.62,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":55074000,"changePercentage":-22.55,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":48941000,"changePercentage":-27.74,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":3806000,"changePercentage":626.34,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":2327000,"changePercentage":-18.58,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":195501000,"changePercentage":-16.32,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":51072000,"changePercentage":-23.1,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":4627000,"changePercentage":-11.87,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":46445000,"changePercentage":-24.06,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":144429000,"changePercentage":-13.63,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":44079000,"changePercentage":139.01,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":100350000,"changePercentage":-32.55,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":-37429000,"changePercentage":-253.55,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":-37429000,"changePercentage":-253.55,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":158072000,"changePercentage":-38.73,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":48706000,"changePercentage":105.58,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-10857000,"changePercentage":90.95,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":-0.14516,"changePercentage":-252.16,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-47766696.702346005,"changePercentage":1.46,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-66847677.093196,"changePercentage":-109.35,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-45416708.534471,"changePercentage":-7.41,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-21430968.558725,"changePercentage":-307.02,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":41312008.996477,"changePercentage":11646.26,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":1207618.866277,"changePercentage":237.52,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":42512600.986558,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-2408210.856357999,"changePercentage":-236.53,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-25417215.040842,"changePercentage":-186.99,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":131502.96881299998,"changePercentage":-99.55,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":-25548718.009656,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":558134.737864,"changePercentage":234.24,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-50394748.399698004,"changePercentage":-1345.21,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-68055300,"changePercentage":-112.45,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:56Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-05-01T08:58:36Z","bearsSay":["Adaptimmune Therapeutics PLC's stock outlook is negatively affected by a recent reduction in the 12-month price target from $4 to $3.50 per American Depositary Share (ADS), indicating a pessimistic view of future performance. The competitive landscape highlights concerns about the treatment burden associated with alternative therapies, particularly chemotherapy, which may impact market adoption of Adaptimmune's TCR therapies that are administered as one-time treatments. Additionally, there are implications regarding the company's ability to differentiate its products in a challenging oncology market, which may hinder growth prospects."],"bullsSay":["Adaptimmune Therapeutics PLC is poised for growth with projected sales of its afami-cel therapy expected to rise from $41 million in 2025 to $142 million by 2030, indicating a robust demand trajectory. Similarly, lete-cel is forecasted to generate $235 million in sales by 2031, beginning from $57 million in 2027, suggesting strong market potential and broader adoption supported by its relationship with Tecelra. Furthermore, positive results from the IGNYTE-ESO study and a strategic corporate restructuring position the company for enhanced operational efficiency and potential increased returns on capital, bolstering a favorable outlook for its stock."],"charts":[],"chartsLastUpdated":null,"etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.95,"sell":0.05,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"EXEL","name":"Exelixis","displayName":"Exelixis","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"DISABLED","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"EXEL","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":45.4,"high":45.75,"low":44.7132,"volume":51,"volumeDate":"2025-07-25","last":44.79,"open":45.29,"gainPercentage":-1.344,"gainValue":-0.61,"ask":45.56,"bid":44.5,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":12214591300,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":3265557.2258,"highPriceLast52Weeks":49.62,"lowPriceLast52Weeks":22.8,"companyName":"Exelixis, Inc.","longBusinessDescription":"Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.","dividendRate":0,"salesOrRevenue":2168701000,"oneYearAnnualRevenueGrowthRate":18.4947831066196,"threeYearAnnualRevenueGrowthRate":14.7896,"fiveYearAnnualRevenueGrowthRate":18.3438,"earningsGrowth":244.8702,"totalDebt":215834000,"totalAssets":2986976000,"floatAsPercentOfSharesOutstanding":96.7969,"dividendYield":0,"betaTwelveMonth":0.5335,"salesOrRevenueTtm":2298922000,"ebitdaTtm":844281000,"debtToEquityRatioQuarterly":8.78098979645466,"totalEnterpriseValue":9116780920,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":5.89,"currentRatio":3.49911050307941,"peratio":20.32},"recommendation":{"currentConsensusRating":2,"recommendationTargetPrice":36.3,"totalRatings":28,"strongSellRatings":0,"sellRatings":0,"holdRatings":10,"buyRatings":7,"strongBuyRatings":11,"lastUpdated":"2025-07-22T12:46:25Z"},"earningEstimates":[{"actual":0.2,"estimate":0.16,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-02T20:47:06Z","audioUrl":"https://files.quartr.com/audio-files/02656-2025-04-09-06-28-50.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/aa27e-2025-04-09-06-57-32.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c714a-2025-04-09-06-59-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-02T21:00:00Z","earningsSummary":null},{"actual":0.35,"estimate":0.06,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-17T21:27:50Z","audioUrl":"https://files.quartr.com/audio-files/78958-2022-10-19-11-56-27.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e2389-2023-02-27-11-44-52.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0f771-2023-01-25-12-35-29.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-17T00:37:23Z","earningsSummary":null},{"actual":0.26,"estimate":0.14,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-10T21:03:20Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_05_10_23_00_Q1_2022_Exelixis_Inc_Earnings_Call.WW0D3DCA0CQU.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9a8a3-2022-11-01-08-56-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/57128-2023-01-25-02-23-42.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-10T13:07:09Z","earningsSummary":null},{"actual":0.28,"estimate":0.19,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-09T20:59:00Z","audioUrl":"https://files.quartr.com/audio-files/88627-2022-08-09-11-30-33.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/1d5c4-2022-11-01-08-45-06.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/17517-2022-08-09-08-03-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-09T21:00:00Z","earningsSummary":null},{"actual":0.31,"estimate":0.2,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-01T20:07:49Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_11_01T21_00_00_00_00_Exelixis_Inc_Earnings_Call_Q3_2022.FSZ1EGMJO1X4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2cb17-2023-02-27-11-22-52.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4f3cb-2022-11-01-08-25-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-01T21:00:00Z","earningsSummary":null},{"actual":-0.03,"estimate":-0.12,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-07T21:19:14Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_07T22_00_00_00_00_Exelixis_Inc_Earnings_Call_Q4_2023.MD1RXTWNDV8Q_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/deae7-2023-02-27-11-09-52.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/74c9f-2023-02-07-09-12-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-07T22:00:00Z","earningsSummary":{"summary":"Exelixis showed strong revenue growth and strategic wins in Q4 2022.\nThe company faces challenges with net losses and gross to net expectations.\nOpportunities lie in pipeline advancement, zanzalintinib development, and new business activities.\nOverall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.","headline":"Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023","lastUpdated":"2024-05-05T21:05:34.755364Z"}},{"actual":0.16,"estimate":0.15,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-09T20:21:54Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_05_09T21_00_00_00_00_Exelixis_Inc_Q1_2023.X3GW6XSD8E4W_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/00f4e-2023-05-09-11-21-12.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ead4b-2023-05-09-08-02-30.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-09T21:00:00Z","earningsSummary":{"summary":"Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R\u0026D advancements.\nChallenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.\nOpportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.","headline":"Exelixis reports strong Q1 earnings, advances promising pipeline programs","lastUpdated":"2024-05-07T03:07:15.155731Z"}},{"actual":0.31,"estimate":0.22,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-01T20:10:10Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_01T21_00_00_00_00_Exelixis_Inc_Q2_2023.NA1G1BX9CULW_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2df71-2023-08-02-06-58-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6519b-2023-08-01-08-44-41.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-01T21:00:00Z","earningsSummary":{"summary":"Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R\u0026D efforts.\nThe company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.\nWhile facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.\nOverall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.","headline":"Exelixis reports robust Q2 earnings, advances pipeline for growth","lastUpdated":"2024-05-07T08:56:13.704947Z"}},{"actual":0.1,"estimate":0.15,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-01T20:28:35Z","audioUrl":"https://files.quartr.com/audio-files/92e41-2023-11-01-10-24-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/45225-2023-11-01-09-23-08.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1416f-2023-11-01-08-04-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-01T21:00:00Z","earningsSummary":{"summary":"Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.\nThe company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.\nOpportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.\nOverall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R\u0026D Day excitement.","headline":"Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities","lastUpdated":"2024-05-06T21:39:50.974412Z"}},{"actual":0.33,"estimate":0.22,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-06T21:06:32Z","audioUrl":"https://files.quartr.com/audio-files/3623c-2024-02-06-11-19-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7a25b-2024-02-07-10-46-26.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/72a5f-2024-02-06-09-46-25.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-06T22:00:00Z","earningsSummary":{"summary":"Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.\nWhile facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.\nOpportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.","headline":"Exelixis reports robust 2023 performance, eyes growth through collaborations","lastUpdated":"2024-05-07T05:29:20.630214Z"}},{"actual":0.17,"estimate":0.24,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-30T20:19:16Z","audioUrl":"https://files.quartr.com/audio-files/6a3d3-2024-04-30-10-01-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a4593-2024-05-01-01-36-20.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/eedee-2024-04-30-08-13-16.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-30T21:00:00Z","earningsSummary":{"summary":"Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.\nCompany is focused on advancing new indications, returning capital to shareholders, and pipeline development.\nChallenges include study criteria, market capture, and capital allocation decisions.\nExciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.","headline":"Exelixis reports strong Q1 earnings, focuses on pipeline advancement","lastUpdated":"2024-05-07T01:37:12.411732Z"}},{"actual":0.84,"estimate":0.3,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-06T20:06:19Z","audioUrl":"https://files.quartr.com/audio-files/7c221-2024-08-06-10-57-14.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ce55a-2024-08-06-09-47-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/0952e-2024-08-06-08-02-14.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-06T21:00:00Z","earningsSummary":{"summary":"Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.","headline":"Exelixis excels in Q2 with cabozantinib driving revenue growth","lastUpdated":"2024-08-07T00:38:35.750366Z"}},{"actual":0.47,"estimate":0.35,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-29T20:08:16Z","audioUrl":"https://files.quartr.com/audio-files/5c4d7-2024-10-29-10-05-16.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/eac62-2024-10-29-09-01-22.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/368fc-2024-10-29-08-38-09.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-29T21:00:00Z","earningsSummary":{"summary":"Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.","headline":"Exelixis excels in Q3 2024 with revenue growth and increased guidance","lastUpdated":"2024-10-30T00:27:17.566816Z"}},{"actual":0.55,"estimate":0.49,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-11T21:07:44Z","audioUrl":"https://files.quartr.com/audio-files/a4469-2025-02-11-11-28-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/72281-2025-02-11-10-50-57.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c6fb3-2025-02-11-09-06-10.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-11T22:00:00Z","earningsSummary":{"summary":"Exelixis delivered strong financial performance in Q4 2024, showcasing growth in revenues and net income. With a healthy cash position and share repurchases, the company is well-positioned for future success. Navigating regulatory activities and advancing pipeline therapies are key challenges, but the growth prospects for cabo and zanza offer promising opportunities.","headline":"Exelixis excels in Q4 2024, eyes $3B revenue goal for cabo","lastUpdated":"2025-02-12T08:51:26.306678Z"}},{"actual":0.62,"estimate":0.44,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-13T20:13:49Z","audioUrl":"https://files.quartr.com/audio-files/9c9ea-2025-05-13-10-59-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f5251-2025-05-13-10-10-33.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/536ee-2025-05-13-08-28-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-13T21:00:00Z","earningsSummary":{"summary":"Exelixis demonstrated robust performance in Q1 2025, driven by strong revenue growth and operational achievements. Strategic initiatives like advancing Zanza and optimizing capital allocation position the company for future success. While facing challenges in forecasting and market dynamics, Exelixis has opportunities to expand market reach and drive growth. Overall, Exelixis's strong financial performance and strategic focus indicate a positive outlook for the company's future.","headline":"Exelixis excels in Q1 2025, eyes revenue growth and innovation","lastUpdated":"2025-05-13T23:41:22.947487Z"}},{"actual":null,"estimate":0.61,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:50Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-28T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-02","title":"Earnings data Q3 2021","quarter":"Q3","hash":"396cafe48bc80bcf50ccec4c7ddcf349c7f0bc56a0c94a0cdf13d48de4a06f5f"},{"date":"2022-02-17","title":"Earnings data Q4 2021","quarter":"Q4","hash":"9562b060eb7fa61416b65d90d801b1f9581f6b8f4ecf430142a7c367d18dafe0"},{"date":"2022-05-10","title":"Earnings data Q1 2022","quarter":"Q1","hash":"d076c828ff65dfeab9c1e011466ad599f9af44cff21e210ef40c59e2152089dd"},{"date":"2022-08-09","title":"Earnings data Q2 2022","quarter":"Q2","hash":"ebf54b0ef163f99a24c936ff44c53ccb3718d71212ac9859fef6ea2b0ce5b256"},{"date":"2022-11-01","title":"Earnings data Q3 2022","quarter":"Q3","hash":"3bfe1147e054dd7973436c64cb760e8137bddee2ec7e7be44c2c0129ebe2cf4f"},{"date":"2023-02-07","title":"Earnings data Q4 2022","quarter":"Q4","hash":"bb8e577eabaf920495f9b43ac24a8c910db09e0d08616906cd73733ef18a2c66"},{"date":"2023-05-09","title":"Earnings data Q1 2023","quarter":"Q1","hash":"da7426323752ed0458c0e9d9b60b3f7296175dadae4e29d4876d4b6088006a5e"},{"date":"2023-08-01","title":"Earnings data Q2 2023","quarter":"Q2","hash":"9dd563c73c7dda801c1f0c448ee5d59680d4cc01e853616d52563bc77bc1cab0"},{"date":"2023-11-01","title":"Earnings data Q3 2023","quarter":"Q3","hash":"7adb9fd098e82c44ca25d528ac3886537149fb1ef285e337dce7cdfd49202104"},{"date":"2024-02-06","title":"Earnings data Q4 2023","quarter":"Q4","hash":"482830f7ce6cfc34e4fa09e8eb089fe58b5367c02761a557220df06089fd6315"},{"date":"2024-04-30","title":"Earnings data Q1 2024","quarter":"Q1","hash":"7a35457a042071b5a8ad7e73338463547da2df504c5e3cc7ef708af3eb030aaa"},{"date":"2024-08-06","title":"Earnings data Q2 2024","quarter":"Q2","hash":"609cd6dd91864b5deb86368661c1375bf20f4157427b550b6122cd137202e846"},{"date":"2024-10-29","title":"Earnings data Q3 2024","quarter":"Q3","hash":"a5d0ce8ede7b812fe451f90d6b32430ccb7ab14a83df2b597b3bc1ed1a831281"},{"date":"2025-02-11","title":"Earnings data Q4 2024","quarter":"Q4","hash":"cdac9e8c07838eff5d31af55346a0ed4caaceeb28de332a7a0f057ed77856160"},{"date":"2025-05-13","title":"Earnings data Q1 2025","quarter":"Q1","hash":"d094dcafde5054197cd978214a53430717ea34274b23b86087d472836f6fba76"},{"date":"2025-07-28","title":"Earnings data Q2 2025","quarter":"Q2","hash":"5214f989ba4caa96cb30760b6a8b2a816a8ffc4842b453fc166a059e8b714a7e"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Exelixis","companyDescription":"Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":555447000,"changePercentage":30.62,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":19172000,"changePercentage":-9.8,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":536275000,"changePercentage":32.75,"valueToRevenueRatio":0.9654836555062859},{"financialKey":"OPERATING_EXPENSES","value":349416000,"changePercentage":2.27,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":349416000,"changePercentage":2.27,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":186859000,"changePercentage":199.95,"valueToRevenueRatio":0.33641193489207794},{"financialKey":"EBITDA","value":194204000,"changePercentage":182.79,"valueToRevenueRatio":0.3496355187803697},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":7345000,"changePercentage":15.16,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":159616000,"changePercentage":327.73,"valueToRevenueRatio":null},{"financialKey":"EPS","value":0.5539,"changePercentage":353.64,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":2837247000,"changePercentage":1.19,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":1396502000,"changePercentage":8.05,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":1031316000,"changePercentage":7.07,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":294437000,"changePercentage":16.62,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":24853000,"changePercentage":17.75,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":45896000,"changePercentage":-17.44,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":1440745000,"changePercentage":-4.67,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":115030000,"changePercentage":-9.58,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":63684000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":1262031000,"changePercentage":-4.42,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":706223000,"changePercentage":4.51,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":399102000,"changePercentage":6.99,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":399102000,"changePercentage":6.99,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":307121000,"changePercentage":1.45,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":187125000,"changePercentage":-7.12,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":119996000,"changePercentage":18.49,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":2131024000,"changePercentage":0.14,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":2131024000,"changePercentage":0.14,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":2837247000,"changePercentage":1.19,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":187125000,"changePercentage":-7.12,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-844191000,"changePercentage":-10.82,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":7.74825,"changePercentage":7.42,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":159616000,"changePercentage":327.73,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":211437000,"changePercentage":207.22,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":194201000,"changePercentage":97.6,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":17236000,"changePercentage":158.51,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":49764000,"changePercentage":-55.49,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":2952000,"changePercentage":-69.54,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":72216000,"changePercentage":-44.44,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-25404000,"changePercentage":8.89,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-294823000,"changePercentage":-60.19,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":-272307000,"changePercentage":-53.79,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-22516000,"changePercentage":-222.21,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-33622000,"changePercentage":-879.38,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":208485000,"changePercentage":252.58,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:24Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-24T03:53:38Z","bearsSay":["Exelixis Inc is facing significant risks that could adversely impact its stock outlook, primarily stemming from anticipated declines in market share for cabozantinib across various cancer settings due to potential failures in clinical programs, particularly regarding zanzalintinib. The company's revenue guidance appears conservative, not factoring in potential contributions from neuroendocrine tumors (NETs), which may signify future financial strain if the product fails to meet market expectations. Furthermore, the company's critical clinical data and ongoing developments indicate concerns over tolerability and competitive positioning that could further dilute its market presence, leading to negative long-term outlooks."],"bullsSay":["Exelixis Inc continues to show robust growth, particularly with its cabozantinib (Cabo) franchise, which reported 20% year-over-year growth in the fourth quarter, amounting to $515.2 million in net product revenue for FY 2024. The company's strategic positioning in the metastatic renal cell carcinoma (RCC) market, along with a positive survey suggesting a significant demand for Cabo among oncologists treating advanced neuroendocrine tumors (NETs), indicates considerable upside potential for the treatment. Additionally, Exelixis is projected to achieve over $2 billion in revenue by 2025, bolstered by anticipated expansions in market penetration and the ongoing development of zanzalintinib."],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.57,"sell":0.43,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"ABT","name":"Abbott Labs","displayName":"Abbott Labs","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"ABT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":125.83,"high":125.98,"low":124.695,"volume":127,"volumeDate":"2025-07-25","last":125.64,"open":125.28,"gainPercentage":-0.151,"gainValue":-0.19,"ask":125.6,"bid":125,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":218593497600,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":6686017.6613,"highPriceLast52Weeks":141.23,"lowPriceLast52Weeks":99.92,"companyName":"Abbott Laboratories","longBusinessDescription":"Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.","dividendRate":2.32,"salesOrRevenue":41950000000,"oneYearAnnualRevenueGrowthRate":4.58999227106136,"threeYearAnnualRevenueGrowthRate":-0.7289,"fiveYearAnnualRevenueGrowthRate":6.1508,"earningsGrowth":139.9814,"totalDebt":15275000000,"totalAssets":81414000000,"floatAsPercentOfSharesOutstanding":99.3275,"dividendYield":1.8499999999999999,"betaTwelveMonth":0.2218,"salesOrRevenueTtm":43109000000,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":205261280000,"industry":"MedicalSpecialties","sector":"HealthTechnology","preTaxInterestCoverageRatio":11.3615257048093,"fiveYearAverageDebtEquityRatio":43.69,"currentRatio":null,"peratio":15.74},"recommendation":{"currentConsensusRating":1.8,"recommendationTargetPrice":127.81,"totalRatings":31,"strongSellRatings":0,"sellRatings":1,"holdRatings":4,"buyRatings":14,"strongBuyRatings":12,"lastUpdated":"2025-07-18T18:43:04Z"},"earningEstimates":[{"actual":1.32,"estimate":1.21,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-01-26T12:35:19Z","audioUrl":"https://files.quartr.com/audio-files/bd743-2022-10-19-09-26-59.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/041ca-2022-01-26-06-38-26-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/90fd8-2023-01-25-12-00-17.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-01-26T18:26:38Z","earningsSummary":null},{"actual":1.73,"estimate":1.47,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-20T11:37:12Z","audioUrl":"https://files.quartr.com/audio-files/09032-2022-10-28-04-38-13.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/e9dd6-2022-04-20-10-33-49-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8058d-2023-07-12-01-45-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-20T10:49:33Z","earningsSummary":null},{"actual":1.43,"estimate":1.12,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-20T11:39:19Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_20_15_00_Q2_2022_Abbott_Laboratories_Earnings_Call.H67IN5Y1H6X0.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a7229-2022-07-20-12-30-26.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/71c4a-2024-08-29-06-48-39.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-20T01:19:00Z","earningsSummary":null},{"actual":1.15,"estimate":0.94,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-19T11:30:58Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_10_19T13_00_00_00_00_Abbott_Laboratories_Earnings_Call_Q3_2022.99956CIWOQA4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/92c0a-2022-10-19-11-41-19.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/1d4dc-2022-10-19-11-23-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-19T13:00:00Z","earningsSummary":null},{"actual":1.03,"estimate":0.92,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-01-25T12:31:53Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_01_25T14_00_00_00_00_Abbott_Laboratories_Earnings_Call_Q4_2022.Z5CM3WC9DB7C_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/reports/3091f-2023-01-25-02-40-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/c86b8-2023-01-25-12-06-58.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-01-25T14:00:00Z","earningsSummary":{"summary":"Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.\nThe company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.\nWhile facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.\nInvestors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.","headline":"Abbott Labs reports solid Q4 performance and eyes growth opportunities","lastUpdated":"2024-05-07T04:22:21.598681Z"}},{"actual":1.03,"estimate":0.99,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-19T11:16:28Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_04_19T13_00_00_00_00_Abbott_Laboratories_Q1_2023.5SB8FBLP9Q81_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/17de8-2023-04-19-12-56-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/2ffc9-2023-04-19-12-56-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-19T13:00:00Z","earningsSummary":{"summary":"Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.","headline":"Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities","lastUpdated":"2024-05-06T22:04:57.892269Z"}},{"actual":1.08,"estimate":1.05,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-20T11:34:26Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_07_20T13_30_00_00_00_Abbott_Laboratories_Q2_2023.MQNYTXF35MPR_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/92540-2023-07-20-02-59-27.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/55b3b-2023-07-20-11-53-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-20T13:30:00Z","earningsSummary":{"summary":"Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.\nDespite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.\nThe company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.\nBy navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.","headline":"Abbott Labs excels in Q2 with strong sales growth and innovation","lastUpdated":"2024-05-05T10:01:59.477247Z"}},{"actual":1.14,"estimate":1.04,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-18T11:36:52Z","audioUrl":"https://files.quartr.com/audio-files/ef37b-2023-10-18-02-16-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/79fa1-2023-10-18-12-30-09.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/c6fdc-2023-10-18-11-58-38.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-18T13:00:00Z","earningsSummary":{"summary":"Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.\nThe company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.\nWhile challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.\nOverall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.","headline":"Abbott Labs excels in Q3, eyes growth in China and innovation","lastUpdated":"2024-05-07T01:50:21.866891Z"}},{"actual":1.19,"estimate":1.19,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-01-24T12:32:50Z","audioUrl":"https://files.quartr.com/audio-files/d1dcb-2024-01-24-03-19-05.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6938f-2024-01-24-12-07-48.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/24c83-2024-01-24-12-26-38.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-01-24T14:00:00Z","earningsSummary":{"summary":"Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.","headline":"Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth","lastUpdated":"2024-05-07T07:22:13.877525Z"}},{"actual":0.98,"estimate":0.95,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-17T11:36:28Z","audioUrl":"https://files.quartr.com/audio-files/2b37c-2024-04-17-02-07-19.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/941eb-2024-04-17-11-27-52.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/fe4e7-2024-04-17-11-48-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-17T13:00:00Z","earningsSummary":{"summary":"Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.","headline":"Abbott Labs excels in Q1, raises guidance on strong performance","lastUpdated":"2024-05-07T00:54:30.721995Z"}},{"actual":1.14,"estimate":1.1,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-18T11:31:20Z","audioUrl":"https://files.quartr.com/audio-files/ed12b-2024-07-18-02-11-12.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6d2be-2024-07-18-12-24-04.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/15d2f-2024-07-18-11-04-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-18T13:00:00Z","earningsSummary":{"summary":"Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.\nThe company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.\nWhile facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.","headline":"Abbott Labs excels in Q2, raises guidance amid strong segment performance","lastUpdated":"2024-07-18T16:17:07.932977Z"}},{"actual":1.21,"estimate":1.2,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-16T11:33:02Z","audioUrl":"https://files.quartr.com/audio-files/180cb-2024-10-16-02-31-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/8df9d-2024-10-16-12-38-34.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/42ce6-2024-10-16-11-13-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-16T13:00:00Z","earningsSummary":{"summary":"Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.","headline":"Abbott Labs excels in Q3 with strong sales growth and strategic advancements","lastUpdated":"2024-10-16T16:17:58.250920Z"}},{"actual":1.34,"estimate":1.34,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-01-22T12:03:43Z","audioUrl":"https://files.quartr.com/audio-files/a3e60-2025-01-22-03-17-53.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/783b0-2025-01-22-03-18-29.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/fc943-2025-01-22-12-25-15.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-01-22T14:30:00Z","earningsSummary":{"summary":"Abbott Labs reported a robust Q4 2024 performance with strong sales growth and increased earnings per share, driven by key segments like Nutrition, Diagnostics, and Medical Devices. The company's focus on innovation, market dynamics, and product portfolios positions it well for future growth and market leadership.\nWhile facing challenges related to sustaining growth momentum and navigating market uncertainties, Abbott Labs has opportunities to capitalize on its strengths and drive further growth through strategic investments and market expansion. Addressing margin expansion, operational efficiency, and market demands will be crucial for achieving forecasted targets in 2025.\nOverall, Abbott Labs' strong financial performance, diverse product portfolio, and strategic focus on innovation present a positive outlook for future growth and market competitiveness. By leveraging opportunities in market dynamics and product innovation, the company can continue to deliver value to shareholders and maintain its position as a key player in the healthcare industry.","headline":"Abbott Labs excels in Q4 2024, poised for growth in 2025","lastUpdated":"2025-01-22T18:06:06.972843Z"}},{"actual":1.09,"estimate":1.07,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-16T11:30:40Z","audioUrl":"https://files.quartr.com/audio-files/407ce-2025-04-16-02-26-23.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0bdb1-2025-04-16-11-58-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/7e186-2025-04-16-11-53-36.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-16T13:00:00Z","earningsSummary":{"summary":"Abbott Labs showcased robust financial performance in Q1 2025, driven by growth in key segments and gross margin expansion. While facing challenges in certain segments like Diagnostics, the company's diversified revenue streams and innovation efforts are key strengths. Opportunities in clinical trials, emerging markets, and a diversified business model position Abbott for sustained growth and profitability.","headline":"Abbott Labs reports strong Q1 earnings, eyes growth in diversified segments","lastUpdated":"2025-04-16T15:31:39.567410Z"}},{"actual":1.26,"estimate":1.25,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-17T11:43:41Z","audioUrl":"https://files.quartr.com/audio-files/25294-2025-07-17-02-01-19.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/87d55-2025-07-17-12-24-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/463c8-2025-07-17-11-38-31.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-07-17T13:00:00Z","earningsSummary":{"summary":"Abbott Labs showcased solid financial performance in Q2 2025, driven by sales growth, margin expansion, and successful product advancements. Despite challenges in the Diagnostics segment, the company remains optimistic about sustaining growth and achieving long-term objectives, with a focus on key growth areas in Medical Devices, EPD, and Structural Heart.","headline":"Abbott Labs reports strong Q2 performance, eyes growth opportunities","lastUpdated":"2025-07-17T15:41:25.297044Z"}},{"actual":null,"estimate":1.3,"period":"Q3 2025","fiscalQuarter":"Q3","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:14Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-10-15T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2022-01-26","title":"Earnings data Q4 2021","quarter":"Q4","hash":"1e85581254bb605755e5b54a217ae9e174b1bece1da335a54946e00663bcab22"},{"date":"2022-04-20","title":"Earnings data Q1 2022","quarter":"Q1","hash":"7309e200ddb787c03716bbb994a0d7a88f12808c036685a65ef5d7157875a286"},{"date":"2022-07-20","title":"Earnings data Q2 2022","quarter":"Q2","hash":"3571588940c45600d7f220ddb619e40aaa9dd3051aecb384059ee3d613aa9a78"},{"date":"2022-10-19","title":"Earnings data Q3 2022","quarter":"Q3","hash":"127143c647544196e0294964f8680f98b490a53ffc5eb36df545a6ca8e428f37"},{"date":"2023-01-25","title":"Earnings data Q4 2022","quarter":"Q4","hash":"8eac77cd04e33c83477a35d5d1b202b2be0271f44c80b22a9aeae325ece15563"},{"date":"2023-04-19","title":"Earnings data Q1 2023","quarter":"Q1","hash":"c4cd065c78fd5cb9259cf0ab6503a115f0b531429fd22c66f9b4f266c932650b"},{"date":"2023-07-20","title":"Earnings data Q2 2023","quarter":"Q2","hash":"f543a93717beaffdc375a5edf291a2eb9ae9946e18fc88c64cc3d03cabfbbdb1"},{"date":"2023-10-18","title":"Earnings data Q3 2023","quarter":"Q3","hash":"cb2f7e781e4fe67cdd0530e6be8498114832dc2dcb71bf75fc245abfff72d533"},{"date":"2024-01-24","title":"Earnings data Q4 2023","quarter":"Q4","hash":"adad1547c9cb7124bec51d4983178be9bdfc436031d2307524172503829bc6b1"},{"date":"2024-04-17","title":"Earnings data Q1 2024","quarter":"Q1","hash":"3450e5b8525a02d11a2658461c562753a34148d32deb74b08e4e57eb99788c74"},{"date":"2024-07-18","title":"Earnings data Q2 2024","quarter":"Q2","hash":"e6bafe78ac0be2d15084921bcaa68ac8fbf1d2a643995e917862e63c4b9c8e28"},{"date":"2024-10-16","title":"Earnings data Q3 2024","quarter":"Q3","hash":"0e4f8c6bf32362cb4e31f3f9ffdb02efa70d714c73ca8bb2d9b57047a1277f6a"},{"date":"2025-01-22","title":"Earnings data Q4 2024","quarter":"Q4","hash":"c09a1c896f899e518d80659861e1a97e9f38e7606401cfd71470a6b6ae918299"},{"date":"2025-04-16","title":"Earnings data Q1 2025","quarter":"Q1","hash":"fde748f06489c784cce58f84f2da8524335ba7ad2a70f5d0e115523d4ddc6715"},{"date":"2025-07-17","title":"Earnings data Q2 2025","quarter":"Q2","hash":"d374e42efb24aa22be9b26ed2d909905e6b969295b4c3e28bcdcd27dae58827d"},{"date":"2025-10-15","title":"Earnings data Q3 2025","quarter":"Q3","hash":"49653fa37405daa3c3501bbd55b970deaef3d16723e7306ae6caa438808b41c7"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Abbott Labs","companyDescription":"Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.","executives":null,"brands":[{"id":"0a0ac13a-8169-43ec-b4e5-fa585d338059","name":"St. Jude Medical","description":"St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.","imageUrl":null}]},"etfFundamental":null,"financials":{"periodKey":"Q2 2025","values":[{"financialKey":"REVENUE","value":11142000000,"changePercentage":7.37,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":4798000000,"changePercentage":-5.4,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":6344000000,"changePercentage":19.59,"valueToRevenueRatio":0.5693771315742236},{"financialKey":"OPERATING_EXPENSES","value":4245000000,"changePercentage":17.3,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":3825000000,"changePercentage":5.69,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":420000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":2099000000,"changePercentage":24.5,"valueToRevenueRatio":0.1883862861245737},{"financialKey":"EBITDA","value":0,"changePercentage":-100,"valueToRevenueRatio":0},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":-2099000000,"changePercentage":-360.75,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":1779000000,"changePercentage":37.16,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.016,"changePercentage":37.19,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":100,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":0,"changePercentage":-100,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:12:50Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.59,"priorDividend":0.55,"dividendYieldPercentage":1.73,"announcementDate":"2025-06-13","exDividendDate":"2025-07-15","payableDate":"2025-08-15","recordDate":"2025-07-15","updatedAt":"2025-06-13T16:33:12Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-07-11T02:45:59Z","bearsSay":["Abbott Laboratories is facing significant challenges due to decreased sales from COVID-19 testing, which plummeted from $8.4 billion in 2022 to $1.6 billion in 2023, impacting overall revenue expectations. Additionally, the company is projected to experience headwinds from foreign currency fluctuations and macroeconomic pressures, including inflation and supply chain issues, which could negatively impact performance in 2025. Furthermore, Abbott's growth prospects may be hindered by competitive pressures, geopolitical risks affecting international expansion, and regulatory hurdles for new product introductions, all contributing to a negative outlook on the stock."],"bullsSay":["Abbott Laboratories reported a strong performance in its Medical Device division, achieving sales of $5.05 billion, reflecting a growth of 14% year-over-year, driven by advancements in electrophysiology and structural heart products. The company anticipates organic sales growth of 7.5% to 8.5% for 2025, suggesting robust future performance and resilience despite the absence of COVID-19 testing revenues. Additionally, Abbott's commitment to shareholder returns is evident in its nearly 50 consecutive years of dividend increases, with a current payout ratio of 46% and a yield of 1.8%, highlighting financial stability and investor confidence."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Nutrition","dataPoints":[{"key":"21 Q3","value":2108},{"key":"21 Q4","value":2042},{"key":"22 Q1","value":1894},{"key":"22 Q2","value":1953},{"key":"22 Q3","value":1795},{"key":"22 Q4","value":1817},{"key":"23 Q1","value":1967},{"key":"23 Q2","value":2076},{"key":"23 Q3","value":2073},{"key":"23 Q4","value":2038},{"key":"24 Q1","value":2068},{"key":"24 Q2","value":2150},{"key":"24 Q3","value":2066},{"key":"24 Q4","value":2129},{"key":"25 Q1","value":2146},{"key":"25 Q2","value":2212}]},{"title":"Diagnostics","dataPoints":[{"key":"21 Q3","value":3912},{"key":"21 Q4","value":4471},{"key":"22 Q1","value":5286},{"key":"22 Q2","value":4322},{"key":"22 Q3","value":3671},{"key":"22 Q4","value":3305},{"key":"23 Q1","value":2688},{"key":"23 Q2","value":2317},{"key":"23 Q3","value":2449},{"key":"23 Q4","value":2534},{"key":"24 Q1","value":2214},{"key":"24 Q2","value":2195},{"key":"24 Q3","value":2412},{"key":"24 Q4","value":2520},{"key":"25 Q1","value":2054},{"key":"25 Q2","value":2173}]},{"title":"Established Pharmaceuticals","dataPoints":[{"key":"21 Q3","value":1265},{"key":"21 Q4","value":1203},{"key":"22 Q1","value":1147},{"key":"22 Q2","value":1223},{"key":"22 Q3","value":1326},{"key":"22 Q4","value":1216},{"key":"23 Q1","value":1189},{"key":"23 Q2","value":1287},{"key":"23 Q3","value":1368},{"key":"23 Q4","value":1222},{"key":"24 Q1","value":1226},{"key":"24 Q2","value":1294},{"key":"24 Q3","value":1406},{"key":"24 Q4","value":1268},{"key":"25 Q1","value":1260},{"key":"25 Q2","value":1383}]},{"title":"Medical Devices","dataPoints":[{"key":"21 Q3","value":3632},{"key":"21 Q4","value":3749},{"key":"22 Q1","value":3565},{"key":"22 Q2","value":3757},{"key":"22 Q3","value":3615},{"key":"22 Q4","value":3750},{"key":"23 Q1","value":3900},{"key":"23 Q2","value":4295},{"key":"23 Q3","value":4249},{"key":"23 Q4","value":4443},{"key":"24 Q1","value":4453},{"key":"24 Q2","value":4734},{"key":"24 Q3","value":4747},{"key":"24 Q4","value":5052},{"key":"25 Q1","value":4895},{"key":"25 Q2","value":5369}]},{"title":"Other","dataPoints":[{"key":"21 Q3","value":11},{"key":"21 Q4","value":3},{"key":"22 Q1","value":3},{"key":"22 Q2","value":2},{"key":"22 Q3","value":3},{"key":"22 Q4","value":3},{"key":"23 Q1","value":3},{"key":"23 Q2","value":3},{"key":"23 Q3","value":4},{"key":"23 Q4","value":4},{"key":"24 Q1","value":3},{"key":"24 Q2","value":4},{"key":"24 Q3","value":4},{"key":"24 Q4","value":5},{"key":"25 Q1","value":3},{"key":"25 Q2","value":5}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q3","value":59.52},{"key":"21 Q4","value":58.44},{"key":"22 Q1","value":58.07},{"key":"22 Q2","value":56.17},{"key":"22 Q3","value":55.53},{"key":"22 Q4","value":54.48},{"key":"23 Q1","value":55.56},{"key":"23 Q2","value":55.07},{"key":"23 Q3","value":54.59},{"key":"23 Q4","value":55.51},{"key":"24 Q1","value":55.2},{"key":"24 Q2","value":55.64},{"key":"24 Q3","value":55.82},{"key":"24 Q4","value":54.96},{"key":"25 Q1","value":56.86},{"key":"25 Q2","value":56.43}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q3","value":23.29},{"key":"21 Q4","value":20.73},{"key":"22 Q1","value":24.48},{"key":"22 Q2","value":21.1},{"key":"22 Q3","value":17},{"key":"22 Q4","value":12.92},{"key":"23 Q1","value":15.48},{"key":"23 Q2","value":15.45},{"key":"23 Q3","value":16.23},{"key":"23 Q4","value":17.38},{"key":"24 Q1","value":13.91},{"key":"24 Q2","value":16.08},{"key":"24 Q3","value":17.48},{"key":"24 Q4","value":17.41},{"key":"25 Q1","value":16.34},{"key":"25 Q2","value":18.41}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q3","value":19.21},{"key":"21 Q4","value":17.34},{"key":"22 Q1","value":20.57},{"key":"22 Q2","value":17.92},{"key":"22 Q3","value":13.78},{"key":"22 Q4","value":10.23},{"key":"23 Q1","value":13.52},{"key":"23 Q2","value":13.78},{"key":"23 Q3","value":14.15},{"key":"23 Q4","value":15.56},{"key":"24 Q1","value":12.29},{"key":"24 Q2","value":12.54},{"key":"24 Q3","value":15.47},{"key":"24 Q4","value":84.09},{"key":"25 Q1","value":12.79},{"key":"25 Q2","value":15.96}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Amortization of intangible assets","dataPoints":[{"key":"21 Q3","value":520},{"key":"21 Q4","value":514},{"key":"22 Q1","value":512},{"key":"22 Q2","value":507},{"key":"22 Q3","value":498},{"key":"22 Q4","value":496},{"key":"23 Q1","value":491},{"key":"23 Q2","value":498},{"key":"23 Q3","value":496},{"key":"23 Q4","value":481},{"key":"24 Q1","value":472},{"key":"24 Q2","value":471},{"key":"24 Q3","value":470},{"key":"24 Q4","value":465},{"key":"25 Q1","value":420},{"key":"25 Q2","value":420}]},{"title":"Research and development","dataPoints":[{"key":"21 Q3","value":672},{"key":"21 Q4","value":762},{"key":"22 Q1","value":697},{"key":"22 Q2","value":684},{"key":"22 Q3","value":782},{"key":"22 Q4","value":725},{"key":"23 Q1","value":654},{"key":"23 Q2","value":715},{"key":"23 Q3","value":672},{"key":"23 Q4","value":700},{"key":"24 Q1","value":684},{"key":"24 Q2","value":698},{"key":"24 Q3","value":713},{"key":"24 Q4","value":749},{"key":"25 Q1","value":716},{"key":"25 Q2","value":725}]},{"title":"Selling, general, and administrative","dataPoints":[{"key":"21 Q3","value":2767},{"key":"21 Q4","value":3048},{"key":"22 Q1","value":2787},{"key":"22 Q2","value":2757},{"key":"22 Q3","value":2731},{"key":"22 Q4","value":2973},{"key":"23 Q1","value":2762},{"key":"23 Q2","value":2740},{"key":"23 Q3","value":2723},{"key":"23 Q4","value":2724},{"key":"24 Q1","value":2959},{"key":"24 Q2","value":2936},{"key":"24 Q3","value":2895},{"key":"24 Q4","value":2907},{"key":"25 Q1","value":3061},{"key":"25 Q2","value":3091}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q3","value":23.44},{"key":"21 Q4","value":7.17},{"key":"22 Q1","value":13.76},{"key":"22 Q2","value":10.11},{"key":"22 Q3","value":-4.74},{"key":"22 Q4","value":-12.01},{"key":"23 Q1","value":-18.06},{"key":"23 Q2","value":-11.36},{"key":"23 Q3","value":-2.56},{"key":"23 Q4","value":1.49},{"key":"24 Q1","value":2.23},{"key":"24 Q2","value":4},{"key":"24 Q3","value":4.85},{"key":"24 Q4","value":7.16},{"key":"25 Q1","value":3.95},{"key":"25 Q2","value":7.37}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q3","value":16.72},{"key":"21 Q4","value":14.51},{"key":"22 Q1","value":1.27},{"key":"22 Q2","value":1.65},{"key":"22 Q3","value":1.31},{"key":"22 Q4","value":-3.01},{"key":"23 Q1","value":-2.23},{"key":"23 Q2","value":0.13},{"key":"23 Q3","value":-2.99},{"key":"23 Q4","value":-6.89},{"key":"24 Q1","value":5.32},{"key":"24 Q2","value":3.85},{"key":"24 Q3","value":4.81},{"key":"24 Q4","value":5.53},{"key":"25 Q1","value":1.99},{"key":"25 Q2","value":3.19}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q3","value":1775},{"key":"21 Q4","value":1782},{"key":"22 Q1","value":1775},{"key":"22 Q2","value":1765},{"key":"22 Q3","value":1764},{"key":"22 Q4","value":1754},{"key":"23 Q1","value":1752},{"key":"23 Q2","value":1750},{"key":"23 Q3","value":1748},{"key":"23 Q4","value":1748},{"key":"24 Q1","value":1750},{"key":"24 Q2","value":1751},{"key":"24 Q3","value":1748},{"key":"24 Q4","value":1746},{"key":"25 Q1","value":1747},{"key":"25 Q2","value":1751}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q3","value":217970},{"key":"21 Q4","value":228096},{"key":"22 Q1","value":220100},{"key":"22 Q2","value":199445},{"key":"22 Q3","value":186984},{"key":"22 Q4","value":180662},{"key":"23 Q1","value":183960},{"key":"23 Q2","value":185500},{"key":"23 Q3","value":182491.2},{"key":"23 Q4","value":174625.2},{"key":"24 Q1","value":200550},{"key":"24 Q2","value":185606},{"key":"24 Q3","value":191755.6},{"key":"24 Q4","value":201837.6},{"key":"25 Q1","value":222393.1},{"key":"25 Q2","value":230956.9}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q3","value":4.99},{"key":"21 Q4","value":4.97},{"key":"22 Q1","value":4.63},{"key":"22 Q2","value":4.43},{"key":"22 Q3","value":4.49},{"key":"22 Q4","value":4.48},{"key":"23 Q1","value":4.72},{"key":"23 Q2","value":4.65},{"key":"23 Q3","value":4.5},{"key":"23 Q4","value":4.26},{"key":"24 Q1","value":5.03},{"key":"24 Q2","value":4.47},{"key":"24 Q3","value":4.51},{"key":"24 Q4","value":4.6},{"key":"25 Q1","value":5.37},{"key":"25 Q2","value":5.18}]}],"overlayChart":null}],"chartsLastUpdated":"2025-07-17T12:34:17Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.39,"sell":0.61,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"BMY","name":"Bristol-Myers","displayName":"Bristol-Myers","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"BMY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":48.98,"high":49.275,"low":48.71,"volume":554,"volumeDate":"2025-07-25","last":48.94,"open":49.02,"gainPercentage":-0.082,"gainValue":-0.04,"ask":49.16,"bid":48.71,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":99596815200,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":14326431.0806,"highPriceLast52Weeks":63.33,"lowPriceLast52Weeks":44,"companyName":"Bristol Myers Squibb Co.","longBusinessDescription":"Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.","dividendRate":2.46,"salesOrRevenue":48300000000,"oneYearAnnualRevenueGrowthRate":7.31902413011599,"threeYearAnnualRevenueGrowthRate":1.4446,"fiveYearAnnualRevenueGrowthRate":15.2105,"earningsGrowth":186.408,"totalDebt":51200000000,"totalAssets":92603000000,"floatAsPercentOfSharesOutstanding":99.9219,"dividendYield":5.029999999999999,"betaTwelveMonth":0.2889,"salesOrRevenueTtm":47636000000,"ebitdaTtm":18948000000,"debtToEquityRatioQuarterly":294.663292886307,"totalEnterpriseValue":155041120000,"industry":"PharmaceuticalsMajor","sector":"HealthTechnology","preTaxInterestCoverageRatio":4.96045197740113,"fiveYearAverageDebtEquityRatio":157.82,"currentRatio":1.27889488990445,"peratio":18.37},"recommendation":{"currentConsensusRating":2.4,"recommendationTargetPrice":63.09,"totalRatings":33,"strongSellRatings":0,"sellRatings":2,"holdRatings":16,"buyRatings":8,"strongBuyRatings":7,"lastUpdated":"2025-07-10T16:13:56Z"},"earningEstimates":[{"actual":2,"estimate":1.92,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-10-27T11:09:31Z","audioUrl":"https://files.quartr.com/audio-files/7e8f9-2022-10-19-04-37-52.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/9385b-2023-02-20-07-21-51.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6358a-2024-08-29-11-36-52.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-10-27T00:00:00Z","earningsSummary":null},{"actual":1.83,"estimate":1.8,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-04T12:10:13Z","audioUrl":"https://files.quartr.com/audio-files/705c8-2022-10-19-10-28-24.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a196a-2022-02-04-02-26-54-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2021/default.aspx?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-04T02:54:00Z","earningsSummary":null},{"actual":1.96,"estimate":1.91,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-04-29T11:14:39Z","audioUrl":"https://files.quartr.com/audio-files/3e33b-2022-10-28-04-06-47.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/13933-2022-04-29-04-27-50-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d9ee9-2023-01-25-01-41-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-04-29T16:50:27Z","earningsSummary":null},{"actual":1.93,"estimate":1.82,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-07-27T11:06:32Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_07_27_14_00_Q2_2022_Bristol_Myers_Squibb_Co_Earnings_Call.27AE5EPN1WQT_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6d8e5-2022-07-27-11-02-58.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/9171b-2022-07-27-11-42-05.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-07-27T01:29:00Z","earningsSummary":null},{"actual":1.99,"estimate":1.83,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-10-26T07:51:28Z","audioUrl":"https://files.quartr.com/audio-files/cf3d2-2022-10-26-01-13-22.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/edb18-2022-10-26-11-35-56.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/4fadd-2022-10-26-10-02-41.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-10-26T12:00:00Z","earningsSummary":null},{"actual":1.82,"estimate":1.72,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-02T12:03:18Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_02T14_00_00_00_00_Bristol_Myers_Squibb_Co_Earnings_Call_Q4_2022.2DIUAG2W3V95_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6e05f-2023-02-20-07-36-50.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/conference-calls/4964f-2023-02-02-12-43-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-02T14:00:00Z","earningsSummary":{"summary":"Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.\nThe company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.\nChallenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.","headline":"Bristol-Myers reports robust 2022 performance and outlines growth strategies","lastUpdated":"2024-05-06T16:51:43.170809Z"}},{"actual":2.05,"estimate":1.97,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-04-27T11:11:57Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_04_27T12_00_00_00_00_Bristol_Myers_Squibb_Company_Q1_2023.IS0UOKMSJL77_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/d5f75-2023-04-27-11-53-45.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/35a37-2023-04-27-11-36-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-04-27T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.\nWhile facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.\nBy reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.","headline":"Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges","lastUpdated":"2024-05-06T16:49:39.052633Z"}},{"actual":1.75,"estimate":1.98,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-07-27T11:01:19Z","audioUrl":"https://files.quartr.com/audio-files/b1f41-2023-07-27-03-29-27.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/aeb03-2023-07-27-11-34-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cc4bc-2023-07-27-11-17-21.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-07-27T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.\nWhile facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.\nOpportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R\u0026D insights.\nOverall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.","headline":"Bristol-Myers reports robust Q2 sales and strategic growth initiatives","lastUpdated":"2024-05-06T18:53:52.101198Z"}},{"actual":2,"estimate":1.76,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-10-26T11:00:46Z","audioUrl":"https://files.quartr.com/audio-files/38cc9-2023-10-26-02-01-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ea8fa-2023-10-26-11-31-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/72a32-2023-10-26-11-14-08.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-10-26T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.","headline":"Bristol-Myers reports robust Q3 performance, eyes growth opportunities","lastUpdated":"2024-05-07T00:18:59.113782Z"}},{"actual":1.7,"estimate":1.53,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-02T12:02:26Z","audioUrl":"https://files.quartr.com/audio-files/a89d6-2024-02-02-03-36-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/f72e2-2024-02-02-12-24-57.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/d7320-2024-02-02-02-11-19.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-02T13:00:00Z","earningsSummary":{"summary":"Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.\nDespite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.\nThe company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.","headline":"Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives","lastUpdated":"2024-05-06T19:43:18.099416Z"}},{"actual":-4.4,"estimate":-4.44,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-04-25T11:04:51Z","audioUrl":"https://files.quartr.com/audio-files/8f291-2024-04-25-01-33-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/0fa3c-2024-04-25-12-41-01.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/412df-2024-04-25-11-20-04.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-04-25T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.\nDespite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.\nThe company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.\nOpportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.","headline":"Bristol-Myers meets Q1 expectations, focuses on growth opportunities","lastUpdated":"2024-05-06T18:37:32.689252Z"}},{"actual":2.07,"estimate":1.63,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-07-26T11:00:50Z","audioUrl":"https://files.quartr.com/audio-files/ebbae-2024-07-26-01-25-19.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/db85a-2024-07-26-11-01-56.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/106d0-2024-07-26-11-07-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-07-26T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.\nThe company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.\nWith a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.","headline":"Bristol-Myers reports strong Q2 performance, bullish on pipeline growth","lastUpdated":"2024-07-26T21:06:24.049661Z"}},{"actual":1.8,"estimate":1.49,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-10-31T11:00:13Z","audioUrl":"https://files.quartr.com/audio-files/5b711-2024-10-31-01-49-17.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/a2f9a-2024-10-31-11-08-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/cfc93-2024-10-31-11-33-51.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-10-31T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.\nThe company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.\nChallenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.\nOpportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.","headline":"Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress","lastUpdated":"2024-10-31T16:04:39.599280Z"}},{"actual":1.67,"estimate":1.47,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-06T11:59:43Z","audioUrl":"https://files.quartr.com/audio-files/2af8e-2025-02-06-02-27-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/23e1a-2025-02-06-02-21-42.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/754a8-2025-02-06-12-16-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-06T13:00:00Z","earningsSummary":{"summary":"Bristol-Myers' strong 2024 performance and focus on operational excellence position the company for continued growth.\nChallenges include generic entry concerns but opportunities lie in upcoming launches and pipeline assets.\nThe company's commitment to reshaping its portfolio and generating returns for shareholders underscores its strategic vision.","headline":"Bristol-Myers reports robust 2024 performance and outlines growth strategies","lastUpdated":"2025-02-06T15:54:22.129055Z"}},{"actual":1.8,"estimate":1.49,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-04-24T10:59:56Z","audioUrl":"https://files.quartr.com/audio-files/7aaab-2025-04-24-01-06-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/3c5a8-2025-04-24-11-59-07.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/6425c-2025-04-24-11-13-01.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-04-24T12:00:00Z","earningsSummary":{"summary":"Bristol-Myers' strong Q1 performance, focus on strategic priorities, and robust growth portfolio position the company for continued success and sustained growth. Despite challenges from certain study results, the company remains resilient, with increased revenue guidance, pipeline advancements, and a disciplined approach to business development. Opportunities in new studies, therapeutic advancements, and policy monitoring underscore Bristol-Myers' commitment to innovation, growth, and defending its industry position.","headline":"Bristol-Myers reports robust Q1 earnings, boosts guidance amid growth","lastUpdated":"2025-04-24T15:41:51.218028Z"}},{"actual":null,"estimate":1.16,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:30:28Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-07-31T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-10-27","title":"Earnings data Q3 2021","quarter":"Q3","hash":"82d148a7aedb122fc6b954fa4d315a058131f756a5260956423786621004731e"},{"date":"2022-02-04","title":"Earnings data Q4 2021","quarter":"Q4","hash":"e605ac21ad936291d8187480221a046996c24c86724f23c21834dd191ba486b1"},{"date":"2022-04-29","title":"Earnings data Q1 2022","quarter":"Q1","hash":"c858a8b4b5dca9d3e4c0b608b3a389048bf4e15ec7cd1085c0b6df78d79c6d6e"},{"date":"2022-07-27","title":"Earnings data Q2 2022","quarter":"Q2","hash":"61a77a0ccc98bb5fc32265156910e78b78d460edeb45641e7c1404fc22129449"},{"date":"2022-10-25","title":"Earnings data Q3 2022","quarter":"Q3","hash":"ebe08cf39000c4f8820cba65933cc1030edafe6e2180e9e605c79cea90feb99a"},{"date":"2023-02-02","title":"Earnings data Q4 2022","quarter":"Q4","hash":"6d894a68d48a032cdb7f2818d42e8c9c818394ee7328296ad70565013c42d73d"},{"date":"2023-04-27","title":"Earnings data Q1 2023","quarter":"Q1","hash":"c4d818e6f12b1e33ff30a3c9c4432d4ed15a87b9da65c3a74a83ade9c7504c25"},{"date":"2023-07-27","title":"Earnings data Q2 2023","quarter":"Q2","hash":"3567795a594462e00bdfecf9f1aa2dd76192d21d3324e6cf58245946fd44b534"},{"date":"2023-10-26","title":"Earnings data Q3 2023","quarter":"Q3","hash":"574ce8a432b06c67b8878ec3caeb74a32f39c4326b777e209a0dbb931a2bc449"},{"date":"2024-02-02","title":"Earnings data Q4 2023","quarter":"Q4","hash":"7042c641e306b6c036f1da185d47a12f218c3559951d3064f505e2858a499e91"},{"date":"2024-04-25","title":"Earnings data Q1 2024","quarter":"Q1","hash":"5273b66a74515bbf3d99b5bcdbdb592dbf1db1d385568a141532c3f7e50dae9e"},{"date":"2024-07-26","title":"Earnings data Q2 2024","quarter":"Q2","hash":"29b18a5c664f6743e6ed6e54f7289d27d657a299ad549466be99d568c6d12dd2"},{"date":"2024-10-31","title":"Earnings data Q3 2024","quarter":"Q3","hash":"1304d2057b26dc732b32b6e6dcea44acbc86dd9cc3a228f323b314e713ff4f18"},{"date":"2025-02-06","title":"Earnings data Q4 2024","quarter":"Q4","hash":"4c1f802f94e5f0966bb9b3c356a2fc50a9d10a701406454ebbdf5ca4e4711113"},{"date":"2025-04-24","title":"Earnings data Q1 2025","quarter":"Q1","hash":"ea23140a8520d62d687899815b184ca3f5a1186984c0f8a01b52db08152a66c2"},{"date":"2025-07-31","title":"Earnings data Q2 2025","quarter":"Q2","hash":"bf3f02696219d22bafcea063a8f2068d8232ceca50168eb523a343e5a69b5a03"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Bristol-Myers","companyDescription":"Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":11201000000,"changePercentage":-5.6,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":3861000000,"changePercentage":-26.81,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":7340000000,"changePercentage":11.38,"valueToRevenueRatio":0.6552986340505312},{"financialKey":"OPERATING_EXPENSES","value":3819000000,"changePercentage":-24.45,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":3819000000,"changePercentage":-24.45,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":3521000000,"changePercentage":129.38,"valueToRevenueRatio":0.31434693330952596},{"financialKey":"EBITDA","value":4549000000,"changePercentage":11.22,"valueToRevenueRatio":0.4061244531738238},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":1028000000,"changePercentage":-59.77,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":2462000000,"changePercentage":120.68,"valueToRevenueRatio":null},{"financialKey":"EPS","value":1.2039,"changePercentage":120.45,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":92427000000,"changePercentage":-6.67,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":30783000000,"changePercentage":7.37,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":11782000000,"changePercentage":21.82,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":14586000000,"changePercentage":3.74,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":2666000000,"changePercentage":-10.69,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":1749000000,"changePercentage":-10.4,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":61644000000,"changePercentage":-12.39,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":8428000000,"changePercentage":2.96,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":44223000000,"changePercentage":-18.85,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":8992000000,"changePercentage":17.11,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":74979000000,"changePercentage":-9.1,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":24070000000,"changePercentage":-6.78,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":3726000000,"changePercentage":-41.41,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":1454000000,"changePercentage":-2.22,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":18890000000,"changePercentage":5.08,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":50909000000,"changePercentage":-10.15,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":47513000000,"changePercentage":-6.93,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":3396000000,"changePercentage":-39.48,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":17448000000,"changePercentage":5.44,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":17389000000,"changePercentage":5.45,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":59000000,"changePercentage":1.72,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":92427000000,"changePercentage":-6.67,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":51239000000,"changePercentage":-10.75,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":39457000000,"changePercentage":-17.35,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":8.54496,"changePercentage":5.04,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":2462000000,"changePercentage":120.68,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":1954000000,"changePercentage":-31.05,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":3825000000,"changePercentage":45.11,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-1871000000,"changePercentage":-1044.95,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":-499000000,"changePercentage":97.46,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":260000000,"changePercentage":-8.45,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":-404000000,"changePercentage":-184.52,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":321000000,"changePercentage":-98.42,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-676000000,"changePercentage":98.34,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":-993000000,"changePercentage":-106.78,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":1258000000,"changePercentage":3.8,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-103000000,"changePercentage":-6.19,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":66000000,"changePercentage":246.67,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":528000000,"changePercentage":124.16,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":1694000000,"changePercentage":-33.57,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:14:53Z"},"dividend":{"dividendType":"CASH","dividendFrequency":"QUARTERLY","dividend":0.62,"priorDividend":0.6,"dividendYieldPercentage":5.1,"announcementDate":"2025-06-17","exDividendDate":"2025-07-03","payableDate":"2025-08-01","recordDate":"2025-07-03","updatedAt":"2025-06-18T07:14:33Z"},"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-05-01T07:34:49Z","bearsSay":["Bristol-Myers Squibb's stock faces a negative outlook primarily due to constrained earnings per share (EPS) growth projected through 2029 and significant dependence on the U.S. market, which accounts for nearly 70% of total sales. The company's downside case presents a potential -5% terminal value growth rate along with a -20% reduction in base business, aggravating concerns about the sustainability of key franchises and overall competitive positioning. Furthermore, risks associated with loss of exclusivity on high-margin products and competitive dynamics in the hematology and oncology markets add further pressure to margins and could hinder recovery in key therapeutic areas."],"bullsSay":["Bristol-Myers Squibb's positive outlook is significantly supported by an upward revision in long-term sales projections for its key product, Cobenfy, now expected to reach $5.7 billion by 2030, reflecting a 36% increase from previous estimates. Furthermore, enhancements in sales forecasts for milvexian, which are projected to rise by 26% to $3.9 billion, indicate a strengthening pipeline bolstered by favorable trial results. Additionally, the firm’s substantial potential for peak sales of Cobenfy exceeding $10 billion, alongside increased confidence in product performance, showcases robust growth opportunities within its immuno-oncology and broader therapeutic asset portfolio."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Net product sales","dataPoints":[{"key":"21 Q2","value":11405},{"key":"21 Q3","value":11243},{"key":"21 Q4","value":11609},{"key":"22 Q1","value":11308},{"key":"22 Q2","value":11485},{"key":"22 Q3","value":10813},{"key":"22 Q4","value":11065},{"key":"23 Q1","value":11048},{"key":"23 Q2","value":10917},{"key":"23 Q3","value":10645},{"key":"23 Q4","value":11168},{"key":"24 Q1","value":11559},{"key":"24 Q2","value":11925},{"key":"24 Q3","value":11483},{"key":"24 Q4","value":11811},{"key":"25 Q1","value":10886}]},{"title":"Alliance and other revenues","dataPoints":[{"key":"21 Q2","value":298},{"key":"21 Q3","value":381},{"key":"21 Q4","value":376},{"key":"22 Q1","value":340},{"key":"22 Q2","value":402},{"key":"22 Q3","value":405},{"key":"22 Q4","value":341},{"key":"23 Q1","value":289},{"key":"23 Q2","value":309},{"key":"23 Q3","value":321},{"key":"23 Q4","value":309},{"key":"24 Q1","value":306},{"key":"24 Q2","value":276},{"key":"24 Q3","value":409},{"key":"24 Q4","value":531},{"key":"25 Q1","value":315}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":79.04},{"key":"21 Q3","value":80.29},{"key":"21 Q4","value":80.34},{"key":"22 Q1","value":78.78},{"key":"22 Q2","value":77.11},{"key":"22 Q3","value":79.02},{"key":"22 Q4","value":77.26},{"key":"23 Q1","value":77.36},{"key":"23 Q2","value":74.38},{"key":"23 Q3","value":77.14},{"key":"23 Q4","value":76.08},{"key":"24 Q1","value":75.28},{"key":"24 Q2","value":73.22},{"key":"24 Q3","value":75.13},{"key":"24 Q4","value":61.01},{"key":"25 Q1","value":72.92}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":13.27},{"key":"21 Q3","value":18.55},{"key":"21 Q4","value":15.5},{"key":"22 Q1","value":14.48},{"key":"22 Q2","value":16.47},{"key":"22 Q3","value":19.69},{"key":"22 Q4","value":16.29},{"key":"23 Q1","value":24.43},{"key":"23 Q2","value":16.55},{"key":"23 Q3","value":19.48},{"key":"23 Q4","value":14.58},{"key":"24 Q1","value":-97.06},{"key":"24 Q2","value":10.54},{"key":"24 Q3","value":14.09},{"key":"24 Q4","value":1.41},{"key":"25 Q1","value":26.51}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":9.01},{"key":"21 Q3","value":13.3},{"key":"21 Q4","value":19.79},{"key":"22 Q1","value":10.97},{"key":"22 Q2","value":11.95},{"key":"22 Q3","value":14.31},{"key":"22 Q4","value":17.72},{"key":"23 Q1","value":19.95},{"key":"23 Q2","value":18.46},{"key":"23 Q3","value":17.58},{"key":"23 Q4","value":15.35},{"key":"24 Q1","value":-100.39},{"key":"24 Q2","value":13.76},{"key":"24 Q3","value":10.18},{"key":"24 Q4","value":0.58},{"key":"25 Q1","value":21.92}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Marketing, selling and administrative","dataPoints":[{"key":"21 Q2","value":1882},{"key":"21 Q3","value":1788},{"key":"21 Q4","value":2354},{"key":"22 Q1","value":1831},{"key":"22 Q2","value":1787},{"key":"22 Q3","value":1930},{"key":"22 Q4","value":2266},{"key":"23 Q1","value":1762},{"key":"23 Q2","value":1934},{"key":"23 Q3","value":2003},{"key":"23 Q4","value":2073},{"key":"24 Q1","value":2367},{"key":"24 Q2","value":1928},{"key":"24 Q3","value":1983},{"key":"24 Q4","value":2136},{"key":"25 Q1","value":1584}]},{"title":"Research and development","dataPoints":[{"key":"21 Q2","value":3271},{"key":"21 Q3","value":3251},{"key":"21 Q4","value":2607},{"key":"22 Q1","value":2260},{"key":"22 Q2","value":2321},{"key":"22 Q3","value":2418},{"key":"22 Q4","value":2510},{"key":"23 Q1","value":2321},{"key":"23 Q2","value":2258},{"key":"23 Q3","value":2242},{"key":"23 Q4","value":2478},{"key":"24 Q1","value":2695},{"key":"24 Q2","value":2899},{"key":"24 Q3","value":2374},{"key":"24 Q4","value":3191},{"key":"25 Q1","value":2257}]},{"title":"Amortization of acquired intangible assets","dataPoints":[{"key":"21 Q2","value":2547},{"key":"21 Q3","value":2546},{"key":"21 Q4","value":2417},{"key":"22 Q1","value":2417},{"key":"22 Q2","value":2417},{"key":"22 Q3","value":2418},{"key":"22 Q4","value":2343},{"key":"23 Q1","value":2256},{"key":"23 Q2","value":2257},{"key":"23 Q3","value":2256},{"key":"23 Q4","value":2278},{"key":"24 Q1","value":2357},{"key":"24 Q2","value":2416},{"key":"24 Q3","value":2406},{"key":"24 Q4","value":1693},{"key":"25 Q1","value":830}]},{"title":"Other (income)/ expense, net","dataPoints":[{"key":"21 Q2","value":-2},{"key":"21 Q3","value":-409},{"key":"21 Q4","value":393},{"key":"22 Q1","value":649},{"key":"22 Q2","value":284},{"key":"22 Q3","value":-140},{"key":"22 Q4","value":-217},{"key":"23 Q1","value":-413},{"key":"23 Q2","value":-116},{"key":"23 Q3","value":-258},{"key":"23 Q4","value":-371},{"key":"24 Q1","value":81},{"key":"24 Q2","value":273},{"key":"24 Q3","value":234},{"key":"24 Q4","value":305},{"key":"25 Q1","value":339}]},{"title":"Acquired IPRD","dataPoints":[{"key":"22 Q1","value":333},{"key":"22 Q2","value":400},{"key":"22 Q3","value":30},{"key":"22 Q4","value":52},{"key":"23 Q1","value":75},{"key":"23 Q2","value":158},{"key":"23 Q3","value":80},{"key":"23 Q4","value":600},{"key":"24 Q1","value":12949},{"key":"24 Q2","value":132},{"key":"24 Q3","value":262},{"key":"24 Q4","value":30},{"key":"25 Q1","value":188}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":15.54},{"key":"21 Q3","value":10.28},{"key":"21 Q4","value":8.29},{"key":"22 Q1","value":5.19},{"key":"22 Q2","value":1.57},{"key":"22 Q3","value":-3.49},{"key":"22 Q4","value":-4.83},{"key":"23 Q1","value":-2.67},{"key":"23 Q2","value":-5.56},{"key":"23 Q3","value":-2.25},{"key":"23 Q4","value":0.62},{"key":"24 Q1","value":4.66},{"key":"24 Q2","value":8.69},{"key":"24 Q3","value":8.44},{"key":"24 Q4","value":7.54},{"key":"25 Q1","value":-5.6}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":32.66},{"key":"21 Q3","value":24.13},{"key":"21 Q4","value":-58.24},{"key":"22 Q1","value":31.36},{"key":"22 Q2","value":-6.35},{"key":"22 Q3","value":-7.25},{"key":"22 Q4","value":-10.51},{"key":"23 Q1","value":-19.88},{"key":"23 Q2","value":-9.96},{"key":"23 Q3","value":-5},{"key":"23 Q4","value":1.5},{"key":"24 Q1","value":240.76},{"key":"24 Q2","value":17.82},{"key":"24 Q3","value":14.8},{"key":"24 Q4","value":4.21},{"key":"25 Q1","value":-74.58}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":2227},{"key":"21 Q3","value":2219},{"key":"21 Q4","value":2202},{"key":"22 Q1","value":2146},{"key":"22 Q2","value":2133},{"key":"22 Q3","value":2133},{"key":"22 Q4","value":2108},{"key":"23 Q1","value":2099},{"key":"23 Q2","value":2093},{"key":"23 Q3","value":2057},{"key":"23 Q4","value":2027},{"key":"24 Q1","value":2023},{"key":"24 Q2","value":2027},{"key":"24 Q3","value":2028},{"key":"24 Q4","value":2029},{"key":"25 Q1","value":2031}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":145200.4},{"key":"21 Q3","value":146232.1},{"key":"21 Q4","value":129257.4},{"key":"22 Q1","value":143996.6},{"key":"22 Q2","value":161254.8},{"key":"22 Q3","value":153576},{"key":"22 Q4","value":157678.4},{"key":"23 Q1","value":146720.1},{"key":"23 Q2","value":138975.2},{"key":"23 Q3","value":124654.2},{"key":"23 Q4","value":106417.5},{"key":"24 Q1","value":102970.7},{"key":"24 Q2","value":90606.9},{"key":"24 Q3","value":95113.2},{"key":"24 Q4","value":113421.1},{"key":"25 Q1","value":118407.3}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":3.1},{"key":"21 Q3","value":3.15},{"key":"21 Q4","value":2.7},{"key":"22 Q1","value":3.09},{"key":"22 Q2","value":3.39},{"key":"22 Q3","value":3.42},{"key":"22 Q4","value":3.46},{"key":"23 Q1","value":3.24},{"key":"23 Q2","value":3.09},{"key":"23 Q3","value":2.84},{"key":"23 Q4","value":2.32},{"key":"24 Q1","value":2.17},{"key":"24 Q2","value":1.86},{"key":"24 Q3","value":2},{"key":"24 Q4","value":2.3},{"key":"25 Q1","value":2.64}]}],"overlayChart":null}],"chartsLastUpdated":"2025-04-24T13:28:43Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.45,"sell":0.55,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"CNCR","name":"Loncar Cancer Immunotherapy ETF","displayName":"Loncar Cancer Immunotherapy ETF","availableForFractional":false,"availableForTrade":false,"safetyLabel":null,"trading":"DISABLED","optionsTrading":"DISABLED","optionsSpreadTrading":"DISABLED","tradingFractional":"DISABLED","instrumentClass":"EXCHANGE_TRADED_FUND","daysToIpo":null,"ipoDate":null,"untradableReason":"CORPORATE_ACTION","newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"CNCR","lastUpdated":"2025-05-27T20:00:00Z","batsLastUpdated":"2025-05-27T20:00:00Z","previousClose":8.88,"high":9.41,"low":9.02,"volume":3077,"volumeDate":"2025-05-27","last":9.02,"open":9.41,"gainPercentage":1.577,"gainValue":0.14,"ask":19.92,"bid":7.8,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":null,"instrumentClass":"EXCHANGE_TRADED_FUND","averageDailyVolumeLast3Months":818.5968,"highPriceLast52Weeks":16.27,"lowPriceLast52Weeks":7.881,"companyName":null,"longBusinessDescription":"CNCR tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products.","dividendRate":0,"salesOrRevenue":null,"oneYearAnnualRevenueGrowthRate":null,"threeYearAnnualRevenueGrowthRate":null,"fiveYearAnnualRevenueGrowthRate":null,"earningsGrowth":null,"totalDebt":null,"totalAssets":null,"floatAsPercentOfSharesOutstanding":null,"dividendYield":0,"betaTwelveMonth":1.1674,"salesOrRevenueTtm":null,"ebitdaTtm":null,"debtToEquityRatioQuarterly":null,"totalEnterpriseValue":null,"industry":"InvestmentTrustsOrMutualFunds","sector":"Miscellaneous","preTaxInterestCoverageRatio":null,"fiveYearAverageDebtEquityRatio":null,"currentRatio":null,"peratio":null},"recommendation":null,"earningEstimates":[],"earningDates":[],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Loncar Cancer Immunotherapy ETF","companyDescription":"CNCR tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.","executives":null,"brands":[]},"etfFundamental":{"returnInception":-0.0914,"etfType":"US Equities","category":"Broad Market / Multi-Cap","netExpenseRatio":0.79,"inceptionDate":"2015-10-13","assetsUnderManagement":null,"returnYTD":-0.2673,"return1Month":-0.0772,"return3Month":-0.2304,"return1Year":-0.3997,"return3Year":-0.1426,"return5Year":-0.1851,"return10Year":null,"returnsAsOfDate":"2025-05-27","quarterlyNavBasedReturns":{"returnYTD":-27.67,"return1Month":-12.35,"return3Month":-26.17,"return1Year":-40.38,"return3Year":-14.43,"return5Year":-18.19,"return10Year":null,"returnInception":-9.24,"returnsAsOfDate":"2025-05-23"},"quarterlyPriceBasedReturns":{"returnYTD":-26.73,"return1Month":-7.72,"return3Month":-23.04,"return1Year":-39.97,"return3Year":-14.26,"return5Year":-18.5,"return10Year":null,"returnInception":-9.14,"returnsAsOfDate":"2025-05-27"},"monthlyNavBasedReturns":{"returnYTD":-27.67,"return1Month":-12.35,"return3Month":-26.17,"return1Year":-40.38,"return3Year":-14.43,"return5Year":-18.19,"return10Year":null,"returnInception":-9.24,"returnsAsOfDate":"2025-05-23"},"monthlyPriceBasedReturns":{"returnYTD":-26.73,"return1Month":-7.72,"return3Month":-23.04,"return1Year":-39.97,"return3Year":-14.26,"return5Year":-18.5,"return10Year":null,"returnInception":-9.14,"returnsAsOfDate":"2025-05-27"},"secYieldPercentage":null,"prospectusLink":"https://www.rangeetfs.com/staticdocs/CNCRProspectus"},"financials":null,"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":false},"advancedInfo":{"updateDate":null,"bearsSay":[],"bullsSay":[],"charts":[],"chartsLastUpdated":"1970-01-01T00:00:00Z","etfHoldings":{"totalHoldings":2,"holdings":[]},"etfHoldingsLastUpdated":"2025-05-22T00:00:00Z"},"advancedCryptoData":null,"buySellRatio":null,"advancedInfoAvailable":true,"advancedInfoDummy":false},{"instrument":{"symbol":"MRNA","name":"Moderna","displayName":"Moderna","availableForFractional":true,"availableForTrade":true,"safetyLabel":null,"trading":"BUY_AND_SELL","optionsTrading":"BUY_AND_SELL","optionsSpreadTrading":"BUY_AND_SELL","tradingFractional":"BUY_AND_SELL","instrumentClass":"STOCK","daysToIpo":null,"ipoDate":null,"untradableReason":null,"newSymbol":null,"newSymbolDate":null,"nameAlternatives":[],"rootSymbol":null,"rootSymbolName":null,"marginRequirement":null},"quote":{"symbol":"MRNA","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":34.67,"high":35.09,"low":33.8,"volume":6895,"volumeDate":"2025-07-25","last":34.01,"open":34.95,"gainPercentage":-1.904,"gainValue":-0.66,"ask":34.45,"bid":34.32,"tradingHalted":false},"instrumentCompanyDetails":{"fundamental":{"marketCapitalization":13153095400,"instrumentClass":"STOCK","averageDailyVolumeLast3Months":10850081.9516,"highPriceLast52Weeks":125.68,"lowPriceLast52Weeks":23.15,"companyName":"Moderna, Inc.","longBusinessDescription":"Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.","dividendRate":0,"salesOrRevenue":3236000000,"oneYearAnnualRevenueGrowthRate":-52.6900584795322,"threeYearAnnualRevenueGrowthRate":-37.7052,"fiveYearAnnualRevenueGrowthRate":662.6254,"earningsGrowth":44.2923,"totalDebt":747000000,"totalAssets":14142000000,"floatAsPercentOfSharesOutstanding":88.5572,"dividendYield":0,"betaTwelveMonth":1.3565,"salesOrRevenueTtm":3177000000,"ebitdaTtm":-3537000000,"debtToEquityRatioQuarterly":7.40115239419829,"totalEnterpriseValue":9687720000,"industry":"Biotechnology","sector":"HealthTechnology","preTaxInterestCoverageRatio":-164.375,"fiveYearAverageDebtEquityRatio":6.73,"currentRatio":4.21820448877805,"peratio":-3.9},"recommendation":{"currentConsensusRating":2.7,"recommendationTargetPrice":82.85,"totalRatings":26,"strongSellRatings":0,"sellRatings":4,"holdRatings":15,"buyRatings":2,"strongBuyRatings":5,"lastUpdated":"2025-07-22T16:10:36Z"},"earningEstimates":[{"actual":7.7,"estimate":9.09,"period":"Q3 2021","fiscalQuarter":"Q3","fiscalYear":2021,"lastUpdated":"2021-11-04T11:47:38Z","audioUrl":"https://files.quartr.com/audio-files/9d587-2022-10-19-04-44-36.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/262ff-2021-11-05-12-00-00-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/149c3-2023-01-25-10-27-22.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2021-11-05T00:00:00Z","earningsSummary":null},{"actual":11.29,"estimate":9.9,"period":"Q4 2021","fiscalQuarter":"Q4","fiscalYear":2021,"lastUpdated":"2022-02-24T12:07:47Z","audioUrl":"https://files.quartr.com/audio-files/aa668-2022-10-19-11-37-08.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/213df-2022-02-24-12-02-37-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/f29d9-2023-01-25-12-51-26.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-02-24T12:37:02Z","earningsSummary":null},{"actual":8.58,"estimate":5.21,"period":"Q1 2022","fiscalQuarter":"Q1","fiscalYear":2022,"lastUpdated":"2022-05-04T11:26:04Z","audioUrl":"https://files.quartr.com/audio-files/d1d73-2022-10-28-04-55-17.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b0987-2022-05-04-12-23-07-migrated.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/ace31-2023-01-25-12-04-59.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-05-04T12:07:23Z","earningsSummary":null},{"actual":5.24,"estimate":4.59,"period":"Q2 2022","fiscalQuarter":"Q2","fiscalYear":2022,"lastUpdated":"2022-08-03T11:25:02Z","audioUrl":"https://files.quartr.com/recordings/live_f_2022_08_03_14_00_Q2_2022_Moderna_Inc_Earnings_Call.NKLUNHART1BJ_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/fd9e2-2022-08-03-01-48-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/13720-2022-08-03-11-13-47.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-08-03T11:30:00Z","earningsSummary":null},{"actual":2.53,"estimate":3.29,"period":"Q3 2022","fiscalQuarter":"Q3","fiscalYear":2022,"lastUpdated":"2022-11-03T11:07:09Z","audioUrl":"https://files.quartr.com/audio-files/78e1b-2022-11-03-03-09-43.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/7eb2f-2022-11-03-12-12-11.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/92dd4-2022-11-03-11-52-12.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2022-11-03T12:00:00Z","earningsSummary":null},{"actual":3.61,"estimate":4.68,"period":"Q4 2022","fiscalQuarter":"Q4","fiscalYear":2022,"lastUpdated":"2023-02-23T12:03:46Z","audioUrl":"https://files.quartr.com/recordings/live_f_2023_02_23T13_00_00_00_00_Moderna_Inc_Earnings_Call_Q4_2022.TN85SXQ17IBG_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/b81b6-2023-02-23-01-59-00.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/df5ff-2023-02-23-12-35-06.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-02-23T13:00:00Z","earningsSummary":{"summary":"Moderna's strong financial performance and strategic investments in R\u0026D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.","headline":"Moderna reports robust earnings, eyes growth through innovative vaccines","lastUpdated":"2024-05-07T05:33:32.240363Z"}},{"actual":0.19,"estimate":-1.77,"period":"Q1 2023","fiscalQuarter":"Q1","fiscalYear":2023,"lastUpdated":"2023-05-04T10:34:00Z","audioUrl":"https://files.quartr.com/audio-files/66961-2023-05-04-04-54-46.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/67ead-2023-05-04-12-34-43.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/282a7-2023-05-04-10-50-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-05-04T12:00:00Z","earningsSummary":{"summary":"Moderna's Q1 performance reflects strong earnings, robust R\u0026D investments, and strategic commercial negotiations.\nThe company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.\nChallenges include contract timing uncertainties, market competition, and regulatory approval processes.\nAmidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.","headline":"Moderna posts strong Q1 earnings, eyes market expansion opportunities","lastUpdated":"2024-05-07T02:02:44.244678Z"}},{"actual":-3.62,"estimate":-3.84,"period":"Q2 2023","fiscalQuarter":"Q2","fiscalYear":2023,"lastUpdated":"2023-08-03T10:32:21Z","audioUrl":"https://files.quartr.com/audio-files/live_f_2023_08_03T12_00_00_00_00_Moderna_Inc_Q2_2023.K7KED1ZK9PS4_normalized.mp3?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ab420-2023-08-03-11-19-38.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/3f522-2023-08-03-10-42-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-08-03T12:00:00Z","earningsSummary":{"summary":"Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.\nThe company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.\nChallenges include margin guidance revisions and differing views on vaccine development strategies.\nOpportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.","headline":"Moderna reports Q2 performance, innovation strength, margin challenges","lastUpdated":"2024-05-07T01:21:14.705487Z"}},{"actual":-9.53,"estimate":-1.93,"period":"Q3 2023","fiscalQuarter":"Q3","fiscalYear":2023,"lastUpdated":"2023-11-02T10:34:47Z","audioUrl":"https://files.quartr.com/audio-files/cd358-2023-11-02-01-14-15.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/2d5de-2023-11-02-11-51-53.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/57452-2023-11-02-10-39-35.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2023-11-02T12:00:00Z","earningsSummary":{"summary":"Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.","headline":"Moderna reports $1.8B Spikevax sales, eyes profitability in 2024","lastUpdated":"2024-05-04T03:16:02.461082Z"}},{"actual":0.55,"estimate":-0.97,"period":"Q4 2023","fiscalQuarter":"Q4","fiscalYear":2023,"lastUpdated":"2024-02-22T11:52:58Z","audioUrl":"https://files.quartr.com/audio-files/90497-2024-02-22-02-22-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ee45a-2024-02-22-12-09-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/8ed64-2024-02-22-11-48-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-02-22T13:00:00Z","earningsSummary":{"summary":"Moderna's financials reflect market transition impact with a focus on cost management.\nStrong pipeline progress and confidence in vaccine efficacy milestones for 2024.\nChallenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.\nOpportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.","headline":"Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024","lastUpdated":"2024-05-05T17:41:48.767046Z"}},{"actual":-3.07,"estimate":-3.35,"period":"Q1 2024","fiscalQuarter":"Q1","fiscalYear":2024,"lastUpdated":"2024-05-02T10:37:35Z","audioUrl":"https://files.quartr.com/audio-files/34552-2024-05-02-01-55-20.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/66916-2024-05-02-12-27-39.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/15c99-2024-05-02-10-11-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-05-02T12:00:00Z","earningsSummary":{"summary":"Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.\nWhile facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.\nOpportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.","headline":"Moderna reports Q1 sales dip, eyes growth in pipeline","lastUpdated":"2024-05-07T02:37:49.697767Z"}},{"actual":-3.33,"estimate":-3.39,"period":"Q2 2024","fiscalQuarter":"Q2","fiscalYear":2024,"lastUpdated":"2024-08-01T10:34:56Z","audioUrl":"https://files.quartr.com/audio-files/21c9f-2024-08-01-01-19-09.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6f248-2024-08-01-02-38-26.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/59963-2024-08-01-10-15-34.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-08-01T12:00:00Z","earningsSummary":{"summary":"Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.","headline":"Moderna reports robust Q2 earnings, focuses on innovation and cost management","lastUpdated":"2024-08-01T16:17:38.657204Z"}},{"actual":0.03,"estimate":-1.9,"period":"Q3 2024","fiscalQuarter":"Q3","fiscalYear":2024,"lastUpdated":"2024-11-07T11:45:34Z","audioUrl":"https://files.quartr.com/audio-files/2ba6a-2024-11-07-02-35-10.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/ba738-2024-11-07-12-58-46.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/710da-2024-11-07-11-42-37.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2024-11-07T13:00:00Z","earningsSummary":{"summary":"Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.\nWhile facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.\nOpportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.\nNavigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.","headline":"Moderna reports robust Q3 earnings, eyes global expansion and innovation","lastUpdated":"2024-11-07T18:56:47.135898Z"}},{"actual":-2.91,"estimate":-2.68,"period":"Q4 2024","fiscalQuarter":"Q4","fiscalYear":2024,"lastUpdated":"2025-02-14T11:51:45Z","audioUrl":"https://files.quartr.com/audio-files/5debc-2025-02-14-02-00-25.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/6a00e-2025-02-14-12-38-15.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/b3f75-2025-02-14-11-32-32.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-02-14T13:00:00Z","earningsSummary":{"summary":"Moderna's 2024 performance showcased revenue growth, cost savings, and progress in key programs, despite reporting a loss for the year. The company's strategic focus on high-value programs, cost efficiencies, and product approvals positions it for future growth and innovation. While facing financial challenges and lower revenue expectations for 2025, Moderna has opportunities to drive profitability through cost reductions and new product approvals.","headline":"Moderna reports $3.2B revenue, plans cost reductions for growth","lastUpdated":"2025-02-14T15:42:33.345161Z"}},{"actual":-2.52,"estimate":-3.18,"period":"Q1 2025","fiscalQuarter":"Q1","fiscalYear":2025,"lastUpdated":"2025-05-01T10:32:27Z","audioUrl":"https://files.quartr.com/audio-files/5bd7c-2025-05-01-01-24-11.mpeg?ref=cHVibGljLmNvbQ==","pdfUrl":"https://files.quartr.com/conference-calls/c6573-2025-05-01-11-44-16.pdf?ref=cHVibGljLmNvbQ==","reportUrl":"https://files.quartr.com/reports/485a8-2025-05-01-10-29-33.pdf?ref=cHVibGljLmNvbQ==","eventDate":"2025-05-01T12:00:00Z","earningsSummary":{"summary":"Moderna's Q1 2025 performance met expectations, with a focus on cost reductions and financial discipline. Despite challenges like lower vaccination rates, the company showed improvement in net loss. The strategic strengths lie in expanding markets, diversifying the pipeline, and planned cost-cutting initiatives. Opportunities for growth include optimizing expenses and leveraging revenue potential beyond COVID products. To address challenges and capitalize on opportunities, Moderna must navigate revenue volatility, sustain profitability, and drive operational efficiency. The company's financial outlook remains positive with a strong cash position and planned cost-saving measures.","headline":"Moderna reports Q1 earnings in line with expectations, focuses on cost reductions and growth opportunities","lastUpdated":"2025-05-01T15:43:08.787483Z"}},{"actual":null,"estimate":-2.98,"period":"Q2 2025","fiscalQuarter":"Q2","fiscalYear":2025,"lastUpdated":"2025-07-24T23:31:21Z","audioUrl":null,"pdfUrl":null,"reportUrl":null,"eventDate":"2025-08-01T00:00:00Z","earningsSummary":null}],"earningDates":[{"date":"2021-11-04","title":"Earnings data Q3 2021","quarter":"Q3","hash":"6e22996d6c68ae7ef715994937afadc3097b5015c17f97c47983a52387df86e6"},{"date":"2022-02-24","title":"Earnings data Q4 2021","quarter":"Q4","hash":"323fafb9fd52c2b25bf554ad4064dca03c44c780bc4ac82b77afb2d43d6a30b1"},{"date":"2022-05-04","title":"Earnings data Q1 2022","quarter":"Q1","hash":"8536876145abfe9810ccea6e49d10b6af8285f7f227dd0945f41e782cd3faa98"},{"date":"2022-08-03","title":"Earnings data Q2 2022","quarter":"Q2","hash":"5ec9b2193d4f5a437f5b1c26ef84f86fb6cec70d7dda4dd81480e23ee81c5eee"},{"date":"2022-11-03","title":"Earnings data Q3 2022","quarter":"Q3","hash":"3d5caa8e485e27ec8dce851caf3830593f944dc5acfee40157ebe90dabd5e640"},{"date":"2023-02-23","title":"Earnings data Q4 2022","quarter":"Q4","hash":"c661c3806152cc0f857d0e96334c730fefdd9fa9a0bd08b48bc22a4a3ee832a3"},{"date":"2023-05-04","title":"Earnings data Q1 2023","quarter":"Q1","hash":"c0e4d8c60bb91153ebfdf479a3394fd72407a0610fe1fe07b1ce21e49d649b3c"},{"date":"2023-08-03","title":"Earnings data Q2 2023","quarter":"Q2","hash":"edb9c7d17447994c905752da690a5f903b763f614cccb31357d96791e02a0ad6"},{"date":"2023-11-02","title":"Earnings data Q3 2023","quarter":"Q3","hash":"52a4f547a18546312293aaa652512ce936cb7afd42af85e1d5e4ed5a02b4aaa4"},{"date":"2024-02-22","title":"Earnings data Q4 2023","quarter":"Q4","hash":"bf1b077a68040778d8a87507d2437e4daa780f348205498cffc69b9c2cac2f4a"},{"date":"2024-05-02","title":"Earnings data Q1 2024","quarter":"Q1","hash":"def7a08638430298c826a8091f7c20586159ffa956c5d581e76f594dd8fdd286"},{"date":"2024-08-01","title":"Earnings data Q2 2024","quarter":"Q2","hash":"2e48d7e58e3a7880480f95132076f0f59cfde0707a003aea5668b47aaf3dc532"},{"date":"2024-11-07","title":"Earnings data Q3 2024","quarter":"Q3","hash":"c82d3f47145ce4c9f136deed42e26e969a7a316d11eb4513f2f66c217c48998d"},{"date":"2025-02-14","title":"Earnings data Q4 2024","quarter":"Q4","hash":"c0fc0f299a6cbdb70d0940ef5d606e414f764a3a9776985fb27b2f646d781c90"},{"date":"2025-05-01","title":"Earnings data Q1 2025","quarter":"Q1","hash":"d0fb3589797735ac9510c004ae0830b2d9dc86d3c211665071ce262acf257a95"},{"date":"2025-08-01","title":"Earnings data Q2 2025","quarter":"Q2","hash":"e6b82ebb07e65f07c8b844879fee1fc259b0e9b63f2e7476555a5cc08c47c6c8"}],"roadToIPODetails":null,"slideshowDetail":null,"subInstrument":null,"companyProfileDetail":{"publicLinks":{"linkToTwitter":null,"linkToPortal":null,"linkToCompanyLogo":null},"location":null,"companyName":"Moderna","companyDescription":"Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.","executives":null,"brands":[]},"etfFundamental":null,"financials":{"periodKey":"Q1 2025","values":[{"financialKey":"REVENUE","value":108000000,"changePercentage":-35.33,"valueToRevenueRatio":null},{"financialKey":"COST_OF_REVENUE","value":129000000,"changePercentage":-2.27,"valueToRevenueRatio":null},{"financialKey":"GROSS_PROFIT","value":-21000000,"changePercentage":-160,"valueToRevenueRatio":-0.19444444444444445},{"financialKey":"OPERATING_EXPENSES","value":1029000000,"changePercentage":-20.91,"valueToRevenueRatio":null},{"financialKey":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","value":1029000000,"changePercentage":-20.91,"valueToRevenueRatio":null},{"financialKey":"OPERATING_EXPENSES_OTHER","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"OPERATING_INCOME","value":-1050000000,"changePercentage":17.06,"valueToRevenueRatio":-9.722222222222221},{"financialKey":"EBITDA","value":-1011000000,"changePercentage":17.8,"valueToRevenueRatio":-9.36111111111111},{"financialKey":"DEPRECIATION_AND_AMORTIZATION","value":39000000,"changePercentage":8.33,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME","value":-971000000,"changePercentage":17.36,"valueToRevenueRatio":null},{"financialKey":"EPS","value":-2.5155,"changePercentage":18.22,"valueToRevenueRatio":null},{"financialKey":"TOTAL_ASSETS","value":12704000000,"changePercentage":-24.06,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS","value":6766000000,"changePercentage":-29.52,"valueToRevenueRatio":null},{"financialKey":"CASH_AND_EQUIVALENTS","value":5976000000,"changePercentage":-30.02,"valueToRevenueRatio":null},{"financialKey":"RECEIVABLES","value":306000000,"changePercentage":-20.93,"valueToRevenueRatio":null},{"financialKey":"INVENTORY","value":128000000,"changePercentage":-56.61,"valueToRevenueRatio":null},{"financialKey":"CURRENT_ASSETS_OTHER","value":356000000,"changePercentage":-5.82,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS","value":5938000000,"changePercentage":-16.71,"valueToRevenueRatio":null},{"financialKey":"NET_PPE","value":2964000000,"changePercentage":7.39,"valueToRevenueRatio":null},{"financialKey":"INTANGIBLES","value":101000000,"changePercentage":6.32,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_ASSETS_OTHER","value":2873000000,"changePercentage":-32.78,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES","value":2638000000,"changePercentage":-32.57,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES","value":1604000000,"changePercentage":-32.61,"valueToRevenueRatio":null},{"financialKey":"SHORT_TERM_DEBT","value":43000000,"changePercentage":72,"valueToRevenueRatio":null},{"financialKey":"INCOME_TAX_PAYABLE","value":0,"changePercentage":-100,"valueToRevenueRatio":null},{"financialKey":"CURRENT_LIABILITIES_OTHER","value":1561000000,"changePercentage":-32.22,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES","value":1034000000,"changePercentage":-32.51,"valueToRevenueRatio":null},{"financialKey":"LONG_TERM_DEBT","value":702000000,"changePercentage":-42.08,"valueToRevenueRatio":null},{"financialKey":"NON_CURRENT_LIABILITIES_OTHER","value":332000000,"changePercentage":3.75,"valueToRevenueRatio":null},{"financialKey":"TOTAL_EQUITY","value":10066000000,"changePercentage":-21.46,"valueToRevenueRatio":null},{"financialKey":"STOCKHOLDERS_EQUITY","value":10066000000,"changePercentage":-21.46,"valueToRevenueRatio":null},{"financialKey":"MINORITY_INTEREST","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"TOTAL_LIABILITIES_AND_EQUITY","value":12704000000,"changePercentage":-24.06,"valueToRevenueRatio":null},{"financialKey":"TOTAL_DEBT","value":745000000,"changePercentage":-39.77,"valueToRevenueRatio":null},{"financialKey":"NET_DEBT","value":-5231000000,"changePercentage":28.37,"valueToRevenueRatio":null},{"financialKey":"BOOK_VALUE_PER_SHARE","value":26.01034,"changePercentage":-22.28,"valueToRevenueRatio":null},{"financialKey":"NET_INCOME_CASH_FLOW","value":-971000000,"changePercentage":17.36,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OPERATIONS","value":-1037000000,"changePercentage":-4.85,"valueToRevenueRatio":null},{"financialKey":"FUNDS_FROM_OPERATIONS","value":-826000000,"changePercentage":21.26,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_WORKING_CAPITAL","value":-211000000,"changePercentage":-451.67,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING","value":730000000,"changePercentage":518.64,"valueToRevenueRatio":null},{"financialKey":"CAPITAL_EXPENDITURE","value":127000000,"changePercentage":-35.2,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_INVESTMENTS","value":857000000,"changePercentage":172.93,"valueToRevenueRatio":null},{"financialKey":"PURCHASE_SALE_OF_BUSINESS","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_INVESTING_OTHER_SOURCES","value":-254000000,"changePercentage":35.2,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING","value":4000000,"changePercentage":-71.43,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_STOCK","value":3000000,"changePercentage":-80,"valueToRevenueRatio":null},{"financialKey":"CHANGE_IN_DEBT","value":2000000,"changePercentage":300,"valueToRevenueRatio":null},{"financialKey":"CASH_DIVIDENDS_PAID","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_FINANCING_OTHER_SOURCES","value":-1000000,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"CASH_FROM_OTHER_SOURCES","value":0,"changePercentage":0,"valueToRevenueRatio":null},{"financialKey":"NET_CHANGE_IN_CASH","value":-303000000,"changePercentage":64.64,"valueToRevenueRatio":null},{"financialKey":"FREE_CASH_FLOW","value":-1154000000,"changePercentage":2.62,"valueToRevenueRatio":null}],"financialMapping":[{"key":"REVENUE","name":"Revenue"},{"key":"COST_OF_REVENUE","name":"Cost of revenue"},{"key":"GROSS_PROFIT","name":"Gross profit"},{"key":"OPERATING_EXPENSES","name":"Operating expenses"},{"key":"SELLING_GENERAL_ADMINISTRATIVE_EXPENSES","name":"SG\u0026A"},{"key":"OPERATING_EXPENSES_OTHER","name":"Other"},{"key":"OPERATING_INCOME","name":"Operating income"},{"key":"EBITDA","name":"EBITDA"},{"key":"DEPRECIATION_AND_AMORTIZATION","name":"D\u0026A"},{"key":"NET_INCOME","name":"Net income"},{"key":"EPS","name":"Earnings per share"},{"key":"TOTAL_ASSETS","name":"Total assets"},{"key":"CURRENT_ASSETS","name":"Current assets"},{"key":"CASH_AND_EQUIVALENTS","name":"Cash \u0026 equivalents"},{"key":"RECEIVABLES","name":"Receivables"},{"key":"INVENTORY","name":"Inventory"},{"key":"CURRENT_ASSETS_OTHER","name":"Other"},{"key":"NON_CURRENT_ASSETS","name":"Non-current assets"},{"key":"NET_PPE","name":"Net PPE"},{"key":"INTANGIBLES","name":"Intangibles"},{"key":"NON_CURRENT_ASSETS_OTHER","name":"Other"},{"key":"TOTAL_LIABILITIES","name":"Total liabilities"},{"key":"CURRENT_LIABILITIES","name":"Current liabilities"},{"key":"SHORT_TERM_DEBT","name":"Short term debt"},{"key":"INCOME_TAX_PAYABLE","name":"Income tax payable"},{"key":"CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"NON_CURRENT_LIABILITIES","name":"Non-current liabilities"},{"key":"LONG_TERM_DEBT","name":"Long-term debt"},{"key":"NON_CURRENT_LIABILITIES_OTHER","name":"Other"},{"key":"TOTAL_EQUITY","name":"Total equity"},{"key":"STOCKHOLDERS_EQUITY","name":"Stockholders equity"},{"key":"MINORITY_INTEREST","name":"Minority interest"},{"key":"TOTAL_LIABILITIES_AND_EQUITY","name":"Total liabilities \u0026 equity"},{"key":"TOTAL_DEBT","name":"Total debt"},{"key":"NET_DEBT","name":"Net debt"},{"key":"BOOK_VALUE_PER_SHARE","name":"Book value per share"},{"key":"NET_INCOME_CASH_FLOW","name":"Net income"},{"key":"CASH_FROM_OPERATIONS","name":"Cash from operations"},{"key":"FUNDS_FROM_OPERATIONS","name":"Funds from operations"},{"key":"CHANGE_IN_WORKING_CAPITAL","name":"Change in working capital"},{"key":"CASH_FROM_INVESTING","name":"Cash from investing"},{"key":"CAPITAL_EXPENDITURE","name":"Capital expenditure"},{"key":"PURCHASE_SALE_OF_INVESTMENTS","name":"Purchase/sale of investments"},{"key":"PURCHASE_SALE_OF_BUSINESS","name":"Purchase/sale of business"},{"key":"CASH_FROM_INVESTING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_FINANCING","name":"Cash from financing"},{"key":"CHANGE_IN_STOCK","name":"Change in stock"},{"key":"CHANGE_IN_DEBT","name":"Change in debt"},{"key":"CASH_DIVIDENDS_PAID","name":"Cash dividends paid"},{"key":"CASH_FROM_FINANCING_OTHER_SOURCES","name":"Other sources"},{"key":"CASH_FROM_OTHER_SOURCES","name":"Cash from other sources"},{"key":"NET_CHANGE_IN_CASH","name":"Net change in cash"},{"key":"FREE_CASH_FLOW","name":"Free cash flow"}],"lastUpdated":"2025-07-19T13:13:59Z"},"dividend":null,"earningsCallsDummy":false,"earningsCallsAvailable":true},"advancedInfo":{"updateDate":"2025-05-08T06:06:58Z","bearsSay":["Moderna has reported a significant decline in COVID vaccine sales, with revenues dropping from $18 billion in 2022 to $6.7 billion in 2023, prompting a downward revision of guidance for 2024 due to anticipated market headwinds. The company's valuation of its key products, including Spikevax, has also decreased sharply, reflecting reduced expectations for long-term COVID-related sales, which are now projected to fall further as the pandemic transitions to an endemic phase. Overall, the firm's financial outlook is clouded by uncertainties regarding vaccination rates and limited contributions from other vaccine candidates, leading to expectations of flat or declining top-line revenue through 2025."],"bullsSay":["Moderna's stock outlook remains positive due to its expanding portfolio, which includes 40 mRNA candidates across various therapeutic areas like oncology and infectious diseases, indicating strong growth potential. The company's valuation of key developmental candidates, such as mRNA-4157, has risen to $2.79 billion, showcasing confidence in its future revenue streams from innovative therapies. Additionally, Moderna's commitment to preventive vaccines and alignment with ESG principles supports a sustainable growth model, further enhancing its overall financial stability and resilience in the biotech sector."],"charts":[{"title":"Revenue Segments","description":"Revenue segments as reported by the company.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Collaboration revenue","dataPoints":[{"key":"21 Q2","value":18},{"key":"21 Q3","value":19},{"key":"21 Q4","value":14},{"key":"22 Q1","value":15},{"key":"22 Q2","value":35},{"key":"22 Q3","value":100}]},{"title":"Grant revenue","dataPoints":[{"key":"21 Q2","value":139},{"key":"21 Q3","value":140},{"key":"21 Q4","value":262},{"key":"22 Q1","value":126},{"key":"22 Q2","value":183},{"key":"22 Q3","value":144}]},{"title":"Product sales","dataPoints":[{"key":"21 Q2","value":4197},{"key":"21 Q3","value":4810},{"key":"21 Q4","value":6935},{"key":"22 Q1","value":5925},{"key":"22 Q2","value":4531},{"key":"22 Q3","value":3120},{"key":"22 Q4","value":4859},{"key":"23 Q1","value":1828},{"key":"23 Q2","value":293},{"key":"23 Q3","value":1757},{"key":"23 Q4","value":2793},{"key":"24 Q1","value":167},{"key":"24 Q2","value":184},{"key":"24 Q3","value":1820},{"key":"24 Q4","value":938},{"key":"25 Q1","value":86}]},{"title":"Other revenue","dataPoints":[{"key":"22 Q4","value":225},{"key":"23 Q1","value":34},{"key":"23 Q2","value":51},{"key":"23 Q3","value":74},{"key":"23 Q4","value":18},{"key":"24 Q2","value":57},{"key":"24 Q3","value":42},{"key":"24 Q4","value":28},{"key":"25 Q1","value":22}]}],"overlayChart":null},{"title":"Margins","description":"Gross Profit, Operating Income, and Net Income as a percentage of Revenue","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Gross Margin","dataPoints":[{"key":"21 Q2","value":82.77},{"key":"21 Q3","value":85.46},{"key":"21 Q4","value":86.79},{"key":"22 Q1","value":83.23},{"key":"22 Q2","value":70.92},{"key":"22 Q3","value":67.3},{"key":"22 Q4","value":62.27},{"key":"23 Q1","value":57.46},{"key":"23 Q2","value":-112.5},{"key":"23 Q3","value":-22.4},{"key":"23 Q4","value":66.95},{"key":"24 Q1","value":42.51},{"key":"24 Q2","value":52.28},{"key":"24 Q3","value":72.39},{"key":"24 Q4","value":23.49},{"key":"25 Q1","value":16.66}]},{"title":"Operating Margin","dataPoints":[{"key":"21 Q2","value":70.32},{"key":"21 Q3","value":71.6},{"key":"21 Q4","value":75.02},{"key":"22 Q1","value":69.68},{"key":"22 Q2","value":51.52},{"key":"22 Q3","value":34.66},{"key":"22 Q4","value":31.07},{"key":"23 Q1","value":-19.66},{"key":"23 Q2","value":-542.74},{"key":"23 Q3","value":-109.89},{"key":"23 Q4","value":0.21},{"key":"24 Q1","value":-758.09},{"key":"24 Q2","value":-565.57},{"key":"24 Q3","value":-3.76},{"key":"24 Q4","value":-128.99},{"key":"25 Q1","value":-972.23}]},{"title":"Profit Margin","dataPoints":[{"key":"21 Q2","value":63.84},{"key":"21 Q3","value":67.07},{"key":"21 Q4","value":67.5},{"key":"22 Q1","value":60.28},{"key":"22 Q2","value":46.26},{"key":"22 Q3","value":31},{"key":"22 Q4","value":28.81},{"key":"23 Q1","value":4.24},{"key":"23 Q2","value":-401.17},{"key":"23 Q3","value":-198.26},{"key":"23 Q4","value":7.71},{"key":"24 Q1","value":-703.6},{"key":"24 Q2","value":-530.71},{"key":"24 Q3","value":0.69},{"key":"24 Q4","value":-115.95},{"key":"25 Q1","value":-899.08}]}],"overlayChart":null},{"title":"Operating Expenses","description":"An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.","chartType":"STACKED_VERTICAL_BARS","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Research and Development","dataPoints":[{"key":"21 Q2","value":421},{"key":"21 Q3","value":521},{"key":"21 Q4","value":648},{"key":"22 Q1","value":554},{"key":"22 Q2","value":710},{"key":"22 Q3","value":820},{"key":"22 Q4","value":1211},{"key":"23 Q1","value":1131},{"key":"23 Q2","value":1148},{"key":"23 Q3","value":1160},{"key":"23 Q4","value":1406},{"key":"24 Q1","value":1063},{"key":"24 Q2","value":1221},{"key":"24 Q3","value":1137},{"key":"24 Q4","value":1122},{"key":"25 Q1","value":856}]},{"title":"General and Administrative","dataPoints":[{"key":"21 Q2","value":121},{"key":"21 Q3","value":168},{"key":"21 Q4","value":201},{"key":"22 Q1","value":268},{"key":"22 Q2","value":211},{"key":"22 Q3","value":278},{"key":"22 Q4","value":375},{"key":"23 Q1","value":305},{"key":"23 Q2","value":332},{"key":"23 Q3","value":442},{"key":"23 Q4","value":470},{"key":"24 Q1","value":274},{"key":"24 Q2","value":268},{"key":"24 Q3","value":281},{"key":"24 Q4","value":351},{"key":"25 Q1","value":212}]}],"overlayChart":null},{"title":"Growth","description":"Year over year growth in Revenue and Operating Expenses.","chartType":"AREA","keyType":"STRING","valueType":"PERCENT","valueMultiplier":1,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Y/Y","dataPoints":[{"key":"21 Q2","value":6496.97},{"key":"21 Q3","value":3044.94},{"key":"21 Q4","value":1162.87},{"key":"22 Q1","value":213.16},{"key":"22 Q2","value":9.07},{"key":"22 Q3","value":-32.3},{"key":"22 Q4","value":-29.5},{"key":"23 Q1","value":-69.3},{"key":"23 Q2","value":-92.76},{"key":"23 Q3","value":-45.57},{"key":"23 Q4","value":-44.71},{"key":"24 Q1","value":-91.03},{"key":"24 Q2","value":-29.94},{"key":"24 Q3","value":1.69},{"key":"24 Q4","value":-65.64},{"key":"25 Q1","value":-35.33}]},{"title":"OpEx Y/Y","dataPoints":[{"key":"21 Q2","value":188.3},{"key":"21 Q3","value":75.32},{"key":"21 Q4","value":1.31},{"key":"22 Q1","value":71.97},{"key":"22 Q2","value":69.93},{"key":"22 Q3","value":59.36},{"key":"22 Q4","value":86.81},{"key":"23 Q1","value":74.7},{"key":"23 Q2","value":60.69},{"key":"23 Q3","value":45.9},{"key":"23 Q4","value":18.28},{"key":"24 Q1","value":-6.89},{"key":"24 Q2","value":0.61},{"key":"24 Q3","value":-11.49},{"key":"24 Q4","value":-21.48},{"key":"25 Q1","value":-20.12}]}],"overlayChart":null},{"title":"Outstanding Shares","description":"Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.","chartType":"AREA","keyType":"STRING","valueType":"NUMBER","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":null,"currencySymbol":null,"series":[{"title":"Outstanding Shares","dataPoints":[{"key":"21 Q2","value":402},{"key":"21 Q3","value":404},{"key":"21 Q4","value":405},{"key":"22 Q1","value":402},{"key":"22 Q2","value":396},{"key":"22 Q3","value":390},{"key":"22 Q4","value":385},{"key":"23 Q1","value":386},{"key":"23 Q2","value":381},{"key":"23 Q3","value":381},{"key":"23 Q4","value":381},{"key":"24 Q1","value":382},{"key":"24 Q2","value":384},{"key":"24 Q3","value":385},{"key":"24 Q4","value":385},{"key":"25 Q1","value":386}]}],"overlayChart":null},{"title":"Market Cap","description":"Average market cap for the quarter.","chartType":"AREA","keyType":"STRING","valueType":"MONEY","valueMultiplier":1000000,"valueFormat":null,"isoCurrency":"USD","currencySymbol":"$","series":[{"title":"Market Cap","dataPoints":[{"key":"21 Q2","value":71837.4},{"key":"21 Q3","value":148995.2},{"key":"21 Q4","value":118422},{"key":"22 Q1","value":67696.8},{"key":"22 Q2","value":56588.4},{"key":"22 Q3","value":59163},{"key":"22 Q4","value":62947.5},{"key":"23 Q1","value":63690},{"key":"23 Q2","value":50825.4},{"key":"23 Q3","value":42481.5},{"key":"23 Q4","value":32042.1},{"key":"24 Q1","value":38505.6},{"key":"24 Q2","value":48576},{"key":"24 Q3","value":35343},{"key":"24 Q4","value":18403},{"key":"25 Q1","value":13703}]}],"overlayChart":null},{"title":"Revenue Multiple","description":"Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.","chartType":"AREA","keyType":"STRING","valueType":"PLACEHOLDER","valueMultiplier":1,"valueFormat":"{v}x","isoCurrency":null,"currencySymbol":null,"series":[{"title":"Revenue Multiple","dataPoints":[{"key":"21 Q2","value":4.12},{"key":"21 Q3","value":7.5},{"key":"21 Q4","value":4.11},{"key":"22 Q1","value":2.79},{"key":"22 Q2","value":2.98},{"key":"22 Q3","value":4.4},{"key":"22 Q4","value":3.1},{"key":"23 Q1","value":8.55},{"key":"23 Q2","value":36.94},{"key":"23 Q3","value":5.8},{"key":"23 Q4","value":2.85},{"key":"24 Q1","value":57.64},{"key":"24 Q2","value":50.39},{"key":"24 Q3","value":4.75},{"key":"24 Q4","value":4.76},{"key":"25 Q1","value":31.72}]}],"overlayChart":null}],"chartsLastUpdated":"2025-05-01T15:18:31Z","etfHoldings":null,"etfHoldingsLastUpdated":null},"advancedCryptoData":null,"buySellRatio":{"buy":0.53,"sell":0.47,"lastUpdated":"2025-07-24T00:00:00Z"},"advancedInfoAvailable":true,"advancedInfoDummy":false}],"quotes":[{"symbol":"SYRS","last":"0.02","lastUpdated":"2025-07-24T19:59:59Z","ask":"0","bid":"0","gainPercentage":"2.56","gainValue":"0.001","rawJson":{"symbol":"SYRS","lastUpdated":"2025-07-24T19:59:59Z","batsLastUpdated":"2025-07-24T19:59:59Z","previousClose":0.019,"high":0.02,"low":0,"volume":4651,"last":0.02,"open":0,"gainPercentage":2.56,"gainValue":0.001,"ask":0,"bid":0,"extendedHours":null}},{"symbol":"HTBX","last":"0.07","lastUpdated":"2025-04-21T20:00:00Z","ask":"199999","bid":"0","gainPercentage":"-46.97","gainValue":"-0.062","rawJson":{"symbol":"HTBX","lastUpdated":"2025-04-21T20:00:00Z","batsLastUpdated":"2025-04-21T20:00:00Z","previousClose":0.132,"high":0.131,"low":0.058,"volume":382330,"last":0.07,"open":0.12,"gainPercentage":-46.97,"gainValue":-0.062,"ask":199999,"bid":0,"extendedHours":{"type":"PreMarket","timestamp":"2025-04-21T13:30:00Z","last":0.133,"gainValue":0.063,"gainPercentage":90}}},{"symbol":"CNCR","last":"9.02","lastUpdated":"2025-05-27T20:00:00Z","ask":"19.92","bid":"7.8","gainPercentage":"1.58","gainValue":"0.14","rawJson":{"symbol":"CNCR","lastUpdated":"2025-05-27T20:00:00Z","batsLastUpdated":"2025-05-27T20:00:00Z","previousClose":8.88,"high":9.41,"low":9.02,"volume":3077,"last":9.02,"open":9.41,"gainPercentage":1.58,"gainValue":0.14,"ask":19.92,"bid":7.8,"extendedHours":{"type":"PostMarket","timestamp":"2025-05-27T20:26:15Z","last":9.32,"gainValue":0.3,"gainPercentage":3.33}}},{"symbol":"EXAS","last":"48.77","lastUpdated":"2025-07-24T20:00:00Z","ask":"53","bid":"48.4","gainPercentage":"0.744","gainValue":"0.36","rawJson":{"symbol":"EXAS","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":48.41,"high":49.93,"low":48.26,"volume":6,"last":48.77,"open":48.5,"gainPercentage":0.744,"gainValue":0.36,"ask":53,"bid":48.4,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:35:31Z","last":49,"gainValue":0.23,"gainPercentage":0.472}}},{"symbol":"JNJ","last":"169.56","lastUpdated":"2025-07-24T20:00:00Z","ask":"169.3","bid":"169.12","gainPercentage":"0.272","gainValue":"0.46","rawJson":{"symbol":"JNJ","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":169.1,"high":169.99,"low":168.88,"volume":764,"last":169.56,"open":169.5,"gainPercentage":0.272,"gainValue":0.46,"ask":169.3,"bid":169.12,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:51:54Z","last":169.26,"gainValue":-0.3,"gainPercentage":-0.177}}},{"symbol":"MRK","last":"84.11","lastUpdated":"2025-07-24T20:00:00Z","ask":"84.18","bid":"84","gainPercentage":"0.155","gainValue":"0.13","rawJson":{"symbol":"MRK","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":83.98,"high":84.51,"low":83.52,"volume":855,"last":84.11,"open":84.2,"gainPercentage":0.155,"gainValue":0.13,"ask":84.18,"bid":84,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:39:32Z","last":84.17,"gainValue":0.06,"gainPercentage":0.071}}},{"symbol":"NVS","last":"117.46","lastUpdated":"2025-07-24T20:00:00Z","ask":"117.39","bid":"117.32","gainPercentage":"-0.432","gainValue":"-0.51","rawJson":{"symbol":"NVS","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":117.97,"high":118.11,"low":117.21,"volume":980,"last":117.46,"open":117.5,"gainPercentage":-0.432,"gainValue":-0.51,"ask":117.39,"bid":117.32,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:24:02Z","last":117.51,"gainValue":0.05,"gainPercentage":0.043}}},{"symbol":"INO","last":"1.51","lastUpdated":"2025-07-24T20:00:00Z","ask":"1.53","bid":"1.45","gainPercentage":"-3.205","gainValue":"-0.05","rawJson":{"symbol":"INO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":1.56,"high":1.57,"low":1.48,"volume":270,"last":1.51,"open":1.56,"gainPercentage":-3.205,"gainValue":-0.05,"ask":1.53,"bid":1.45,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:14:08Z","last":1.5,"gainValue":-0.01,"gainPercentage":-0.662}}},{"symbol":"ADAP","last":"0.332","lastUpdated":"2025-07-24T20:00:00Z","ask":"0.38","bid":"0.34","gainPercentage":"14.59","gainValue":"0.042","rawJson":{"symbol":"ADAP","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":0.29,"high":0.358,"low":0.298,"volume":1059,"last":0.332,"open":0.3,"gainPercentage":14.59,"gainValue":0.042,"ask":0.38,"bid":0.34,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:50:18Z","last":0.34,"gainValue":0.008,"gainPercentage":2.38}}},{"symbol":"AMGN","last":"308.55","lastUpdated":"2025-07-24T20:00:00Z","ask":"310","bid":"301.2","gainPercentage":"-0.217","gainValue":"-0.67","rawJson":{"symbol":"AMGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":309.22,"high":311.28,"low":307.35,"volume":1,"last":308.55,"open":309.23,"gainPercentage":-0.217,"gainValue":-0.67,"ask":310,"bid":301.2,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:11:54Z","last":309,"gainValue":0.45,"gainPercentage":0.146}}},{"symbol":"PFE","last":"24.92","lastUpdated":"2025-07-24T20:00:00Z","ask":"24.99","bid":"24.98","gainPercentage":"-0.039","gainValue":"-0.01","rawJson":{"symbol":"PFE","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":24.93,"high":25.11,"low":24.83,"volume":65193,"last":24.92,"open":24.96,"gainPercentage":-0.039,"gainValue":-0.01,"ask":24.99,"bid":24.98,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:47:16Z","last":25.01,"gainValue":0.09,"gainPercentage":0.361}}},{"symbol":"AGIO","last":"39.65","lastUpdated":"2025-07-24T20:00:00Z","ask":"50","bid":"15.86","gainPercentage":"-2.244","gainValue":"-0.91","rawJson":{"symbol":"AGIO","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":40.56,"high":40.98,"low":39.22,"volume":3,"last":39.65,"open":40.53,"gainPercentage":-2.244,"gainValue":-0.91,"ask":50,"bid":15.86,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:58:47Z","last":39.01,"gainValue":-0.64,"gainPercentage":-1.614}}},{"symbol":"ABT","last":"125.64","lastUpdated":"2025-07-24T20:00:00Z","ask":"125.6","bid":"125","gainPercentage":"-0.151","gainValue":"-0.19","rawJson":{"symbol":"ABT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":125.83,"high":125.98,"low":124.69,"volume":127,"last":125.64,"open":125.28,"gainPercentage":-0.151,"gainValue":-0.19,"ask":125.6,"bid":125,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:07:22Z","last":125.16,"gainValue":-0.48,"gainPercentage":-0.382}}},{"symbol":"BDX","last":"183.63","lastUpdated":"2025-07-24T20:00:00Z","ask":"186","bid":"182.88","gainPercentage":"0.575","gainValue":"1.05","rawJson":{"symbol":"BDX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":182.58,"high":185.35,"low":181.33,"volume":4,"last":183.63,"open":182.28,"gainPercentage":0.575,"gainValue":1.05,"ask":186,"bid":182.88,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:30:02Z","last":182.82,"gainValue":-0.81,"gainPercentage":-0.441}}},{"symbol":"LLY","last":"805.43","lastUpdated":"2025-07-24T20:00:00Z","ask":"808","bid":"803.57","gainPercentage":"0.819","gainValue":"6.54","rawJson":{"symbol":"LLY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":798.89,"high":810.14,"low":797.65,"volume":845,"last":805.43,"open":801.36,"gainPercentage":0.819,"gainValue":6.54,"ask":808,"bid":803.57,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:39:01Z","last":805.16,"gainValue":-0.27,"gainPercentage":-0.034}}},{"symbol":"NVAX","last":"7.64","lastUpdated":"2025-07-24T20:00:00Z","ask":"7.76","bid":"7.7","gainPercentage":"-2.551","gainValue":"-0.2","rawJson":{"symbol":"NVAX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":7.84,"high":8.46,"low":7.55,"volume":3481,"last":7.64,"open":8.1,"gainPercentage":-2.551,"gainValue":-0.2,"ask":7.76,"bid":7.7,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:35:43Z","last":7.74,"gainValue":0.1,"gainPercentage":1.31}}},{"symbol":"XBI","last":"87.49","lastUpdated":"2025-07-24T20:00:00Z","ask":"87.92","bid":"87.32","gainPercentage":"-0.827","gainValue":"-0.73","rawJson":{"symbol":"XBI","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":88.22,"high":88.56,"low":87.25,"volume":372,"last":87.49,"open":88.27,"gainPercentage":-0.827,"gainValue":-0.73,"ask":87.92,"bid":87.32,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:44:08Z","last":87.46,"gainValue":-0.03,"gainPercentage":-0.034}}},{"symbol":"NKTR","last":"24.58","lastUpdated":"2025-07-24T20:00:00Z","ask":"25.1","bid":"24.58","gainPercentage":"-1.68","gainValue":"-0.42","rawJson":{"symbol":"NKTR","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":25,"high":25.99,"low":24.3,"volume":64,"last":24.58,"open":25.23,"gainPercentage":-1.68,"gainValue":-0.42,"ask":25.1,"bid":24.58,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:01:20Z","last":24.58,"gainValue":0,"gainPercentage":0}}},{"symbol":"SNY","last":"50.13","lastUpdated":"2025-07-24T20:00:00Z","ask":"50.16","bid":"50.13","gainPercentage":"-0.06","gainValue":"-0.03","rawJson":{"symbol":"SNY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":50.16,"high":50.49,"low":50,"volume":1103,"last":50.13,"open":50.27,"gainPercentage":-0.06,"gainValue":-0.03,"ask":50.16,"bid":50.13,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:33:35Z","last":50.24,"gainValue":0.11,"gainPercentage":0.219}}},{"symbol":"VHT","last":"250.14","lastUpdated":"2025-07-24T20:00:00Z","ask":"255","bid":"246.15","gainPercentage":"-0.501","gainValue":"-1.26","rawJson":{"symbol":"VHT","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":251.4,"high":252.38,"low":249.92,"volume":3,"last":250.14,"open":250.86,"gainPercentage":-0.501,"gainValue":-1.26,"ask":255,"bid":246.15,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:25:20Z","last":251.45,"gainValue":1.31,"gainPercentage":0.524}}},{"symbol":"XLV","last":"135.76","lastUpdated":"2025-07-24T20:00:00Z","ask":"136.27","bid":"135.77","gainPercentage":"-0.374","gainValue":"-0.51","rawJson":{"symbol":"XLV","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":136.27,"high":136.93,"low":135.54,"volume":1283,"last":135.76,"open":136.13,"gainPercentage":-0.374,"gainValue":-0.51,"ask":136.27,"bid":135.77,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:27:38Z","last":136.01,"gainValue":0.25,"gainPercentage":0.184}}},{"symbol":"DVAX","last":"11.16","lastUpdated":"2025-07-24T20:00:00Z","ask":"13.98","bid":"9.3","gainPercentage":"-1.674","gainValue":"-0.19","rawJson":{"symbol":"DVAX","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":11.35,"high":11.48,"low":11.14,"volume":770244,"last":11.16,"open":11.35,"gainPercentage":-1.674,"gainValue":-0.19,"ask":13.98,"bid":9.3,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T23:02:57Z","last":11.09,"gainValue":-0.07,"gainPercentage":-0.627}}},{"symbol":"ABBV","last":"190.83","lastUpdated":"2025-07-24T20:00:00Z","ask":"192.35","bid":"190.15","gainPercentage":"0.147","gainValue":"0.28","rawJson":{"symbol":"ABBV","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":190.55,"high":192.24,"low":189.99,"volume":133,"last":190.83,"open":190.76,"gainPercentage":0.147,"gainValue":0.28,"ask":192.35,"bid":190.15,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:29:39Z","last":191.25,"gainValue":0.42,"gainPercentage":0.22}}},{"symbol":"IDNA","last":"22.27","lastUpdated":"2025-07-24T20:00:00Z","ask":"22.9","bid":"21.24","gainPercentage":"-1.171","gainValue":"-0.264","rawJson":{"symbol":"IDNA","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":22.53,"high":22.6,"low":22.25,"volume":20612,"last":22.27,"open":22.53,"gainPercentage":-1.171,"gainValue":-0.264,"ask":22.9,"bid":21.24,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T20:21:22Z","last":22.25,"gainValue":-0.016,"gainPercentage":-0.072}}},{"symbol":"VXRT","last":"0.408","lastUpdated":"2025-07-24T19:59:41Z","ask":"0","bid":"0","gainPercentage":"-2.857","gainValue":"-0.012","rawJson":{"symbol":"VXRT","lastUpdated":"2025-07-24T19:59:41Z","batsLastUpdated":"2025-07-24T19:59:41Z","previousClose":0.42,"high":0.44,"low":0.402,"volume":745434,"last":0.408,"open":0.42,"gainPercentage":-2.857,"gainValue":-0.012,"ask":0,"bid":0,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T20:03:09Z","last":0.408,"gainValue":0,"gainPercentage":0}}},{"symbol":"BMY","last":"48.94","lastUpdated":"2025-07-24T20:00:00Z","ask":"49.16","bid":"48.71","gainPercentage":"-0.082","gainValue":"-0.04","rawJson":{"symbol":"BMY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":48.98,"high":49.27,"low":48.71,"volume":554,"last":48.94,"open":49.02,"gainPercentage":-0.082,"gainValue":-0.04,"ask":49.16,"bid":48.71,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:16:50Z","last":49.06,"gainValue":0.12,"gainPercentage":0.245}}},{"symbol":"AZN","last":"73.68","lastUpdated":"2025-07-24T20:00:00Z","ask":"73.32","bid":"73.28","gainPercentage":"0.932","gainValue":"0.68","rawJson":{"symbol":"AZN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":73,"high":74.38,"low":73.55,"volume":29476,"last":73.68,"open":74.13,"gainPercentage":0.932,"gainValue":0.68,"ask":73.32,"bid":73.28,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:53:24Z","last":73.4,"gainValue":-0.28,"gainPercentage":-0.38}}},{"symbol":"KPTI","last":"4.43","lastUpdated":"2025-07-24T20:00:00Z","ask":"5.27","bid":"4.22","gainPercentage":"-8.848","gainValue":"-0.43","rawJson":{"symbol":"KPTI","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":4.86,"high":4.91,"low":4.37,"volume":210125,"last":4.43,"open":4.7,"gainPercentage":-8.848,"gainValue":-0.43,"ask":5.27,"bid":4.22,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T22:53:28Z","last":4.35,"gainValue":-0.08,"gainPercentage":-1.806}}},{"symbol":"INCY","last":"70.49","lastUpdated":"2025-07-24T20:00:00Z","ask":"82.8","bid":"70.15","gainPercentage":"-0.283","gainValue":"-0.2","rawJson":{"symbol":"INCY","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":70.69,"high":71.29,"low":70.33,"volume":1680116,"last":70.49,"open":70.81,"gainPercentage":-0.283,"gainValue":-0.2,"ask":82.8,"bid":70.15,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T20:29:45Z","last":70.49,"gainValue":0,"gainPercentage":0}}},{"symbol":"EXEL","last":"44.79","lastUpdated":"2025-07-24T20:00:00Z","ask":"45.56","bid":"44.5","gainPercentage":"-1.344","gainValue":"-0.61","rawJson":{"symbol":"EXEL","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":45.4,"high":45.75,"low":44.71,"volume":51,"last":44.79,"open":45.29,"gainPercentage":-1.344,"gainValue":-0.61,"ask":45.56,"bid":44.5,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:46:51Z","last":45.34,"gainValue":0.55,"gainPercentage":1.23}}},{"symbol":"GILD","last":"113.2","lastUpdated":"2025-07-24T20:00:00Z","ask":"113.66","bid":"113.08","gainPercentage":"-0.317","gainValue":"-0.36","rawJson":{"symbol":"GILD","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":113.56,"high":113.7,"low":112.51,"volume":310,"last":113.2,"open":113.58,"gainPercentage":-0.317,"gainValue":-0.36,"ask":113.66,"bid":113.08,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:36:57Z","last":113.63,"gainValue":0.43,"gainPercentage":0.38}}},{"symbol":"REGN","last":"564.64","lastUpdated":"2025-07-24T20:00:00Z","ask":"591.33","bid":"546","gainPercentage":"-1.354","gainValue":"-7.75","rawJson":{"symbol":"REGN","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":572.39,"high":577.73,"low":563.67,"volume":42,"last":564.64,"open":572.54,"gainPercentage":-1.354,"gainValue":-7.75,"ask":591.33,"bid":546,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:35:34Z","last":568.6,"gainValue":3.96,"gainPercentage":0.701}}},{"symbol":"ATRA","last":"12.23","lastUpdated":"2025-07-24T20:00:00Z","ask":"12.2","bid":"11.39","gainPercentage":"-0.245","gainValue":"-0.03","rawJson":{"symbol":"ATRA","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":12.26,"high":13.46,"low":12.18,"volume":90316,"last":12.23,"open":13.26,"gainPercentage":-0.245,"gainValue":-0.03,"ask":12.2,"bid":11.39,"extendedHours":{"type":"PostMarket","timestamp":"2025-07-24T23:47:13Z","last":12,"gainValue":-0.23,"gainPercentage":-1.881}}},{"symbol":"MRNA","last":"34.01","lastUpdated":"2025-07-24T20:00:00Z","ask":"34.45","bid":"34.32","gainPercentage":"-1.904","gainValue":"-0.66","rawJson":{"symbol":"MRNA","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":34.67,"high":35.09,"low":33.8,"volume":6896,"last":34.01,"open":34.95,"gainPercentage":-1.904,"gainValue":-0.66,"ask":34.45,"bid":34.32,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T09:40:13Z","last":34.4,"gainValue":0.39,"gainPercentage":1.15}}},{"symbol":"TAK","last":"14.66","lastUpdated":"2025-07-24T20:00:00Z","ask":"14.66","bid":"14.44","gainPercentage":"-0.543","gainValue":"-0.08","rawJson":{"symbol":"TAK","lastUpdated":"2025-07-24T20:00:00Z","batsLastUpdated":"2025-07-24T20:00:00Z","previousClose":14.74,"high":14.78,"low":14.62,"volume":23,"last":14.66,"open":14.71,"gainPercentage":-0.543,"gainValue":-0.08,"ask":14.66,"bid":14.44,"extendedHours":{"type":"PreMarket","timestamp":"2025-07-25T08:03:46Z","last":14.68,"gainValue":0.02,"gainPercentage":0.136}}}]},"__N_SSG":true},"page":"/themes/[name]","query":{"name":"fighting-disease"},"buildId":"vtCYKp0Ai9E1UhSXnGgkP","assetPrefix":"https://public.com","isFallback":false,"gsp":true,"customServer":true,"scriptLoader":[]}</script></body></html>